US20190233441A1 - Triazolopyridine compounds, compositions and methods of use thereof - Google Patents

Triazolopyridine compounds, compositions and methods of use thereof Download PDF

Info

Publication number
US20190233441A1
US20190233441A1 US16/373,435 US201916373435A US2019233441A1 US 20190233441 A1 US20190233441 A1 US 20190233441A1 US 201916373435 A US201916373435 A US 201916373435A US 2019233441 A1 US2019233441 A1 US 2019233441A1
Authority
US
United States
Prior art keywords
alkyl
alkylene
compound
optionally substituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/373,435
Inventor
Nicholas C. Ray
Yun-Xing Cheng
Christine Edwards
Simon C. GOODACRE
Wei Li
Snahel Patel
Matthew W. CARTWRIGHT
Mohammed Sajad
Po-Wai Yuen
Mark E. Zak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to US16/373,435 priority Critical patent/US20190233441A1/en
Publication of US20190233441A1 publication Critical patent/US20190233441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the field of the invention pertains to compounds of Formulas 0, I and II, and subformulas thereof, that are inhibitors of a Janus kinase, such as JAK1, as well as compositions containing these compounds, and methods of use including, but not limited to, diagnosis or treatment of patients suffering from a condition responsive to the inhibition of a JAK kinase.
  • Janus kinases JAK1, JAK2, JAK3 and TYK2 are cytoplasmic protein kinases that associate with type I and type II cytokine receptors and regulate cytokine signal transduction. Cytokine engagement with cognate receptors triggers activation of receptor associated JAKs and this leads to JAK-mediated tyrosine phosphorylation of signal transducer and activator of transcription (STAT) proteins and ultimately transcriptional activation of specific gene sets (Schindler et al., 2007, J. Biol. Chem. 282: 20059-63).
  • STAT signal transducer and activator of transcription
  • JAK1, JAK2 and TYK2 exhibit broad patterns of gene expression, while JAK3 expression is limited to leukocytes.
  • Cytokine receptors are typically functional as heterodimers, and as a result, more than one type of JAK kinase is usually associated with cytokine receptor complexes.
  • the specific JAKs associated with different cytokine receptor complexes have been determined in many cases through genetic studies and corroborated by other experimental evidence. Exemplary therapeutic benefits of the inhibition of JAK enzymes are discussed, for example, in International Application No. WO 2013/014567.
  • JAK1 was initially identified in a screen for novel kinases (Wilks A. F., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:1603-1607). Genetic and biochemical studies have shown that JAK1 is functionally and physically associated with the type I interferon (e.g., IFNalpha), type II interferon (e.g., IFNgamma), and IL-2 and IL-6 cytokine receptor complexes (Kisseleva et al., 2002, Gene 285:1-24; Levy et al., 2005, Nat. Rev. Mol. Cell Biol.
  • type I interferon e.g., IFNalpha
  • type II interferon e.g., IFNgamma
  • IL-2 and IL-6 cytokine receptor complexes e.g., IL-2 and IL-6 cytokine receptor complexes
  • JAK1 knockout mice die perinatally due to defects in LIF receptor signaling (Kisseleva et al., 2002, Gene 285:1-24; O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131). Characterization of tissues derived from JAK1 knockout mice demonstrated critical roles for this kinase in the IFN, IL-10, IL-2/IL-4 and IL-6 pathways.
  • a humanized monoclonal antibody targeting the IL-6 pathway was recently approved by the European Commission for the treatment of moderate-to-severe rheumatoid arthritis (Scheinecker et al., 2009, Nat. Rev. Drug Discov. 8:273-274).
  • CD4 T cells play an important role in asthma pathogenesis through the production of TH2 cytokines within the lung, including IL-4, IL-9 and IL-13 (Cohn et al., 2004, Annu. Rev. Immunol. 22:789-815).
  • IL-4 and IL-13 induce increased mucus production, recruitment of eosinophils to the lung, and increased production of IgE (Kasaian et al., 2008, Biochem. Pharmacol. 76(2): 147-155).
  • IL-9 leads to mast cell activation, which exacerbates the asthma symptoms (Kearley et al., 2011, Am. J. Resp. Crit. Care Med., 183(7): 865-875).
  • the IL-4R ⁇ chain activates JAK1 and binds to either IL-4 or IL-13 when combined with the common gamma chain or the IL-13R ⁇ 1 chain respectively (Pernis et al., 2002, J. Clin. Invest. 109(10):1279-1283).
  • the common gamma chain can also combine with IL-9R ⁇ to bind to IL-9, and IL-9R ⁇ activates JAK1 as well (Demoulin et al., 1996, Mol. Cell Biol. 16(9):4710-4716).
  • JAK2 knockout mice die of anemia (O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131).
  • Kinase activating mutations in JAK2 e.g., JAK2 V617F are associated with myeloproliferative disorders in humans.
  • JAK3 associates exclusively with the gamma common cytokine receptor chain, which is present in the IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 cytokine receptor complexes. JAK3 is critical for lymphoid cell development and proliferation and mutations in JAK3 result in severe combined immunodeficiency (SCID) (O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131).
  • SCID severe combined immunodeficiency
  • JAK3 and JAK3-mediated pathways have been targeted for immunosuppressive indications (e.g., transplantation rejection and rheumatoid arthritis) (Baslund et al., 2005, Arthritis & Rheumatism 52: 2686-2692; Changelian et al., 2003, Science 302: 875-878).
  • immunosuppressive indications e.g., transplantation rejection and rheumatoid arthritis
  • TYK2 associates with the type I interferon (e.g., IFNalpha), IL-6, IL-10, IL-12 and IL-23 cytokine receptor complexes (Kisseleva et al., 2002, Gene 285:1-24; Watford, W. T. & O'Shea, J. J., 2006, Immunity 25:695-697). Consistent with this, primary cells derived from a TYK2 deficient human are defective in type I interferon, IL-6, IL-10, IL-12 and IL-23 signaling.
  • a fully human monoclonal antibody targeting the shared p40 subunit of the IL-12 and IL-23 cytokines was recently approved by the European Commission for the treatment of moderate-to-severe plaque psoriasis (Krueger et al., 2007, N. Engl. J. Med. 356:580-92; Reich et al., 2009, Nat. Rev. Drug Discov. 8:355-356).
  • an antibody targeting the IL-12 and IL-23 pathways underwent clinical trials for treating Crohn's Disease (Mannon et al., 2004, N. Engl. J. Med. 351:2069-79).
  • JAK kinases There exists a need in the art for additional or alternative treatments of conditions mediated by JAK kinases, such as those described above.
  • One aspect of the invention includes a compound of Formula 0:
  • One other aspect of the invention includes a compound of Formula I:
  • Another aspect of the present invention includes a compound of Formula II:
  • Another aspect includes a pharmaceutical composition that comprises a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and a pharmaceutically acceptable carrier, diluent or excipient.
  • Another aspect includes use of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for use in therapy, such as the treatment of an inflammatory disease or cancer.
  • Another aspect includes a method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase, such as JAK1 kinase, in a patient.
  • the method can comprise administering to the patient a therapeutically effective amount of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1.
  • Another aspect includes the use of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, in the manufacture of a medicament for the treatment of a disease responsive to the inhibition of a Janus kinase, such as JAK1 kinase.
  • kits for treating a disease or disorder responsive to the inhibition of a Janus kinase such as JAK1 kinase.
  • the kit can comprise a first pharmaceutical composition comprising a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and instructions for use.
  • Halogen or “halo” refers to F, Cl, Br or I. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
  • alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical, wherein the alkyl radical may be optionally substituted.
  • the alkyl radical is one to eighteen carbon atoms (C 1 -C 18 ).
  • the alkyl radical is C 0 -C 6, C 0 -C 5 , C 0 -C 3 , C 1 -C 12 , C 1 -C 10 , C 1 -C 8 , C 1 -C 6 , C 1 -C 5 , C 1 -C 4 , or C 1 -C 3 .
  • C 0 alkyl refers to a bond.
  • alkyl groups include methyl (Me, —CH 3 ), ethyl (Et, —CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, —CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, —CH(CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, —CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, —CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, —CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, —C(CH 3 ) 3 ), 1-pentyl (n-pentyl, —CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (—CH(CH 3 )CH 2 CH 2 CH 2 CH
  • substituents for “optionally substituted alkyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • alkenyl refers to linear or branched-chain monovalent hydrocarbon radical with at least one site of unsaturation, i.e., a carbon-carbon double bond, wherein the alkenyl radical may be optionally substituted, and includes radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.
  • the alkenyl radical is two to eighteen carbon atoms (C 2 -C 18 ).
  • the alkenyl radical is C 2 -C 12 , C 2 -C 10 , C 2 -C 8 , C 2 -C 6 or C 2 -C 3 .
  • Examples include, but are not limited to, ethenyl or vinyl (—CH ⁇ CH 2 ), prop-1-enyl (—CH ⁇ CHCH 3 ), prop-2-enyl (—CH 2 CH ⁇ CH 2 ), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hexa-1,3-dienyl.
  • substituents for “optionally substituted alkenyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • alkynyl refers to a linear or branched monovalent hydrocarbon radical with at least one site of unsaturation, i.e., a carbon-carbon, triple bond, wherein the alkynyl radical may be optionally substituted.
  • the alkynyl radical is two to eighteen carbon atoms (C 2 -C 18 ).
  • the alkynyl radical is C 2 -C 12 , C 2 -C 10 , C 2 -C 8 , C 2 -C 6 or C 2 -C 3 .
  • Examples include, but are not limited to, ethynyl (—C ⁇ CH), prop-1-ynyl (—CCCH 3 ), prop-2-ynyl (propargyl, —CH 2 C ⁇ CH), but-1-ynyl, but-2-ynyl and but-3-ynyl.
  • substituents for “optionally substituted alkynyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • Alkylene refers to a saturated, branched or straight chain hydrocarbon group having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • the divalent alkylene group is one to eighteen carbon atoms (C 1 -C 18 ).
  • the divalent alkylene group is C 0 -C 6 , C 0 -C 5 , C 0 -C 3 , C 1 -C 12 , C 1 -C 10 , C 1 -C 8 , C 1 -C 6 , C 1 -C 5 , C 1 -C 4 , or C 1 -C 3 .
  • the group Co alkylene refers to a bond.
  • Example alkylene groups include methylene (—CH 2 —), 1,1-ethyl (—CH(CH 3 )—), (1,2-ethyl (—CH 2 CH 2 —), 1,1-propyl (—CH(CH 2 CH 3 )—), 2,2-propyl (—C(CH 3 ) 2 —), 1,2-propyl (—CH(CH 3 )CH 2 —), 1,3-propyl (—CH 2 CH 2 CH 2 —), 1,1-dimethyleth-1,2-yl (—C(CH 3 ) 2 CH 2 —), 1,4-butyl (—CH 2 CH 2 CH 2 CH 2 —), and the like.
  • Alkenylene refers to an unsaturated, branched or straight chain hydrocarbon group having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • the alkenylene group is two to eighteen carbon atoms (C 2 -C 18 ).
  • the alkenylene group is C 2 -C 12, C 2 -C 10 , C 2 -C 8 , C 2 -C 6 or C 2 -C 3 .
  • An exemplary alkenylene group is 1,2-ethylene (—CH ⁇ CH—).
  • Alkynylene refers to an unsaturated, branched or straight chain hydrocarbon group having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • the alkynylene radical is two to eighteen carbon atoms (C 2 -C 18 ).
  • the alkynylene radical is C 2 -C 12 , C 2 -C 10 , C 2 -C 8 , C 2 -C 6 or C 2 -C 3 .
  • Example alkynylene radicals include: acetylene (—C ⁇ C—), propargyl (—CH 2 C ⁇ C—), and 4-pentynyl (—CH 2 CH 2 CH 2 C ⁇ C—).
  • heteroalkyl refers to a straight or branched chain monovalent hydrocarbon radical, consisting of the stated number of carbon atoms, or, if none are stated, up to 18 carbon atoms, and from one to five heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms can optionally be oxidized and the nitrogen heteroatom can optionally be quaternized.
  • the heteroatom is selected from O, N and S, wherein the nitrogen and sulfur atoms can optionally be oxidized and the nitrogen heteroatom can optionally be quaternized.
  • the heteroatom(s) can be placed at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule (e.g., —O—CH 2 —CH 3 ).
  • Examples include —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —CH 2 —S—CH 2 —CH 3 , —S(O)—CH 3 , —CH 2 —CH 2 —S(O) 2 —CH 3 , —Si(CH 3 ) 3 and —CH 2 —CH ⁇ N—OCH 3 .
  • heteroalkyl groups can be optionally substituted.
  • substituents for “optionally substituted heteroalkyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizin
  • Amidine means the group —C(NH)—NHR in which R is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl groups are as defined herein.
  • a particular amidine is the group —NH—C(NH)—NH 2 .
  • Amino means primary (i.e., —NH 2 ), secondary (i.e., —NRH) and tertiary (i.e., —NRR) amines, that are optionally substituted, in which R is alkyl, cycloalkyl, aryl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl groups are as defined herein.
  • Particular secondary and tertiary amines are alkylamine, dialkylamine, arylamine, diarylamine, aralkylamine and diaralkylamine, wherein the alkyl and aryl portions can be optionally substituted.
  • Particular secondary and tertiary amines are methylamine, ethylamine, propylamine, isopropylamine, phenylamine, benzylamine, dimethylamine, diethylamine, dipropylamine and diisopropylamine.
  • Aryl refers to a carbocyclic aromatic group, whether or not fused to one or more groups, having the number of carbon atoms designated, or if no number is designated, up to 14 carbon atoms.
  • One example includes aryl groups having 6-14 carbon atoms.
  • Another example includes aryl groups having 6-10 carbon atoms.
  • Examples of aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, 1,2,3,4-tetrahydronaphthalenyl, 1H-indenyl, 2,3-dihydro-1H-indenyl, and the like (see, e.g., Lang's Handbook of Chemistry (Dean, J.
  • a particular aryl is phenyl.
  • Substituted phenyl or substituted aryl means a phenyl group or aryl group substituted with one, two, three, four or five substituents, for example, 1-2, 1-3 or 1-4 substituents, such as chosen from groups specified herein (see “optionally substituted” definition), such as F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesul
  • substituted phenyl examples include a mono- or di(halo)phenyl group such as 2-chlorophenyl, 2-bromophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl, 2,4-difluorophenyl and the like; a mono- or di(hydroxy)phenyl group such as 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 3- or 4-nitrophenyl; a cyanophenyl group, for example, 4-cyanophenyl; a mono- or di(al)phenyl group such as
  • substituted phenyl represents disubstituted phenyl groups where the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy-4-chlorophenyl, 2-chloro-5-difluoromethoxy and the like, as well as trisubstituted phenyl groups where the substituents are different, for example 3-methoxy-4-benzyloxy-6-methyl sulfonylamino, 3-methoxy-4-benzyloxy-6-phenyl sulfonylamino, and tetrasubstituted phenyl groups where the substituents are different such as 3-methoxy-4-benzyloxy-5-methyl-6-phenyl sulfonylamino.
  • Cycloalkyl refers to a non-aromatic, saturated or partially unsaturated hydrocarbon ring group wherein the cycloalkyl group may be optionally substituted independently with one or more substituents described herein.
  • the cycloalkyl group is 3 to 12 carbon atoms (C 3 -C 12 ).
  • cycloalkyl is C 3 -C 8 , C 3 -C 10 or C 5 -C 10 .
  • the cycloalkyl group, as a monocycle is C 3 -C 8 , C 3 -C 6 or C 5 -C 6 .
  • the cycloalkyl group, as a bicycle is C 7 -C 12 .
  • the cycloalkyl group is C 5 -C 12 .
  • monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, perdeuteriocyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl.
  • Exemplary arrangements of bicyclic cycloalkyls having 7 to 12 ring atoms include, but are not limited to, [4,4], [4,5], [5,5], [5,6] or [6,6] ring systems.
  • Exemplary bridged bicyclic cycloalkyls include, but are not limited to, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane.
  • Examples of spiro cycloalkyl include, spiro[2.2]pentane, spiro[2.3]hexane, spiro[2.4]heptane, spiro[2.5]octane and spiro[4.5]decane.
  • substituents for “optionally substituted cycloalkyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • Guanidine or “guanidinyl” means the group —NH—C(NH)—NHR in which R is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl groups are as defined herein.
  • a particular guanidine is the group —NH—C(NH)—NH 2 .
  • Heterocyclic group “heterocyclic”, “heterocycle”, “heterocyclyl”, or “heterocyclo” are used interchangeably and refer to any mono-, bi-, tricyclic or spiro, saturated or unsaturated, aromatic (heteroaryl) or non-aromatic (e.g., heterocycloalkyl), ring system, having 3 to 20 ring atoms, where the ring atoms are carbon, and at least one atom in the ring or ring system is a heteroatom selected from nitrogen, sulfur or oxygen. If any ring atom of a cyclic system is a heteroatom, that system is a heterocycle, regardless of the point of attachment of the cyclic system to the rest of the molecule.
  • heterocyclyl includes 3-11 ring atoms (“members”) and includes monocycles, bicycles, tricycles and spiro ring systems, wherein the ring atoms are carbon, where at least one atom in the ring or ring system is a heteroatom selected from nitrogen, sulfur or oxygen.
  • heterocyclyl includes 1 to 4 heteroatoms.
  • heterocyclyl includes 1 to 3 heteroatoms.
  • heterocyclyl includes 3- to 7-membered monocycles having 1-2, 1-3 or 1-4 heteroatoms selected from nitrogen, sulfur or oxygen.
  • heterocyclyl includes 4- to 6-membered monocycles having 1-2, 1-3 or 1-4 heteroatoms selected from nitrogen, sulfur or oxygen.
  • heterocyclyl includes 3-membered monocycles. In another example, heterocyclyl includes 4-membered monocycles. In another example, heterocyclyl includes 5-6 membered monocycles, e.g., 5-6 membered heteroaryl. In another example, heterocyclyl includes 3-11 membered heterocycloyalkyls, such as 4-11 membered heterocycloalkyls. In some embodiments, a heterocycloalkyl includes at least one nitrogen. In one example, the heterocyclyl group includes 0 to 3 double bonds.
  • Any nitrogen or sulfur heteroatom may optionally be oxidized (e.g., NO, SO, SO 2 ), and any nitrogen heteroatom may optionally be quaternized (e.g., [NR 4 ] + Cl ⁇ , [NR 4 ] + OH ⁇ ).
  • Example heterocycles are oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl, dihydro-1H-pyrrolyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl, piperazinyl, isoquinolinyl, tetrahydroisoquinolinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, dihydropyranyl, tetrahydropyranyl, hexahydrothiopyranyl, hexahydropyrimidinyl, oxazinanyl, thiazinanyl, thi
  • Examples of 5-membered heterocycles containing a sulfur or oxygen atom and one to three nitrogen atoms are thiazolyl, including thiazol-2-yl and thiazol-2-yl N-oxide, thiadiazolyl, including 1,3,4-thiadiazol-5-yl and 1,2,4-thiadiazol-5-yl, oxazolyl, for example oxazol-2-yl, and oxadiazolyl, such as 1,3,4-oxadiazol-5-yl, and 1,2,4-oxadiazol-5-yl.
  • Example 5-membered ring heterocycles containing 2 to 4 nitrogen atoms include imidazolyl, such as imidazol-2-yl; triazolyl, such as 1,3,4-triazol-5-yl; 1,2,3-triazol-5-yl, 1,2,4-triazol-5-yl, and tetrazolyl, such as 1H-tetrazol-5-yl.
  • Example benzo-fused 5-membered heterocycles are benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl.
  • Example 6-membered heterocycles contain one to three nitrogen atoms and optionally a sulfur or oxygen atom, for example pyridyl, such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as pyrimid-2-yl and pyrimid-4-yl; triazinyl, such as 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in particular pyridazin-3-yl, and pyrazinyl.
  • pyridyl such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl
  • pyrimidyl such as pyrimid-2-yl and pyrimid-4-yl
  • triazinyl such as 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl
  • pyridine N-oxides and pyridazine N-oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the 1,3,4-triazin-2-yl groups are other example heterocycle groups. Heterocycles may be optionally substituted.
  • substituents for “optionally substituted heterocycles” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • Heteroaryl refers to any mono-, bi-, or tricyclic ring system where at least one ring is a 5- or 6-membered aromatic ring containing from 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, and in an example embodiment, at least one heteroatom is nitrogen. See, for example, Lang's Handbook of Chemistry (Dean, J. A., ed.) 13 th ed. Table 7-2 [1985]. Included in the definition are any bicyclic groups where any of the above heteroaryl rings are fused to an aryl ring, wherein the aryl ring or the heteroaryl ring is joined to the remainder of the molecule.
  • heteroaryl includes 5-6 membered monocyclic aromatic groups where one or more ring atoms is nitrogen, sulfur or oxygen.
  • Example heteroaryl groups include thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, tetrazolo[1,5-b]pyridazinyl, imidazol[1,2-a]pyrimidinyl and purinyl, as well as benzo-fused derivatives, for example benzoxazolyl, benzofuryl, benzothiazolyl, benzothiadiazol
  • Heteroaryl groups can be optionally substituted.
  • substituents for “optionally substituted heteroaryls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH 2 , NHCH 3 , N(CH 3 ) 2 , NO 2 , N 3 , C(O)CH 3 , COOH, CO 2 CH 3 , methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • Heteroarylene refers to a heteroaryl having two monovalent radical centers derived by the removal of two hydrogen atoms from two different atoms of a parent heteroaryl group.
  • a heterocyclyl group is attached at a carbon atom of the heterocyclyl group.
  • carbon bonded heterocyclyl groups include bonding arrangements at position 2, 3, 4, 5, or 6 of a pyridine ring, position 3, 4, 5, or 6 of a pyridazine ring, position 2, 4, 5, or 6 of a pyrimidine ring, position 2, 3, 5, or 6 of a pyrazine ring, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole ring, position 2, 4, or 5 of an oxazole, imidazole or thiazole ring, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole ring, position 2 or 3 of an aziridine ring, position 2, 3, or 4 of an azetidine ring, position 2, 3, 4, 5, 6, 7, or 8 of a
  • the heterocyclyl group is N-attached.
  • nitrogen bonded heterocyclyl or heteroaryl groups include bonding arrangements at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • alkoxy refers to a linear or branched monovalent radical represented by the formula —OR in which R is alkyl, as defined herein. Alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, mono-, di- and tri-fluoromethoxy and cyclopropoxy.
  • Acyl means a carbonyl containing substituent represented by the formula —C(O)—R in which R is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl are as defined herein.
  • Acyl groups include alkanoyl (e.g., acetyl), aroyl (e.g., benzoyl), and heteroaroyl (e.g., pyridinoyl).
  • Optionally substituted unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 0, 1, 2, 3, 4, or 5 or more, or any range derivable therein) of the substituents listed for that group in which said substituents may be the same or different.
  • an optionally substituted group has 1 substituent.
  • an optionally substituted group has 2 substituents.
  • an optionally substituted group has 3 substituents.
  • an optionally substituted group has 4 substituents.
  • an optionally substituted group has 5 substituents.
  • Optional substituents for alkyl radicals can be a variety of groups, such as those described herein, as well as selected from the group consisting of halogen; oxo; CN; NO; N 3 ; —OR′; perfluoro-C 1 -C 4 alkoxy; unsubstituted C 3 -C 7 cycloalkyl; C 3 -C 7 cycloalkyl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 6 -C 10 aryl (e.g., phen
  • R′, R′′ and R′′′ each independently refer to groups including, for example, hydrogen; unsubstituted C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 1 -C 6 heteroalkyl; C 1 -C 6 heteroalkyl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 6 -C 10 aryl; C 6 -C 10 aryl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy
  • R′ and R′′ When R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S and wherein the ring is optionally substituted with halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′.
  • —NR′R′′ is meant to include 1-pyrrolidinyl and 4-morpholinyl.
  • substituents for aryl and heteroaryl groups are varied.
  • substituents for aryl and heteroaryl groups are selected from the group consisting of halogen; CN; NO, N 3 ; —OR′; perfluoro-C 1 -C 4 alkoxy; unsubstituted C 3 -C 7 cycloalkyl; C 3 -C 7 cycloalkyl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 6 -C 10 aryl (e.g., phenyl); C 6 -C 10 aryl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, or NR′R′′; unsubstituted
  • R′, R′′ and R′′′ each independently refer to groups including, for example, hydrogen; unsubstituted C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 1 -C 6 heteroalkyl; C 1 C 6 heteroalkyl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 6 -C 10 aryl; C 6 -C 10 aryl substituted by halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, or
  • R′ and R′′ When R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S and wherein the ring is optionally substituted with halogen, OH, CN, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′.
  • —NR′R′′ is meant to include 1-pyrrolidinyl and 4-morpholinyl.
  • oxo refers to ⁇ O or ( ⁇ O) 2 .
  • a wavy line “ ” that intersects a bond in a chemical structure indicate the point of attachment of the atom to which the wavy bond is connected in the chemical structure to the remainder of a molecule, or to the remainder of a fragment of a molecule.
  • an arrow together with an asterisk is used in the manner of a wavy line to indicate a point of attachment.
  • divalent groups are described generically without specific bonding configurations. It is understood that the generic description is meant to include both bonding configurations, unless specified otherwise.
  • R 1 —R 2 —R 3 if the group R 2 is described as —CH 2 C(O)—, then it is understood that this group can be bonded both as R 1 —CH 2 C(O)—R 3 , and as R 1 —C(O)CH 2 —R 3 , unless specified otherwise.
  • phrases “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
  • “Pharmaceutically acceptable salts” include both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid and the like, and organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glut
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particular base addition salts are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • Particular organic non-toxic bases include isopropylamine, diethylamine, ethanolamine, tromethamine, dicyclohexylamine, choline, and caffeine.
  • a salt is selected from a hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate, p-toluenesulphonate, bisulphate, benzenesulphonate, ethanesulphonate, malonate, xinafoate, ascorbate, oleate, nicotinate, saccharinate, adipate, formate, glycolate, palmitate, L-lactate, D-lactate, aspartate, malate, L-tartrate, D-tartrate, stearate, furoate (e.g., 2-furoate or 3-furoate), napadisylate (naphthalene-1,5-disulfonate or naphthalene-1-(sulfonic acid)-5
  • a “sterile” formulation is aseptic or free from all living microorganisms and their spores.
  • Stereoisomers refer to compounds that have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. Stereoisomers include diastereomers, enantiomers, conformers and the like.
  • Chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties or biological activities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography such as HPLC.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • d and 1 or (+) and ( ⁇ ) are employed to designate the sign of rotation of plane-polarized light by the compound, with ( ⁇ ) or 1 meaning that the compound is levorotatory.
  • a compound prefixed with (+) or d is dextrorotatory.
  • these stereoisomers are identical except that they are mirror images of one another.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • the terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • Valence tautomers include interconversions by reorganization of some of the bonding electrons.
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.
  • a “solvate” refers to an association or complex of one or more solvent molecules and a compound of the present invention. Examples of solvents that form solvates include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
  • Certain compounds of the present invention can exist in multiple crystalline or amorphous forms. In general, all physical forms are intended to be within the scope of the present invention.
  • the term “hydrate” refers to the complex where the solvent molecule is water.
  • a “metabolite” refers to a product produced through metabolism in the body of a specified compound or salt thereof. Such products can result, for example, from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
  • Metabolite products typically are identified by preparing a radiolabelled (e.g., 14 C or 3 H) isotope of a compound of the invention, administering it in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to a human, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples.
  • a detectable dose e.g., greater than about 0.5 mg/kg
  • an animal such as rat, mouse, guinea pig, monkey, or to a human
  • a detectable dose typically about 30 seconds to 30 hours
  • the metabolite structures are determined in conventional fashion, e.g., by MS, LC/MS or NMR analysis.
  • metabolites In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well known to those skilled in the art.
  • the metabolite products so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention.
  • amino-protecting group refers to a derivative of the groups commonly employed to block or protect an amino group while reactions are carried out on other functional groups on the compound.
  • protecting groups include carbamates, amides, alkyl and aryl groups, and imines, as well as many N-heteroatom derivatives which can be removed to regenerate the desired amine group.
  • Particular amino protecting groups are Pmb (p-Methoxybenzyl), Boc (tert-Butyloxycarbonyl), Fmoc (9-Fluorenylmethyloxycarbonyl) and Cbz (Carbobenzyloxy). Further examples of these groups are found in T. W. Greene and P. G. M.
  • protected amino refers to an amino group substituted with one of the above amino-protecting groups.
  • Carboxy-protecting group refers to those groups that are stable to the conditions of subsequent reaction(s) at other positions of the molecule, which may be removed at the appropriate point without disrupting the remainder of the molecule, to give the unprotected carboxy-group.
  • carboxy protecting groups include, ester groups and heterocyclyl groups. Ester derivatives of the carboxylic acid group may be employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound.
  • ester groups include substituted arylalkyl, including substituted benzyls, such as 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4′-dimethoxybenzhydryl, 2,2′,4,4′ -tetramethoxybenzhydryl, alkyl or substituted alkyl esters such as methyl, ethyl, t-butyl allyl or t-amyl, triphenylmethyl (trityl), 4-methoxytrityl, 4,4′-dimethoxytrityl, 4,4′,4′′-trimethoxytrityl, 2-phenylprop-2-yl, thioesters such as t-butyl
  • carboxy-protecting groups are heterocyclyl groups such as 1,3-oxazolinyl. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protecting Groups in Organic Synthesis, 3′ ed., John Wiley & Sons, Inc., 1999.
  • protected carboxy refers to a carboxy group substituted with one of the above carboxy-protecting groups.
  • Hydroxy-protecting group refers to a derivative of the hydroxy group commonly employed to block or protect the hydroxy group while reactions are carried out on other functional groups on the compound.
  • protecting groups include tetrahydropyranyloxy, benzoyl, acetoxy, carbamoyloxy, benzyl, and silylethers (e.g., TBS, TBDPS) groups. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protecting Groups in Organic Synthesis, 3 rd ed., John Wiley & Sons, Inc., 1999.
  • protected hydroxy refers to a hydroxy group substituted with one of the above hydroxy-protecting groups.
  • a “subject,” “individual,” or “patient” is a vertebrate.
  • the vertebrate is a mammal.
  • Mammals include, but are not limited to, farm animals (such as cows), sport animals, pets (such as guinea pigs, cats, dogs, rabbits and horses), primates, mice and rats.
  • a mammal is a human.
  • administration of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, to a patient the patient is typically in need thereof.
  • Janus kinase refers to JAK1, JAK2, JAK3 and TYK2 protein kinases.
  • a Janus kinase may be further defined as one of JAK1, JAK2, JAK3 or TYK2.
  • any one of JAK1, JAK2, JAK3 and TYK2 may be specifically excluded as a Janus kinase.
  • a Janus kinase is JAK1.
  • a Janus kinase is a combination of JAK1 and JAK2.
  • inhibiting includes any measurable decrease or complete inhibition to achieve a desired result. For example, there may be a decrease of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, reduction of activity (e.g., JAK1 activity) compared to normal.
  • activity e.g., JAK1 activity
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1 is selective for inhibition of JAK1 over JAK3 and TYK2.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-249, 2-1 to 2-481 or 3-1 is selective for inhibition of JAK1 over JAK2, JAK3, or TYK2, or any combination of JAK2, JAK3, or TYK2.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1 is selective for inhibition of JAK1 and JAK2 over JAK3 and TYK2.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1 is selective for inhibition of JAK1 over JAK3.
  • the compound is at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, better inhibitor of a particular Janus kinase (e.g., JAK1) activity compared to another particular Janus kinase (e.g., JAK1) activity, or is at least a 2-, 3-, 4-, 5-, 10-, 25-, 50-, 100-, 250-, or 500-fold better inhibitor of a particular Janus kinase (e.g., JAK1) activity compared to another particular Janus kinase (e.g., JAK1) activity.
  • a particular Janus kinase e.g., JAK1 activity
  • e.g., JAK1 activity is at least a 2-, 3-, 4-, 5-, 10-, 25-, 50-, 100-, 250-,
  • “Therapeutically effective amount” means an amount of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, that (i) treats or prevents the particular disease, condition or disorder, or (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, and optionally (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein.
  • the therapeutically effective amount is an amount sufficient to decrease or alleviate the symptoms of an autoimmune or inflammatory disease (e.g., asthma).
  • a therapeutically effective amount is an amount of a chemical entity described herein sufficient to significantly decrease the activity or number of B-cells.
  • the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; or relieve to some extent one or more of the symptoms associated with the cancer.
  • the drug may prevent growth or kill existing cancer cells, it may be cytostatic or cytotoxic.
  • efficacy can, for example, be measured by assessing the time to disease progression (TTP) or determining the response rate (RR).
  • Treatment refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, stabilized (i.e., not worsening) state of disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, prolonging survival as compared to expected survival if not receiving treatment and remission or improved prognosis.
  • compounds of the invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, are used to delay development of a disease or disorder or to slow the progression of a disease or disorder.
  • Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder, (for example, through a genetic mutation) or those in which the condition or disorder is to be prevented.
  • Inflammatory disorder refers to any disease, disorder or syndrome in which an excessive or unregulated inflammatory response leads to excessive inflammatory symptoms, host tissue damage, or loss of tissue function. “Inflammatory disorder” also refers to a pathological state mediated by influx of leukocytes or neutrophil chemotaxis.
  • Inflammation refers to a localized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute, or wall off (sequester) both the injurious agent and the injured tissue. Inflammation is notably associated with influx of leukocytes or neutrophil chemotaxis. Inflammation can result from infection with pathogenic organisms and viruses and from noninfectious means such as trauma or reperfusion following myocardial infarction or stroke, immune responses to foreign antigens, and autoimmune responses.
  • inflammatory disorders amenable to treatment with a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, encompass disorders associated with reactions of the specific defense system as well as with reactions of the nonspecific defense system.
  • Specific defense system refers to the component of the immune system that reacts to the presence of specific antigens. Examples of inflammation resulting from a response of the specific defense system include the classical response to foreign antigens, autoimmune diseases, and delayed type hypersensitivity responses mediated by T-cells. Chronic inflammatory diseases, the rejection of solid transplanted tissue and organs, e.g., kidney and bone marrow transplants, and graft versus host disease (GVHD), are further examples of inflammatory reactions of the specific defense system.
  • GVHD graft versus host disease
  • nonspecific defense system refers to inflammatory disorders that are mediated by leukocytes that are incapable of immunological memory (e.g., granulocytes, and macrophages).
  • inflammation that result, at least in part, from a reaction of the nonspecific defense system include inflammation associated with conditions such as adult (acute) respiratory distress syndrome (ARDS) or multiple organ injury syndromes; reperfusion injury; acute glomerulonephritis; reactive arthritis; dermatoses with acute inflammatory components; acute purulent meningitis or other central nervous system inflammatory disorders such as stroke; thermal injury; inflammatory bowel disease; granulocyte transfusion associated syndromes; and cytokine-induced toxicity.
  • ARDS adult (acute) respiratory distress syndrome
  • multiple organ injury syndromes reperfusion injury
  • acute glomerulonephritis reactive arthritis
  • dermatoses with acute inflammatory components acute purulent meningitis or other central nervous system inflammatory disorders such as stroke; thermal injury; inflammatory bowel disease; granulocyte transfusion associated syndromes; and
  • Autoimmune disease refers to any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the body's own constituents.
  • Non-limiting examples of autoimmune diseases include rheumatoid arthritis, lupus and multiple sclerosis.
  • Allergic disease refers to any symptoms, tissue damage, or loss of tissue function resulting from allergy.
  • Arthritic disease refers to any disease that is characterized by inflammatory lesions of the joints attributable to a variety of etiologies.
  • Dermatis refers to any of a large family of diseases of the skin that are characterized by inflammation of the skin attributable to a variety of etiologies.
  • Transplant rejection refers to any immune reaction directed against grafted tissue, such as organs or cells (e.g., bone marrow), characterized by a loss of function of the grafted and surrounding tissues, pain, swelling, leukocytosis, and thrombocytopenia.
  • the therapeutic methods of the present invention include methods for the treatment of disorders associated with inflammatory cell activation.
  • “Inflammatory cell activation” refers to the induction by a stimulus (including, but not limited to, cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines), or cell surface expression of new or increased numbers of mediators (including, but not limited to, major histocompatability antigens or cell adhesion molecules) in inflammatory cells (including but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes (i.e., polymorphonuclear leukocytes such as neutrophils, basophils, and eosinophils), mast cells, dendritic cells, Langerhans cells, and endothelial cells). It will be appreciated by persons skilled in the art that the activation of one or a combination of these phenotypes in these cells can contribute to the initiation
  • inflammatory disorders which can be treated according to the methods of this invention include, but are not limited to, asthma, rhinitis (e.g., allergic rhinitis), allergic airway syndrome, atopic dermatitis, bronchitis, rheumatoid arthritis, psoriasis, contact dermatitis, chronic obstructive pulmonary disease and delayed hypersensitivity reactions.
  • rhinitis e.g., allergic rhinitis
  • allergic airway syndrome e.g., atopic dermatitis, bronchitis, rheumatoid arthritis, psoriasis, contact dermatitis, chronic obstructive pulmonary disease and delayed hypersensitivity reactions.
  • cancer and “cancerous”, “neoplasm”, and “tumor” and related terms refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • a “tumor” comprises one or more cancerous cells. Examples of cancer include carcinoma, blastoma, sarcoma, seminoma, glioblastoma, melanoma, leukemia, and myeloid or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer) and lung cancer including small-cell lung cancer, non-small cell lung cancer (“NSCLC”), adenocarcinoma of the lung and squamous carcinoma of the lung.
  • NSCLC non-small cell lung cancer
  • cancers include skin, keratoacanthoma, follicular carcinoma, hairy cell leukemia, buccal cavity, pharynx (oral), lip, tongue, mouth, salivary gland, esophageal, larynx, hepatocellular, gastric, stomach, gastrointestinal, small intestine, large intestine, pancreatic, cervical, ovarian, liver, bladder, hepatoma, breast, colon, rectal, colorectal, genitourinary, biliary passage, thyroid, papillary, hepatic, endometrial, uterine, salivary gland, kidney or renal, prostate, testis, vulval, peritoneum, anal, penile, bone, multiple myeloma, B-cell lymphoma, central nervous system, brain, head and neck, Hodgkin's, and associated metastases.
  • neoplastic disorders include myeloproliferative disorders, such as polycythemia vera, essential thrombocytosis, myelofibrosis, such as primary myelofibrosis, and chronic myelogenous leukemia (CML).
  • myeloproliferative disorders such as polycythemia vera, essential thrombocytosis, myelofibrosis, such as primary myelofibrosis, and chronic myelogenous leukemia (CML).
  • myeloproliferative disorders such as polycythemia vera, essential thrombocytosis, myelofibrosis, such as primary myelofibrosis, and chronic myelogenous leukemia (CML).
  • CML chronic myelogenous leukemia
  • chemotherapeutic agent is an agent useful in the treatment of a given disorder, for example, cancer or inflammatory disorders.
  • chemotherapeutic agents are well-known in the art and include examples such as those disclosed in U.S. Publ. Appl. No. 2010/0048557, incorporated herein by reference. Additionally, chemotherapeutic agents include pharmaceutically acceptable salts, acids or derivatives of any of chemotherapeutic agents, as well as combinations of two or more of them.
  • Package insert is used to refer to instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications or warnings concerning the use of such therapeutic products.
  • compound(s) of this invention include compounds of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and stereoisomers (including atropisomers), geometric isomers, tautomers, solvates, metabolites, isotopes, salts (e.g., pharmaceutically acceptable salts), and prodrugs thereof. In some embodiments, solvates, metabolites, isotopes or prodrugs are excluded, or any combination thereof.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • Exemplary isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
  • Isotopically-labeled compounds can be useful in compound or substrate tissue distribution assays.
  • Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes can be useful for their ease of preparation and detectability.
  • substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements).
  • Positron emitting isotopes such as 15 O, 13 N, 11 C, and 18 F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.
  • Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or in the Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • any limitation discussed with respect to one embodiment of the invention may apply to any other embodiment of the invention.
  • any compound or composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or to utilize any compound or composition of the invention.
  • a or “an” means one or more, unless clearly indicated otherwise.
  • another means at least a second or more.
  • One aspect of the invention provides compounds of Formula 0:
  • Ar 1 is phenylene or 3-11 membered heteroarylene (e.g., 5-11, e.g., 5-6, membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S), wherein Ar 1 is optionally substituted;
  • X is —O— or —N(R 1b )—(CR x1 R y1 ) p —, wherein R x1 and R y1 are each independently hydrogen or C 1 -C 6 alkyl and p is 0 to 6, and wherein the —N(R 1b )— portion of —N(R 1b )—(CR x1 R y1 ) p — is bound to the carbonyl carbon of Formula 0;
  • R 1a is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, phenyl, or 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) and R 1a is optionally substituted by R 9 ;
  • R 1b is hydrogen, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl, and wherein one or more alkylene units of said alkyl group is optionally substituted by —O— and wherein any alkyl or cycloalkyl group is optionally substituted by OH, or
  • R 2 is a 3-11 membered heterocyclyl containing at least 1 nitrogen, selected from groups (a)-(e) and (h)-(j), or a C 5 -C 8 cycloalkenyl ring (f), or a —O—(CR x R y ) q —Ar 2 group (g) where R x and R y are independently hydrogen or C 1 -C 6 alkyl, q is 0 to 3 and Ar 2 is optionally substituted C 6 -C 10 aryl or optionally substituted (e.g., by oxo or (C 1 -C 6 alkyl)phenyl) 5-11 membered heteroaryl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 5-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S):
  • R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, CH 3 , CH 2 CH 3 , OCH 3 , CF 3 , F and Cl;
  • R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C 1 -C 6 alkyl, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)NR a C(O)(C 1 -C 6 alkyl), (C 0 -C 6 alkylene)NR a C(O)(phenyl), (C 0 -C 6 alkylene)C(O)R 8a , (C 0 -C 6 alkylene
  • R 6 and R 7 together form an optionally substituted (e.g., C 1 -C 6 alkyl, CN or oxo) phenyl or optionally substituted (e.g., C 1 -C 6 alkyl, CN or oxo) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R 8 is H, C 1 -C 6 alkyl, (C 0 -C 6 alkylene)phenyl, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), C(O)NR a R b , SO 2 NR a R b , (C 1 -C 6 alkylene)C(O)OR 8a or C(O)R 8a , wherein said alkyl, alkylene, heterocyclyl and phenyl are each independently optionally substituted (e.g., C 1 -C 6 alkyl, C 1 -C 6 alkoxy or CN);
  • R 8a is H, NR a R b , C 1 -C 6 alkyl, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)phenyl, or (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted (e.g., by halogen, OH, CN, NR a R b , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or oxo);
  • R 8aa is H, C 1 -C 6 alkyl optionally substituted by OH, or C(O)NR a R b ; or
  • R 8 and R 8aa together form an optionally substituted (e.g., by oxo) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • 3-11 membered heterocyclyl e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S
  • R 9 is OH, halogen, C 1 -C 6 alkyl, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)phenyl, (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)NR a R b , or C(O)(C 1 -C 6 alkyl), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted (e.g., by OH, CN,
  • R a and R b are selected from the group consisting of hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or CN, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, or (C 0 -C 6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively R a and R b may be joined together with the nitrogen atom to which they are attached to form an optionally substituted (e.g., by CN or C 1 -C 6 alkyl) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • n 1 , m 2 , m 3 and m 4 are each independently 0, 1 or 2;
  • n 0 or 1.
  • a compound of Formula 0 is further defined as a compound of Formula I:
  • Ar 1 is phenylene or 3-11 membered heteroarylene (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S), wherein Ar 1 is optionally substituted;
  • X is —O— or —N(R 1b )—(CR x1 R y1 ) p —, wherein R x1 and R y1 are each independently hydrogen or C 1 -C 6 alkyl and p is 0 to 6, and wherein the —N(R 1b )— portion of —N(R 1b )—(CR x1 R y1 ) p — is bound to the carbonyl carbon of Formula I, as in:
  • R 1a is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, phenyl, or 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) and R 1a is optionally substituted by R 9 ;
  • R 1b is hydrogen, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl, and wherein one or more alkylene units of said alkyl group is optionally substituted by —O— and wherein any alkyl or cycloalkyl group is optionally substituted by OH, or
  • R 2 is a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl or 4-11 membered heterocycloalkyl) containing at least 1 nitrogen, selected from groups (a)-(e), or a C 5 -C 8 cycloalkenyl ring (f), or a —O—(CR x R y ) q —Ar 2 group (g) where R x and R y are independently hydrogen or C 1 -C 6 alkyl, q is 0 to 3 and Ar 2 is optionally substituted C 6 -C 10 aryl or optionally substituted 5-11 membered heteroaryl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S:
  • R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, CH 3 , CH 2 CH 3 , OCH 3 , CF 3 , F and Cl; for example, R 3 -R 5 may each be hydrogen;
  • R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C 1 -C 6 alkyl, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)NR a C(O)(C 1 -C 6 alkyl), (C 0 -C 6 alkylene)C(O)R 8a , (C 0 -C 6 alkylene)C(O)OR 8a , C 1 -C 6 alkoxy, —O—
  • R 6 and R 7 together form an optionally substituted phenyl or optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R 8 is C 1 -C 6 alkyl, (C 0 -C 6 alkylene)phenyl, C(O)N a R b , SO 2 NR a R b , C(O)OR 8a or C(O)R 8a , wherein said alkyl, alkylene and phenyl are each independently optionally substituted;
  • R 8a is C 1 -C 6 alkyl, (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)phenyl, or (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • R 8aa is H
  • R 8 and R 8aa together form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • 3-11 membered heterocyclyl e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S
  • R 9 is OH, halogen, C 1 -C 6 alkyl, (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)phenyl, (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)NR a R b , or C(O)(C 1 -C 6 alkyl), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • R a and R b are independently at each occurrence selected from the group consisting of hydrogen, C 1 -C 6 alkyl, (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl, or (C 0 -C 6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively R a and R b may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • 3-11 membered heterocyclyl e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1
  • n 1 , m 2 , m 3 and m 4 are each independently 0, 1 or 2;
  • n 0 or 1.
  • a compound of Formula 0 is further defined as a compound of Formula Ia:
  • Ar 1 , X, R 1a , R 3 -R 7 , m 1 , m 2 and n are as defined herein.
  • n 1 is 1 and m 2 is 1, or m 1 is 2 and m 2 is 1.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib or If, R 6 and R 7 are attached to the ring at the same carbon atom.
  • R 6 is C 1 -C 6 alkyl or C 1 -C 6 -alkoxy
  • R 7 is optionally substituted phenyl, such as phenyl substituted by halogen, CN, C 1 -C 6 alkyl or C 1 -C 6 alkoxy.
  • R 6 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or optionally substituted phenyl, such as phenyl substituted by halogen, CN, C 1 -C 6 alkyl or C 1 -C 6 alkoxy
  • R 7 is OH, (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)CN or —O—(C 0 -C 6 alkyl)CN.
  • R 6 is hydrogen and R 7 is selected from (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)CN, C 1 -C 6 -alkoxy, —O—(C 3 -C 6 cycloalkyl), —O—(C 0 -C 6 alkylene)C(O)NR a R b , and —O—(C 1 -C 6 alkylene)CN.
  • R 6 and R 7 together form a 3-11 membered heterocycloalkyl (such as a heterocycloalkyl containing at least one nitrogen) optionally substituted by oxo.
  • R 7a is selected from hydrogen, halogen, OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl and CN.
  • a compound of Formula 0 is further defined as a compound of Formula Ib:
  • Ar 1 , X, R 1a , R 3 -R 7 , m 1 , m 2 and n are as defined herein.
  • m 1 is 1 and m 2 is 2, or m 1 is 2 and m 2 is 1, or m 1 is 1 and m 2 is 1.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib or If, R 6 is H and R 7 and is substituted phenyl.
  • a compound of the present invention such as a compound of Formula 0, I or Ib, the moiety shown below,
  • R 7a is selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and CN.
  • a compound of Formula 0 is further defined as a compound of Formula Ic:
  • Ar 1 , X, R 1a , R 3 -R 5 , R 8 , m 3 , m 4 and n are as defined herein.
  • m 3 is 1 and m 4 is 1, or m 3 is 1 and m 4 is 2, or m 3 is 1 and m 4 is 0.
  • a compound of the present invention such as a compound of Formula 0, I, Ic, Id or Ie, the following moiety, shown below,
  • a compound of Formula 0 is further defined as a compound of Formula Id:
  • Ar 1 , R 1a , R 1b , R 3 -R 5 , R 8 , m 3 , m 4 and n are as defined herein.
  • m 3 is 1 and m 4 is 1, m 3 is 1 and m 4 is 1, or m 3 is 1 and m 4 is 2.
  • R 8 is substituted phenyl, such as mono- or disubstituted phenyl, C(O)NR a R b or C(O)R 8a .
  • a compound of Formula 0 is further defined as a compound of Formula Ie:
  • Ar 1 , R 1a , R 1b , R 3 -R 6 , R 8 , m 3 , m 4 and n are as defined herein.
  • m 3 is 0 and m 4 is 1 or m 3 is 1 and m 4 is 1.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ie or If, R 6 is hydrogen.
  • R 8 is C(O)NR a R b .
  • a compound of Formula 1 is further defined as a compound of Formula If:
  • Ar 1 , R 1a , R 1b , R 3 -R 7 , m 3 , m 4 and n are as defined herein.
  • a compound of the present invention such as a compound of Formula 0, I or If, m 3 is 1 and m 4 is 1.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, or If, R 7 is OH or C 1 -C 6 -alkoxy.
  • compounds of the present invention such as a compound of Formula 0, I, Ia, Ib, or If, one or both of R 6 and R 7 is located at the para position of the ring. In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R 6 and R 7 are attached to different ring atoms. In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R 6 and R 7 are both attached to the same ring atom.
  • a compound of Formula 0 is further defined as a compound of Formula Ig:
  • R 7a is selected from hydrogen, OH, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl and CN, and q is either 0 or 1, and when q is 1, then R x and R y are hydrogen.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar 1 is unsubstituted phenylene or unsubstituted 3-11 membered heteroarylene.
  • Ar 1 is optionally substituted phenylene or optionally substituted pyrazolylene.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar 1 is unsubstituted phenylene or unsubstituted pyrazolylene. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar 1 is unsubstituted phenylene and n is 0.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar 1 is unsubstituted pyrazolylene and n is 1.
  • Ar 1 such as phenyl, is not substituted by halogen, methyl, methoxy, ethoxy, isopropoxy, OH, CF 3 , or —OCH 2 C(O)N(CH 3 ) 2 .
  • Ar 1 is not unsubstituted or substituted pyridyl.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib or Ic, the moiety
  • —X—R 1a is C 1 -C 6 alkoxy or —O— 3-11 membered heterocycloalkyl (such as heterocycloalkyl containing at least one nitrogen).
  • —X—R 1a may be —OCH 3 , —OC 2 H 5 , or
  • R 8a is C 1 -C 6 alkyl.
  • —X-R 1a is —N(R 1b )—(CR x1 R y1 ) p —R 1a .
  • R 1b is C 1 -C 6 alkyl optionally substituted by C 1 -C 6 alkoxy
  • p is 0-3
  • R x1 and R y1 are each independently hydrogen or C 1 -C 6 alkyl
  • R 1a is C 1 -C 6 alkyl
  • R 9 is NR a R b .
  • R 1b is C 1 -C 6 alkyl optionally substituted by C 1 -C 6 alkoxy
  • p is 0-3
  • R x1 and R y1 are each independently hydrogen or C 1 -C 6 alkyl
  • R 1a is 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by R 9 .
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, or Ic
  • p is 0 and R 1a and R 1b are joined to form a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by R 9 .
  • —X—R 1a is —N(R 1b )—(CR x1 R y1 ) p —R 1a and is selected from
  • —X—R 1a is —N(R 1b )—(CR x1 R y1 ) p —R 1a and is selected from
  • R 9 is optionally substituted C 1 -C 6 alkyl or optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S).
  • the optional substituents of optionally substituted C 1 -C 6 alkyl of R 9 or optionally substituted 3-11 membered heterocyclyl of R 9 are selected from OH; CN; NR a R b ; C 1 -C 6 alkyl; C 3 -C 8 cycloalkyl; C 1 -C 6 alkoxy; phenyl; 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by C 1 -C 6 alkyl or NR a R b ; C(O)C 1 -C 6 alkyl; and C(O)— 3-11 membered heterocycl
  • the group —X—R 1a is a group selected from:
  • R 1b and R 1c are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl and p1 and p2 are independently 0, 1 or 2;
  • R 1b is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl
  • p is 0-6, such as 1-3
  • R x and R y are independently hydrogen or C 1 -C 6 alkyl
  • Het 1 is a 5-, 6- or 7-membered heterocycloalkyl ring or a 6-membered heteroaryl ring.
  • Exemplary structures include
  • R 1d and R 1e are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, or R 1d and R 1e are joined in a ring optionally containing a further heteroatom selected from O, N and S, such as one further N or one further O, and p1, p2 and p3 are independently 0, 1 or 2.
  • An exemplary group is
  • Het 2 is a 3-11 (e.g., 4-7) membered heterocycloalkyl ring or 3-11 (e.g., 5-6) membered heteroaryl ring.
  • Exemplary structures include
  • Het 2 is a 3-11 (e.g., 4-7) membered heterocycloalkyl or 3-11 (e.g., 5-6) membered heteroaryl ring;
  • R 1c is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; or
  • R 1d and R 1e are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, or R 1d and R 1e are joined in a ring optionally containing a further heteroatom selected from O, N and S, such as one further N or one further O;
  • R 1b is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl
  • a spirocyclic group comprising two 4-, 5- or 6- membered rings optionally containing further 1-4 heteroatoms, selected from O, N and S, such as N or O, such as
  • R 1b is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl
  • R 1c is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl.
  • R 1b , R 1c and R 1d are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; p is 0-6, such as 1-3; R x and R y are independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl; or
  • R 1c is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl.
  • An exemplary group is
  • p1 and p2 are independently 0, 1 or 2 and one of X 1 and X 2 is nitrogen and the other is CH;
  • R 1d and R 1c are independently hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl or R 1d and R 1e are joined in a ring optionally containing a further 1-3 heteroatoms, such as O, N or S, such as a further N atom or a further O atom;
  • R 1c is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; or
  • p4 is 0 or 1.
  • the group —X—R 1a is a group selected from:
  • R 1c is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl and p1 and p2 are independently 0, 1 or 2.
  • An exemplary group is
  • R Ia is selected from the following:
  • R Ia is selected from the moieities shown in Table I or Table II, or stereoisomers thereof In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R Ia is not hydrogen.
  • R 2 is selected from the following:
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 1b is hydrogen or CH 3 .
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, p is 0, 1, 2 or 3. In some embodiments of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, p is 0, 1 or 2.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, CH 3 , CH 2 CH 3 , OCH 3 , CF 3 , F and Cl.
  • I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 3 , and R 5 are each independently selected from the group consisting of hydrogen, CH 3 , CH 2 CH 3 , CF 3 , F and Cl.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 3 is hydrogen.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 4 is hydrogen.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 5 is hydrogen.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R 3 , R 4 and R 5 are each independently hydrogen. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, none of R 3 , R 4 and R 5 are OCH 3 .
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, X is not O.
  • Another aspect of the invention provides compounds of Formula II:
  • Q 1 is a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl or 4-11 membered heterocycloalkyl) containing at least 1 nitrogen, selected from groups (a)-(e), or a C 5 -C 8 cycloalkenyl ring (f), or a —O—(CR x R y ) q —Ar 2 group (g) where R x and R y are independently hydrogen or C 1 -C 6 alkyl, q is 0 to 3 and Ar 2 is optionally substituted C 6 -C 10 aryl or optionally substituted 5-11 membered heteroaryl:
  • R 6 and R 7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C 1 -C 6 alkyl, (C 0 -C 6 alkylene)C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C 0 -C 6 alkylene)C(O)NR a R b , (C 0 -C 6 alkylene)NR a C(O)(C 1 -C 6 alkyl), (C 0 -C 6 alkylene)C(O)R 8a , (C 0 -C 6 alkylene)C(O)OR 8a , C 1 -C 6 alkoxy, —O—
  • R 6 and R 7 together form an optionally substituted phenyl or optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R 8 is C 1 -C 6 alkyl, (C 0 -C 6 alkylene)phenyl, C(O)NR a R b , SO 2 NR a R b , C(O)OR 8a or C(O)R 8a , wherein said alkyl, alkylene and phenyl are each independently optionally substituted;
  • R 8a is C 1 -C 6 alkyl, (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)phenyl, or (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • R 8aa is H
  • R 8 and R 8aa together form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • 3-11 membered heterocyclyl e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S
  • R 9 is OH, halogen, C 1 -C 6 alkyl, (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl, (C 0 -C 6 alkylene)phenyl, (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C 0 -C 6 alkylene) C(O)NR a R b , (C 0 -C 6 alkylene) NR a R b , or C(O)(C 1 -C 6 alkyl), wherein said alkyl, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • R a and R b are independently at each occurrence hydrogen, C 1 -C 6 alkyl, (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl, or (C 0 -C 6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively R a and R b may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • 3-11 membered heterocyclyl e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from
  • n 1 , m 2 , m 3 and m 4 are each independently 0, 1 or 2;
  • Q 2 is C 3 -C 8 cycloalkyl optionally substituted with C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, OH, SH, NH 2 , CN or N 3 .
  • Q 1 is ring (a). In certain embodiments, Q 1 is ring (b). In certain embodiments, Q 1 is ring (c). In certain embodiments, Q 1 is ring (d). In certain embodiments, Q 1 is ring (e). In certain embodiments, Q 1 is ring (f). In certain embodiments, Q 1 is ring (g). In certain embodiments, Q 1 is a C 3 -C 8 cyclopropyl ring optionally substituted with one or more substituents selected from C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, OH, CN, OCF 3 and N 3 .
  • Q 2 is a cyclopropyl group. In certain embodiments, Q 2 is a cyclobutanyl group. In certain embodiments, Q 2 is a cyclopentyl group. In certain embodiments, Q 2 is a cyclohexyl group. In certain embodiments, Q 2 is a cycloheptyl group. In certain embodiments, Q 2 is a cyclooctyl group. In certain embodiments, Q 1 is ring (a) and Q 2 is an unsubstituted C 3 -C 8 cycloalkyl group. In certain embodiments, Q 1 is ring (a) and Q 2 is an unsubstituted cyclopropyl group.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, or If, R 6 and R 7 are attached to the ring at the same carbon atom.
  • R 6 and R 7 are independently selected from the group consisting of hydrogen; halogen; OH; CN; phenyl; phenyl substituted by halogen, CN, C 1 -C 6 alkyl or C 1 -C 6 alkoxy; C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by OH or CN; (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl; (C 0 -C 6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membere
  • R 6 is C 1 -C 6 alkyl or C 1 -C 6 -alkoxy
  • R 7 is optionally substituted phenyl, such as phenyl substituted by halogen, CN, C 1 -C 6 alkyl or C 1 -C 6 alkoxy.
  • R 6 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or optionally substituted phenyl, such as phenyl substituted by halogen, CN, C 1 -C 6 alkyl or C 1 -C 6 alkoxy
  • R 7 is OH, (C 0 -C 6 alkylene) C(O)NR a R b , (C 0 -C 6 alkylene) CN or —O—(C 0 -C 6 alkyl)CN.
  • R 6 is hydrogen and R 7 is selected from (C 0 -C 6 alkylene) C(O)NR a R b , (C 0 -C 6 alkylene)CN, C 1 -C 6 -alkoxy, —O—(C 3 -C 6 cycloalkyl), —O—(C 0 -C 6 alkylene)C(O)NR a R b , and —O—(C 1 -C 6 alkylene)CN.
  • R 6 and R 7 together form a 3-11 membered heterocycloalkyl, such as containing 1-4 heteroatoms selected from O, N and S, optionally substituted by oxo.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, or If, optional substituents of R 6 and R 7 , or R 6 taken together with R 7 , are selected from the group consisting of halogen, CN, OH, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 alkoxy-C 1 -C 6 alkyl-C 1 -C 6 alkoxy.
  • R 8 is selected from the R 8 examples of Table II.
  • R 8 is selected from the group consisting of C 1 -C 6 alkyl optionally substituted with halogen, CN, C 1 -C 6 alkoxy, or OH; (C 0 -C 6 alkylene)phenyl, such as (C 0 -C 1 alkylene)phenyl, where the alkylene is unsubstituted, where the phenyl may be optionally substituted with halogen, CN, oxo or OH; C(O)NR a R b , wherein R a and R b are each independently hydrogen or C 1 -C 6 alkyl optionally substituted by halogen, OH or CN, or R a and R b together form
  • optional substituents of R 8 are selected from the group consisting of halogen, oxo, CN, OH, C 1 -C 6 alkyl, NH 2 , NH(C 1 -C 6 alkyl), and N(C 1 -C 6 alkyl) 2 .
  • a compound of the present invention such as a compound of Formula 0, I, Ic, Id or Ie, R 8 and R 8aa together form a 3-11 membered heterocyclyl (e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S) optionally substituted by halogen, oxo, CN, OH, C 1 -C 6 alkyl or C 1 -C 6 alkoxy.
  • a 3-11 membered heterocyclyl e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, R 6 , R 7 and R 8 are each independently selected from C(O)NR a R b , C(O)R 8a , and C(O)OR 8a .
  • R a R b are independently selected from hydrogen, C 1 -C 6 alkyl, or (C 1 -C 6 alkylene)phenyl, or R a and R b are taken together to form a 3-11 membered heterocyclyl (e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S) optionally substituted by halogen, C 1 -C 6 alkyl, oxo, OH, CN, NH 2 , NHCH 3 , or N(CH 3 ) 2 .
  • a 3-11 membered heterocyclyl e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S
  • R 8a is selected from C 1 -C 6 alkyl optionally substituted by halogen, CN, OH, NH 2 , NHCH 3 , or N(CH 3 ) 2 ; C 3 -C 8 cycloalkyl optionally substituted by C 1 -C 6 alkyl or C 1 -C 6 alkoxy; 3-11 membered heterocyclyl (e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S) optionally substituted by halogen, CN, OH, oxo, NH 2 , NHCH 3 , N(CH 3 ) 2 , or C 1 -C 6 alkyl.
  • halogen CN, OH, NH 2 , NHCH 3 , N(CH 3 ) 2
  • C 1 -C 6 alkyl optionally substituted by halogen,
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If or Ig, R 9 , independently at each occurrence, is OH; halogen; C 1 -C 6 alkyl optionally substituted with halogen, OH, CN, C 1 -C 6 alkoxy, 5-6 membered heteroaryl (e.g., containing 1-4 heteroatoms selected from O, N and S), 3-11 membered heterocycloalkyl (e.g., containing 1-4 heteroatoms selected from O, N and S), NH 2 , NHCH 3 , or N(CH 3 ) 2 ; NH 2 , NHCH 3 , or N(CH 3 ) 2 ; (C 0 -C 6 alkylene) C 3 -C 8 cycloalkyl wherein the cycloalkyl is optionally substituted by halogen, C 1 -C 6 alkyl, CN,
  • an optional substituent of R 9 is selected from the group consisting of halogen, CN, OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or NR a R b , wherein R a and R b are independently selected from the group consisting of NH 2 , NHCH 3 , and N(CH 3 ) 2 , or R a and R b may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl, e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S, and wherein said optional substituents of said 3-11 membered heterocyclyl group are selected from the group consisting of halogen, CN, OH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or NR a R
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, R a and R b , independently at each occurrence, are selected from the group consisting of NH 2 , NHCH 3 , and N(CH 3 ) 2 , or R a and R b may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl, e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S, and wherein said optional substituents of said 3-11 membered heterocyclyl group are selected from CN, halogen, OH, C(O)(C 1 -C 6 alkyl) (e.g., C(O)CH 3 ), 5-6 membered heteroaryl
  • n is 0. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0. In some embodiments of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0 and p is 0. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0 and p is 0-6.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0 and p is 1-6. In some embodiments, of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 1 and p is 0. In some embodiments of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 1 and p is 0-6. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 1 and p is 1-6.
  • a compound of the present invention such as a compound of Formula 0, I or II
  • Ar 2 is unsubstituted phenyl.
  • Ar 2 is unsubstituted phenyl
  • q is 0 or 1
  • R x and R y are each independently hydrogen.
  • a compound of Formula 0 or I excludes a compound of Formula Ia.
  • a compound of Formula 0 or I excludes a compound of Formula Ib.
  • a compound of Formula 0 or I excludes a compound of Formula Ic.
  • a compound of Formula 0 or I excludes a compound of Formula Id. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ie. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula If. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ig. In some embodiments, a compound of Formula 0 or I excludes two or more compounds of Formula Ia, Ib, Ic, Id, le, If or Ig.
  • any substituent indicated as “optionally substituted”, such as portions of R 2 , R 6 , R 7 , R 6 together with R 7 , R 8 , R 8 a, R 8 together with R 8aa , or R 9 may be optionally substituted by, e.g., halogen; oxo; CN; NO, N 3 ; —OR; perfluoro-C 1 -C 4 alkoxy; unsubstituted C 3 -C 7 cycloalkyl; C 3 -C 7 cycloalkyl substituted by halogen, CN, OH, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 6 -C 10 aryl (e.g., halogen; oxo; CN; NO, N 3 ; —OR; perfluoro-C 1 -C 4 alkoxy; un
  • R′, R′′ and R′′′ each independently refer to groups including, for example, hydrogen; unsubstituted C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, CN, OH, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 1 -C 6 heteroalkyl; C 1 -C 6 heteroalkyl substituted by halogen, CN, OH, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′; unsubstituted C 6 -C 10 aryl; C 6 -C 10 aryl substituted by halogen, CN, OH, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy
  • R′ and R′′ When R′ and R′′ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S and wherein the ring is optionally substituted with halogen, CN, OH, unsubstituted C 1 -C 6 alkyl, unsubstituted C 1 -C 6 alkoxy, oxo or NR′R′′.
  • Examples 1-1 to 1-303, 2-1 to 2-486 and 3-1 are also provided. See Table A. Although specific salts may be shown in Table A, it is to be understood that other salts are contemplated, as described herein. Should there be any discrepancy between an Example's structure in Table A and an Example of Table I or II, Table A's structure prevails.
  • Compounds of the invention may contain one or more asymmetric carbon atoms. Accordingly, the compounds may exist as diastereomers, enantiomers or mixtures thereof.
  • the syntheses of the compounds may employ racemates, diastereomers or enantiomers as starting materials or as intermediates. Mixtures of particular diastereomeric compounds may be separated, or enriched in one or more particular diastereomers, by chromatographic or crystallization methods. Similarly, enantiomeric mixtures may be separated, or enantiomerically enriched, using the same techniques or others known in the art.
  • Each of the asymmetric carbon or nitrogen atoms may be in the R or S configuration and both of these configurations are within the scope of the invention.
  • stereochemistry of any particular chiral atom is not specified, then all stereoisomers are contemplated and included as the compounds of the invention. Where stereochemistry is specified by a solid wedge or dashed line representing a particular configuration, then that stereoisomer is so specified and defined. Unless otherwise specified, if solid wedges or dashed lines are used, relative stereochemistry is intended.
  • Another aspect includes prodrugs of the compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, including known amino-protecting and carboxy-protecting groups which are released, for example hydrolyzed, to yield the compound of the present invention under physiologic conditions.
  • prodrugs of the compounds of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, including known amino-protecting and carboxy-protecting groups which are released, for example hydrolyzed, to yield the compound of the present invention under physiologic conditions.
  • prodrug refers to a precursor or derivative form of a pharmaceutically active substance that is less efficacious to the patient compared to the parent drug and is capable of being enzymatically or hydrolytically activated or converted into the more active parent form. See, e.g., Wilman, “Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Harbor (1986) and Stella et al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery,” Directed Drug Delivery, Borchardt et al., (ed.), pp. 247-267, Humana Press (1985).
  • Prodrugs include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, ⁇ -lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, and 5-fluorocytosine and 5-fluorouridine prodrugs.
  • a particular class of prodrugs are compounds in which a nitrogen atom in an amino, amidino, aminoalkyleneamino, iminoalkyleneamino or guanidino group is substituted with a hydroxy group, an alkylcarbonyl (—CO—R) group, an alkoxycarbonyl (—CO—OR), or an acyloxyalkyl-alkoxycarbonyl (—CO—O—R—O—CO—R) group where R is a monovalent or divalent group, for example alkyl, alkylene or aryl, or a group having the Formula —C(O)—O—CP1P2-haloalkyl, where P1 and P2 are the same or different and are hydrogen, alkyl, alkoxy, cyano, halogen, alkyl or aryl.
  • the nitrogen atom is one of the nitrogen atoms of the amidino group of the compounds of Formula 0, Formula I or Formula II.
  • Prodrugs may be prepared by reacting a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, with an activated group, such as acyl groups, to bond, for example, a nitrogen atom in the compound to the exemplary carbonyl of the activated acyl group.
  • an activated group such as acyl groups
  • activated carbonyl compounds are those containing a leaving group bonded to the carbonyl group, and include, for example, acyl halides, acyl amines, acyl pyridinium salts, acyl alkoxides, acyl phenoxides such as p-nitrophenoxy acyl, dinitrophenoxy acyl, fluorophenoxy acyl, and difluorophenoxy acyl.
  • the reactions are generally carried out in inert solvents at reduced temperatures such as ⁇ 78 to about 50° C.
  • the reactions may also be carried out in the presence of an inorganic base, for example potassium carbonate or sodium bicarbonate, or an organic base such as an amine, including pyridine, trimethylamine, triethylamine, triethanolamine, or the like.
  • a free carboxyl group of a compound of the invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or suitable free carboxyl-containing compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, can be derivatized as an amide or alkyl ester.
  • compounds of the present invention comprising free hydroxy groups can be derivatized as prodrugs by converting the hydroxy group into a group such as, but not limited to, a phosphate ester, hemisuccinate, dimethylaminoacetate, or phosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D. et al., (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Advanced Drug Delivery Reviews, 19:115.
  • Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups.
  • More specific examples include replacement of the hydrogen atom of the alcohol group with a group such as (C 1 -C 6 )alkanoyloxymethyl, 1-((C 1 -C 6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1 -C 6 )alkanoyloxy)ethyl, (C 1 -C 6 )alkoxycarbonyloxymethyl, N-(C 1 -C 6 )alkoxycarbonylaminomethyl, succinoyl, (C 1 -C 6 )alkanoyl, alpha-amino(C 1 -C 4 )alkanoyl, arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl, where each alpha-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH) 2 , —P(O)(O(C 1 -C 6 )alky
  • leaving group refers to a portion of a first reactant in a chemical reaction that is displaced from the first reactant in the chemical reaction.
  • Examples of leaving groups include, but are not limited to, halogen atoms, alkoxy and sulfonyloxy groups.
  • Example sulfonyloxy groups include, but are not limited to, alkylsulfonyloxy groups (for example methyl sulfonyloxy (mesylate group) and trifluoromethylsulfonyloxy (triflate group)) and arylsulfonyloxy groups (for example p-toluenesulfonyloxy (tosylate group) and p-nitrosulfonyloxy (nosylate group)).
  • Compounds of the present invention may be synthesized by synthetic routes described herein.
  • processes well-known in the chemical arts can be used, in addition to, or in light of, the description contained herein.
  • the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, N.Y. (1967-1999 ed.), Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)), or Comprehensive Heterocyclic Chemistry, Editors Katrizky and Rees, Pergamon Press, 1984.
  • Compounds may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, or 10 to 100 compounds. Libraries of compounds may be prepared by a combinatorial ‘split and mix’ approach or by multiple parallel syntheses using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.
  • a compound library comprising at least 2 compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, le, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1.
  • reaction Schemes 1-24 depicted below provide routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used. Although some specific starting materials and reagents are depicted in the Schemes and discussed below, other starting materials and reagents can be substituted to provide a variety of derivatives or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
  • Suitable amino-protecting groups include acetyl, trifluoroacetyl, benzyl, phenylsulfonyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc).
  • BOC t-butoxycarbonyl
  • CBz benzyloxycarbonyl
  • Fmoc 9-fluorenylmethyleneoxycarbonyl
  • Scheme 1 provides details of the reactions available for the preparation of compounds of the invention wherein R 2 of Formula 0 is of type (a).
  • Compound (1-3) can be prepared from 3-bromo-2-aminopyridine (1-1) according to WO2009/155551, incorporated herein by reference, and may undergo a Buchwald-Hartwig cross-coupling reaction with an aryl halide, an example of which would be ethyl 4-iodobenzoate, using a catalyst such as tris(dibenzylideneacetone)dipalladium (0) (Pd 2 (dba) 3 ) or palladium (II) acetate (Pd(OAc) 2 ), a phosphine ligand such as 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) and a base such as caesium carbonate.
  • a catalyst such as tris(dibenzylideneacetone)dipalladium
  • (1-1) has additional substituents in the pyridine ring
  • a compound (1-3) having additional substitution in the 6-membered ring can be prepared.
  • a wide range of substituted 3-bromo-2-aminopyridines are known in the literature and are commercially available and the preparations of compounds (i), (ii) and (iii) from the corresponding substituted 3-bromo-2-aminopyridine, using analogous chemistry to that shown for (1-3) in Scheme 1, are described in WO2011/092272, WO2010/141796 and WO2010/141796, respectively, each incorporated herein by reference.
  • An ester (1-4) can be hydrolysed to the corresponding carboxylic acid (1-5) using standard conditions which would be dependent upon the particular ester group present.
  • An amide (1-6) may be formed from (1-5) using an amine R′R 2 NH under standard coupling conditions, for example using (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) (HATU) in the presence of a base such as N,N-diisopropylethylamine (DIPEA).
  • DIPEA N,N-diisopropylethylamine
  • Intermediate (1-6) may also be prepared directly from (1-3) and amide (1-7) using the same chemistries in an alternative sequence.
  • Compound (1-6) may then be converted into (1-9) by reaction with a cyclic secondary amine (1-8) via a Buchwald-Hartwig cross-coupling using a palladium catalyst such as Pd 2 (dba) 3 and a suitable ligand such as Xantphos in the presence of a base providing structures of Formula 0 with R 2 being of type (a).
  • ester (1-4) may undergo a palladium catalysed amination with (1-8) to give (1-10).
  • the ester moiety in (1-10) may then be hydrolysed under standard conditions to give an acid (1-11) which then may be reacted with an amine R 1 R 2 NH to give a compound (1-9).
  • R 3 or R 4 may be further elaborated.
  • R 4 is CH 2 CN (2-1)
  • the nitrile group may be converted into the corresponding primary amide (2-2).
  • Reagents suitable for this conversion include acetaldoxime in the presence of palladium (II) acetate and triphenylphosphine.
  • the nitrile group in (2-1) may also be hydrolysed to the corresponding carboxylic acid (2-3) which in turn can be treated with an amine R 4 R 5 NH under standard amidation conditions to provide compounds of type (2-4).
  • R 4 in the compounds of Scheme 1 is an ester, exemplified by structure (3-1) of Scheme 3, this group may be hydrolysed under standard conditions to give an acid of type (3-2). Common amidation conditions may then be used to prepare an amide (3-3) from (3-2) and a suitable amine R 3 R 4 NH.
  • the cyclic secondary amine (1-8) of Scheme 1, in which R 4 is hydroxyl and R 3 is an optionally substituted alkyl, aryl or heteroaryl group, may be prepared according to Scheme 4.
  • Reaction of a suitably nitrogen protected aminoketone (4-1) with either a Grignard reagent or an organolithium may provide the alcohol (4-2).
  • Deprotection of the amine nitrogen to give amine (4-3) can then be achieved using conditions designed to remove the protecting group of choice.
  • Schemes 5 to 8 and 18 to 24 describe the methods that can be used to prepare other cyclic secondary amines (1-8), of Scheme 1, which are required for preparation of examples where the required amine (1-8) is hitherto unknown in the scientific literature.
  • the methods use standard reactions known to those skilled in the art.
  • Scheme 5 provides a preparation of 1-oxa-3,7-diazaspiro[4.4]nonan-2-one (5-4).
  • Scheme 6 describes routes to secondary amines (1-8) of Scheme 1 in which R 3 is phenyl or substituted phenyl and R 4 is either cyano (6-6) or hydroxymethyl (6-5).
  • a cyanomethylbenzene with a base such as sodium hydride and subsequent reaction of the resultant anion with commercially available (6-1) may provide (6-2).
  • the deprotection of (6-2) under acidic conditions gives amine (6-6).
  • Scheme 7 shows methods that can be used to prepare a secondary amine (1-8) of Scheme 1 in which R 3 is hydrogen and R 4 is 2-(2-methoxyethoxy)pyridin-4-ylmethoxy (7-4).
  • Boc-protected 4-piperidinol (7-2) with a base such as potassium tert-butoxide, and reaction with commercially available 4-(chloromethyl)-2-(2-methoxyethoxy)pyridine (7-1) in the presence of an iodide source such as terabutylammonium iodide gives (7-3).
  • an iodide source such as terabutylammonium iodide
  • Scheme 8 describes routes to amines 1-8 from Scheme 1 in which R 3 is a phenyl or substituted phenyl and R 4 is either cyanomethyl (8-6), hydroxyethyl (8-9) or cyanoethyl (8-12).
  • R 3 is a phenyl or substituted phenyl
  • R 4 is either cyanomethyl (8-6), hydroxyethyl (8-9) or cyanoethyl (8-12).
  • the synthesis of intermediates of type (8-5) is described in Journal of Medicinal Chemistry, 2011, 54 (11), 3756-3767 and Boc deprotection can be achieved by treatment with acid. Reduction of the nitrile in (8-5) firstly to the aldehyde (8-7) using diisobutylaluminium hydride and then to the alcohol (8-8) with sodium borohydride provides (8-8) which can be Boc-deprotected in acid to give (8-9).
  • Scheme 9 indicates how other compounds of the invention may be prepared wherein R 2 of Formula 0 is of type (d). Ester (1-4) or amide (1-6) from Scheme 1 may undergo a palladium catalysed Buchwald-Hartwig cross-coupling with a diamine (9-1). Where R 3 in (9-5), or indeed (9-3), is a protecting group, it may be removed under standard conditions and the resulting amine (9-6) may be further modified through alkylation, arylation, acylation, sulfonylation etc.
  • Scheme 10 indicates how other compounds of the invention may be prepared wherein R 2 of Formula 0 is of type (c).
  • Either ester (1-4) or amide (1-6) from Scheme 1 may be reacted with a suitable boronate ester or boronic acid in a Suzuki-Miyaura cross-coupling reaction.
  • An example of a palladium catalyst that may be useful in such a transformation would be bis(triphenylphosphine)palladium (II) dichloride (Pd(PPh 3 ) 2 Cl 2 ).
  • R 3 in intermediate (10-2) or (10-5) is a protecting group, it may be removed under standard conditions to give amines (10-3) and (10-6), respectively.
  • the latter may be further modified using standard chemistries, examples of which are given in Scheme 11.
  • the ester may later be converted into an amide if required.
  • Scheme 12 indicates how other compounds of the invention may be prepared wherein R 2 of Formula 0 is of type (f).
  • Either ester (1-4) or amide (1-6) from Scheme 1 may be reacted with a suitable boronate ester (12-1) or boronic acid in a Suzuki-Miyaura cross-coupling to give (12-2) and (12-4), respectively.
  • the palladium catalyst may be for example Pd(PPh 3 ) 2 Cl 2 or Pd 2 (dba) 3 and the base may be sodium or cesium carbonate or sodium tert-butoxide.
  • Groups R 3 and R 4 may be further modified using standard chemistries.
  • Scheme 13 shows an alternative approach available for the preparation of compounds of the invention.
  • the Group R 1 may be incorporated into a 2-aminopyridine (13-1) prior to formation of the bicycle (13-3) which may then be further modified using the methodologies described herein.
  • This method is of particular use in the synthesis of compounds of Formula 0 wherein R 2 is of type (g).
  • a method for preparing compounds (13-1) from 3-bromo-2-aminopyridine is available in WO2012/020848, incorporated herein by reference.
  • Scheme 18 describes routes to amines 1-8 from Scheme 1 in which R 3 is a phenyl or substituted phenyl and R 4 is methyl acetamido.
  • Reduction of the nitrile (6-2) using a metal catalyzed reduction under an atmosphere of hydrogen with a reagent such as Raney Nickel may be used to afford the methylamino intermediate (18-1) which may be protected as the acetamide using acetic anhydride and a base to afford acetamide intermediate (18-2).
  • Boc deprotection under standard acidic conditions may be used to afford the amine (18-3).
  • Scheme 19 describes routes to amines 1-8 from Scheme 1 in which R 3 is ethyl-(2,2,2-trifluoroethyl)amine and R 4 is hydroxymethyl.
  • Deprotonation adjacent to the nitrile of commercially available (19-1), using a base such as LDA, followed by treatment with BOM-Cl affords the benzyloxy intermediate (19-2).
  • the nitrile of intermediate (18-2) may be reduced to the aldehyde (18-3) using a suitable reducing agent such as DIBAl-H.
  • the aldehyde may then be converted to the amine (18-4) using trifluoroethylamine and a reducing agent such as sodium cyanoborohydride.
  • Hydrogenation of the benzyloxy intermediate (19-4) using palladium catalysis under an atmosphere of hydrogen may be used to prepare the hydroxymethyl intermediate (19-5). Removal of the Boc protecting group under standard conditions may be used to give the amine (19-6).
  • Reduction of the ester in intermediate (20-2) using, for example, DIBAl-H affords the alcohol (20-3) which may then be oxidized to the aldehyde (20-4) using an oxidant such as DMP.
  • the aldehyde of (20-4) may be converted to the difluoromethyl intermediate (20-5) using a reagent such as DAST.
  • Reduction of the nitrile in Intermediate (20-5), using DIBAl-H for example, may afford the aldehyde (20-6) which may be further reduced to the alcohol (20-7) by treatment with sodium borohydride. Boc deprotection under standard conditionds may be used to prepare the amine (20-8).
  • Scheme 21 describes routes to amines 1-8 from Scheme 1 in which R 3 is a phenyl or substituted phenyl and R 4 is a propane-1,2-diol.
  • Treatment of methanesulfonate ester (8-10) with a base such as potassium tert-butoxide may provide the alkene (21-1).
  • Intermediate (21-1) may be treated with an oxidant such as osmium tetroxide to afford diol (21-2). Boc deprotection under standard conditions may be used to give the amine (21-3).
  • Scheme 22 describes a route to the amine (22-4) in which R 3 is a cycloalkyl and R 4 is either cyanomethyl.
  • Conjugate addition to Intermediate (8-2) using reagents such as a Grignard and copper(I) iodide may be used to prepare intermediate (22-1).
  • Hydrolysis of the ester in Intermediate (22-1) with a base such as potassium hydroxide followed by decarboxylation using a reagent such as copper (I) oxide may be used to give Intermediate (22-3).
  • Boc deprotection under standard conditions may be used to give the amine (22-4)
  • Scheme 23 describes routes to amines 1-8 from Scheme 1 in which R 3 is a phenyl or substituted phenyl and R 4 is a propionic acid ethyl ester.
  • Hydrolysis of the nitrile (8-6) under acidic conditions with a reagent such as HCl in acetic acid gives the acid (23-1).
  • Esterification of the acid with an alcohol such as ethanol under acidic conditions gives the ester (23-2).
  • Boc deprotection under standard conditions may be used to give the amine (23-3).
  • Scheme 24 describes routes to amines 1-8 from Scheme 1 in which R 3 is a phenyl or substituted phenyl and R 4 is either carboxylic acid (24-6), difluoroethyl (24-7), 2-hydroxyethyl (24-8), 2-hydroxytrifluoroethyl (24-9), or methoxymethyl (24-10).
  • Hydrolysis of the nitrile (6-2) under acidic conditions with a reagent such as HCl in acetic acid may be used to afford the acid (24-1).
  • Treatment of the aldehyde (8-7) with a reagent such as DAST may be used to afford the difluoroethyl intermediate (24-2).
  • Scheme 25 describes a route to compounds of the invention wherein Ar 1 is a pyrazole.
  • Ester (16.2) from Scheme 16 may undergo a palladium catalysed Buchwald-Hartwig cross-coupling with an amine (1-8).
  • R 1 in (25-1) is a protecting group, it may be removed under standard conditions and the resulting acid (25-2) may be further modified through an amide coupling to afford amides of the Formula 25-3.
  • Scheme 26 describes an alternative route towards compounds where Ar 1 is a pyrazole.
  • the 2-iodo analogue (16-1) may undergo a palladium catalysed Buchwald-Hartwig cross-coupling with a protected aminopyrazole, such as the SEM amino pyrazole, to afford compounds of Formula (26-1).
  • Compounds of Formula (26-1) may then undergo a further palladium catalysed Buchwald-Hartwig cross-coupling with an amine (1-8) to afford compounds of Formula (26-2).
  • the pyrazole protecting group in (26-2) may then be removed under standard conditions to afford compounds of Formula (26-3) which may be subsequently alkylated with a suitable alkylating agent and base to afford compounds of formula (25-1).
  • Compounds of Formula (25-1) may be further modified as in Scheme 25 to afford amides of Formula (25-3).
  • each of the exemplary Schemes it may be advantageous to separate reaction products from one another or from starting materials.
  • the desired products of each step or series of steps is separated or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art.
  • separations involve multiphase extraction, crystallization or trituration from a solvent or solvent mixture, distillation, sublimation, or chromatography.
  • Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; supercritical fluid; high, medium, and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
  • SMB simulated moving bed
  • reagents selected to bind to or render otherwise separable a desired product, unreacted starting material, reaction by product, or the like.
  • reagents include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media, or the like.
  • the reagents can be acids in the case of a basic material, bases in the case of an acidic material, binding reagents such as antibodies, binding proteins, selective chelators such as crown ethers, liquid/liquid ion extraction reagents (LIX), or the like.
  • Example separation methods include boiling point, and molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction, and the like.
  • One skilled in the art will apply techniques most likely to achieve the desired separation.
  • Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC column or supercritical fluid chromatography.
  • a single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York, 1994; Lochmuller, C. H., J. Chromatogr., 113(3):283-302 (1975)).
  • Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.
  • suitable method including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.
  • Diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, ⁇ -methyl- ⁇ -phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid.
  • the diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography.
  • addition of chiral carboxylic or sulfonic acids such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
  • the substrate to be resolved is reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York, 1994, p. 322).
  • Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the pure or enriched enantiomer.
  • a method of determining optical purity involves making chiral esters, such as a menthyl ester, e.g., ( ⁇ ) menthyl chloroformate in the presence of base, or Mosher ester, ⁇ -methoxy- ⁇ -(trifluoromethyl)phenyl acetate (Jacob, J. Org. Chem. 47:4165 (1982)), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric enantiomers or diastereomers.
  • chiral esters such as a menthyl ester, e.g., ( ⁇ ) menthyl chloroformate in the presence of base, or Mosher ester, ⁇ -methoxy- ⁇ -(trifluoromethyl)phenyl acetate (Jacob, J. Org. Chem. 47:4165 (1982)
  • Stable diastereomers of atropisomeric compounds can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (WO 96/15111, incorporated herein by reference).
  • a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (Chiral Liquid Chromatography W. J. Lough, Ed., Chapman and Hall, New York, (1989); Okamoto, J. of Chromatogr. 513:375-378 (1990)).
  • Enriched or purified enantiomers can be distinguished by methods used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism.
  • the absolute stereochemistry of chiral centers and enatiomers can be determined by x-ray crystallography.
  • Positional isomers for example E and Z forms, of compounds of Formula 0, Formula I or Formula II, and intermediates for their synthesis, may be observed by characterization methods such as NMR and analytical HPLC.
  • the E and Z isomers may be separated, for example by preparatory HPLC.
  • JAK kinase inhibitors such as JAK1 inhibitors
  • inflammatory diseases such as asthma.
  • compositions or medicaments containing a compound of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and a pharmaceutically acceptable carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments.
  • a compound of the invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1
  • a pharmaceutically acceptable carrier, diluent or excipient such as well as methods of using the compounds of the invention to prepare such compositions and medicaments.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1 may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • physiologically acceptable carriers i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • the pH of the formulation depends mainly on the particular use and the concentration of compound, but typically ranges anywhere from about 3 to about 8.
  • a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1 is formulated in an acetate buffer, at pH 5.
  • the compounds of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, are sterile.
  • the compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
  • compositions are formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range for oral administration will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a human, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses.
  • the daily dose range for inhaled administration will lie within the range of from about 0.1 ⁇ g to about 1 mg per kg body weight of a human, preferably 0.1 ⁇ g to 50 ⁇ g per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
  • the compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal, inhaled and epidural and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, inhaled administration is employed.
  • the compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, lozenges, granules, solutions, dispersions, suspensions, syrups, sprays, vapors, suppositories, gels, emulsions, patches, etc.
  • compositions may contain components conventional in pharmaceutical preparations, e.g., diluents (e.g., glucose, lactose or mannitol), carriers, pH modifiers, buffers, sweeteners, bulking agents, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, perfuming agents, flavoring agents, other known additives as well as further active agents.
  • diluents e.g., glucose, lactose or mannitol
  • Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005.
  • carriers include solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, pp 1289-1329, 1990). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • preservatives e.g., antibacterial agents, antifungal agents
  • isotonic agents e.g., absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavor
  • excipients include dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof.
  • a pharmaceutical composition may comprise different types of carriers or excipients depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration.
  • tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers, for example, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example, magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, or acceptable wetting agents such as sodium lauryl sulfate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example, methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavoring or coloring agents.
  • suspending agents for example, sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats
  • emulsifying agents for example, lecithin, sorbitan monooleate, or acacia
  • non-aqueous vehicles which may include edible oils
  • almond oil fractionated coconut oil
  • oily esters such as glycer
  • a compound For topical application to the skin, a compound may be made up into a cream, lotion or ointment.
  • Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
  • Compounds of the invention may also be formulated for inhalation, for example, as a nasal spray, or dry powder or aerosol inhalers.
  • inhalation the compound is typically in the form of microparticles, which can be prepared by a variety of techniques, including spray-drying, freeze-drying and micronisation.
  • Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, such as by using propellant-driven metered aerosols or propellant-free administration of micronized compounds from, for example, inhalation capsules or other “dry powder” delivery systems.
  • a composition of the invention may be prepared as a suspension for delivery from a nebulizer or as an aerosol in a liquid propellant, for example, for use in a pressurized metered dose inhaler (PMDI).
  • PMDI pressurized metered dose inhaler
  • Propellants suitable for use in a PMDI are known to the skilled person, and include CFC-12, HFA-134a, HFA-227, HCFC-22 (CCl 2 F 2 ) and HFA-152 (CH 4 F 2 and isobutane).
  • a composition of the invention is in dry powder form, for delivery using a dry powder inhaler (DPI).
  • DPI dry powder inhaler
  • Microparticles for delivery by administration may be formulated with excipients that aid delivery and release.
  • microparticles may be formulated with large carrier particles that aid flow from the DPI into the lung.
  • Suitable carrier particles are known, and include lactose particles; they may have a mass median aerodynamic diameter of, for example, greater than 90 ⁇ m.
  • a compound such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-4816 or 3-1, may be dosed as described depending on the inhaler system used.
  • the administration forms may additionally contain excipients as described above, or, for example, propellants (e.g., Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g., lactose in the case of powder inhalers) or, if appropriate, further active compounds.
  • propellants e.g., Frigen in the case of metered aerosols
  • surface-active substances e.g., emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g., lactose in the case of powder inhalers) or, if appropriate, further active
  • compounds of the invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be delivered in multi-chamber devices thus allowing for delivery of combination agents.
  • the compound such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may also be administered parenterally in a sterile medium.
  • the compound can either be suspended or dissolved in the vehicle.
  • adjuvants such as a local anaesthetic, preservative or buffering agents can be dissolved in the vehicle.
  • the compounds of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, inhibit the activity of a Janus kinase, such as JAK1 kinase.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, inhibits the phosphorylation of signal transducers and activators of transcription (STATs) by JAK1 kinase as well as STAT mediated cytokine production.
  • STATs signal transducers and activators of transcription
  • Compounds of the present invention are useful for inhibiting JAK1 kinase activity in cells through cytokine pathways, such as IL-6, IL-15, IL-7, IL-2, IL-4, IL-9, IL-10, IL-13, IL-21, G-CSF, IFNalpha, IFNbeta or IFNgamma pathways.
  • cytokine pathways such as IL-6, IL-15, IL-7, IL-2, IL-4, IL-9, IL-10, IL-13, IL-21, G-CSF, IFNalpha, IFNbeta or IFNgamma pathways.
  • a method of contacting a cell with a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, to inhibit a Janus kinase activity in the cell (e.g., JAK1 activity).
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, to inhibit a Janus kinase activity in the cell (e.g., JAK1 activity).
  • the compounds of the present invention can be used for the treatment of immunological disorders driven by aberrant IL-6, IL-15, IL-7, IL-2, IL-4, IL9, IL-10, IL-13, IL-21, G-CSF, IFNalpha, IFNbeta or IFNgamma cytokine signaling
  • one embodiment includes compounds of of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for use in therapy.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, in the treatment of an inflammatory disease.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for the preparation of a medicament for the treatment of an inflammatory disease, such as asthma.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for use in the treatment of an inflammatory disease, such as asthma.
  • Another embodiment includes a method of preventing, treating or lessening the severity of a disease or condition, such as asthma, responsive to the inhibition of a Janus kinase activity, such as JAK1 kinase activity, in a patient.
  • the method can include the step of administering to a patient a therapeutically effective amount of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1.
  • the disease or condition responsive to the inhibition of a Janus kinase, such as JAK1 kinase is asthma.
  • the disease or condition is cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, multiple sclerosis, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, asthma, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation (e.g., transplant rejection), immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving T cell activation, CNS disorders or a myeloproliferative disorder.
  • the inflammatory disease is rheumatoid arthritis, psoriasis, asthma, inflammatory bowel disease, contact dermatitis or delayed hypersensitivity reactions.
  • the autoimmune disease is rheumatoid arthritis, lupus or multiple sclerosis.
  • the cancer is breast, ovary, cervix, prostate, testis, penile, genitourinary tract, seminoma, esophagus, larynx, gastric, stomach, gastrointestinal, skin, keratoacanthoma, follicular carcinoma, melanoma, lung, small cell lung carcinoma, non-small cell lung carcinoma (NSCLC), lung adenocarcinoma, squamous carcinoma of the lung, colon, pancreas, thyroid, papillary, bladder, liver, biliary passage, kidney, bone, myeloid disorders, lymphoid disorders, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, salivary gland, pharynx, small intestine, colon, rectum, anal, renal, prostate, vulval, thyroid, large intestine, endometrial, uterine, brain, central nervous system, cancer of the peritoneum, hepatocellular cancer, head cancer, neck cancer,
  • the disease is a myeloproliferative disorder.
  • the myeloproliferative disorder is polycythemia vera, essential thrombocytosis, myelofibrosis or chronic myelogenous leukemia (CML).
  • Another embodiment includes the use of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for the manufacture of a medicament for the treatment of a disease described herein (e.g., an inflammatory disorder, an immunological disorder or cancer).
  • a disease described herein e.g., an inflammatory disorder, an immunological disorder or cancer.
  • the compounds of the present invention may be employed alone or in combination with other agents for treatment.
  • the second compound of a pharmaceutical composition or dosing regimen typically has complementary activities to the compound of this invention such that they do not adversely affect each other.
  • agents are suitably present in combination in amounts that are effective for the purpose intended.
  • the compounds may be administered together in a unitary pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially. Such sequential administration may be close or remote in time.
  • compositions comprising a therapeutically effective amount of a compound of the invention and one or more other therapeutic agents.
  • Suitable therapeutic agents for a combination therapy with compounds of the invention include, but are not limited to: an adenosine A2A receptor antagonist; an anti-infective; a non-steroidal Glucocorticoid Receptor (GR Receptor) agonist; an antioxidant; a ⁇ 2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; a formyl peptide receptor antagonist; a histone deacetylase activator; a chloride channel hCLCA1 blocker; an epithelial sodium channel blocker (ENAC blocker; an inter-cellular adhesion molecule 1 blocker (ICAM blocker); an IKK2 inhibitor; a JNK inhibitor; a cyclooxygenase inhibitor (COX inhibitor); a lipoxygenase inhibitor; a leukotriene receptor antagonist; a dual ⁇ 2 a
  • compounds of the invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be combined with: (1) corticosteroids, such as alclometasone dipropionate, amelometasone, beclomethasone dipropionate, budesonide, butixocort propionate, biclesonide, blobetasol propionate, desisobutyrylciclesonide, dexamethasone, dtiprednol dicloacetate, fluocinolone acetonide, fluticasone furoate, fluticasone propionate, loteprednol etabonate (topical) or mometasone furoate; (2) ⁇ 2-adrenoreceptor agonists such as salbutamol, albuterol, terbutaline, f
  • the compounds of the present invention can be used in combination with one or more additional drugs, for example anti-hyperproliferative, anti-cancer, cytostatic, cytotoxic, anti-inflammatory or chemotherapeutic agents, such as those agents disclosed in U.S. Publ. Appl. No. 2010/0048557, incorporated herein by reference.
  • additional drugs for example anti-hyperproliferative, anti-cancer, cytostatic, cytotoxic, anti-inflammatory or chemotherapeutic agents, such as those agents disclosed in U.S. Publ. Appl. No. 2010/0048557, incorporated herein by reference.
  • a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, can be also used in combination with radiation therapy or surgery, as is known in the art.
  • kits for treating a disease or disorder responsive to the inhibition of a Janus kinase, such as a JAK1 kinase.
  • the kit can comprise:
  • a first pharmaceutical composition comprising a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1; and
  • kit further comprises:
  • a second pharmaceutical composition such as a pharmacueitcal composition comprising an agent for treatment as described above, such as an agent for treatment of an inflammatory disorder, or a chemotherapeutic agent.
  • the instructions describe the simultaneous, sequential or separate administration of said first and second pharmaceutical compositions to a patient in need thereof.
  • first and second compositions are contained in separate containers. In another embodiment, the first and second compositions are contained in the same container.
  • Containers for use include, for example, bottles, vials, syringes, blister pack, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container includes a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, or composition thereof, which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the label or package insert indicates that the compound or composition is used for treating the condition of choice, such as asthma or cancer.
  • the label or package inserts indicates that the compound or composition can be used to treat a disorder.
  • the label or package insert may indicate that the patient to be treated is one having a disorder characterized by overactive or irregular Janus kinase activity, such as overactive or irregular JAK1 activity.
  • the label or package insert may also indicate that the compound or composition can be used to treat other disorders.
  • the kit may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • a pharmaceutically acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution.
  • LCMS Analytical Methods High Pressure Liquid Chromatography-Mass Spectrometry (LCMS) experiments to determine retention times (RT) and associated mass ions were performed using one of the following methods with either UV detector monitoring at 220 nm and 254 nm or evaporative light scattering detection, and mass spectrometry scanning 110-800 amu in ESI+ ionization mode.
  • Example 1-1 (see Table I) (120 mg, 56.1%).
  • Step 1 A microwave vial was charged with 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid ethyl ester (1.00 g, 2.77 mmol), 4-(4-chloro-phenyl)-piperidin-4-ol (879 mg, 4.15 mmol), tris(dibenzylideneacetone)dipalladium(0) (256 mg, 0.28 mmol), cesium carbonate (1.81 g, 5.54 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (321 mg, 0.55 mmol) and dioxane (12 mL).
  • the vessel was sealed, evacuated and refilled with argon three times before being purged with argon whilst being sonicated for 5 minutes.
  • the reaction mixture was stirred at 110° C. for 18 hours then cooled to room temperature before being filtered through a pad of Celite®, eluting with ethyl acetate.
  • the filtrate was concentrated in vacuo before being purified by flash chromatography on silica eluting with 0-4% MeOH in dichloromethane.
  • Step 2 A mixture of 4- ⁇ 8-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino ⁇ -benzoic acid ethyl ester (5.12 g, 10.41 mmol), 2M LiOH aqueous solution (10.41 mL, 20.82 mmol), methanol (25 mL), THF (150 mL) and water (15 mL) was stirred at 55° C. for 18 hours then at room temperature for 24 hours. The methanol and THF were removed in vacuo before the solution was adjusted to pH 4 with 1M HCl.
  • Step 1 To the solution of 2-(4-chlorophenyl)acetonitrile (20.1 g, 132.59 mmol, 1.00 equiv) and tert-butyl N,N-bis(2-chloroethyl)carbamate (35.4 g, 146.19 mmol, 1.10 equiv) in anhydrous DMF (200 mL) was added sodium hydride (27 g, 60% in mineral oil, 666.73 mmol, 3.00 equiv) portionwise at 0° C. under N 2 over 2 hr. The resulting solution was stirred at 60° C. for 1.5 hr, and then stirred overnight at room temperature.
  • 2-(4-chlorophenyl)acetonitrile 20.1 g, 132.59 mmol, 1.00 equiv
  • tert-butyl N,N-bis(2-chloroethyl)carbamate 35.4 g, 146.19 mmol, 1.10
  • Step 2 The solution of tert-butyl 4-(4-chlorophenyl)-4-cyanopiperidine-1-carboxylate (1 g, 3.12 mmol, 1.00 equiv) in anhydrous tetrahydrofuran (5 mL, 61.71 mmol) was placed in a 100-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, then diisobutyl aluminium hydride (1 M in hexane, 7.8 mL, 7.81 mmol) was added dropwise with cooling in an ice/water bath. The resulting solution was stirred for 1.5 hr at ambient temperature. The reaction mixture was poured into 100 mL water/ice.
  • Step 3 The solution of tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate (610 mg, 1.88 mmol, 1.00 equiv) in methanol (5 mL, 123.49 mmol) was placed in a 100-mL round-bottom flask, then NaBH 4 (144 mg, 3.81 mmol, 2.00 equiv) was added in ice/water bath. The resulting solution was stirred at room temperature overnight. The reaction was quenched by the addition of three drops of water. The resulting mixture was concentrated under vacuum.
  • Step 4 The solution of tert-butyl 4-(4-chlorophenyl)-4-(hydroxymethyl) piperidine-1-carboxylate (300 mg, 0.92 mmol, 1.00 equiv) in HCl/dioxane (1M, 10 mL) was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum, and sat. aq. NaHCO 3 was added to the residue to make pH>10. The resulting mixture was concentrated to dryness under vacuum.
  • Step 5 The solution of 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (242 mg, 0.55 mmol, 1.50 equiv) in 1,4-dioxane (20 mL) was placed in a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, then [4-(4-chlorophenyl)piperidin-4-yl]methanol (160 mg, 0.71 mmol, 1.00 equiv), Cs 2 CO 3 (357 mg, 1.10 mmol, 2.00 equiv), Pd 2 (dba) 3 .CHCl 3 (314.6 mg, 0.30 mmol, 0.45 equiv), BINAP (377.7 mg, 0.61 mmol, 0.90 equiv) was added.
  • Step 1 Into a 2-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl 4-oxopiperidine-1-carboxylate (100 g, 501.89 mmol, 1.00 equiv), toluene (800 mL), ethyl 2-cyanoacetate (56.8 g, 502.15 mmol, 1.00 equiv), NH 4 OAc (38.5 g, 1.00 equiv), acetic acid (80 mL). The resulting solution was stirred for 3 h at 110° C. The reaction mixture was cooled to room temperature and concentrated under vacuum.
  • Step 2 Into a 3-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (100 g, 339.74 mmol, 1.00 equiv), tetrahydrofuran (500 mL), CuI (19.4 g, 101.86 mmol, 0.30 equiv). The bromo(4-chlorophenyl)magnesium (1M in THF, 1.02 L, 3.00 equiv) was added dropwise at 0° C. The resulting solution was stirred for 2 h at 0° C.
  • Step 3 Into a 3-L 3-necked round-bottom flask, was placed tert-butyl 4-(4-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (100 g, 245.76 mmol, 1.00 equiv), ethanol (500 mL), water (500 mL), potassium hydroxide (30 g, 534.71 mmol, 2.18 equiv). The resulting solution was stirred for 20 h at room temperature. EtOH was removed under vacuum.
  • Step 4 Into a 2-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-[1-[(tert-butoxy)carbonyl]-4-(4-chlorophenyl)piperidin-4-yl]-2-cyanoacetic acid (76 g, 200.61 mmol, 1.00 equiv), acetonitrile (800 mL), Cu 2 O (28 g, 195.68 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at 85° C. The reaction mixture was cooled to room temperature and concentrated under vacuum. The residual solid was suspended in 500 mL of EA and the solid was filtered off.
  • 2-[1-[(tert-butoxy)carbonyl]-4-(4-chlorophenyl)piperidin-4-yl]-2-cyanoacetic acid 76 g, 200.61 mmol, 1.00 equiv
  • acetonitrile 800
  • Step 5 Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl 4-(4-chlorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate (5 g, 14.93 mmol, 1.00 equiv) and anhydrous tetrahydrofuran (80 mL). DIBAL-H solution (1 M in hexane, 30 mL, 2.00 equiv) was added dropwise at 0° C. The resulting solution was stirred for 2 h at 0° C. The reaction was then quenched by addition of 40 mL of water/ice.
  • Step 6 Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 4-(4-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (3 g, 8.88 mmol, 1.00 equiv) in methanol (80 mL), NaBH 4 (680 mg, 17.89 mmol, 1.00 equiv) was added portionwise. The resulting solution was stirred for 10 min at 25° C. The reaction was then quenched by the addition of 5 mL of water. The resulting mixture was concentrated under vacuum.
  • Step 7 To a mixture of tert-butyl 4-(4-chlorophenyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate (600.00 mg, 1.77 mmol, 1.00 equiv) and DIPEA (930 mg, 7.06 mmol, 4.00 equiv) in dry dichloromethane (20.00 mL, 314.60 mmol, 178.20 equiv) was added Ms 2 O (630 mg, 3.53 mmol, 2.00 equiv) dropwise under N 2 . The resulting solution was stirred for 4 h at ambient temperature. The resulting mixture was concentrated under vacuum.
  • Step 8 A mixture of tert-butyl 4-(4-chlorophenyl)-4-[2-(methanesulfonyloxy)ethyl]piperidine-1-carboxylate (550.00 mg, 1.32 mmol, 1.00 equiv) and NaCN (650 mg, 13.16 mmol, 10.00 equiv) in DMSO (20.00 mL) was stirred overnight at 100° C. The reaction mixture was cooled, and diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 3 ⁇ 20 mL of H 2 O. The organic phase was dried over Na 2 SO 4 , and concentrated under vacuum.
  • Step 9 A mixture of tert-butyl 4-(4-chlorophenyl)-4-(2-cyanoethyl)piperidine-1-carboxylate (360 mg, 1.03 mmol, 1.00 equiv) in 1M HCl/1,4-dioxane (30 mL) was stirred for 2 h at 25° C. The reaction mixture was concentrated under vacuum. The residue was dissolved in 5 mL of H 2 O. The pH value of the solution was adjusted to 8 with potassium carbonate. The resulting mixture was concentrated to dryness under vacuum. The residue was purified on a silica gel column with dichloromethane/methanol (5/1). The collected fractions were combined and concentrated under vacuum.
  • Step 10 Into a 100-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, was placed 3-[4-(4-chlorophenyl)piperidin-4-yl]propanenitrile (180 mg, 0.72 mmol, 1.00 equiv), 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (320 mg, 0.72 mmol, 1.00 equiv), 1,4-dioxane (20 mL, 335.12 mmol, 463.10 equiv), Cs 2 CO 3 (473 mg, 1.45 mmol, 2.00 equiv), XantPhos (84 mg, 0.15 mmol, 0.20 equiv), Pd 2 (dba) 3 (70 mg, 0.08 mmol, 0.10 equiv).
  • Step 1 The mixture of 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (150 mg, 0.338 mmol) piperidine-4-carboxylic acid ethyl ester (159.4 mg, 1.01 mmol) X-phos (39 mg, 0.067 mmol) Pd 2 (dba) 3 (47 mg, 0.067 mmol) Cs 2 CO 3 (329 mg, 1.01 mmol) in t-BuOH (3 mL) was heated to 100° C. and stirred for 1 h on microwave.
  • Step 2 To a solution of 1-(2- ⁇ 4-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-phenylamino ⁇ -[1,2,4]triazolo[1,5-a]pyridine-8-yl)-piperidin-4-carboxylic acid ethyl ester (100 mg, 0.192 mmol) in dioxane (2 mL) was added 1M NaOH aq (0.2 mL) and the mixture was heated to 80° C. and stirred for 2h.
  • Step 1 To a solution of 4-iodobenzoic acid ethyl ester (5.0 g, 18.1 mmol) was added 1M NaOH aq (18.1 mL, 18.1 mmol) and the mixture was heated to 100° C. and stirred for 1.5 h. The solvent was evaporated, the residue was adjusted to pH 6, and the precipitated solid was filtered off and washed with water to give 4-iodobenzoic acid (4.0 g, 89% yield).
  • Step 2 To a mixture of 4-iodobenzoic acid (1.0 g, 4 mmol) HATU (1.8 g, 4.8 mmol) in DMF was added DIPEA (1.5 g, 12 mmol) at 0° C. and the mixture was stirred for 10 min, then methyl-(1-methyl-piperidin-4-yl)-amine (1.02 g, 8 mmol) was added, and the reaction mixture was stirred for 2 h at r,t. The reaction mixture was poured into water and the mixture was extracted with EtOAc three times.
  • Step 3 The mixture of 3-benzyloxy-pyridin-2-ylamine (400 mg, 2 mmol) EtOCONCS (282 uL) in dioxane was stirred overnight at rt the solvent was evaporated and the residue (600 mg) was used for the next step without purification.
  • Step 4 To a solution of NH 2 OH-HCl (704 mg, 10.6 mmol) DIPEA (1 mL, 6.6 mmol) in MeOH (4 mL) and EtOH (4 mL) was added a solution of the thiourea prepared in step 3 (600 mg, 2.12 mmol) in MeOH (4 mL) and EtOH (4 mL) at rt the mixture was stirred at r,t for 1 h and then at 60° C. for 2 h. The solvent was evaporated and saturated NaHCO 3 solution was added to the residue.
  • Step 5 The mixture of 8-benzyloxy-[1,2,4]triazolo[1,5-a]pyridine-2-ylamine (150 mg, 0.625 mmol), 4-iodo-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (268.5 mg, 0.75 mmol) Pd 2 (dba) 3 (57 mg, 0.0625 mmol) Cs 2 CO 3 (610 mg,1.87 mmol) Xantphos (72 mg, 0.125 mmol) in dioxane was stirred for 2 h at 120° C. The solvent was concentrated, water was added and the mixture was extracted three times with EtOAc.
  • Step 1 To a solution of 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-benzoic acid (1 g, 3.0 mmol), methyl-(1-methyl-piperidin-4-yl)-amine (460 mg, 3.6 mmol) and DIPEA (2.65 ml, 15 mmol) in DMSO (10.0 mL) was added HATU (1.37 g, 3.6 mmol). The reaction mixture was stirred at 50° C. for 4 hours.
  • reaction mixture was diluted with water (10 mL), extracted with EtOAc (3 ⁇ 10 mL), the combined organic layer was concentrated, then purified by preparative HPLC (YMC—Actus Triart C18 150 ⁇ 30 mm ⁇ 5 um column eluting with acetonitrile/water+0.05% NH 4 OH) to give N-methyl-N-(1-methyl-piperidin-4-yl)-4-(8-phenoxy-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-benzamide (20.0 mg, 19.6%).
  • Step 1 A mixture of 2,3-dihydro-1,3-benzoxazol-2-one (3 g, 22.2 mmol) and phenyl[(trifluoromethane)sulfonyloxy]-lambda-3-iodanyl trifluoromethanesulfonate (11.6 g, 23.1 mmol) in in trifluoroacetic acid (50 mL) was heated under reflux for 30 min. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum.
  • Step 2 A mixture of 5-hydroxy-2,3-dihydro-1,3-benzoxazol-2-one (500 mg, 3.31 mmol), (bromomethyl)benzene (570 mg, 3.33 mmol) and sodium carbonate (350 mg, 3.30 mmol) in N,N-dimethylformamide (10 mL) was heated at 40° C. for 3 h then allowed to cool to room temperature. The pH of the reaction mixture was adjusted to ⁇ 6 by the addition of 3 N HCl. EtOAc (100 mL) was added and the resulting mixture was washed with water (3 ⁇ 30 mL) and brine (2 ⁇ 30 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum.
  • Step 3 A microwave vial was charged with 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (220 mg, 0.50 mmol), CuI (9.45 mg, 0.05 mmol), Cs 2 CO 3 (485 mg, 1.49 mmol), 3-benzyl-5-hydroxy-2,3-dihydro-1,3-benzoxazol-2-one (120 mg, 0.50 mmol), pyridine-2-carboxylic acid (12.2 mg, 0.10 mmol) and 1,4-dioxane (10 mL). The vessel was evacuated and refilled with nitrogen 3 times.
  • Step 1 A mixture of tert-butyl 4-(4-chlorophenyl)-4-[2-(methanesulfonyloxy)-ethyl]piperidine-1-carboxylate (Example 1e, step 7, 1.1 g, 2.63 mmol) and t-BuOK (580 mg, 5.17 mmol) in THF (50 mL) was heated under nitrogen at 60° C. for 4 h then cooled to room temperature.
  • Step 2 A mixture of tert-butyl-4-(4-chlorophenyl)-4-ethenylpiperidine-1-carboxylate (400 mg, 1.24 mmol) and a solution of saturated HCl in 1,4-dioxane (10 mL) was stirred for 1 h at room temperature then concentrated under vacuum. The residue was dissolved in H 2 O (5 mL) and solid K 2 CO 3 (2 g) was added. The resulting mixture was concentrated under vacuum and the residue was triturated with a mixture of DCM/MeOH (3/1(v/v), 40 mL).
  • Step 3 A microwave vial was charged with 4-(4-chlorophenyl)-4-ethenylpiperidine (130 mg, 0.59 mmol), 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (250 mg, 0.56 mmol), Pd 2 (dba) 3 .CHCl 3 (30 mg, 0.03 mmol), BINAP (36 mg, 0.06 mmol), Cs 2 CO 3 (390 mg, 1.20 mmol) and 1,4-dioxane (10 mL). The sealed vial was evacuated and refilled with nitrogen 3 times.
  • Step 4 A mixture of 4-([8-[4-(4-chlorophenyl)-4-ethenylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (200 mg, 0.34 mmol), 4-methylmorpholin-4-ium-4-olate (80 mg, 0.68 mmol) and osmium tetraoxide (174 mg, 0.68 mmol) in THF (30 mL) was stirred at room temperature for 20 h.
  • Methyl magnesium bromide (3 M in Et 2 O, 0.28 mL, 0.9 mmol) was added to a solution of 4-([8-[4-(4-chlorophenyl)-4-formylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (50 mg, 0.09 mmol) in THF (10 mL) at 0° C. The resulting solution was stirred at 0° C. for 1 h then quenched by the addition of MeOH (2 mL).
  • Step 1 A mixture of tert-butyl 4-(4-chlorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate (2 g, 5.97 mmol) and a solution of saturated HCl in 1,4-dioxane (30 mL) was stirred at room temperature overnight. The resulting mixture was concentrated under vacuum, the residue dissolved in H 2 O (20 mL) and the pH of the solution was adjusted to 9 by the addition of solid potassium carbonate.
  • Step 3 A mixture of 4-([8-[4-(4-chlorophenyl)-4-(cyanomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (400 mg, 0.67 mmol) in concentrated HCl (4 mL) and AcOH (1 mL) was heated at 100° C. for 20 h then allowed to cool to room temperature.
  • Step 4 Thionyl chloride (4 mL, 55 mmol) was added dropwise to a solution of 2-[4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]acetic acid (450 mg, 0.73 mmol) in ethanol (20 mL) at room temperature. The resulting solution was heated at 80° C. for 3 h then allowed to cool to room temperature. The resulting mixture was concentrated under vacuum and the resultant residue treated with saturated aqueous NaHCO 3 solution (4 mL).
  • Step 1 DAST (0.5 mL, 2.87 mmol) was added dropwise to a solution of tert-butyl 4-(4-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (1.6 g, 4.74 mmol) in DCM (100 mL) at 0° C. The resulting solution was stirred at 0° C. for 10 min then quenched by the addition of water (30 mL). The resulting solution was extracted with DCM (2 ⁇ 100 mL) and the combined organic layer was concentrated under vacuum.
  • DAST 0.5 mL, 2.87 mmol
  • Step 2 A mixture of tert-butyl-4-(4-chlorophenyl)-4-(2,2-difluoroethyl)-piperidine-1-carboxylate (500 mg, 1.39 mmol) in saturated HCl solution of 1,4-dioxane (30 mL) was stirred at room temperature for 2 h. The reaction mixture was concentrated under vacuum, the residue dissolved in H 2 O (5 mL) and solid K 2 CO 3 (1 g) was added. The resulting mixture was concentrated under vacuum and the residue was triturated with DCM (100 mL).
  • Step 3 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (300 mg, 0.68 mmol) and 4-(4-chlorophenyl)-4-(2,2-difluoroethyl)piperidine (260 mg, 1.00 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica eluting with DCM/MeOH (5/1). Appropriate fractions were combined and concentrated under vacuum.
  • Step 1 Acetic anhydride (2.5 g, 24.49 mmol) was added to a solution of tert-butyl 4-(aminomethyl)-4-(4-chlorophenyl)piperidine-1-carboxylate (800 mg, 2.46 mmol) (prepared according to the procedure contained in Journal of Medicinal Chemistry, 2008, 51(7), 2147-2157) and DIPEA (3.2 g, 24.8 mmol) in DCM (50 mL). On complete addition the reaction mixture was stirred at room temperature for 20 h then concentrated under vacuum.
  • tert-butyl 4-(aminomethyl)-4-(4-chlorophenyl)piperidine-1-carboxylate 800 mg, 2.46 mmol
  • DIPEA 3.2 g, 24.8 mmol
  • Step 2 A mixture of tert-butyl 4-(4-chlorophenyl)-4-(acetamidomethyl)piperidine-1-carboxylate (900 mg, 2.45 mmol) in a saturated solution of HCl in 1,4-dioxane (20 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum and the residue was dissolved in H 2 O (5 mL) and treated with solid K 2 CO 3 (1 g). The resulting mixture was concentrated under vacuum and the residue triturated with a mixture of DCM/MeOH (3/1(v/v), 50 mL).
  • Step 3 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (420 mg, 0.95 mmol) and N-[4-(4-chlorophenyl)piperidin-4-yl]methylacetamide (266 mg, 1.00 mmol) were coupled following the procedure detailed in Example 1j, step 3. The resulting mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM/MeOH (3/1).
  • Example 1s 4-([8-[4-(4-chlorophenyl)-4-(acetamidomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-265 in Table I)
  • Step 1 Sodium hydride (4.00 g, 166 mmol) was added portionwise to a solution of 2-(4-bromophenyl)acetonitrile (8 g, 40.8 mmol) and tert-butyl-N,N-bis(2-chloroethyl)carbamate (10.0 g, 41.3 mmol) in DMF (100 mL). On complete addition the resulting solution was stirred at room temperature for 1 h and at 65° C. for an additional 2 h. The reaction mixture was allowed to cool to room temperature, poured into crushed ice (200 g) and extracted with DCM (3 ⁇ 500 mL).
  • Step 2 Into a 250-mL pressure tank reactor purged and maintained with an inert atmosphere of nitrogen, were placed tert-butyl-4-(4-bromophenyl)-4-cyanopiperidine-1-carboxylate (5 g, 13.69 mmol), DIPEA (5 g, 38.69 mmol), Pd(dppf)Cl 2 (1.00 g, 1.37 mmol), DMSO (2.2 g, 28.16 mmol) and MeOH (150 mL) and the resulting solution was heated at 100° C. for 20 h under a pressure of 10 atm of CO. The reaction mixture was allowed to cool to room temperature and the solvent evaporated.
  • tert-butyl-4-(4-bromophenyl)-4-cyanopiperidine-1-carboxylate 5 g, 13.69 mmol
  • DIPEA 5 g, 38.69 mmol
  • Pd(dppf)Cl 2 (1.00 g, 1.37 mmol
  • Step 3 DIBAl-H (1 M in hexanes, 20 mL, 20 mmol) was added dropwise to a solution of tert-butyl-4-cyano-4-[4-(methoxycarbonyl)phenyl]piperidine-1-carboxylate (3.5 g, 10.2 mmol) and THF (100 mL) at 0° C. The resulting solution was stirred at 0° C. for 0.5 h, quenched by the addition of water (3 mL) and concentrated under vacuum. The resultant residue was purified by column chromatography on silica eluting with petroleum ether on a gradient of EtOAc (1/4 to 4/1).
  • Step 4 A mixture of tert-butyl 4-cyano-4-[4-(hydroxymethyl)phenyl]piperidine-1-carboxylate (3.00 g, 9.48 mmol), sodium bicarbonate (800 mg, 9.52 mmol) and DMP (4 g, 9.43 mmol) in DCM (100 mL) was stirred at room temperature for 20 h. The resulting mixture was evaporated and the resultant residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/4).
  • Step 5 DAST (2.0 mL, 12.4 mmol) was added to a solution of tert-butyl 4-cyano-4-(4-formylphenyl)piperidine-1-carboxylate (2.50 g, 7.95 mmol) in DCM (100 mL) under nitrogen. The resulting solution was stirred at room temperature for 20 h and quenched by the addition of saturated aqueous NaHCO 3 solution (50 mL). The resulting solution was extracted with DCM (3 ⁇ 100 mL) and the combined organic layer was dried over Na 2 SO 4 and concentrated.
  • Step 6 DIBAl-H (1 M in hexanes, 3 mL, 3 mmol) was added dropwise to a solution of tert-butyl-4-cyano-4-[4-(difluoromethyl)phenyl]piperidine-1-carboxylate (500 mg, 1.49 mmol) in diethyl ether (50 mL) under nitrogen at 0° C. The resulting solution was stirred at 0° C. for 1 h then quenched by the addition of water (1 mL).
  • Step 7 NaBH 4 (38 mg, 1.00 mmol) was added to a solution of crude tert-butyl-4-[4-(difluoromethyl)phenyl]-4-formylpiperidine-1-carboxylate (340 mg, 1.00 mmol) in MeOH (10 mL). The resulting solution was stirred at room temperature for 10 min then quenched by the addition of water (2 mL). The reaction mixture was concentrated under vacuum and the resultant residue was purified by flash chromatography on silica gel eluting with hexane on a gradient of EtOAc (1/4 to 4/1).
  • Step 8 A mixture of tert-butyl 4-[4-(difluoromethyl)phenyl]-4-(hydroxymethyl)piperidine-1-carboxylate (150 mg, 0.44 mmol) in a saturated solution of HCl in 1,4-dioxane (10 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum to afford crude [4-[4-(difluoromethyl)phenyl]piperidin-4-yl]methanol as a light yellow solid (90 mg) as the hydrochloride salt.
  • Step 9 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide; hydrochloride salt (200 mg, 0.45 mmol) and 4-[4-(difluoromethyl)phenyl]piperidin-4-ylmethanol (110 mg, 0.46 mmol) were coupled following the procedure detailed in Example 1j, step 3. The resulting mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM/MeOH (3/1).
  • Example 1u 4-([8-[4-(hydroxymethyl)-4-[4-(methylsulfanyl)phenyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-251 in Table I)
  • Step 1 Sodium hydride (370 mg, 15.42 mmol) was added portionwise to a mixture of 2-[4-(methylsulfanyl)phenyl]acetonitrile (500 mg, 3.06 mmol) and tert-butyl-N,N-bis(2-chloroethyl)carbamate (890 mg, 3.68 mmol) in N,N-dimethylformamide (20 mL) at 0° C. The resulting solution was stirred for 10 min at 0° C. and then heated at 60° C. for 2 h. The reaction mixture was allowed to cool to room temperature and poured onto saturated aqueous ammonium chloride solution (50 mL). EtOAc (200 mL) was added and the phases were separated.
  • 2-[4-(methylsulfanyl)phenyl]acetonitrile 500 mg, 3.06 mmol
  • tert-butyl-N,N-bis(2-chloroethyl)carbamate 890 mg
  • Step 2 DIBAl-H (1 M in hexanes, 3.4 mL, 3.4 mmol) was added dropwise to a solution of tert-butyl-4-cyano-4-[4-(methylsulfanyl)phenyl]piperidine-1-carboxylate (570 mg, 1.71 mmol) in diethyl ether (20 mL) at 0° C. The resulting solution was stirred at 0° C. for 10 min and quenched by the addition of water (1 mL), citric (0.5 g) and celite (5 g). The precipitated solid was removed by filtration.
  • Step 3 NaBH 4 (68 mg, 1.80 mmol) was added to a solution of tert-butyl-4-formyl-4-[4-(methylsulfanyl)phenyl]piperidine-1-carboxylate (300 mg, 0.89 mmol) in MeOH (10 mL). The resulting solution was stirred for 30 min at room temperature then quenched by the addition of water (2 mL).
  • Step 4 A mixture of tert-butyl-4-(hydroxymethyl)-4-[4-(methylsulfanyl)-phenyl]piperidine-1-carboxylate (150 mg, 0.44 mmol) in a saturated solution of HCl in 1,4-dioxane (10 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum, H 2 O (10 mL) was added and the pH of the solution was adjusted to 9 by the addition of solid potassium carbonate. The resulting mixture was concentrated under vacuum and the residue was triturated with a mixture of DCM/MeOH (5/1(v/v), 30 mL).
  • Step 5 4-[4-(methylsulfanyl)-phenyl]piperidin-4-ylmethanol (170 mg, 0.72 mmol) and 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (317 mg, 0.72 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated and the residue was purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/10 to 1/2).
  • Step 1 A mixture of 1,4-dioxaspiro[4.5]decan-8-one (10 g, 64.0 mmol), ethyl 2-cyanoacetate (7.24 g, 64.0 mmol), NH 4 OAc (4.94 g, 64.1 mmol) and acetic acid (20 mL, 349 mmol) in toluene (200 mL) was heated under nitrogen at 110° C. for 3 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum, diluted with EtOAc (200 mL), washed with H 2 O (50 mL) and concentrated under vacuum.
  • Step 2 A solution of bromo(4-chlorophenyl)magnesium (1 M in THF, 12 mL, 12 mmol) was added dropwise to a mixture of ethyl 2-cyano-2-[1,4-dioxaspiro[4.5]decan-8-ylidene]acetate (1.00 g, 3.98 mmol) and CuI (230 mg, 1.21 mmol) in THF (20 mL) under nitrogen at 0° C. The resulting solution was stirred for 2 h at 0° C., quenched by the addition of 10 mL of ethanol and concentrated under vacuum.
  • Step 3 A solution of KOH (1.2 g, 21.39 mmol) in water (10 mL) was added dropwise to a solution of ethyl 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]-2-cyanoacetate (1.2 g, 3.30 mmol) in ethanol (10 mL). On complete addition the mixture was stirred at room temperature for 20 h then concentrated under vacuum. The resultant residue was dissolved in H 2 O (20 mL) and washed with diethylether (2 ⁇ 50 mL). The pH of the aqueous phase was adjusted to 6 by the addition of 6N HCl and the resulting mixture was concentrated under vacuum.
  • Step 4 A mixture of 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]-2-cyanoacetic acid (1 g, 2.98 mmol) and Cu 2 O (480 mg, 3.35 mmol) in MeCN (30 mL) was heated under nitrogen at 85° C. for 2 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum.
  • Step 5 A mixture of 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]acetonitrile (600 mg, 2.06 mmol) and PTSA (71 mg, 0.41 mmol) in propan-2-one (20 mL) and water (5 mL) was heated at 80° C. for 20 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. Water (20 mL) was added and the aqueous phase extracted with EtOAc (2 ⁇ 100 mL).
  • Step 6 A solution of n-BuLi (2.5 M in hexanes, 0.6 mL, 1.5 mmol) was added dropwise to a solution of diisopropylamine (190 mg, 1.88 mmol) in THF (20 mL) under nitrogen at ⁇ 70° C. The resulting solution was stirred at ⁇ 70° C. for 0.5 h then a solution of 2-[1-(4-chlorophenyl)-4-oxocyclohexyl]acetonitrile (300 mg, 1.21 mmol) in a minimum amount of THF was added. The resulting solution was stirred at ⁇ 70° C.
  • Step 7 A mixture of 4-(4-chlorophenyl)-4-(cyanomethyl)cyclohex-1-en-1-yl trifluoromethanesulfonate (130 mg, 0.34 mmol), KOAc (100 mg, 1.02 mmol), 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (105 mg, 0.41 mmol) and Pd(dppf)Cl 2 (57 mg, 0.08 mmol, 0.20 equiv) in DMSO (10 mL) was heated under nitrogen at 70° C. for 16 h.
  • Step 8 A mixture of 2-[1-(4-chlorophenyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]acetonitrile (150 mg, 0.42 mmol), 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (190 mg, 0.43 mmol), K 3 PO 4 (270 mg, 1.27 mmol) and Pd(PPh 3 ) 4 (100 mg, 0.09 mmol) in 1,4-dioxane (30 mL) and water (3 mL) was degassed and refilled with nitrogen 3 times.
  • reaction mixture was heated at 100° C. for 20 h, allowed to cool to room temperature and concentrated under vacuum.
  • residue was purified using a short pad of silica gel eluting with DCM/MeOH (10/1). Appropriate fractions were combined and concentrated under vacuum.
  • Step 1 DIBAl-H (1 M in hexane, 30 mL, 30 mmol) was added dropwise to a solution of tert-butyl-4-[(benzyloxy)methyl]-4-cyanopiperidine-1-carboxylate (4 g, 12.11 mmol) in diethyl ether (100 mL) under nitrogen at 0° C. The resulting solution was stirred at 0° C. for 1 h then quenched by the addition of water (2 mL). The precipitated solid was removed by filtration and the filtrate was concentrated under vacuum.
  • Step 2 A mixture of tert-butyl-4-[(benzyloxy)methyl]-4-formylpiperidine-1-carboxylate (1 g, 3.00 mmol), 2,2,2-trifluoroethan-1-amine (1.5 g, 15.14 mmol), and tetrakis(propan-2-yloxy)titanium (850 mg, 2.99 mmol) in ethanol (30 mL) was heated under nitrogen at 60° C. for 2 h. AcOH (0.1 mL, 1.75 mmol) was added, followed by NaBH 3 CN (370 mg, 5.89 mmol). The resulting solution was heated at 60° C. for an additional 2 h then allowed to cool to room temperature.
  • Step 3 A mixture of tert-butyl-4-[(benzyloxy)methyl]-4-[[(2,2,2-trifluoroethyl)amino]methyl]piperidine-1-carboxylate (300 mg, 0.72 mmol) and 10% Pd/C (50 mg) in MeOH (20 mL) and aqueous 6 N HCl solution (1 mL) was stirred under H 2 at room temperature for 20 h. The catalyst was removed by filtration and the filtrate was concentrated under vacuum.
  • Step 4 A solution of tert-butyl-4-(hydroxymethyl)-4-[[(2,2,2-trifluoroethyl)amino]-methyl]piperidine-1-carboxylate (120 mg, 0.37 mmol) in a saturated solution of HCl in 1,4-dioxane (6 mL) was stirred at room temperature for 1 h. The resulting mixture was evaporated, H 2 O (1mL) was added, followed by solid K 2 CO 3 (0.5 g). The resulting mixture was concentrated under vacuum and the residue was triturated with a mixture of DCM/MeOH (3/1(v/v), 30 mL) and the remaining solid was removed by filtration.
  • Step 5 (4-[[(2,2,2-trifluoroethyl)amino]-methyl]piperidin-4-yl)methanol (55 mg, 0.24 mmol) and 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (100 mg, 0.23 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated under vacuum and the residue purified using a short pad of silica gel eluting with DCM/MeOH (10/1).
  • Step 1 A solution of bromo(cyclopentyl)magnesium (1 M in THF, 20 mL, 115.4 mmol) was added dropwise to a mixture of tert-butyl-4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (Example 1e, step 2, 2 g, 6.79 mmol) and CuI (380 mg, 2.00 mmol) in THF (20 mL) under nitrogen at 0° C. The resulting solution was stirred 0° C. for 2 h at then quenched by the addition of ethanol (10 mL).
  • Step 2 A mixture of potassium hydroxide (2.0 g, 35.65 mmol) and tert-butyl-4-(1-cyano-2-ethoxy-2-oxoethyl)-4-cyclopentylpiperidine-1-carboxylate (1.7 g, 4.66 mmol) in ethanol (20 mL) and water (20 mL) was stirred at room temperature overnight. The reaction mixture was evaporated to half original volume and washed with ether (3 ⁇ 30 mL). The pH of the aqueous phase was adjusted to 6 by the addition of 6N HCl aqueous solution and the resulting mixture was concentrated under vacuum.
  • Step 4 A mixture of tert-butyl-4-(cyanomethyl)-4-cyclopentylpiperidine-1-carboxylate (830 mg, 2.84 mmol) in saturated HCl in 1,4-dioxane (30 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum and the residue was dissolved in H 2 O (10 mL). The pH of the aqueous phase was adjusted to 9 by the addition of solid potassium carbonate. The resultant mixture was concentrated under vacuum and the residue triturated with a mixture of DCM and MeOH (5/1(v/v), 10 mL).
  • Step 5 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol) and 2-(4-cyclopentylpiperidin-4-yl)acetonitrile (173 mg, 0.90 mmol) were coupled following the procedure detailed in Example 1j, step 3. The resulting mixture was concentrated under vacuum and the residue purified using a short pad of silica gel eluting with DCM/MeOH (10/1).
  • Step 1 A mixture of tert-butyl 4-[2-amino-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,2,3,6-tetrahydropyridine-1-carboxylate (13 g, 41.22 mmol) in a saturated solution of HCl in 1,4-dioxane (150 mL) was stirred at room temperature overnight. The precipitated solid was collected by filtration to afford 10 g of (crude) of the hydrochloride salt of 8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine as a yellow solid.
  • Step 2 A mixture of 8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine hydrochloride (10 g, 39.73 mmol), DIPEA (14 g, 108.32 mmol), 4,4,4-trifluorobutanoic acid (6 g, 42.23 mmol) and HATU (16 g, 42.08 mmol) in N,N-dimethylformamide (100 mL) was stirred at room temperature overnight. The reaction mixture was evaporated; water (250 mL) and EtOAc (200 mL) were added.
  • Step 3 tert-butyl nitrite (15.20 g, 147.4 mmol) was added to a solution of 1-(4-[2-amino-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,2,3,6-tetrahydropyridin-1-yl)-4,4,4-trifluorobutan-1-one (10.0 g, 29.5 mmol) and CuI (11.23 g, 59.0 mmol) in MeCN (150 mL) under nitrogen. The mixture was stirred for 20 min at room temperature then heated at 55° C. for 30 min. The reaction mixture was allowed to cool to room temperature and the precipitated solid removed by filtration.
  • the filtrate was concentrated under vacuum and the residue was dissolved in water (500 mL).
  • the pH of the aqueous phase was adjusted to 7 by the addition of 2M aqueous sodium hydroxide solution then extracted with DCM (3 ⁇ 200 mL).
  • the combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate and concentrated.
  • the residue was purified by column chromatography eluting with DCM/EtOAc (3/1).
  • Step 4 A degassed mixture of tert-butyl-2-(4-amino-1H-pyrazol-1-yl)acetate (796 mg, 4.04 mmol), Cs 2 CO 3 (2.63 g, 8.07 mmol), 4,4,4-trifluoro-1-(4-2-iodo-[1,2,4]triazolo[1,5-a]pyridin-8-yl-1,2,3,6-tetrahydropyridin-1-yl)butan-1-one (2 g, 4.44 mmol), Pd 2 (dba) 3 .CHCl 3 (418 mg, 0.40 mmol) and XantPhos (468 mg, 0.81 mmol) in 1,4-dioxane (100 mL) was was heated at 100° C.
  • Step 5 A mixture of tert-butyl-2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetate (1.2 g, 2.31 mmol) in DCM (15 mL) and TFA (20 mL) was stirred at room temperature overnight.
  • Step 6 A mixture of 2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetic acid hydrochloride (200 mg, 0.40 mmol), DIPEA (104 mg, 0.80 mmol), N-methyl-1-(2-methylpropyl)piperidin-4-amine (88 mg, 0.52 mmol) and HATU (198 mg, 0.52 mmol) in DMF (5 mL) was stirred at room temperature for 3 h.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge Prep C18 OBD Column, 5 um, 19*150 mm,; mobile phase, water with 10 mmol NH 3 .H 2 O and MeCN (40% MeCN up to 55% over 10 min, up to 95% over 1 min, hold 95.0% for 1 min, down to 40% over 2 min); Detection, UV 254/220 nm to afford 94.3 mg (38%) of N-methyl-N-[1-(2-methylpropyl)piperidin-4-yl]-2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetamide as a yellow solid.
  • Step 1 A microwave vial was charged with 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-amine (630 mg, 2.95 mmol), 8-bromo-2-iodo-[1,2,4]triazolo[1,5-a]pyridine (960 mg, 2.96 mmol), Pd 2 (dba) 3 (150 mg, 0.16 mmol), XantPhos (170 mg, 0.29 mmol), Cs 2 CO 3 (1.9 g, 5.83 mmol) and 1,4-dioxane (15 mL). The vessel was evacuated and refilled with nitrogen 3 times. The reaction mixture was heated at 60° C. for 20 h then allowed to cool to room temperature.
  • Step 2 N-[8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1-[[2-(trimethylsilyl)-ethoxy]methyl]-1H-pyrazol-4-amine (400 mg, 0.98 mmol) and [4-(4-chlorophenyl)piperidin-4-yl]methanol (270 mg, 1.20 mmol) were coupled following the procedure detailed in Example 1j, step 3.
  • Step 3 A mixture of [4-(4-chlorophenyl)-1-[2-[(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl)amino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]methanol (650 mg, 1.17 mmol) in a saturated solution of HCl in 1,4-dioxane (20 mL) was stirred at room temperature for 20 h.
  • Step 4 A mixture of [4-(4-chlorophenyl)-1-[2-[(1H-pyrazol-4-yl)amino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]methanol (400 mg, 0.94 mmol), Cs 2 CO 3 (1.00 g, 3.07 mmol) and tert-butyl-2-bromoacetate (190 mg, 0.97 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc (100 mL) and washed with H 2 O (3 ⁇ 30 mL).
  • Step 6 A mixture of 2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetic acid (100 mg, 0.207 mmol), HATU (95 mg, 0.250 mmol), DIPEA (108 mg, 0.836 mmol) and methyl 3-(piperazin-1-yl)propanoate (72 mg, 0.418 mmol) in N,N-dimethylformamide (10 mL) was stirred at room temperature overnight then concentrated under vacuum.
  • Step 1 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol) and octahydrocyclopenta[c]pyrrol-5-ol (86 mg, 0.68 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated and the residue was purified by flash chromatography on silica eluting with DCM on a gradient of MeOH (1/10 to 1/5).
  • Step 2 A mixture of 4-[(8-[5-hydroxy-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (280 mg, 0.57 mmol), 4-methylmorpholin-4-ium-4-olate (340 mg, 2.90 mmol) and rutheniumoylolate; tetrapropylazanium (200 mg, 0.57 mmol) in DCM (20 mL) was stirred at room temperature for 0.5 h.
  • Step 1 Benzenesulfonyl chloride (329 mg, 1.86 mmol) was added dropwise to a solution of tert-butyl-4-amino-4-methylpiperidine-1-carboxylate (400 mg, 1.87 mmol) and DIPEA (1 mL, 6.05 mmol) in DCM (50 mL) at room temperature. The resulting solution was stirred for 2 h then concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1:5) to afford 540 mg (82%) of tert-butyl-4-benzene-sulfonamido-4-methylpiperidine-1-carboxylate as a white solid.
  • LCMS Methodhod 12
  • Step 1 A mixture of tert-butyl 4-benzenesulfonamido-4-methylpiperidine-1-carboxylate (350 mg, 0.99 mmol) and sodium hydride (80 mg, 3.33 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 20 min before addition of iodomethane (560 mg, 3.95 mmol). The resulting solution was stirred for 2 h at room temperature and then quenched by the addition of H 2 O (50 mL). The resulting solution was extracted with EtOAc (100 mL) and the layers separated.
  • Step 2 N-methyl-N-(4-methylpiperidin-4-yl)benzenesulfonamide hydrochloride (230 mg, 79%) was prepared from tert-butyl-4-methyl-4-(N-methylbenzene-sulfonamido)piperidine-1-carboxylate (350 mg).
  • Step 3 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (150 mg, 0.34 mmol) and N-methyl-N-(4-methylpiperidin-4-yl)benzenesulfonamide hydrochloride (150 mg, 0.49 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was allowed to cool to room temperature and the precipitated solid was removed by filtration.
  • Example 1ad 4-[[8-(4-acetamido-4-methylpiperidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-260 in Table I)
  • Step 1 Acetyl chloride (350 mg, 4.46 mmol) was added dropwise to a solution of tert-butyl 4-amino-4-methylpiperidine-1-carboxylate (600 mg, 2.80 mmol) and DIPEA (2 mL, 12.10 mmol) in DCM (50 mL). The reaction mixture was stirred at room temperature for 2 h then washed with H 2 O (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford 850 mg of tert-butyl-4-acetamido-4-methylpiperidine-1-carboxylate as brown oil.
  • Step 3 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol) and N-(4-methylpiperidin-4-yl)acetamide (106 mg, 0.68 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was allowed to cool to room temperature and the precipitated solid removed by filtration.
  • Step 1 To a solution of 4-((8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (2.5g, 5.1mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1.8, 6.12mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (360mg, 0.5 mmol) in dioxane (60 mL) was added saturated sodium carbonate (20 mL); then the reaction mixture was degassed and heated at 110° C.
  • Step 2 A mixture of tert-butyl 4-(2-((4-(methyl(1-methylpiperidin-4-yl)carbamoyl)phenyl) amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1.7 g, 3.1 mmol) in methanolic hydrochloride solution (4 M, 10 mL) was stirred at room temperature for 1.5 h.
  • Step 3 To a mixture of N-methyl-N-(1-methylpiperidin-4-yl)-4-((8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)benzamide; bis-hydrochloride salt (100 mg, 0.224 mmol) and Et 3 N (75 mg, 0.448 mmol) in dichloromethane (5 mL) was added dropwise cyclopropanecarbonyl chloride (26 mg, 0.248 mmol) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred 0.5 h. MeOH (1 ml) was added and the reaction mixture was concentrated.
  • the resultant reaction mixture was warmed to room temperature and stirred for 18 hours before the further addition of a solution of 4,4,4-trifluoro-butyric acid (1.88 g, 11.71 mmol) in dichloromethane (5 mL) and stirred for 5 hours at room temperature.
  • the reaction was quenched with water then diluted with a mixture of dichloromethane/water/acetonitrile.
  • the suspension was loaded onto a SCX-2 cartridge and eluted with a mixture of dichloromethane/methanol/water/acetonitrile.
  • the solution was concentrated in vacuo giving the title compound as a triethylamine salt.
  • the salt was suspended in dioxane (160 mL) and water (40 mL) before being treated with SCX-2 resin (50 g). The mixture was stirred for 20 minutes before the suspension was filtered and the filtrate concentrated in vacuo. The resultant residue was taken up into 1M NaOH and washed with ethyl acetate ( ⁇ 3) then diethyl ether. The yellow aqueous phase was acidified with 1M HCl to pH 5, forming a precipitate. The precipitate was collected by filtration and washed with water then diethyl ether before being dried under reduced pressure. This gave the title compound as an off white solid (3.73 g, 73%).
  • the resultant residue was quenched with water and the resultant solid collected by filtration.
  • the solid was washed with water, methanol and diethyl ether and left to air dry.
  • the solid was purified by flash column chromatography on silica eluting with toluene on a gradient of acetic acid (10-20%). Appropriate fractions were collected and evaporated to afford a solid.
  • the solid was triturated with methanol then diethyl ether to afford a white solid (6.2 g, 68%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application is a continuation of U.S. application Ser. No. 15/842,642, filed Dec. 14, 2017, which is a continuation of U.S. application Ser. No. 15/499,662, filed Apr. 27, 2017, which is a continuation of U.S. application Ser. No. 15/061,760, filed Mar. 4, 2016, which is a continuation of International Application No. PCT/CN2014/085276, filed Aug. 27, 2014, which claims the benefit of priority to U.S. Provisional Application Ser. No. 61/874,038, filed Sep. 5, 2013, each of which is incorporated herein by reference in its entirety.
    • FIELD OF THE INVENTION
  • The field of the invention pertains to compounds of Formulas 0, I and II, and subformulas thereof, that are inhibitors of a Janus kinase, such as JAK1, as well as compositions containing these compounds, and methods of use including, but not limited to, diagnosis or treatment of patients suffering from a condition responsive to the inhibition of a JAK kinase.
    • BACKGROUND OF INVENTION
  • Cytokine pathways mediate a broad range of biological functions, including many aspects of inflammation and immunity. Janus kinases (JAK), including JAK1, JAK2, JAK3 and TYK2, are cytoplasmic protein kinases that associate with type I and type II cytokine receptors and regulate cytokine signal transduction. Cytokine engagement with cognate receptors triggers activation of receptor associated JAKs and this leads to JAK-mediated tyrosine phosphorylation of signal transducer and activator of transcription (STAT) proteins and ultimately transcriptional activation of specific gene sets (Schindler et al., 2007, J. Biol. Chem. 282: 20059-63). JAK1, JAK2 and TYK2 exhibit broad patterns of gene expression, while JAK3 expression is limited to leukocytes. Cytokine receptors are typically functional as heterodimers, and as a result, more than one type of JAK kinase is usually associated with cytokine receptor complexes. The specific JAKs associated with different cytokine receptor complexes have been determined in many cases through genetic studies and corroborated by other experimental evidence. Exemplary therapeutic benefits of the inhibition of JAK enzymes are discussed, for example, in International Application No. WO 2013/014567.
  • JAK1 was initially identified in a screen for novel kinases (Wilks A. F., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:1603-1607). Genetic and biochemical studies have shown that JAK1 is functionally and physically associated with the type I interferon (e.g., IFNalpha), type II interferon (e.g., IFNgamma), and IL-2 and IL-6 cytokine receptor complexes (Kisseleva et al., 2002, Gene 285:1-24; Levy et al., 2005, Nat. Rev. Mol. Cell Biol. 3:651-662; O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131). JAK1 knockout mice die perinatally due to defects in LIF receptor signaling (Kisseleva et al., 2002, Gene 285:1-24; O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131). Characterization of tissues derived from JAK1 knockout mice demonstrated critical roles for this kinase in the IFN, IL-10, IL-2/IL-4 and IL-6 pathways. A humanized monoclonal antibody targeting the IL-6 pathway (Tocilizumab) was recently approved by the European Commission for the treatment of moderate-to-severe rheumatoid arthritis (Scheinecker et al., 2009, Nat. Rev. Drug Discov. 8:273-274).
  • CD4 T cells play an important role in asthma pathogenesis through the production of TH2 cytokines within the lung, including IL-4, IL-9 and IL-13 (Cohn et al., 2004, Annu. Rev. Immunol. 22:789-815). IL-4 and IL-13 induce increased mucus production, recruitment of eosinophils to the lung, and increased production of IgE (Kasaian et al., 2008, Biochem. Pharmacol. 76(2): 147-155). IL-9 leads to mast cell activation, which exacerbates the asthma symptoms (Kearley et al., 2011, Am. J. Resp. Crit. Care Med., 183(7): 865-875). The IL-4Rα chain activates JAK1 and binds to either IL-4 or IL-13 when combined with the common gamma chain or the IL-13Rα1 chain respectively (Pernis et al., 2002, J. Clin. Invest. 109(10):1279-1283). The common gamma chain can also combine with IL-9Rα to bind to IL-9, and IL-9Rα activates JAK1 as well (Demoulin et al., 1996, Mol. Cell Biol. 16(9):4710-4716). While the common gamma chain activates JAK3, it has been shown that JAK1 is dominant over JAK3, and inhibition of JAK1 is sufficient to inactivate signaling through the common gamma chain despite JAK3 activity (Haan et al., 2011, Chem. Biol. 18(3):314-323). Inhibition of IL-4, IL-13 and IL-9 signaling by blocking the JAK/STAT signaling pathway can alleviate asthmatic symptoms in pre-clinical lung inflammation models (Mathew et al., 2001, J. Exp. Med. 193(9): 1087-1096; Kudlacz et. al., 2008, Eur. J. Pharmacol. 582(1-3): 154-161).
  • Biochemical and genetic studies have shown an association between JAK2 and single-chain (e.g., EPO), IL-3 and interferon gamma cytokine receptor families (Kisseleva et al., 2002, Gene 285:1-24; Levy et al., 2005, Nat. Rev. Mol. Cell Biol. 3:651-662; O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131). Consistent with this, JAK2 knockout mice die of anemia (O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131). Kinase activating mutations in JAK2 (e.g., JAK2 V617F) are associated with myeloproliferative disorders in humans.
  • JAK3 associates exclusively with the gamma common cytokine receptor chain, which is present in the IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 cytokine receptor complexes. JAK3 is critical for lymphoid cell development and proliferation and mutations in JAK3 result in severe combined immunodeficiency (SCID) (O'Shea et al., 2002, Cell, 109 (suppl.): S121-S131). Based on its role in regulating lymphocytes, JAK3 and JAK3-mediated pathways have been targeted for immunosuppressive indications (e.g., transplantation rejection and rheumatoid arthritis) (Baslund et al., 2005, Arthritis & Rheumatism 52: 2686-2692; Changelian et al., 2003, Science 302: 875-878).
  • TYK2 associates with the type I interferon (e.g., IFNalpha), IL-6, IL-10, IL-12 and IL-23 cytokine receptor complexes (Kisseleva et al., 2002, Gene 285:1-24; Watford, W. T. & O'Shea, J. J., 2006, Immunity 25:695-697). Consistent with this, primary cells derived from a TYK2 deficient human are defective in type I interferon, IL-6, IL-10, IL-12 and IL-23 signaling. A fully human monoclonal antibody targeting the shared p40 subunit of the IL-12 and IL-23 cytokines (Ustekinumab) was recently approved by the European Commission for the treatment of moderate-to-severe plaque psoriasis (Krueger et al., 2007, N. Engl. J. Med. 356:580-92; Reich et al., 2009, Nat. Rev. Drug Discov. 8:355-356). In addition, an antibody targeting the IL-12 and IL-23 pathways underwent clinical trials for treating Crohn's Disease (Mannon et al., 2004, N. Engl. J. Med. 351:2069-79).
  • There exists a need in the art for additional or alternative treatments of conditions mediated by JAK kinases, such as those described above.
    • SUMMARY OF INVENTION
  • One aspect of the invention includes a compound of Formula 0:
  • Figure US20190233441A1-20190801-C00001
  • stereoisomers and salts thereof, wherein Ar1, R1a, R2-R5, X and n are defined herein.
  • One other aspect of the invention includes a compound of Formula I:
  • Figure US20190233441A1-20190801-C00002
  • stereoisomers and salts thereof, wherein Ar1, R1a, R2-R5, X and n are defined herein.
  • Another aspect of the present invention includes a compound of Formula II:
  • Figure US20190233441A1-20190801-C00003
  • and stereoisomers and salts thereof, wherein Q1 and Q2 are defined herein.
  • Also provided herein are compounds of Formulas Ia, Ib, Ic, Id, Ie, If, and Ig, as described below.
  • Another aspect includes a pharmaceutical composition that comprises a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and a pharmaceutically acceptable carrier, diluent or excipient.
  • Another aspect includes use of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for use in therapy, such as the treatment of an inflammatory disease or cancer.
  • Another aspect includes a method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase, such as JAK1 kinase, in a patient. The method can comprise administering to the patient a therapeutically effective amount of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1.
  • Another aspect includes the use of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, in the manufacture of a medicament for the treatment of a disease responsive to the inhibition of a Janus kinase, such as JAK1 kinase.
  • Another aspect includes a kit for treating a disease or disorder responsive to the inhibition of a Janus kinase, such as JAK1 kinase. The kit can comprise a first pharmaceutical composition comprising a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and instructions for use.
    • DETAILED DESCRIPTION OF THE INVENTION Definitions
  • “Halogen” or “halo” refers to F, Cl, Br or I. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
  • The term “alkyl” refers to a saturated linear or branched-chain monovalent hydrocarbon radical, wherein the alkyl radical may be optionally substituted. In one example, the alkyl radical is one to eighteen carbon atoms (C1-C18). In other examples, the alkyl radical is C0-C6, C0-C5, C0-C3, C1-C12, C1-C10, C1-C8, C1-C6, C1-C5, C1-C4, or C1-C3. C0 alkyl refers to a bond. Examples of alkyl groups include methyl (Me, —CH3), ethyl (Et, —CH2CH3), 1-propyl (n-Pr, n-propyl, —CH2CH2CH3), 2-propyl (i-Pr, i-propyl, —CH(CH3)2), 1-butyl (n-Bu, n-butyl, —CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, —CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, —CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, —C(CH3)3), 1-pentyl (n-pentyl, —CH2CH2CH2CH2CH3), 2-pentyl (—CH(CH3)CH2CH2CH3), 3-pentyl (—CH(CH2CH3)2), 2-methyl-2-butyl (—C(CH3)2CH2CH3), 3-methyl- 2-butyl (—CH(CH3)CH(CH3)2), 3-methyl-1-butyl (—CH2CH2CH(CH3)2), 2-methyl-1-butyl (—CH2CH(CH3)CH2CH3), 1-hexyl (—CH2CH2CH2CH2CH2CH3), 2-hexyl (—CH(CH3)CH2CH2CH2CH3), 3-hexyl (—CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (—C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (—CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (—CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (—C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (—CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (—C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (—CH(CH3)C(CH3)3, 1-heptyl and 1-octyl. In some embodiments, substituents for “optionally substituted alkyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • The term “alkenyl” refers to linear or branched-chain monovalent hydrocarbon radical with at least one site of unsaturation, i.e., a carbon-carbon double bond, wherein the alkenyl radical may be optionally substituted, and includes radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations. In one example, the alkenyl radical is two to eighteen carbon atoms (C2-C18). In other examples, the alkenyl radical is C2-C12, C2-C10, C2-C8, C2-C6 or C2-C3. Examples include, but are not limited to, ethenyl or vinyl (—CH═CH2), prop-1-enyl (—CH═CHCH3), prop-2-enyl (—CH2CH═CH2), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hexa-1,3-dienyl. In some embodiments, substituents for “optionally substituted alkenyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • The term “alkynyl” refers to a linear or branched monovalent hydrocarbon radical with at least one site of unsaturation, i.e., a carbon-carbon, triple bond, wherein the alkynyl radical may be optionally substituted. In one example, the alkynyl radical is two to eighteen carbon atoms (C2-C18). In other examples, the alkynyl radical is C2-C12, C2-C10, C2-C8, C2-C6 or C2-C3. Examples include, but are not limited to, ethynyl (—C≡CH), prop-1-ynyl (—CCCH3), prop-2-ynyl (propargyl, —CH2C≡CH), but-1-ynyl, but-2-ynyl and but-3-ynyl. In some embodiments, substituents for “optionally substituted alkynyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • “Alkylene” refers to a saturated, branched or straight chain hydrocarbon group having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. In one example, the divalent alkylene group is one to eighteen carbon atoms (C1-C18). In other examples, the divalent alkylene group is C0-C6, C0-C5, C0-C3, C1-C12, C1-C10, C1-C8, C1-C6, C1-C5, C1-C4, or C1-C3. The group Co alkylene refers to a bond. Example alkylene groups include methylene (—CH2—), 1,1-ethyl (—CH(CH3)—), (1,2-ethyl (—CH2CH2—), 1,1-propyl (—CH(CH2CH3)—), 2,2-propyl (—C(CH3)2—), 1,2-propyl (—CH(CH3)CH2—), 1,3-propyl (—CH2CH2CH2—), 1,1-dimethyleth-1,2-yl (—C(CH3)2CH2—), 1,4-butyl (—CH2CH2CH2CH2—), and the like.
  • “Alkenylene” refers to an unsaturated, branched or straight chain hydrocarbon group having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. In one example, the alkenylene group is two to eighteen carbon atoms (C2-C18). In other examples, the alkenylene group is C2-C12, C2-C10, C2-C8, C2-C6 or C2-C3. An exemplary alkenylene group is 1,2-ethylene (—CH═CH—).
  • “Alkynylene” refers to an unsaturated, branched or straight chain hydrocarbon group having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. In one example, the alkynylene radical is two to eighteen carbon atoms (C2-C18). In other examples, the alkynylene radical is C2-C12, C2-C10, C2-C8, C2-C6 or C2-C3. Example alkynylene radicals include: acetylene (—C≡C—), propargyl (—CH2C≡C—), and 4-pentynyl (—CH2CH2CH2C≡C—).
  • The term “heteroalkyl” refers to a straight or branched chain monovalent hydrocarbon radical, consisting of the stated number of carbon atoms, or, if none are stated, up to 18 carbon atoms, and from one to five heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms can optionally be oxidized and the nitrogen heteroatom can optionally be quaternized. In some embodiments, the heteroatom is selected from O, N and S, wherein the nitrogen and sulfur atoms can optionally be oxidized and the nitrogen heteroatom can optionally be quaternized. The heteroatom(s) can be placed at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule (e.g., —O—CH2—CH3). Examples include —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —Si(CH3)3 and —CH2—CH═N—OCH3. Up to two heteroatoms can be consecutive, such as, for example, —CH2—NH—OCH3 and —CH2—O—Si(CH3)3. Heteroalkyl groups can be optionally substituted. In some embodiments, substituents for “optionally substituted heteroalkyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • “Amidine” means the group —C(NH)—NHR in which R is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl groups are as defined herein. A particular amidine is the group —NH—C(NH)—NH2.
  • “Amino” means primary (i.e., —NH2), secondary (i.e., —NRH) and tertiary (i.e., —NRR) amines, that are optionally substituted, in which R is alkyl, cycloalkyl, aryl, or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl groups are as defined herein. Particular secondary and tertiary amines are alkylamine, dialkylamine, arylamine, diarylamine, aralkylamine and diaralkylamine, wherein the alkyl and aryl portions can be optionally substituted. Particular secondary and tertiary amines are methylamine, ethylamine, propylamine, isopropylamine, phenylamine, benzylamine, dimethylamine, diethylamine, dipropylamine and diisopropylamine.
  • “Aryl” refers to a carbocyclic aromatic group, whether or not fused to one or more groups, having the number of carbon atoms designated, or if no number is designated, up to 14 carbon atoms. One example includes aryl groups having 6-14 carbon atoms. Another example includes aryl groups having 6-10 carbon atoms. Examples of aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, 1,2,3,4-tetrahydronaphthalenyl, 1H-indenyl, 2,3-dihydro-1H-indenyl, and the like (see, e.g., Lang's Handbook of Chemistry (Dean, J. A., ed.) 13th ed. Table 7-2 [1985]). A particular aryl is phenyl. Substituted phenyl or substituted aryl means a phenyl group or aryl group substituted with one, two, three, four or five substituents, for example, 1-2, 1-3 or 1-4 substituents, such as chosen from groups specified herein (see “optionally substituted” definition), such as F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list. Examples of the term “substituted phenyl” include a mono- or di(halo)phenyl group such as 2-chlorophenyl, 2-bromophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl, 2,4-difluorophenyl and the like; a mono- or di(hydroxy)phenyl group such as 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 3- or 4-nitrophenyl; a cyanophenyl group, for example, 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 4-methylphenyl, 2,4-dimethylphenyl, 2-methylphenyl, 4-(isopropyl)phenyl, 4-ethylphenyl, 3-(n-propyl)phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 3,4-dimethoxyphenyl, 3-methoxy-4-benzyloxyphenyl, 3-ethoxyphenyl, 4-(isopropoxy)phenyl, 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 3- or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such 4-carboxyphenyl, a mono- or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 3-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 3-(N-methylsulfonylamino))phenyl. Also, the term “substituted phenyl” represents disubstituted phenyl groups where the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy-4-chlorophenyl, 2-chloro-5-difluoromethoxy and the like, as well as trisubstituted phenyl groups where the substituents are different, for example 3-methoxy-4-benzyloxy-6-methyl sulfonylamino, 3-methoxy-4-benzyloxy-6-phenyl sulfonylamino, and tetrasubstituted phenyl groups where the substituents are different such as 3-methoxy-4-benzyloxy-5-methyl-6-phenyl sulfonylamino.
  • “Cycloalkyl” refers to a non-aromatic, saturated or partially unsaturated hydrocarbon ring group wherein the cycloalkyl group may be optionally substituted independently with one or more substituents described herein. In one example, the cycloalkyl group is 3 to 12 carbon atoms (C3-C12). In other examples, cycloalkyl is C3-C8, C3-C10 or C5-C10. In other examples, the cycloalkyl group, as a monocycle, is C3-C8, C3-C6 or C5-C6. In another example, the cycloalkyl group, as a bicycle, is C7-C12. In another example, the cycloalkyl group, as a spiro system, is C5-C12. Examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, perdeuteriocyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl. Exemplary arrangements of bicyclic cycloalkyls having 7 to 12 ring atoms include, but are not limited to, [4,4], [4,5], [5,5], [5,6] or [6,6] ring systems. Exemplary bridged bicyclic cycloalkyls include, but are not limited to, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane. Examples of spiro cycloalkyl include, spiro[2.2]pentane, spiro[2.3]hexane, spiro[2.4]heptane, spiro[2.5]octane and spiro[4.5]decane. In some embodiments, substituents for “optionally substituted cycloalkyls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • “Guanidine” or “guanidinyl” means the group —NH—C(NH)—NHR in which R is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl groups are as defined herein. A particular guanidine is the group —NH—C(NH)—NH2.
  • “Heterocyclic group”, “heterocyclic”, “heterocycle”, “heterocyclyl”, or “heterocyclo” are used interchangeably and refer to any mono-, bi-, tricyclic or spiro, saturated or unsaturated, aromatic (heteroaryl) or non-aromatic (e.g., heterocycloalkyl), ring system, having 3 to 20 ring atoms, where the ring atoms are carbon, and at least one atom in the ring or ring system is a heteroatom selected from nitrogen, sulfur or oxygen. If any ring atom of a cyclic system is a heteroatom, that system is a heterocycle, regardless of the point of attachment of the cyclic system to the rest of the molecule. In one example, heterocyclyl includes 3-11 ring atoms (“members”) and includes monocycles, bicycles, tricycles and spiro ring systems, wherein the ring atoms are carbon, where at least one atom in the ring or ring system is a heteroatom selected from nitrogen, sulfur or oxygen. In one example, heterocyclyl includes 1 to 4 heteroatoms. In one example, heterocyclyl includes 1 to 3 heteroatoms. In another example, heterocyclyl includes 3- to 7-membered monocycles having 1-2, 1-3 or 1-4 heteroatoms selected from nitrogen, sulfur or oxygen. In another example, heterocyclyl includes 4- to 6-membered monocycles having 1-2, 1-3 or 1-4 heteroatoms selected from nitrogen, sulfur or oxygen. In another example, heterocyclyl includes 3-membered monocycles. In another example, heterocyclyl includes 4-membered monocycles. In another example, heterocyclyl includes 5-6 membered monocycles, e.g., 5-6 membered heteroaryl. In another example, heterocyclyl includes 3-11 membered heterocycloyalkyls, such as 4-11 membered heterocycloalkyls. In some embodiments, a heterocycloalkyl includes at least one nitrogen. In one example, the heterocyclyl group includes 0 to 3 double bonds. Any nitrogen or sulfur heteroatom may optionally be oxidized (e.g., NO, SO, SO2), and any nitrogen heteroatom may optionally be quaternized (e.g., [NR4]+Cl−, [NR4]+OH−). Example heterocycles are oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl, dihydro-1H-pyrrolyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl, piperazinyl, isoquinolinyl, tetrahydroisoquinolinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, dihydropyranyl, tetrahydropyranyl, hexahydrothiopyranyl, hexahydropyrimidinyl, oxazinanyl, thiazinanyl, thioxanyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, oxazepinyl, oxazepanyl, diazepanyl, 1,4-diazepanyl, diazepinyl, thiazepinyl, thiazepanyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,1-dioxoisothiazolidinonyl, oxazolidinonyl, imidazolidinonyl, 4,5,6,7-tetrahydro[2H]indazolyl, tetrahydrobenzoimidazolyl, 4,5,6,7-tetrahydrobenzo [d]imidazolyl, 1,6-dihydroimidazol[4,5-d]pyrrolo[2,3-b]pyridinyl, thiazinyl, oxazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl, oxathiazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, imidazolinyl, dihydropyrimidyl, tetrahydropyrimidyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, thiapyranyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrimidinonyl, pyrimidindionyl, pyrimidin-2,4-dionyl, piperazinonyl, piperazindionyl, pyrazolidinylimidazolinyl, 3-azabicyclo[3.1.0]hexanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 2-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 2-azabicyclo[2.2.2]octanyl, 8-azabicyclo[2.2.2]octanyl, 7-oxabicyclo[2.2.1]heptane, azaspiro[3.5]nonanyl, azaspiro[2.5]octanyl, azaspiro[4.5]decanyl, 1-azaspiro[4.5]decan-2-only, azaspiro[5.5]undecanyl, tetrahydroindolyl, octahydroindolyl, tetrahydroisoindolyl, tetrahydroindazolyl, 1,1-dioxohexahydrothiopyranyl. Examples of 5-membered heterocycles containing a sulfur or oxygen atom and one to three nitrogen atoms are thiazolyl, including thiazol-2-yl and thiazol-2-yl N-oxide, thiadiazolyl, including 1,3,4-thiadiazol-5-yl and 1,2,4-thiadiazol-5-yl, oxazolyl, for example oxazol-2-yl, and oxadiazolyl, such as 1,3,4-oxadiazol-5-yl, and 1,2,4-oxadiazol-5-yl. Example 5-membered ring heterocycles containing 2 to 4 nitrogen atoms include imidazolyl, such as imidazol-2-yl; triazolyl, such as 1,3,4-triazol-5-yl; 1,2,3-triazol-5-yl, 1,2,4-triazol-5-yl, and tetrazolyl, such as 1H-tetrazol-5-yl. Example benzo-fused 5-membered heterocycles are benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl. Example 6-membered heterocycles contain one to three nitrogen atoms and optionally a sulfur or oxygen atom, for example pyridyl, such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as pyrimid-2-yl and pyrimid-4-yl; triazinyl, such as 1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in particular pyridazin-3-yl, and pyrazinyl. The pyridine N-oxides and pyridazine N-oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the 1,3,4-triazin-2-yl groups, are other example heterocycle groups. Heterocycles may be optionally substituted. For example, substituents for “optionally substituted heterocycles” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • “Heteroaryl” refers to any mono-, bi-, or tricyclic ring system where at least one ring is a 5- or 6-membered aromatic ring containing from 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, and in an example embodiment, at least one heteroatom is nitrogen. See, for example, Lang's Handbook of Chemistry (Dean, J. A., ed.) 13th ed. Table 7-2 [1985]. Included in the definition are any bicyclic groups where any of the above heteroaryl rings are fused to an aryl ring, wherein the aryl ring or the heteroaryl ring is joined to the remainder of the molecule. In one embodiment, heteroaryl includes 5-6 membered monocyclic aromatic groups where one or more ring atoms is nitrogen, sulfur or oxygen. Example heteroaryl groups include thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, tetrazolo[1,5-b]pyridazinyl, imidazol[1,2-a]pyrimidinyl and purinyl, as well as benzo-fused derivatives, for example benzoxazolyl, benzofuryl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoimidazolyl and indolyl. Heteroaryl groups can be optionally substituted. In some embodiments, substituents for “optionally substituted heteroaryls” include one to four instances of F, Cl, Br, I, OH, SH, CN, NH2, NHCH3, N(CH3)2, NO2, N3, C(O)CH3, COOH, CO2CH3, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, SO2, phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, phenyl and heterocyclic portions thereof may be optionally substituted, such as by one to four instances of substituents selected from this same list.
  • “Heteroarylene” refers to a heteroaryl having two monovalent radical centers derived by the removal of two hydrogen atoms from two different atoms of a parent heteroaryl group.
  • In particular embodiments, a heterocyclyl group is attached at a carbon atom of the heterocyclyl group. By way of example, carbon bonded heterocyclyl groups include bonding arrangements at position 2, 3, 4, 5, or 6 of a pyridine ring, position 3, 4, 5, or 6 of a pyridazine ring, position 2, 4, 5, or 6 of a pyrimidine ring, position 2, 3, 5, or 6 of a pyrazine ring, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole ring, position 2, 4, or 5 of an oxazole, imidazole or thiazole ring, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole ring, position 2 or 3 of an aziridine ring, position 2, 3, or 4 of an azetidine ring, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline ring or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline ring.
  • In certain embodiments, the heterocyclyl group is N-attached. By way of example, nitrogen bonded heterocyclyl or heteroaryl groups include bonding arrangements at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline.
  • The term “alkoxy” refers to a linear or branched monovalent radical represented by the formula —OR in which R is alkyl, as defined herein. Alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, mono-, di- and tri-fluoromethoxy and cyclopropoxy.
  • “Acyl” means a carbonyl containing substituent represented by the formula —C(O)—R in which R is hydrogen, alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl and heterocyclyl are as defined herein. Acyl groups include alkanoyl (e.g., acetyl), aroyl (e.g., benzoyl), and heteroaroyl (e.g., pyridinoyl).
  • “Optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 0, 1, 2, 3, 4, or 5 or more, or any range derivable therein) of the substituents listed for that group in which said substituents may be the same or different. In an embodiment, an optionally substituted group has 1 substituent. In another embodiment an optionally substituted group has 2 substituents. In another embodiment an optionally substituted group has 3 substituents. In another embodiment an optionally substituted group has 4 substituents. In another embodiment an optionally substituted group has 5 substituents.
  • Optional substituents for alkyl radicals, alone or as part of another substituent (e.g., alkoxy), as well as alkylenyl, alkenyl, alkynyl, heteroalkyl, heterocycloalkyl, and cycloalkyl, also each alone or as part of another substituent, can be a variety of groups, such as those described herein, as well as selected from the group consisting of halogen; oxo; CN; NO; N3; —OR′; perfluoro-C1-C4 alkoxy; unsubstituted C3-C7 cycloalkyl; C3-C7 cycloalkyl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C6-C10 aryl (e.g., phenyl); C6-C10 aryl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or NR′R″; unsubstituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; —NR′R″; —SR′; —SiR′R″R″; —OC(O)R; —C(O)R; —CO2R; —CONR′R″; —OC(O)NR′R″; —NR″C(O)R; —NR′″C(O)NR′R″; —NR″C(O)2R; —S(O)2R; —S(O)2NR′R″; —NR′S(O)2R″; —NR′″S(O)2NR′R″; amidinyl; guanidinyl; —(CH2)1-4—OR; —(CH2)1-4—NR′R″; —(CH2)1-4—SR; —(CH2)1- 4—SiR′R″R″; —(CH2)1-4—OC(O)R; —(CH2)1-4—C(O)R; —(CH2)1-4—CO2R; and —(CH2)1-4CONR′R″, or combinations thereof, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″ and R′″ each independently refer to groups including, for example, hydrogen; unsubstituted C1-C6 alkyl; C1-C6 alkyl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C1-C6 heteroalkyl; C1-C6 heteroalkyl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C6-C10 aryl; C6-C10 aryl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or NR′R″; unsubstituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); and 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S and wherein the ring is optionally substituted with halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″. For example, —NR′R″ is meant to include 1-pyrrolidinyl and 4-morpholinyl.
  • Similarly, optional substituents for the aryl and heteroaryl groups are varied. In some embodiments, substituents for aryl and heteroaryl groups are selected from the group consisting of halogen; CN; NO, N3; —OR′; perfluoro-C1-C4 alkoxy; unsubstituted C3-C7 cycloalkyl; C3-C7 cycloalkyl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C6-C10 aryl (e.g., phenyl); C6-C10 aryl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or NR′R″; unsubstituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; —NR′R″; —SR; —SiR′R″R′″; —OC(O)R′; —C(O)R′; —CO2R′; —CONR′R″; —OC(O)NR′R″; —NR″C(O)R′; —NR′″C(O)NR′R″; —NR″C(O)2R′; —S(O)2R′; —S(O)2NR′R″; —NR′S(O)2R″; —NR′″S(O)2NR′R″; amidinyl; guanidinyl; —(CH2)1-4—OR′; —(CH2)1-4—NR′R″; —(CH2)1-4—SR′; —(CH2)1-4—SiR′R″R′″; —(CH2)1-4—OC(O)R′; —(CH2)1-4—C(O)R′; —(CH2)1-4—CO2R′; and —(CH2)1-4CONR′R″, or combinations thereof, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″ and R′″ each independently refer to groups including, for example, hydrogen; unsubstituted C1-C6 alkyl; C1-C6 alkyl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C1-C6 heteroalkyl; C1C6 heteroalkyl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C6-C10 aryl; C6-C10 aryl substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or NR′R″; unsubstituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); and 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) substituted by halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S and wherein the ring is optionally substituted with halogen, OH, CN, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″. For example, —NR′R″ is meant to include 1-pyrrolidinyl and 4-morpholinyl.
  • The term “oxo” refers to ═O or (═O)2.
  • As used herein a wavy line “
    Figure US20190233441A1-20190801-P00001
    ” that intersects a bond in a chemical structure indicate the point of attachment of the atom to which the wavy bond is connected in the chemical structure to the remainder of a molecule, or to the remainder of a fragment of a molecule. In some embodiments, an arrow together with an asterisk is used in the manner of a wavy line to indicate a point of attachment.
  • In certain embodiments, divalent groups are described generically without specific bonding configurations. It is understood that the generic description is meant to include both bonding configurations, unless specified otherwise. For example, in the group R1—R2—R3, if the group R2 is described as —CH2C(O)—, then it is understood that this group can be bonded both as R1—CH2C(O)—R3, and as R1—C(O)CH2—R3, unless specified otherwise.
  • The phrase “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
  • Compounds of the present invention may be in the form of a salt, such as a pharmaceutically acceptable salt. “Pharmaceutically acceptable salts” include both acid and base addition salts. “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid and the like, and organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particular base addition salts are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particular organic non-toxic bases include isopropylamine, diethylamine, ethanolamine, tromethamine, dicyclohexylamine, choline, and caffeine.
  • In some embodiments, a salt is selected from a hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate, p-toluenesulphonate, bisulphate, benzenesulphonate, ethanesulphonate, malonate, xinafoate, ascorbate, oleate, nicotinate, saccharinate, adipate, formate, glycolate, palmitate, L-lactate, D-lactate, aspartate, malate, L-tartrate, D-tartrate, stearate, furoate (e.g., 2-furoate or 3-furoate), napadisylate (naphthalene-1,5-disulfonate or naphthalene-1-(sulfonic acid)-5-sulfonate), edisylate (ethane-1,2-disulfonate or ethane-1-(sulfonic acid)-2-sulfonate), isethionate (2-hydroxyethylsulfonate), 2-mesitylenesulphonate, 2-naphthalenesulphonate, 2,5-dichlorobenzenesulphonate, D-mandelate, L-mandelate, cinnamate, benzoate, adipate, esylate, malonate, mesitylate (2-mesitylenesulphonate), napsylate (2-naphthalenesulfonate), camsylate (camphor-10-sulphonate, for example (1S)-(+)-10-camphorsulfonic acid salt), glutamate, glutarate, hippurate (2-(benzoylamino)acetate), orotate, xylate (p-xylene-2-sulphonate), and pamoic (2,2′-dihydroxy-1,1′-dinaphthylmethane-3,3′-dicarboxylate).
  • A “sterile” formulation is aseptic or free from all living microorganisms and their spores.
  • “Stereoisomers” refer to compounds that have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. Stereoisomers include diastereomers, enantiomers, conformers and the like.
  • “Chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • “Diastereomer” refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties or biological activities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography such as HPLC.
  • “Enantiomers” refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (−) are employed to designate the sign of rotation of plane-polarized light by the compound, with (−) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • The term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some of the bonding electrons.
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. A “solvate” refers to an association or complex of one or more solvent molecules and a compound of the present invention. Examples of solvents that form solvates include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. Certain compounds of the present invention can exist in multiple crystalline or amorphous forms. In general, all physical forms are intended to be within the scope of the present invention. The term “hydrate” refers to the complex where the solvent molecule is water.
  • A “metabolite” refers to a product produced through metabolism in the body of a specified compound or salt thereof. Such products can result, for example, from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
  • Metabolite products typically are identified by preparing a radiolabelled (e.g., 14C or 3H) isotope of a compound of the invention, administering it in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to a human, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS, LC/MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well known to those skilled in the art. The metabolite products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention.
  • “Amino-protecting group” as used herein refers to a derivative of the groups commonly employed to block or protect an amino group while reactions are carried out on other functional groups on the compound. Examples of such protecting groups include carbamates, amides, alkyl and aryl groups, and imines, as well as many N-heteroatom derivatives which can be removed to regenerate the desired amine group. Particular amino protecting groups are Pmb (p-Methoxybenzyl), Boc (tert-Butyloxycarbonyl), Fmoc (9-Fluorenylmethyloxycarbonyl) and Cbz (Carbobenzyloxy). Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protecting Groups in Organic Synthesis, 3rd ed., John Wiley & Sons, Inc., 1999. The term “protected amino” refers to an amino group substituted with one of the above amino-protecting groups.
  • “Carboxy-protecting group” as used herein refers to those groups that are stable to the conditions of subsequent reaction(s) at other positions of the molecule, which may be removed at the appropriate point without disrupting the remainder of the molecule, to give the unprotected carboxy-group. Examples of carboxy protecting groups include, ester groups and heterocyclyl groups. Ester derivatives of the carboxylic acid group may be employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound. Examples of such ester groups include substituted arylalkyl, including substituted benzyls, such as 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4′-dimethoxybenzhydryl, 2,2′,4,4′ -tetramethoxybenzhydryl, alkyl or substituted alkyl esters such as methyl, ethyl, t-butyl allyl or t-amyl, triphenylmethyl (trityl), 4-methoxytrityl, 4,4′-dimethoxytrityl, 4,4′,4″-trimethoxytrityl, 2-phenylprop-2-yl, thioesters such as t-butyl thioester, silyl esters such as trimethylsilyl, t-butyldimethylsilyl esters, phenacyl, 2,2,2-trichloroethyl, beta-(trimethylsilyl)ethyl, beta-(di(n-butyl)methylsilyl)ethyl, p-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, 1-(trimethylsilylmethyl)prop-1-en-3-yl, and like moieties. Another example of carboxy-protecting groups are heterocyclyl groups such as 1,3-oxazolinyl. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protecting Groups in Organic Synthesis, 3′ ed., John Wiley & Sons, Inc., 1999. The term “protected carboxy” refers to a carboxy group substituted with one of the above carboxy-protecting groups. “Hydroxy-protecting group” as used herein refers to a derivative of the hydroxy group commonly employed to block or protect the hydroxy group while reactions are carried out on other functional groups on the compound. Examples of such protecting groups include tetrahydropyranyloxy, benzoyl, acetoxy, carbamoyloxy, benzyl, and silylethers (e.g., TBS, TBDPS) groups. Further examples of these groups are found in T. W. Greene and P. G. M. Wuts, “Protecting Groups in Organic Synthesis, 3rd ed., John Wiley & Sons, Inc., 1999. The term “protected hydroxy” refers to a hydroxy group substituted with one of the above hydroxy-protecting groups.
  • A “subject,” “individual,” or “patient” is a vertebrate. In certain embodiments, the vertebrate is a mammal. Mammals include, but are not limited to, farm animals (such as cows), sport animals, pets (such as guinea pigs, cats, dogs, rabbits and horses), primates, mice and rats. In certain embodiments, a mammal is a human. In embodiments comprising administration of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, to a patient, the patient is typically in need thereof.
  • The term “Janus kinase” refers to JAK1, JAK2, JAK3 and TYK2 protein kinases. In some embodiments, a Janus kinase may be further defined as one of JAK1, JAK2, JAK3 or TYK2. In any embodiment, any one of JAK1, JAK2, JAK3 and TYK2 may be specifically excluded as a Janus kinase. In some embodiments, a Janus kinase is JAK1. In some embodiments, a Janus kinase is a combination of JAK1 and JAK2.
  • The terms “inhibiting” and “reducing,” or any variation of these terms, includes any measurable decrease or complete inhibition to achieve a desired result. For example, there may be a decrease of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, reduction of activity (e.g., JAK1 activity) compared to normal.
  • In some embodiments, a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, is selective for inhibition of JAK1 over JAK3 and TYK2. In some embodiments, a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-249, 2-1 to 2-481 or 3-1, is selective for inhibition of JAK1 over JAK2, JAK3, or TYK2, or any combination of JAK2, JAK3, or TYK2. In some embodiments, a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, is selective for inhibition of JAK1 and JAK2 over JAK3 and TYK2. In some embodiments, a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, is selective for inhibition of JAK1 over JAK3. By “selective for inhibition” it is meant that the compound is at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, better inhibitor of a particular Janus kinase (e.g., JAK1) activity compared to another particular Janus kinase (e.g., JAK1) activity, or is at least a 2-, 3-, 4-, 5-, 10-, 25-, 50-, 100-, 250-, or 500-fold better inhibitor of a particular Janus kinase (e.g., JAK1) activity compared to another particular Janus kinase (e.g., JAK1) activity.
  • “Therapeutically effective amount” means an amount of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, that (i) treats or prevents the particular disease, condition or disorder, or (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, and optionally (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. In some embodiments, the therapeutically effective amount is an amount sufficient to decrease or alleviate the symptoms of an autoimmune or inflammatory disease (e.g., asthma). In some embodiments, a therapeutically effective amount is an amount of a chemical entity described herein sufficient to significantly decrease the activity or number of B-cells. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth or kill existing cancer cells, it may be cytostatic or cytotoxic. For cancer therapy, efficacy can, for example, be measured by assessing the time to disease progression (TTP) or determining the response rate (RR).
  • “Treatment” (and variations such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, stabilized (i.e., not worsening) state of disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, prolonging survival as compared to expected survival if not receiving treatment and remission or improved prognosis. In some embodiments, compounds of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, are used to delay development of a disease or disorder or to slow the progression of a disease or disorder. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder, (for example, through a genetic mutation) or those in which the condition or disorder is to be prevented.
  • “Inflammatory disorder” refers to any disease, disorder or syndrome in which an excessive or unregulated inflammatory response leads to excessive inflammatory symptoms, host tissue damage, or loss of tissue function. “Inflammatory disorder” also refers to a pathological state mediated by influx of leukocytes or neutrophil chemotaxis.
  • “Inflammation” refers to a localized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute, or wall off (sequester) both the injurious agent and the injured tissue. Inflammation is notably associated with influx of leukocytes or neutrophil chemotaxis. Inflammation can result from infection with pathogenic organisms and viruses and from noninfectious means such as trauma or reperfusion following myocardial infarction or stroke, immune responses to foreign antigens, and autoimmune responses. Accordingly, inflammatory disorders amenable to treatment with a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, encompass disorders associated with reactions of the specific defense system as well as with reactions of the nonspecific defense system.
  • “Specific defense system” refers to the component of the immune system that reacts to the presence of specific antigens. Examples of inflammation resulting from a response of the specific defense system include the classical response to foreign antigens, autoimmune diseases, and delayed type hypersensitivity responses mediated by T-cells. Chronic inflammatory diseases, the rejection of solid transplanted tissue and organs, e.g., kidney and bone marrow transplants, and graft versus host disease (GVHD), are further examples of inflammatory reactions of the specific defense system.
  • The term “nonspecific defense system” refers to inflammatory disorders that are mediated by leukocytes that are incapable of immunological memory (e.g., granulocytes, and macrophages). Examples of inflammation that result, at least in part, from a reaction of the nonspecific defense system include inflammation associated with conditions such as adult (acute) respiratory distress syndrome (ARDS) or multiple organ injury syndromes; reperfusion injury; acute glomerulonephritis; reactive arthritis; dermatoses with acute inflammatory components; acute purulent meningitis or other central nervous system inflammatory disorders such as stroke; thermal injury; inflammatory bowel disease; granulocyte transfusion associated syndromes; and cytokine-induced toxicity.
  • “Autoimmune disease” refers to any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the body's own constituents. Non-limiting examples of autoimmune diseases include rheumatoid arthritis, lupus and multiple sclerosis.
  • “Allergic disease” as used herein refers to any symptoms, tissue damage, or loss of tissue function resulting from allergy. “Arthritic disease” as used herein refers to any disease that is characterized by inflammatory lesions of the joints attributable to a variety of etiologies. “Dermatitis” as used herein refers to any of a large family of diseases of the skin that are characterized by inflammation of the skin attributable to a variety of etiologies. “Transplant rejection” as used herein refers to any immune reaction directed against grafted tissue, such as organs or cells (e.g., bone marrow), characterized by a loss of function of the grafted and surrounding tissues, pain, swelling, leukocytosis, and thrombocytopenia. The therapeutic methods of the present invention include methods for the treatment of disorders associated with inflammatory cell activation.
  • “Inflammatory cell activation” refers to the induction by a stimulus (including, but not limited to, cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines), or cell surface expression of new or increased numbers of mediators (including, but not limited to, major histocompatability antigens or cell adhesion molecules) in inflammatory cells (including but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes (i.e., polymorphonuclear leukocytes such as neutrophils, basophils, and eosinophils), mast cells, dendritic cells, Langerhans cells, and endothelial cells). It will be appreciated by persons skilled in the art that the activation of one or a combination of these phenotypes in these cells can contribute to the initiation, perpetuation, or exacerbation of an inflammatory disorder.
  • In some embodiments, inflammatory disorders which can be treated according to the methods of this invention include, but are not limited to, asthma, rhinitis (e.g., allergic rhinitis), allergic airway syndrome, atopic dermatitis, bronchitis, rheumatoid arthritis, psoriasis, contact dermatitis, chronic obstructive pulmonary disease and delayed hypersensitivity reactions.
  • The terms “cancer” and “cancerous”, “neoplasm”, and “tumor” and related terms refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. A “tumor” comprises one or more cancerous cells. Examples of cancer include carcinoma, blastoma, sarcoma, seminoma, glioblastoma, melanoma, leukemia, and myeloid or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer) and lung cancer including small-cell lung cancer, non-small cell lung cancer (“NSCLC”), adenocarcinoma of the lung and squamous carcinoma of the lung. Other cancers include skin, keratoacanthoma, follicular carcinoma, hairy cell leukemia, buccal cavity, pharynx (oral), lip, tongue, mouth, salivary gland, esophageal, larynx, hepatocellular, gastric, stomach, gastrointestinal, small intestine, large intestine, pancreatic, cervical, ovarian, liver, bladder, hepatoma, breast, colon, rectal, colorectal, genitourinary, biliary passage, thyroid, papillary, hepatic, endometrial, uterine, salivary gland, kidney or renal, prostate, testis, vulval, peritoneum, anal, penile, bone, multiple myeloma, B-cell lymphoma, central nervous system, brain, head and neck, Hodgkin's, and associated metastases. Examples of neoplastic disorders include myeloproliferative disorders, such as polycythemia vera, essential thrombocytosis, myelofibrosis, such as primary myelofibrosis, and chronic myelogenous leukemia (CML).
  • A “chemotherapeutic agent” is an agent useful in the treatment of a given disorder, for example, cancer or inflammatory disorders. Examples of chemotherapeutic agents are well-known in the art and include examples such as those disclosed in U.S. Publ. Appl. No. 2010/0048557, incorporated herein by reference. Additionally, chemotherapeutic agents include pharmaceutically acceptable salts, acids or derivatives of any of chemotherapeutic agents, as well as combinations of two or more of them.
  • “Package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications or warnings concerning the use of such therapeutic products.
  • The terms “compound(s) of this invention,” and “compound(s) of the present invention” and the like, unless otherwise indicated, include compounds of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and stereoisomers (including atropisomers), geometric isomers, tautomers, solvates, metabolites, isotopes, salts (e.g., pharmaceutically acceptable salts), and prodrugs thereof. In some embodiments, solvates, metabolites, isotopes or prodrugs are excluded, or any combination thereof.
  • Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-249, 2-1 to 2-481 or 3-1, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 32P, 33P, 35S, 18F, 36Cl, 123I, and 125I, respectively. Isotopically-labeled compounds (e.g., those labeled with 3H and 14C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes can be useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, in compounds of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, one or more hydrogen atoms are replaced by 2H or 3H, or one or more carbon atoms are replaced by 13C- or 14C-enriched carbon. Positron emitting isotopes such as 15O, 13N, 11C, and 18F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or in the Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • It is specifically contemplated that any limitation discussed with respect to one embodiment of the invention may apply to any other embodiment of the invention. Furthermore, any compound or composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or to utilize any compound or composition of the invention.
  • The use of the term “or” is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”
  • Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.
  • As used herein, “a” or “an” means one or more, unless clearly indicated otherwise. As used herein, “another” means at least a second or more.
  • Headings used herein are intended only for organizational purposes.
    • Inhibitors of Janus Kinase
  • One aspect of the invention provides compounds of Formula 0:
  • Figure US20190233441A1-20190801-C00004
  • and stereoisomers and salts thereof, wherein:
  • Ar1 is phenylene or 3-11 membered heteroarylene (e.g., 5-11, e.g., 5-6, membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S), wherein Ar1 is optionally substituted;
  • X is —O— or —N(R1b)—(CRx1Ry1)p—, wherein Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl and p is 0 to 6, and wherein the —N(R1b)— portion of —N(R1b)—(CRx1Ry1)p— is bound to the carbonyl carbon of Formula 0;
  • R1a is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, phenyl, or 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) and R1a is optionally substituted by R9;
  • R1b is hydrogen, C1-C6 alkyl, or C3-C8 cycloalkyl, and wherein one or more alkylene units of said alkyl group is optionally substituted by —O— and wherein any alkyl or cycloalkyl group is optionally substituted by OH, or
      • when p is 0 and X is —N(R1b)—, R1a and R1b may be joined together with the nitrogen atom to which R1a and R1b is attached to form a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by R9;
  • R2 is a 3-11 membered heterocyclyl containing at least 1 nitrogen, selected from groups (a)-(e) and (h)-(j), or a C5-C8 cycloalkenyl ring (f), or a —O—(CRxRy)q—Ar2 group (g) where Rx and Ry are independently hydrogen or C1-C6 alkyl, q is 0 to 3 and Ar2 is optionally substituted C6-C10 aryl or optionally substituted (e.g., by oxo or (C1-C6 alkyl)phenyl) 5-11 membered heteroaryl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 5-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S):
  • Figure US20190233441A1-20190801-C00005
  • R3, R4 and R5 are each independently selected from the group consisting of hydrogen, CH3, CH2CH3, OCH3, CF3, F and Cl;
  • R6 and R7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaC(O)(C1-C6 alkyl), (C0-C6 alkylene)NRaC(O)(phenyl), (C0-C6 alkylene)C(O)R8a, (C0-C6 alkylene)C(O)OR8a, C1-C6 alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, —C═N—O—(C1-C6 alkyl), —O—(C1-C6 alkyl)3- 11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene)NRaSO2(C1-C6 alkyl), (C0-C6 alkylene)NRaSO2(phenyl), and —O—(3-11 membered heterocyclyl) (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); wherein said alkyl, alkylene, alkoxy, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted (e.g., by halogen, CN, oxo, OH, C1-C6 alkyl, —O(C1-C6 alkylene)—O—(C1-C6 alkylene), CONRaRb, CHF2, CH2F, CF3, —S—(C1-C6 alkyl), C1-C6 alkoxy, or NRaRb);
  • or R6 and R7 together form an optionally substituted (e.g., C1-C6 alkyl, CN or oxo) phenyl or optionally substituted (e.g., C1-C6 alkyl, CN or oxo) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R8 is H, C1-C6 alkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), C(O)NRaRb, SO2NRaRb, (C1-C6 alkylene)C(O)OR8a or C(O)R8a, wherein said alkyl, alkylene, heterocyclyl and phenyl are each independently optionally substituted (e.g., C1-C6 alkyl, C1-C6 alkoxy or CN);
  • R8a is H, NRaRb, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, or (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted (e.g., by halogen, OH, CN, NRaRb, C1-C6 alkyl, C1-C6 alkoxy, or oxo);
  • R8aa is H, C1-C6 alkyl optionally substituted by OH, or C(O)NRaRb; or
  • or R8 and R8aa together form an optionally substituted (e.g., by oxo) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R9, independently at each occurrence, is OH, halogen, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaRb, or C(O)(C1-C6 alkyl), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted (e.g., by OH, CN, halogen, NRaRb, 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), or C1-C6 alkyl optionally substituted by halogen);
  • Ra and Rb, independently at each occurrence, are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted by halogen or CN, (C0-C6 alkylene)C3-C8 cycloalkyl, or (C0-C6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted (e.g., by CN or C1-C6 alkyl) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • m1, m2, m3 and m4 are each independently 0, 1 or 2; and
  • n is 0 or 1.
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula I:
  • Figure US20190233441A1-20190801-C00006
  • and stereoisomers and salts thereof, wherein:
  • Ar1 is phenylene or 3-11 membered heteroarylene (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S), wherein Ar1 is optionally substituted;
  • X is —O— or —N(R1b)—(CRx1Ry1)p—, wherein Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl and p is 0 to 6, and wherein the —N(R1b)— portion of —N(R1b)—(CRx1Ry1)p— is bound to the carbonyl carbon of Formula I, as in:
  • Figure US20190233441A1-20190801-C00007
  • R1a is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, phenyl, or 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) and R1a is optionally substituted by R9;
  • R1b is hydrogen, C1-C6 alkyl, or C3-C8 cycloalkyl, and wherein one or more alkylene units of said alkyl group is optionally substituted by —O— and wherein any alkyl or cycloalkyl group is optionally substituted by OH, or
      • when p is 0 and X is —N(R1b)—, R1a and R1b may be joined together with the nitrogen atom to which R1a and R1b is attached to form a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S; a 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S; or the 3-11 membered heterocyclyl contains at least one nitrogen) optionally substituted by R9;
  • R2 is a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl or 4-11 membered heterocycloalkyl) containing at least 1 nitrogen, selected from groups (a)-(e), or a C5-C8 cycloalkenyl ring (f), or a —O—(CRxRy)q—Ar2 group (g) where Rx and Ry are independently hydrogen or C1-C6 alkyl, q is 0 to 3 and Ar2 is optionally substituted C6-C10 aryl or optionally substituted 5-11 membered heteroaryl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S:
  • Figure US20190233441A1-20190801-C00008
  • R3, R4 and R5 are each independently selected from the group consisting of hydrogen, CH3, CH2CH3, OCH3, CF3, F and Cl; for example, R3-R5 may each be hydrogen;
  • R6 and R7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaC(O)(C1-C6 alkyl), (C0-C6 alkylene)C(O)R8a, (C0-C6 alkylene)C(O)OR8a, C1-C6 alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, and —O— (3-11 membered heterocyclyl) (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); wherein said alkyl, alkylene, alkoxy, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted,
  • or R6 and R7 together form an optionally substituted phenyl or optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R8 is C1-C6 alkyl, (C0-C6 alkylene)phenyl, C(O)NaRb, SO2NRaRb, C(O)OR8a or C(O)R8a, wherein said alkyl, alkylene and phenyl are each independently optionally substituted;
  • R8a is C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, or (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • R8aa is H; or
  • or R8 and R8aa together form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R9, independently at each occurrence, is OH, halogen, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaRb, or C(O)(C1-C6 alkyl), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • Ra and Rb are independently at each occurrence selected from the group consisting of hydrogen, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, or (C0-C6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • m1, m2, m3 and m4 are each independently 0, 1 or 2; and
  • n is 0 or 1.
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula Ia:
  • Figure US20190233441A1-20190801-C00009
  • wherein Ar1, X, R1a, R3-R7, m1, m2 and n are as defined herein.
  • In some embodiments, in a compound of the present invention, such as a compound of Formula 0, I or Ia, m1 is 1 and m2 is 1, or m1 is 2 and m2 is 1.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or If, R6 and R7 are attached to the ring at the same carbon atom. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or If, R6 is C1-C6 alkyl or C1-C6-alkoxy, and R7 is optionally substituted phenyl, such as phenyl substituted by halogen, CN, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or If, R6 is C1-C6 alkyl, C3-C6 cycloalkyl or optionally substituted phenyl, such as phenyl substituted by halogen, CN, C1-C6 alkyl or C1-C6 alkoxy, and R7 is OH, (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)CN or —O—(C0-C6 alkyl)CN. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or If, R6 is hydrogen and R7 is selected from (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)CN, C1-C6-alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, and —O—(C1-C6 alkylene)CN. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or If, R6 and R7 together form a 3-11 membered heterocycloalkyl (such as a heterocycloalkyl containing at least one nitrogen) optionally substituted by oxo.
  • In some embodiments of compounds of the present invention, such as a compound of Formula 0, I or Ia, the moiety shown below,
  • Figure US20190233441A1-20190801-C00010
  • is selected from
  • Figure US20190233441A1-20190801-C00011
  • wherein R7a is selected from hydrogen, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and CN.
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula Ib:
  • Figure US20190233441A1-20190801-C00012
  • wherein Ar1, X, R1a, R3-R7, m1, m2 and n are as defined herein.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or Ib, m1 is 1 and m2 is 2, or m1 is 2 and m2 is 1, or m1 is 1 and m2 is 1.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or If, R6 is H and R7 and is substituted phenyl.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or Ib, the moiety shown below,
  • Figure US20190233441A1-20190801-C00013
  • is selected from
  • Figure US20190233441A1-20190801-C00014
  • wherein R7a is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl and CN.
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula Ic:
  • Figure US20190233441A1-20190801-C00015
  • wherein Ar1, X, R1a, R3-R5, R8, m3, m4 and n are as defined herein.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or Ic, m3 is 1 and m4 is 1, or m3 is 1 and m4 is 2, or m3 is 1 and m4 is 0.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ic, Id or Ie, the following moiety, shown below,
  • Figure US20190233441A1-20190801-C00016
  • is selected from
  • Figure US20190233441A1-20190801-C00017
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula Id:
  • Figure US20190233441A1-20190801-C00018
  • wherein Ar1, R1a, R1b, R3-R5, R8, m3, m4 and n are as defined herein.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or Id, m3 is 1 and m4 is 1, m3 is 1 and m4 is 1, or m3 is 1 and m4 is 2.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ic, Id, or Ie, R8 is substituted phenyl, such as mono- or disubstituted phenyl, C(O)NRaRb or C(O)R8a.
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula Ie:
  • Figure US20190233441A1-20190801-C00019
  • wherein Ar1, R1a, R1b, R3-R6, R8, m3, m4 and n are as defined herein.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or Ie, m3 is 0 and m4 is 1 or m3 is 1 and m4 is 1.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ie or If, R6 is hydrogen.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Id, Ie or If, R8 is C(O)NRaRb.
  • In some embodiments, a compound of Formula 0, is further defined as a compound of Formula If:
  • Figure US20190233441A1-20190801-C00020
  • wherein Ar1, R1a, R1b, R3-R7, m3, m4 and n are as defined herein.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or If, m3 is 1 and m4 is 1.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R7 is OH or C1-C6-alkoxy.
  • In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, one or both of R6 and R7 is located at the para position of the ring. In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 and R7 are attached to different ring atoms. In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 and R7 are both attached to the same ring atom.
  • In some embodiments, a compound of Formula 0 is further defined as a compound of Formula Ig:
  • Figure US20190233441A1-20190801-C00021
  • wherein Ar1, R1a, R1b, R3-R5, R7a and n are as defined herein, R7a is selected from hydrogen, OH, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and CN, and q is either 0 or 1, and when q is 1, then Rx and Ry are hydrogen.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar1 is unsubstituted phenylene or unsubstituted 3-11 membered heteroarylene. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar1 is optionally substituted phenylene or optionally substituted pyrazolylene. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar1 is unsubstituted phenylene or unsubstituted pyrazolylene. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar1 is unsubstituted phenylene and n is 0. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar1 is unsubstituted pyrazolylene and n is 1. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, Ar1, such as phenyl, is not substituted by halogen, methyl, methoxy, ethoxy, isopropoxy, OH, CF3, or —OCH2C(O)N(CH3)2. In some embodiments, Ar1 is not unsubstituted or substituted pyridyl.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib or Ic, the moiety
  • Figure US20190233441A1-20190801-C00022
  • is further defined as
  • Figure US20190233441A1-20190801-C00023
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, —X—R1a is C1-C6 alkoxy or —O— 3-11 membered heterocycloalkyl (such as heterocycloalkyl containing at least one nitrogen). For example, —X—R1a may be —OCH3, —OC2H5, or
  • Figure US20190233441A1-20190801-C00024
  • wherein R8a is C1-C6 alkyl.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, —X-R1a is —N(R1b)—(CRx1Ry1)p—R1a. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, R1b is C1-C6 alkyl optionally substituted by C1-C6 alkoxy, p is 0-3, Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl, R1a is C1-C6 alkyl and R9 is NRaRb. In other embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, R1b is C1-C6 alkyl optionally substituted by C1-C6 alkoxy, p is 0-3, Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl, and R1a is 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by R9. In yet other embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, p is 0 and R1a and R1b are joined to form a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by R9.In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, —X—R1a is —N(R1b)—(CRx1Ry1)p—R1a and is selected from
  • Figure US20190233441A1-20190801-C00025
    Figure US20190233441A1-20190801-C00026
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or Ic, —X—R1a is —N(R1b)—(CRx1Ry1)p—R1a and is selected from
  • Figure US20190233441A1-20190801-C00027
    Figure US20190233441A1-20190801-C00028
    Figure US20190233441A1-20190801-C00029
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R9 is optionally substituted C1-C6 alkyl or optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S). For example, in some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, or Ig, the optional substituents of optionally substituted C1-C6 alkyl of R9 or optionally substituted 3-11 membered heterocyclyl of R9 are selected from OH; CN; NRaRb; C1-C6 alkyl; C3-C8 cycloalkyl; C1-C6 alkoxy; phenyl; 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by C1-C6 alkyl or NRaRb; C(O)C1-C6 alkyl; and C(O)— 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) optionally substituted by C1-C6 alkyl.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, the group —X—R1a is a group selected from:
  • (i) A group
  • Figure US20190233441A1-20190801-C00030
  • wherein R1b and R1c are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl and p1 and p2 are independently 0, 1 or 2;
  • (ii) A group
  • Figure US20190233441A1-20190801-C00031
  • wherein R1b is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl; p is 0-6, such as 1-3; Rx and Ry are independently hydrogen or C1-C6 alkyl; Het1 is a 5-, 6- or 7-membered heterocycloalkyl ring or a 6-membered heteroaryl ring. Exemplary structures include
  • Figure US20190233441A1-20190801-C00032
  • (iii) A group
  • Figure US20190233441A1-20190801-C00033
  • wherein R1d and R1e are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl, or R1d and R1e are joined in a ring optionally containing a further heteroatom selected from O, N and S, such as one further N or one further O, and p1, p2 and p3 are independently 0, 1 or 2. An exemplary group is
  • Figure US20190233441A1-20190801-C00034
  • (iv) A group
  • Figure US20190233441A1-20190801-C00035
  • wherein p1 and p2 are independently 0, 1 or 2; Het2 is a 3-11 (e.g., 4-7) membered heterocycloalkyl ring or 3-11 (e.g., 5-6) membered heteroaryl ring.
  • Exemplary structures include
  • Figure US20190233441A1-20190801-C00036
  • (v) A group
  • Figure US20190233441A1-20190801-C00037
  • wherein p1 and p2 are independently 0, 1 or 2; Het2 is a 3-11 (e.g., 4-7) membered heterocycloalkyl or 3-11 (e.g., 5-6) membered heteroaryl ring;
  • (vi) A bridged bicyclic group such as
  • Figure US20190233441A1-20190801-C00038
  • and R1c is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl; or
  • Figure US20190233441A1-20190801-C00039
  • wherein p is 0, 1 or 2, R1d and R1e are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl, or R1d and R1e are joined in a ring optionally containing a further heteroatom selected from O, N and S, such as one further N or one further O;
  • (vii) A bridged bicyclic group such as
  • Figure US20190233441A1-20190801-C00040
  • wherein R1b is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
  • (viii) A spirocyclic group comprising two 4-, 5- or 6- membered rings optionally containing further 1-4 heteroatoms, selected from O, N and S, such as N or O, such as
  • Figure US20190233441A1-20190801-C00041
  • wherein p1, p2, p3, p4 and p5 are independently selected from 0, 1 and 2, R1b is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl, and R1c is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl. An exemplary group is
  • Figure US20190233441A1-20190801-C00042
  • (ix) A group
  • Figure US20190233441A1-20190801-C00043
  • wherein R1b, R1c and R1d are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl; p is 0-6, such as 1-3; Rx and Ry are independently hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl; or
  • (x) A bicyclic group
  • Figure US20190233441A1-20190801-C00044
  • wherein p1, p2, p3 and p4 are independently selected from 0, 1 and 2 and R1c is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl. An exemplary group is
  • Figure US20190233441A1-20190801-C00045
  • (xi) A bicyclic group
  • Figure US20190233441A1-20190801-C00046
  • wherein p1 and p2 are independently 0, 1 or 2 and one of X1 and X2 is nitrogen and the other is CH;
  • (xii) A bicyclic group
  • Figure US20190233441A1-20190801-C00047
  • wherein p1, p2, p3 and p4 are independently selected from 0, 1 and 2 and R1d and R1c are independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl or R1d and R1e are joined in a ring optionally containing a further 1-3 heteroatoms, such as O, N or S, such as a further N atom or a further O atom;
  • (xiii) A bicyclic group
  • Figure US20190233441A1-20190801-C00048
  • wherein p3 and p4 are independently 0, 1 or 2 and R1c is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl; or
  • (xiv) A bicyclic group
  • Figure US20190233441A1-20190801-C00049
  • wherein p4 is 0 or 1.
  • In some embodiments the group —X—R1a is a group selected from:
  • (i) A group
  • Figure US20190233441A1-20190801-C00050
  • wherein R1c is hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl and p1 and p2 are independently 0, 1 or 2. An exemplary group is
  • Figure US20190233441A1-20190801-C00051
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, RIa is selected from the following:
  • Figure US20190233441A1-20190801-C00052
    Figure US20190233441A1-20190801-C00053
    Figure US20190233441A1-20190801-C00054
    Figure US20190233441A1-20190801-C00055
    Figure US20190233441A1-20190801-C00056
  • and stereoisomers thereof.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, RIa is selected from the moieities shown in Table I or Table II, or stereoisomers thereof In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, RIa is not hydrogen.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R2 is selected from the following:
  • Figure US20190233441A1-20190801-C00057
    Figure US20190233441A1-20190801-C00058
    Figure US20190233441A1-20190801-C00059
    Figure US20190233441A1-20190801-C00060
    Figure US20190233441A1-20190801-C00061
    Figure US20190233441A1-20190801-C00062
    Figure US20190233441A1-20190801-C00063
    Figure US20190233441A1-20190801-C00064
    Figure US20190233441A1-20190801-C00065
    Figure US20190233441A1-20190801-C00066
    Figure US20190233441A1-20190801-C00067
    Figure US20190233441A1-20190801-C00068
    Figure US20190233441A1-20190801-C00069
    Figure US20190233441A1-20190801-C00070
  • and stereoisomers thereof.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R1b is hydrogen or CH3.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, p is 0, 1, 2 or 3. In some embodiments of a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, p is 0, 1 or 2.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, CH3, CH2CH3, OCH3, CF3, F and Cl. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R3, and R5 are each independently selected from the group consisting of hydrogen, CH3, CH2CH3, CF3, F and Cl. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R3 is hydrogen. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R4 is hydrogen. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R5 is hydrogen. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, R3, R4 and R5 are each independently hydrogen. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, none of R3, R4 and R5 are OCH3.
  • In some embodiments of a compound of the present invention such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, X is not O.
  • Another aspect of the invention provides compounds of Formula II:
  • Figure US20190233441A1-20190801-C00071
  • and stereoisomers and salts thereof, wherein:
  • Q1 is a 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl or 4-11 membered heterocycloalkyl) containing at least 1 nitrogen, selected from groups (a)-(e), or a C5-C8 cycloalkenyl ring (f), or a —O—(CRxRy)q—Ar2 group (g) where Rx and Ry are independently hydrogen or C1-C6 alkyl, q is 0 to 3 and Ar2 is optionally substituted C6-C10 aryl or optionally substituted 5-11 membered heteroaryl:
  • Figure US20190233441A1-20190801-C00072
  • R6 and R7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaC(O)(C1-C6 alkyl), (C0-C6 alkylene)C(O)R8a, (C0-C6 alkylene)C(O)OR8a, C1-C6 alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, and —O— (3-11 membered heterocyclyl) (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); wherein said alkyl, alkylene, alkoxy, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted,
  • or R6 and R7 together form an optionally substituted phenyl or optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R8 is C1-C6 alkyl, (C0-C6 alkylene)phenyl, C(O)NRaRb, SO2NRaRb, C(O)OR8a or C(O)R8a, wherein said alkyl, alkylene and phenyl are each independently optionally substituted;
  • R8a is C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, or (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • R8aa is H; or
  • or R8 and R8aa together form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • R9, independently at each occurrence, is OH, halogen, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene) NRaRb, or C(O)(C1-C6 alkyl), wherein said alkyl, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
  • Ra and Rb are independently at each occurrence hydrogen, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, or (C0-C6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S);
  • m1, m2, m3 and m4 are each independently 0, 1 or 2; and
  • Q2 is C3-C8 cycloalkyl optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, F, Cl, Br, I, OH, SH, NH2, CN or N3.
  • In certain embodiments, Q1 is ring (a). In certain embodiments, Q1 is ring (b). In certain embodiments, Q1 is ring (c). In certain embodiments, Q1 is ring (d). In certain embodiments, Q1 is ring (e). In certain embodiments, Q1 is ring (f). In certain embodiments, Q1 is ring (g). In certain embodiments, Q1 is a C3-C8 cyclopropyl ring optionally substituted with one or more substituents selected from C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, F, Cl, Br, I, OH, CN, OCF3 and N3. In certain embodiments, Q2 is a cyclopropyl group. In certain embodiments, Q2 is a cyclobutanyl group. In certain embodiments, Q2 is a cyclopentyl group. In certain embodiments, Q2 is a cyclohexyl group. In certain embodiments, Q2 is a cycloheptyl group. In certain embodiments, Q2 is a cyclooctyl group. In certain embodiments, Q1 is ring (a) and Q2 is an unsubstituted C3-C8 cycloalkyl group. In certain embodiments, Q1 is ring (a) and Q2 is an unsubstituted cyclopropyl group.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 and R7 are attached to the ring at the same carbon atom. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 and R7 are independently selected from the group consisting of hydrogen; halogen; OH; CN; phenyl; phenyl substituted by halogen, CN, C1-C6 alkyl or C1-C6 alkoxy; C1-C6 alkyl; C1-C6 alkyl substituted by OH or CN; (C0-C6 alkylene) C3-C8 cycloalkyl; (C0-C6 alkylene) 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), such as piperidinyl; (C0-C6 alkylene)C(O)NRaRb; (C0-C6 alkylene)NRaC(O)(C1-C6 alkyl); (C0-C6 alkylene) C(O)R8a; (C0-C6 alkylene) C(O)OR8a; C1-C6 alkoxy; C1-C6 alkoxy substituted by CN; —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene) C(O)NRaRb, and —O— (3-11 membered heterocyclyl) (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S).
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 is C1-C6 alkyl or C1-C6-alkoxy, and R7 is optionally substituted phenyl, such as phenyl substituted by halogen, CN, C1-C6 alkyl or C1-C6 alkoxy. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 is C1-C6 alkyl, C3-C6 cycloalkyl or optionally substituted phenyl, such as phenyl substituted by halogen, CN, C1-C6 alkyl or C1-C6 alkoxy, and R7 is OH, (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene) CN or —O—(C0-C6 alkyl)CN. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 is hydrogen and R7 is selected from (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene)CN, C1-C6-alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, and —O—(C1-C6 alkylene)CN. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, R6 and R7 together form a 3-11 membered heterocycloalkyl, such as containing 1-4 heteroatoms selected from O, N and S, optionally substituted by oxo.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, or If, optional substituents of R6 and R7, or R6 taken together with R7, are selected from the group consisting of halogen, CN, OH, oxo, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 alkoxy-C1-C6 alkyl-C1-C6 alkoxy.
  • In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ic, Id, or Ie, R8 is selected from the R8 examples of Table II. In some embodiments of compounds of the present invention, such as a compound of Formula 0, I, Ic, Id or Ie, R8 is selected from the group consisting of C1-C6 alkyl optionally substituted with halogen, CN, C1-C6 alkoxy, or OH; (C0-C6 alkylene)phenyl, such as (C0-C1 alkylene)phenyl, where the alkylene is unsubstituted, where the phenyl may be optionally substituted with halogen, CN, oxo or OH; C(O)NRaRb, wherein Ra and Rb are each independently hydrogen or C1-C6 alkyl optionally substituted by halogen, OH or CN, or Ra and Rb together form a 3-11 membered heterocycloalkyl group, such as containing 1-4 heteroatoms selected from O, N and S, optionally substituted with C1-C6 alkyl, oxo, CN or OH; SO2NRaRb, wherein Ra and Rb are each independently hydrogen or C1-C6 alkyl optionally substituted by halogen, OH or CN, or Ra and Rb together form a 3-11 membered heterocycloalkyl group, such as containing 1-4 heteroatoms selected from O, N and S, optionally substituted by C1-C6 alkyl, halogen, oxo, CN or OH; C(O)OR8a or C(O)R8a, wherein R8a is C1-C6 alkyl optionally substituted by halogen, C1-C6 alkoxy, oxo, CN or OH, or R8a is a C3-C8 cycloalkyl group optionally substituted by C1-C6 alkyl, or R8a is a 3-11 membered heterocycloyalkyl, such as containing 1-4 heteroatoms selected from O, N and S, optionally substituted by C1-C6 alkyl, halogen, oxo, CN or OH.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ic, Id or Ie, optional substituents of R8 are selected from the group consisting of halogen, oxo, CN, OH, C1-C6 alkyl, NH2, NH(C1-C6 alkyl), and N(C1-C6 alkyl)2.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ic, Id or Ie, R8 and R8aa together form a 3-11 membered heterocyclyl (e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S) optionally substituted by halogen, oxo, CN, OH, C1-C6 alkyl or C1-C6 alkoxy.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, R6, R7 and R8 are each independently selected from C(O)NRaRb, C(O)R8a, and C(O)OR8a. In some embodiments, RaRb are independently selected from hydrogen, C1-C6 alkyl, or (C1-C6 alkylene)phenyl, or Ra and Rb are taken together to form a 3-11 membered heterocyclyl (e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S) optionally substituted by halogen, C1-C6 alkyl, oxo, OH, CN, NH2, NHCH3, or N(CH3)2. In some embodiments, R8a is selected from C1-C6 alkyl optionally substituted by halogen, CN, OH, NH2, NHCH3, or N(CH3)2; C3-C8 cycloalkyl optionally substituted by C1-C6 alkyl or C1-C6 alkoxy; 3-11 membered heterocyclyl (e.g., a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1-4 heteroatoms selected from O, N and S) optionally substituted by halogen, CN, OH, oxo, NH2, NHCH3, N(CH3)2, or C1-C6 alkyl.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If or Ig, R9, independently at each occurrence, is OH; halogen; C1-C6 alkyl optionally substituted with halogen, OH, CN, C1-C6 alkoxy, 5-6 membered heteroaryl (e.g., containing 1-4 heteroatoms selected from O, N and S), 3-11 membered heterocycloalkyl (e.g., containing 1-4 heteroatoms selected from O, N and S), NH2, NHCH3, or N(CH3)2; NH2, NHCH3, or N(CH3)2; (C0-C6 alkylene) C3-C8 cycloalkyl wherein the cycloalkyl is optionally substituted by halogen, C1-C6 alkyl, CN, OH, oxo or NRaRb; (C0-C6 alkylene)phenyl wherein the phenyl is optionally substituted by halogen, CN, OH, C1-C6 alkyl, or NRaRb; (C0-C6 alkylene)3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S), wherein the heterocyclyl is optionally substituted by halogen, CN, OH, oxo, C1-C6 alkyl, C(O)C1-C6 alkyl, NRaRb or 5-6 membered heteroaryl optionally substituted by C1-C6 alkyl; (C0-C6 alkylene)C(O)NRaRb; (C0-C6 alkylene)NRaRb; or C(O)(C1-C6 alkyl); wherein unless otherwise specified, Ra and Rb are independently at each occurrence hydrogen, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, or (C0-C6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl, e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S, and wherein said optional substituents of said 3-11 membered heterocyclyl group are selected from CN, halogen, OH, C(O)CH3, 5-6 membered heteroaryl optionally substituted by C1-C6 alkyl or halogen, and C1-C6 alkyl optionally substituted by halogen, OH, CN, oxo, or C1-C6 alkoxy. In some embodiments, Ra and Rb are selected from NH2, NHCH3, and N(CH3)2.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If or Ig, an optional substituent of R9 is selected from the group consisting of halogen, CN, OH, C1-C6 alkyl, C1-C6 alkoxy, or NRaRb, wherein Ra and Rb are independently selected from the group consisting of NH2, NHCH3, and N(CH3)2, or Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl, e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S, and wherein said optional substituents of said 3-11 membered heterocyclyl group are selected from CN, halogen, OH, C(O)(C1-C6 alkyl) (e.g., C(O)CH3), 5-6 membered heteroaryl optionally substituted with C1-C6 alkyl or halogen, and C1-C6 alkyl optionally substituted by halogen, OH, CN, oxo, OH or C1-C6 alkoxy.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, Ra and Rb, independently at each occurrence, are selected from the group consisting of NH2, NHCH3, and N(CH3)2, or Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl, e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S, and wherein said optional substituents of said 3-11 membered heterocyclyl group are selected from CN, halogen, OH, C(O)(C1-C6 alkyl) (e.g., C(O)CH3), 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S optionally substituted with halogen, OH, CN or C1-C6 alkyl, and C1-C6 alkyl optionally substituted by halogen, OH, CN, oxo, OH or C1-C6 alkoxy.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0 and p is 0. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0 and p is 0-6. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 0 and p is 1-6. In some embodiments, of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 1 and p is 0. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 1 and p is 0-6. In some embodiments of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, or Ig, n is 1 and p is 1-6.
  • In some embodiments of a compound of the present invention, such as a compound of Formula 0, I or II, Ar2 is unsubstituted phenyl. In some embodiments in a compound of the present invention, such as a compound of Formula 0, I or II, Ar2 is unsubstituted phenyl, q is 0 or 1, and Rx and Ry are each independently hydrogen. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ia. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ib. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ic. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Id. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ie. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula If. In some embodiments, a compound of Formula 0 or I excludes a compound of Formula Ig. In some embodiments, a compound of Formula 0 or I excludes two or more compounds of Formula Ia, Ib, Ic, Id, le, If or Ig.
  • In any compound of the present invention, including a compound of Formula 0 or I, Ia, Ib, Ic, Id, le, If, or Ig, any substituent indicated as “optionally substituted”, such as portions of R2, R6, R7, R6 together with R7, R8, R8a, R8 together with R8aa, or R9, may be optionally substituted by, e.g., halogen; oxo; CN; NO, N3; —OR; perfluoro-C1-C4 alkoxy; unsubstituted C3-C7 cycloalkyl; C3-C7 cycloalkyl substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C6-C10 aryl (e.g., phenyl); C6-C10 aryl substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or NR′R″; unsubstituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; —NR′R″; —SR; —SiR′R″R′″; —OC(O)R′; —C(O)R′; —CO2R′; —CONR′R″; —OC(O)NR′R″; —NR″C(O)R′; —NR′″C(O)NR′R″; —NR″C(O)2R′; —S(O)2R′; —S(O)2NR′R″; —NR′S(O)2R″; —NR′″S(O)2NR′R″; amidinyl; guanidinyl; —(CH2)1-4—OR′; —(CH2)1-4—NR′R″; —(CH2)1-4—SR′; —(CH2)1-4—SiR′R″R′″; —(CH2)1-4—OC(O)R′; —(CH2)1-4—C(O)R′; —(CH2)1-4—CO2R′; and —(CH2)1-4CONR′R″, or combinations thereof, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R′, R″ and R′″ each independently refer to groups including, for example, hydrogen; unsubstituted C1-C6 alkyl; C1-C6 alkyl substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C1-C6 heteroalkyl; C1-C6 heteroalkyl substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″; unsubstituted C6-C10 aryl; C6-C10 aryl substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, or NR′R″; unsubstituted 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S); and 3-11 membered heterocyclyl (e.g., 5-6 membered heteroaryl containing 1 to 4 heteroatoms selected from O, N and S or 4-11 membered heterocycloalkyl containing 1 to 4 heteroatoms selected from O, N and S) substituted by halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S and wherein the ring is optionally substituted with halogen, CN, OH, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, oxo or NR′R″.
  • Also provided is a compound selected from Examples 1-1 to 1-303, 2-1 to 2-486 and 3-1, or any combination thereof. See Table A. Although specific salts may be shown in Table A, it is to be understood that other salts are contemplated, as described herein. Should there be any discrepancy between an Example's structure in Table A and an Example of Table I or II, Table A's structure prevails.
  • TABLE A
    Exemplary Compounds of the Present Invention
    Ex. Structure Name
    1-1
    Figure US20190233441A1-20190801-C00073
         		N-methyl-4-[[8-(4- methyl-4-phenyl-1- piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methyl-4- piperidyl)benzamide; hydrochloride
    1-2
    Figure US20190233441A1-20190801-C00074
         		4-[[8-(4-cyclohexyl-4- hydroxy-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-3
    Figure US20190233441A1-20190801-C00075
         		4-[[8-(4-hydroxy-1- piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; hydrochloride
    1-4
    Figure US20190233441A1-20190801-C00076
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(4- phenyl-3,6-dihydro-2H- pyridin-1-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-5
    Figure US20190233441A1-20190801-C00077
         		4-[[8-(4-methoxy-4- phenyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; hydrochloride
    1-6
    Figure US20190233441A1-20190801-C00078
         		4-[[8-(4-hydroxy-4- methyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; hydrochloride
    1-7
    Figure US20190233441A1-20190801-C00079
         		4-[[8-(4-hydroxy-4- phenyl-azepan-1-yl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-8
    Figure US20190233441A1-20190801-C00080
         		4-[[8-(4-methoxy-1- piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-9
    Figure US20190233441A1-20190801-C00081
         		4-[[8-(4-acetamido-1- piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; hydrochloride
    1-10
    Figure US20190233441A1-20190801-C00082
         		4-[[8-(4-acetylpiperazin- 1-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-11
    Figure US20190233441A1-20190801-C00083
         		4-[[8-(4-cyano-1- piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-12
    Figure US20190233441A1-20190801-C00084
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(1- piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide; dihydrochloride
    1-13
    Figure US20190233441A1-20190801-C00085
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(4- phenylpiperazin-1-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-14
    Figure US20190233441A1-20190801-C00086
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(4- phenyl-2,3,6,7- tetrahydroazepin-1-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-15
    Figure US20190233441A1-20190801-C00087
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(5- phenyl-2,3,4,7- tetrahydroazepin-1-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-16
    Figure US20190233441A1-20190801-C00088
         		4-[[8-(4-fluoro-4- phenyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-17
    Figure US20190233441A1-20190801-C00089
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-18
    Figure US20190233441A1-20190801-C00090
         		4-[[8-[4-(3- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-19
    Figure US20190233441A1-20190801-C00091
         		4-[[8-[4-hydroxy-4-(3- pyridyl)-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-20
    Figure US20190233441A1-20190801-C00092
         		4-[[8-[4-hydroxy-4-(4- pyridyl)-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-21
    Figure US20190233441A1-20190801-C00093
         		4-[[8-[4-(4- cyanophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-22
    Figure US20190233441A1-20190801-C00094
         		4-[[8-[4-(3- cyanophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-23
    Figure US20190233441A1-20190801-C00095
         		4-[[8-[4- (cyanomethoxy)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-24
    Figure US20190233441A1-20190801-C00096
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(2- oxo-1-oxa-3,7- diazaspiro[4.4]nonan-7- yl)-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-25
    Figure US20190233441A1-20190801-C00097
         		4-[[8-[(9aS)- 3,4,6,7,9,9a-hexahydro- 1H-pyrazino[2,1- c][1,4]oxazin-8-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-26
    Figure US20190233441A1-20190801-C00098
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(8- oxo-2,7- diazaspiro[4.4]nonan-2- yl)-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-27
    Figure US20190233441A1-20190801-C00099
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(3- oxo-2,8- diazaspiro[4.5]decan-8- yl)-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-28
    Figure US20190233441A1-20190801-C00100
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(2- oxo-1-oxa-3,8- diazaspiro[4.5]decan-8- yl)-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-29
    Figure US20190233441A1-20190801-C00101
         		4-[[8-[4-(1-hydroxy-1- methyl-ethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-30
    Figure US20190233441A1-20190801-C00102
         		4-[[8-[4-(2-amino-2- oxo-ethyl)-4-phenyl-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-31
    Figure US20190233441A1-20190801-C00103
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(6- oxo-3,4,7,8,9,9a- hexahydro-1H- pyrazino[1,2- c]pyrimidin-2-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-32
    Figure US20190233441A1-20190801-C00104
         		4-[[8-[(9aS)-4-oxo- 6,7,9,9a-tetrahydro-1H- pyrazino[2,1- c][1,4]oxazin-8-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-33
    Figure US20190233441A1-20190801-C00105
         		4-[[8-[(9aR)-4-oxo- 6,7,9,9a-tetrahydro-1H- pyrazino[2,1- c][1,4]oxazin-8-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-34
    Figure US20190233441A1-20190801-C00106
         		4-[[8-[4-(3,3- dimethylazetidine-1- carbonyl)piperazin-1- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-35
    Figure US20190233441A1-20190801-C00107
         		4-[[8-[4-(2- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-36
    Figure US20190233441A1-20190801-C00108
         		4-[[8-[4-(4-ethylphenyl)- 4-hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-37
    Figure US20190233441A1-20190801-C00109
         		4-[[8-[4-(4- fluorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-38
    Figure US20190233441A1-20190801-C00110
         		4-[[8-[4-hydroxy-4-(4- isopropylphenyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-39
    Figure US20190233441A1-20190801-C00111
         		4-[[8-[4-hydroxy-4-(p- tolyl)-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-40
    Figure US20190233441A1-20190801-C00112
         		4-[[8-[4-hydroxy-4-(4- methoxyphenyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-41
    Figure US20190233441A1-20190801-C00113
         		4-[[8-[4-(cyanomethyl)- 4-phenyl-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-42
    Figure US20190233441A1-20190801-C00114
         		4-[[8-[4-(3,3- dimethylazetidine-1- carbonyl)-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-43
    Figure US20190233441A1-20190801-C00115
         		4-[[8-(4-hydroxy-4- phenyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-44
    Figure US20190233441A1-20190801-C00116
         		4-[[8-[4-[[2-(2- methoxyethoxy)-4- pyridyl]methoxy]-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-45
    Figure US20190233441A1-20190801-C00117
         		4-[8-(4-cyano-4- phenyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-46
    Figure US20190233441A1-20190801-C00118
         		4-[[8-(3,4-dihydro-1H- isoquinolin-2-yl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-47
    Figure US20190233441A1-20190801-C00119
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3- (methylamino)azetidin- 1-yl]methanone
    1-48
    Figure US20190233441A1-20190801-C00120
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2- methyl-1,3,3a,4,6,6a- hexahydropyrrolo[3,4- c]pyrrol-5-yl)methanone
    1-49
    Figure US20190233441A1-20190801-C00121
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(7- methyl-9-oxa-3,7- diazabicyclo[3.3.1]nonan- 3-yl)methanone
    1-50
    Figure US20190233441A1-20190801-C00122
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(9- methyl-3-oxa-7,9- diazabicyclo[3.3.1]nonan- 7-yl)methanone
    1-51
    Figure US20190233441A1-20190801-C00123
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- hydroxy-4-(pyrrolidin-1- ylmethyl)azepan-1- yl]methanone
    1-52
    Figure US20190233441A1-20190801-C00124
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(1- methyl-2- piperidyl)pyrrolidin-1- yl]methanone
    1-53
    Figure US20190233441A1-20190801-C00125
         		1-[2-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-2,6- diazaspiro[3.3]heptan-6- yl]ethanone
    1-54
    Figure US20190233441A1-20190801-C00126
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(4- cyclopropylpiperazin-1- yl)methanone
    1-55
    Figure US20190233441A1-20190801-C00127
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(3- methyl-3,6- diazabicyclo[3.2.1]octan- 6-yl)methanone
    1-56
    Figure US20190233441A1-20190801-C00128
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(4- cyclobutylpiperazin-1- yl)methanone
    1-57
    Figure US20190233441A1-20190801-C00129
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(5-methyl-3- pyridyl)methyl]benzamide
    1-58
    Figure US20190233441A1-20190801-C00130
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(6-methyl-3- pyridyl)methyl]benzamide
    1-59
    Figure US20190233441A1-20190801-C00131
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(7- methyl-2,7- diazaspiro[3.4]octan-2- yl)methanone
    1-60
    Figure US20190233441A1-20190801-C00132
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(5- methyl-2,5- diazaspiro[3.4]octan-2- yl)methanone
    1-61
    Figure US20190233441A1-20190801-C00133
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(4-methyl-1- piperidyl)ethyl]benzamide
    1-62
    Figure US20190233441A1-20190801-C00134
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methylpyrrolidin- 3-yl)benzamide
    1-63
    Figure US20190233441A1-20190801-C00135
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(4-methyl-2- pyridyl)methyl]benzamide
    1-64
    Figure US20190233441A1-20190801-C00136
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(2-methyl-3- pyridyl)methyl]benzamide
    1-65
    Figure US20190233441A1-20190801-C00137
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(1-ethylpyrrolidin- 3-yl)methyl]-N-methyl- benzamide
    1-66
    Figure US20190233441A1-20190801-C00138
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(8- methyl-2,8- diazaspiro[5.5]undecan- 2-yl)methanone
    1-67
    Figure US20190233441A1-20190801-C00139
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-[(1- methylimidazol-2- yl)methyl]piperazin-1- yl]methanone
    1-68
    Figure US20190233441A1-20190801-C00140
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(3- pyridyl)pyrrolidin-1- yl]methanone
    1-69
    Figure US20190233441A1-20190801-C00141
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[6- (hydroxymethyl)-4- methyl-1,4-diazepan-1- yl]methanone
    1-70
    Figure US20190233441A1-20190801-C00142
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(8- methyl-5-oxa-2,8- diazaspiro[3.5]nonan-2- yl)methanone
    1-71
    Figure US20190233441A1-20190801-C00143
         		4-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]- N,N,1-trimethyl- piperazine-2- carboxamide
    1-72
    Figure US20190233441A1-20190801-C00144
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(5- methyl-2- pyridyl)pyrrolidin-1- yl]methanone
    1-73
    Figure US20190233441A1-20190801-C00145
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-[6- (dimethylamino)-2- methyl-pyrimidin-4-yl]- 1-piperidyl]methanone
    1-74
    Figure US20190233441A1-20190801-C00146
         		1-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-N,N- dimethyl-2-(4- pyridyl)pyrrolidine-2- carboxamide
    1-75
    Figure US20190233441A1-20190801-C00147
         		[(3aS,6aS)-1-methyl- 2,3,3a,4,6,6a- hexahydropyrrolo[3,4- b]pyrrol-5-yl]-[4-[[8-[4- (4-chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-76
    Figure US20190233441A1-20190801-C00148
         		[(3aS,6aS)-5-methyl- 2,3,3a,4,6,6a- hexahydropyrrolo[2,3- c]pyrrol-1-yl]-[4-[[8-[4- (4-chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-77
    Figure US20190233441A1-20190801-C00149
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- [(dimethylamino)methyl]- 4-hydroxy-azepan-1- yl]methanone
    1-78
    Figure US20190233441A1-20190801-C00150
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(4- methylpiperazine-1- carbonyl)morpholin-4- yl]methanone
    1-79
    Figure US20190233441A1-20190801-C00151
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-[4- (dimethylamino)-6- methyl-2- pyridyl]pyrrolidin-1- yl]methanone
    1-80
    Figure US20190233441A1-20190801-C00152
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-[2- (dimethylamino)ethyl]- 1-piperidyl]methanone
    1-81
    Figure US20190233441A1-20190801-C00153
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(7- methyl-2,7- diazaspiro[3.5]nonan-2- yl)methanone
    1-82
    Figure US20190233441A1-20190801-C00154
         		1-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]- N,N,4-trimethyl- piperazine-2- carboxamide
    1-83
    Figure US20190233441A1-20190801-C00155
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(4- pyridyl)-1- piperidyl]methanone
    1-84
    Figure US20190233441A1-20190801-C00156
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- hydroxyethyl)piperazin- 1-yl]methanone
    1-85
    Figure US20190233441A1-20190801-C00157
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-[2-(2- pyridyl)ethyl]benzamide
    1-86
    Figure US20190233441A1-20190801-C00158
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- (dimethylamino)-1- piperidyl]methanone
    1-87
    Figure US20190233441A1-20190801-C00159
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1- methylpyrrolidin-3- yl)benzamide
    1-88
    Figure US20190233441A1-20190801-C00160
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3- (dimethylamino)pyrrolidin- 1-yl]methanone
    1-89
    Figure US20190233441A1-20190801-C00161
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(3R)-quinuclidin-3- yl]benzamide
    1-90
    Figure US20190233441A1-20190801-C00162
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(4- methylpiperazin-1- yl)methanone
    1-91
    Figure US20190233441A1-20190801-C00163
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(2,6- dimethylmorpholin-4- yl)ethyl]benzamide
    1-92
    Figure US20190233441A1-20190801-C00164
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methylazetidin-3- yl)benzamide
    1-93
    Figure US20190233441A1-20190801-C00165
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1,1-dimethyl-2- morpholino- ethyl)benzamide
    1-94
    Figure US20190233441A1-20190801-C00166
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2-methyl-2- morpholino- propyl)benzamide
    1-95
    Figure US20190233441A1-20190801-C00167
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(4-hydroxy-1- piperidyl)ethyl]benzamide
    1-96
    Figure US20190233441A1-20190801-C00168
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[3-(4- methylpiperazin-1- yl)propyl]benzamide
    1-97
    Figure US20190233441A1-20190801-C00169
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(4- methylpiperazin-1- yl)ethyl]benzamide
    1-98
    Figure US20190233441A1-20190801-C00170
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(3- morpholinopropyl)benzamide
    1-99
    Figure US20190233441A1-20190801-C00171
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[1-methyl-2-(1- piperidyl)ethyl]benzamide
    1-100
    Figure US20190233441A1-20190801-C00172
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(3-methyl-1- piperidyl)ethyl]benzamide
    1-101
    Figure US20190233441A1-20190801-C00173
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2- morpholinoethyl)benzamide
    1-102
    Figure US20190233441A1-20190801-C00174
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(1- methylpyrrolidin-2- yl)ethyl]benzamide
    1-103
    Figure US20190233441A1-20190801-C00175
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(l-methyl-2- piperidyl)methyl]benzamide
    1-104
    Figure US20190233441A1-20190801-C00176
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(1-methyl-4- piperidyl)methyl]benzamide
    1-105
    Figure US20190233441A1-20190801-C00177
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methyl-4- piperidyl)benzamide
    1-106
    Figure US20190233441A1-20190801-C00178
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2-pyrrolidin-1- ylethyl)benzamide
    1-107
    Figure US20190233441A1-20190801-C00179
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(dimethylamino)- 1-methyl-ethyl]benzamide
    1-108
    Figure US20190233441A1-20190801-C00180
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2- (dimethylami- no)ethyl]benzamide
    1-109
    Figure US20190233441A1-20190801-C00181
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-[(3-methyl-2- pyridyl)methyl]benzamide
    1-110
    Figure US20190233441A1-20190801-C00182
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(3- pyridyl)-1- piperidyl]methanone
    1-111
    Figure US20190233441A1-20190801-C00183
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(4- pyridylmethyl)benzamide
    1-112
    Figure US20190233441A1-20190801-C00184
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- pyridyl)piperazin-1- yl]methanone
    1-113
    Figure US20190233441A1-20190801-C00185
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(4- methylpiperazine-1- carbonyl)-1- piperidyl]methanone
    1-114
    Figure US20190233441A1-20190801-C00186
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(4- pyridyl)-1,4-diazepan-1- yl]methanone
    1-115
    Figure US20190233441A1-20190801-C00187
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-ethyl-N-(4- pyridylmethyl)benzamide
    1-116
    Figure US20190233441A1-20190801-C00188
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- imidazol-1- ylethyl)piperazin-1- yl]methanone
    1-117
    Figure US20190233441A1-20190801-C00189
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(4- methylpiperazin-1-yl)-1- piperidyl]methanone
    1-118
    Figure US20190233441A1-20190801-C00190
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- (2,6-dimethylmorpholin- 4-yl)-1- piperidyl]methanone
    1-119
    Figure US20190233441A1-20190801-C00191
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- morpholinoethyl)piperazin- 1-yl]methanone
    1-120
    Figure US20190233441A1-20190801-C00192
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2-methoxyethyl)-N- (1-methyl-4- piperidyl)benzamide
    1-121
    Figure US20190233441A1-20190801-C00193
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(2- pyridylmethyl)-1- piperidyl]methanone
    1-122
    Figure US20190233441A1-20190801-C00194
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- pyridylmethyl)piperazin- 1-yl]methanone
    1-123
    Figure US20190233441A1-20190801-C00195
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(3- pyridylmethyl)piperazin- 1-yl]methanone
    1-124
    Figure US20190233441A1-20190801-C00196
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(2- pyridylmethyl)pyrrolidin- 1-yl]methanone
    1-125
    Figure US20190233441A1-20190801-C00197
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(4- morpholino-1- piperidyl)methanone
    1-126
    Figure US20190233441A1-20190801-C00198
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(3- pyridyl)piperazin-1- yl]methanone
    1-127
    Figure US20190233441A1-20190801-C00199
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(3- morpholinopyrrolidin-1- yl)methanone
    1-128
    Figure US20190233441A1-20190801-C00200
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-cyclopropyl-N-(1- methyl-4- piperidyl)benzamide
    1-129
    Figure US20190233441A1-20190801-C00201
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(1-isopropylpyrrolidin- 3-yl)methyl]-N-methyl- benzamide
    1-130
    Figure US20190233441A1-20190801-C00202
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-isopropyl-4- piperidyl)-N-methyl- benzamide
    1-131
    Figure US20190233441A1-20190801-C00203
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(4- isobutylpiperazin-1- yl)methanone
    1-132
    Figure US20190233441A1-20190801-C00204
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(4- pyrrolidin-1-yl-1- piperidyl)methanone
    1-133
    Figure US20190233441A1-20190801-C00205
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- methoxyethyl)piperazin- 1-yl]methanone
    1-134
    Figure US20190233441A1-20190801-C00206
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-[2-(3- pyridyl)ethyl]benzamide
    1-135
    Figure US20190233441A1-20190801-C00207
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-[2-(4- pyridyl)ethyl]benzamide
    1-136
    Figure US20190233441A1-20190801-C00208
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- (cyclopropylmethyl)piperazin- 1-yl]methanone
    1-137
    Figure US20190233441A1-20190801-C00209
         		1,3,4,6,7,8,9,9a- octahydropyrido[1,2- a]pyrazin-2-yl-[4-[[8-[4- (4-chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-138
    Figure US20190233441A1-20190801-C00210
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(3- pyridylmethyl)benzamide
    1-139
    Figure US20190233441A1-20190801-C00211
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-[2- (dimethylami- no)ethyl]piperazin- 1-yl]methanone
    1-140
    Figure US20190233441A1-20190801-C00212
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[1-(6-methyl-2- pyridyl)ethyl]benzamide
    1-141
    Figure US20190233441A1-20190801-C00213
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(1-methyl-3- piperidyl)methyl]benzamide
    1-142
    Figure US20190233441A1-20190801-C00214
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-cyclopropyl-N-(2- pyridylmethyl)benzamide
    1-143
    Figure US20190233441A1-20190801-C00215
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(3- morpholino-1- piperidyl)methanone
    1-144
    Figure US20190233441A1-20190801-C00216
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- pyridyl)-1- piperidyl]methanone
    1-145
    Figure US20190233441A1-20190801-C00217
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(3- pyridylmethyl)-1- piperidyl]methanone
    1-146
    Figure US20190233441A1-20190801-C00218
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(4- pyridylmethyl)pyrrolidin- 1-yl]methanone
    1-147
    Figure US20190233441A1-20190801-C00219
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(4- pyridyl)pyrrolidin-1- yl]methanone
    1-148
    Figure US20190233441A1-20190801-C00220
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(2- pyridyl)morpholin-4- yl]methanone
    1-149
    Figure US20190233441A1-20190801-C00221
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(2- pyridyl)-1- piperidyl]methanone
    1-150
    Figure US20190233441A1-20190801-C00222
         		4-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-N- methyl-1-(2- phenylethyl)piperazine- 2-carboxamide
    1-151
    Figure US20190233441A1-20190801-C00223
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-[[6- (dimethylamino)pyrimidin- 4-yl]methyl]pyrrolidin-1- yl]methanone
    1-152
    Figure US20190233441A1-20190801-C00224
         		1-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-N,4- dimethyl-piperazine-2- carboxamide
    1-153
    Figure US20190233441A1-20190801-C00225
         		1-benzyl-4-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-N- methyl-piperazine-2- carboxamide
    1-154
    Figure US20190233441A1-20190801-C00226
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(1-methyl-4- piperidyl)ethyl]benzamide
    1-155
    Figure US20190233441A1-20190801-C00227
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(3- pyridylmethyl)pyrrolidin- 1-yl]methanone
    1-156
    Figure US20190233441A1-20190801-C00228
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-[(5- methyl-2- pyridyl)methyl]pyrrolidin- 1-yl]methanone
    1-157
    Figure US20190233441A1-20190801-C00229
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(2- pyridylmethyl)pyrrolidin- 1-yl]methanone
    1-158
    Figure US20190233441A1-20190801-C00230
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- pyridylmethyl)-1- piperidyl]methanone
    1-159
    Figure US20190233441A1-20190801-C00231
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(6-methyl-2- pyridyl)ethyl]benzamide
    1-160
    Figure US20190233441A1-20190801-C00232
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(3- pyridyl)ethyl]benzamide
    1-161
    Figure US20190233441A1-20190801-C00233
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(4- pyridyl)ethyl]benzamide
    1-162
    Figure US20190233441A1-20190801-C00234
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(2- pyridyl)ethyl]benzamide
    1-163
    Figure US20190233441A1-20190801-C00235
         		4-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-N,1- dimethyl-piperazine-2- carboxamide
    1-164
    Figure US20190233441A1-20190801-C00236
         		1-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-N,N- dimethyl-azetidine-3- carboxamide
    1-165
    Figure US20190233441A1-20190801-C00237
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(4- methylpiperazine-1- carbonyl)azetidin-1- yl]methanone
    1-166
    Figure US20190233441A1-20190801-C00238
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[(3S)-3- (dimethylamino)pyrrolidin- 1-yl]methanone
    1-167
    Figure US20190233441A1-20190801-C00239
         		3-[4-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazin- 1-yl]propanenitrile
    1-168
    Figure US20190233441A1-20190801-C00240
         		3,4,6,7,8,8a-hexahydro- 1H-pyrrolo[1,2- a]pyrazin-2-yl-[4-[[8-[4- (4-chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-169
    Figure US20190233441A1-20190801-C00241
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(6- quinolylmethyl)benzamide
    1-170
    Figure US20190233441A1-20190801-C00242
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-[(1-methyl-3- piperidyl)methyl]benzamide
    1-171
    Figure US20190233441A1-20190801-C00243
         		N-(1-benzylpyrrolidin-3- yl)-4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-benzamide
    1-172
    Figure US20190233441A1-20190801-C00244
         		[4-[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- (tetrahydrofuran-2- ylmethyl)piperazin-1- yl]methanone
    1-173
    Figure US20190233441A1-20190801-C00245
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(1- piperidyl)ethyl]benzamide
    1-174
    Figure US20190233441A1-20190801-C00246
         		1-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]-4- isopropyl-N-methyl- piperazine-2- carboxamide
    1-175
    Figure US20190233441A1-20190801-C00247
         		N-(2-aminoethyl)-4-[[8- [4-(4-chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-176
    Figure US20190233441A1-20190801-C00248
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-pyrrolidin-3-yl- benzamide
    1-177
    Figure US20190233441A1-20190801-C00249
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]- piperazin-1-yl- methanone
    1-178
    Figure US20190233441A1-20190801-C00250
         		(1-methyl-4-piperidyl)- 4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoate
    1-179
    Figure US20190233441A1-20190801-C00251
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(3- piperidyl)benzamide
    1-180
    Figure US20190233441A1-20190801-C00252
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(pyrrolidin-3- ylmethyl)benzamide
    1-181
    Figure US20190233441A1-20190801-C00253
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(4- piperidyl)benzamide
    1-182
    Figure US20190233441A1-20190801-C00254
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(pyrrolidin-2- ylmethyl)benzamide
    1-183
    Figure US20190233441A1-20190801-C00255
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(3- piperidylmethyl)benzamide
    1-184
    Figure US20190233441A1-20190801-C00256
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(4- piperidylmethyl)benzamide
    1-185
    Figure US20190233441A1-20190801-C00257
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2- piperidylmethyl)benzamide
    1-186
    Figure US20190233441A1-20190801-C00258
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(3- piperidyl)ethyl]benzamide
    1-187
    Figure US20190233441A1-20190801-C00259
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2-piperazin-1- ylethyl)benzamide
    1-188
    Figure US20190233441A1-20190801-C00260
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(morpholin-2- ylmethyl)benzamide
    1-189
    Figure US20190233441A1-20190801-C00261
         		(3-aminoazetidin-1-yl)- [4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-190
    Figure US20190233441A1-20190801-C00262
         		3,3a,4,5,6,6a-hexahydro- 2H-pyrrolo[2,3-c]pyrrol- 1-yl-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-191
    Figure US20190233441A1-20190801-C00263
         		[3-(aminomethyl)azetidin- 1-yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-192
    Figure US20190233441A1-20190801-C00264
         		[3-(aminomethyl)pyrrolidin- 1-yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-193
    Figure US20190233441A1-20190801-C00265
         		[4-(aminomethyl)-1- piperidyl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-194
    Figure US20190233441A1-20190801-C00266
         		N-(2-aminoethyl)-4-[[8- [4-(4-chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-benzamide
    1-195
    Figure US20190233441A1-20190801-C00267
         		[2-(aminomethyl)pyrrolidin- 1-yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-196
    Figure US20190233441A1-20190801-C00268
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2- (hydroxymethyl)piperazin- 1-yl]methanone
    1-197
    Figure US20190233441A1-20190801-C00269
         		2,3,3a,4,6,6a-hexahydro- 1H-pyrrolo[3,4-c]pyrrol- 5-yl-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-198
    Figure US20190233441A1-20190801-C00270
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(3S)-3- piperidyl]benzamide
    1-199
    Figure US20190233441A1-20190801-C00271
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,7- diazaspiro[3.5]nonan-2- yl)methanone
    1-200
    Figure US20190233441A1-20190801-C00272
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(3- methylpiperazin-1- yl)methanone
    1-201
    Figure US20190233441A1-20190801-C00273
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,7- diazaspiro[3.5]nonan-7- yl)methanone
    1-202
    Figure US20190233441A1-20190801-C00274
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(3- piperidyl)benzamide
    1-203
    Figure US20190233441A1-20190801-C00275
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,6- diazaspiro[3.3]heptan-2- yl)methanone
    1-204
    Figure US20190233441A1-20190801-C00276
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,4- diazepan-1- yl)methanone
    1-205
    Figure US20190233441A1-20190801-C00277
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,6- diazaspiro[3.4]octan-6- yl)methanone
    1-206
    Figure US20190233441A1-20190801-C00278
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3- (methylamino)pyrrolidin- 1-yl]methanone
    1-207
    Figure US20190233441A1-20190801-C00279
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,7- diazaspiro[4.4]nonan-2- yl)methanone
    1-208
    Figure US20190233441A1-20190801-C00280
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,7- diazaspiro[4.4]nonan-7- yl)methanone
    1-209
    Figure US20190233441A1-20190801-C00281
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,7- diazaspiro[4.4]nonan-1- yl)methanone
    1-210
    Figure US20190233441A1-20190801-C00282
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,8- diazaspiro[3.5]nonan-2- yl)methanone
    1-211
    Figure US20190233441A1-20190801-C00283
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,6- diazaspiro[4.5]decan-2- yl)methanone
    1-212
    Figure US20190233441A1-20190801-C00284
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,9- diazaspiro[4.5]decan-2- yl)methanone
    1-213
    Figure US20190233441A1-20190801-C00285
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,8- diazaspiro[4.5]decan-8- yl)methanone
    1-214
    Figure US20190233441A1-20190801-C00286
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,8- diazaspiro[4.5]decan-2- yl)methanone
    1-215
    Figure US20190233441A1-20190801-C00287
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,8- diazaspiro[5.5]undecan- 2-yl)methanone
    1-216
    Figure US20190233441A1-20190801-C00288
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,9- diazaspiro[5.5]undecan- 2-yl)methanone
    1-217
    Figure US20190233441A1-20190801-C00289
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,9- diazaspiro[5.5]undecan- 9-yl)methanone
    1-218
    Figure US20190233441A1-20190801-C00290
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(3,9- diazaspiro[5.5]undecan- 3-yl)methanone
    1-219
    Figure US20190233441A1-20190801-C00291
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,8- diazaspiro[5.5]undecan- 8-yl)methanone
    1-220
    Figure US20190233441A1-20190801-C00292
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-oxa-8- azaspiro[4.5]decan-3- ylmethyl)benzamide
    1-221
    Figure US20190233441A1-20190801-C00293
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-oxa-8- azaspiro[4.5]decan-3- yl)benzamide
    1-222
    Figure US20190233441A1-20190801-C00294
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-oxa-8- azaspiro[4.5]decan-2- ylmethyl)benzamide
    1-223
    Figure US20190233441A1-20190801-C00295
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,9- diazaspiro[4.6]undecan- 9-yl)methanone
    1-224
    Figure US20190233441A1-20190801-C00296
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(2,7- diazaspiro[3.4]octan-2- yl)methanone
    1-225
    Figure US20190233441A1-20190801-C00297
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1- oxa-4,8- diazaspiro[5.5]undecan- 4-yl)methanone
    1-226
    Figure US20190233441A1-20190801-C00298
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,8- diazaspiro[4.5]decan-8- yl)methanone
    1-227
    Figure US20190233441A1-20190801-C00299
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,8- diazaspiro[4.5]decan-1- yl)methanone
    1-228
    Figure US20190233441A1-20190801-C00300
         		(2-amino-7- azaspiro[3.5]nonan-7- yl)-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-229
    Figure US20190233441A1-20190801-C00301
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1- oxa-4,8- diazaspiro[5.5]undecan- 8-yl)methanone
    1-230
    Figure US20190233441A1-20190801-C00302
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1- oxa-4,9- diazaspiro[5.5]undecan- 9-yl)methanone
    1-231
    Figure US20190233441A1-20190801-C00303
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1- oxa-4,9- diazaspiro[5.5]undecan- 4-yl)methanone
    1-232
    Figure US20190233441A1-20190801-C00304
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]- [(1R,5R)-3,6- diazabicyclo[3.2.0]heptan- 3-yl]methanone
    1-233
    Figure US20190233441A1-20190801-C00305
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1,9- diazaspiro[4.5]decan-1- yl)methanone
    1-234
    Figure US20190233441A1-20190801-C00306
         		[(3aS,6aS)-2,3,3a,4,6,6a- hexahydro-1H- pyrrolo[2,3-c]pyrrol-5- yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-235
    Figure US20190233441A1-20190801-P00899
    		 [(3aR,6aS)-
    2,3,3a,4,6,6a-hexahydro-
    1H-pyrrolo[3,4-c]pyrrol-
    5-yl]-[4-[[8-[4-(4-
    chlorophenyl)-4-
    hydroxy-1-piperidyl]-
    [1,2,4]triazolo[1,5-
    a]pyridin-2-
    yl]amino]phenyl]methanone
    1-236
    Figure US20190233441A1-20190801-P00899
    		 [4-[[8-[4-(4-
    chlorophenyl)-4-
    hydroxy-1-piperidyl]-
    [1,2,4]triazolo[1,5-
    a]pyridin-2-
    yl]amino]phenyl]-(1,7-
    diazaspiro[3.5]nonan-7-
    yl)methanone
    1-237
    Figure US20190233441A1-20190801-C00307
         		[(1S,5R)-5-amino-3- azabicyclo[3.1.0]hexan- 3-yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-238
    Figure US20190233441A1-20190801-C00308
         		N-[(1R,5S)-3- azabicyclo[3.1.0]hexan- 6-yl]-4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-239
    Figure US20190233441A1-20190801-C00309
         		[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(9- oxa-3,7- diazabicyclo[3.3.1]nonan- 3-yl)methanonen
    1-240
    Figure US20190233441A1-20190801-C00310
         		[4-(aminomethyl)-3- azabicyclo[2.1.1]hexan- 3-yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-241
    Figure US20190233441A1-20190801-C00311
         		[(3aS,6aS)-3,3a,4,5,6,6a- hexahydro-2H- pyrrolo[2,3-c]pyrrol-1- yl]-[4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-242
    Figure US20190233441A1-20190801-C00312
         		[(4aR,7aR)- 3,4a,5,6,7,7a-hexahydro- 2H-pyrrolo[3,4- b][1,4]oxazin-4-yl]-[4- [[8-[4-(4-chlorophenyl)- 4-hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-243
    Figure US20190233441A1-20190801-C00313
         		[(4aS,7aR)- 3,4a,5,6,7,7a-hexahydro- 2H-pyrrolo[3,4- b][1,4]oxazin-4-yl]-[4- [[8-[4-(4-chlorophenyl)- 4-hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-244
    Figure US20190233441A1-20190801-C00314
         		2,3,4a,5,6,7,8,8a- octahydropyrido[4,3- b][1,4]oxazin-4-yl-[4- [[8-[4-(4-chlorophenyl)- 4-hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]methanone
    1-245
    Figure US20190233441A1-20190801-C00315
         		4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2-oxa-9- azaspiro[5.5]undecan-3- ylmethyl)benzamide
    1-246
    Figure US20190233441A1-20190801-C00316
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-247
    Figure US20190233441A1-20190801-C00317
         		4-[[8-[4-(4- chlorophenyl)-4-(2- cyanoethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-248
    Figure US20190233441A1-20190801-C00318
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[(8- phenoxy- [1,2,4]triazolo[1,5- a]pyridin-2- yl)amino]benzamide
    1-249
    Figure US20190233441A1-20190801-C00319
         		4-[(8-benzyloxy- [1,2,4]triazolo[1,5- a]pyridin-2-yl)amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-250
    Figure US20190233441A1-20190801-C00320
         		4-[[8-[4-(4- chlorophenyl)-4-[(E)- methoxyiminomethyl]- 1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-251
    Figure US20190233441A1-20190801-C00321
         		4-[[8-[4- (hydroxymethyl)-4-(4- methylsulfanylphenyl)- 1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-252
    Figure US20190233441A1-20190801-C00322
         		4-[[8-[4-(4- chlorophenyl)-4-(1- hydroxyethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-253
    Figure US20190233441A1-20190801-C00323
         		4-[[8-[4-(4- chlorophenyl)-4-(2,2,2- trifluoro-1-hydroxy- ethyl)-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-254
    Figure US20190233441A1-20190801-C00324
         		ethyl 2-[4-(4- chlorophenyl)-1-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-4- piperidyl]acetate
    1-255
    Figure US20190233441A1-20190801-C00325
         		4-[[8-[4-(4- chlorophenyl)-4-(2- hydroxyethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; formic acid
    1-256
    Figure US20190233441A1-20190801-C00326
         		4-[[8-[4-(4- chlorophenyl)-4-(2,2- difluoroethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; formic acid
    1-257
    Figure US20190233441A1-20190801-C00327
         		4-[[8-[4-(cyanomethyl)- 4-cyclopentyl-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-258
    Figure US20190233441A1-20190801-C00328
         		4-[[8-[4-(4- chlorophenyl)-4- (methoxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; formic acid
    1-259
    Figure US20190233441A1-20190801-C00329
         		N-benzyl-4-methyl-1-[2- [4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8- yl]piperidine-4- carboxamide
    1-260
    Figure US20190233441A1-20190801-C00330
         		4-[[8-(4-acetamido-4- methyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-261
    Figure US20190233441A1-20190801-C00331
         		4-[[8-[4- [benzenesulfo- nyl(methyl)amino]- 4-methyl-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-262
    Figure US20190233441A1-20190801-C00332
         		4-[[8-[4-(4- chlorophenyl)-4-methyl- 1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-263
    Figure US20190233441A1-20190801-C00333
         		4-[[8-[4-(4-chloro-3- fluoro-phenyl)-4- (cyanomethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-264
    Figure US20190233441A1-20190801-C00334
         		4-[[8-[(3-benzyl-2-oxo- 1,3-benzoxazol-5- yl)oxy]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-265
    Figure US20190233441A1-20190801-C00335
         		4-[[8-[4-(aminomethyl)- 4-(4-chlorophenyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; formic acid
    1-266
    Figure US20190233441A1-20190801-C00336
         		4-[[8-[4- (hydroxymethyl)-4- [(2,2,2- trifluoroethylamino)methyl]- 1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-267
    Figure US20190233441A1-20190801-C00337
         		4-[[8-[4-[4- (difluoromethyl)phenyl]- 4-(hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-268
    Figure US20190233441A1-20190801-C00338
         		4-[[8-[4- (acetamidomethyl)-4- (4-chlorophenyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-269
    Figure US20190233441A1-20190801-C00339
         		4-(4-chlorophenyl)-1-[2- [4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]piperidine-4- carboxylic acid; formic acid
    1-270
    Figure US20190233441A1-20190801-C00340
         		4-[[8-[4-(4- chlorophenyl)-4-(1,2- dihydroxyethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-271
    Figure US20190233441A1-20190801-C00341
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[[1-(2,2,2- trifluoroethyl)-4- piperidyl]methyl]benzamide
    1-272
    Figure US20190233441A1-20190801-C00342
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(3-methyl-1- piperidyl)ethyl]benzamide
    1-273
    Figure US20190233441A1-20190801-C00343
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-(3,5-dimethyl-1- piperidyl)ethyl]benzamide
    1-274
    Figure US20190233441A1-20190801-C00344
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(5- methyl-2,5- diazaspiro[3.4]octan-2- yl)methanone
    1-275
    Figure US20190233441A1-20190801-C00345
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-(1- methyl-2,3,3a,4,6,6a- hexahydropyrrolo[2,3- c]pyrrol-5-yl)methanone
    1-276
    Figure US20190233441A1-20190801-C00346
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4-(2- pyridyl)-1- piperidyl]methanone
    1-277
    Figure US20190233441A1-20190801-C00347
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-[(2S,6S)-2,6- dimethylmorpholin-4- yl]ethyl]benzamide
    1-278
    Figure US20190233441A1-20190801-C00348
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[2-[(2R,6S)-2,6- dimethylmorpholin-4- yl]ethyl]benzamide
    1-279
    Figure US20190233441A1-20190801-C00349
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3-(4- pyridyl)pyrrolidin-1- yl]methanone
    1-280
    Figure US20190233441A1-20190801-C00350
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-cyclopentyl-4- piperidyl)benzamide
    1-281
    Figure US20190233441A1-20190801-C00351
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- [(2S,6S)-2,6- dimethylmorpholin-4-yl]- 1-piperidyl]methanone
    1-282
    Figure US20190233441A1-20190801-C00352
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[4- [(2R,6S)-2,6- dimethylmorpholin-4-yl]- 1-piperidyl]methanone
    1-283
    Figure US20190233441A1-20190801-C00353
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[3- (methylamino)azetidin- 1-yl]methanone
    1-284
    Figure US20190233441A1-20190801-C00354
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-[(6-methyl-3- pyridyl)methyl]benzamide
    1-285
    Figure US20190233441A1-20190801-C00355
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(2-methyl-2- morpholino- propyl)benzamide
    1-286
    Figure US20190233441A1-20190801-C00356
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]-N-(3- morpholinopropyl)benzamide
    1-287
    Figure US20190233441A1-20190801-C00357
         		4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-ethyl-N-(4- pyridylmethyl)benzamide
    1-288
    Figure US20190233441A1-20190801-C00358
         		[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]phenyl]-[2-(4- pyridyl)pyrrolidin-1- yl]methanone
    1-289
    Figure US20190233441A1-20190801-C00359
         		2-[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]pyrazol-1-yl]- 1-[4-(morpholinomethyl)-1- piperidyl]ethanone
    1-290
    Figure US20190233441A1-20190801-C00360
         		formic acid; methyl 3-[4- [2-[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]pyrazol-1- yl]acetyl]piperazin-1- yl]propanoate
    1-291
    Figure US20190233441A1-20190801-C00361
         		2-[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]pyrazol-1-yl]- 1-[4-(methylamino)-1- piperidyl]ethanone
    1-292
    Figure US20190233441A1-20190801-C00362
         		4-[[8-[(3aR,6aS)-5- hydroxy-5-phenyl- 1,3,3a,4,6,6a- hexahydrocyclopenta[c]pyrrol- 2-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-293
    Figure US20190233441A1-20190801-C00363
         		4-[[8-(5-benzyl-2,5- diazabicyclo[2.2.1]heptan- 2-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-294
    Figure US20190233441A1-20190801-C00364
         		4-[[8-[4-(4- chlorophenyl)-4- (cyanomethyl)cyclohexen- 1-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-295
    Figure US20190233441A1-20190801-C00365
         		N-(3- morpholinopropyl)-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,4- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    1-296
    Figure US20190233441A1-20190801-C00366
         		3-[[1-[2-[4-[[8-[4-(4- chlorophenyl)-4- (hydroxymethyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]pyrazol-1- yl]acetyl]-4-piperidyl]- methyl- amino]propanenitrile
    1-297
    Figure US20190233441A1-20190801-C00367
         		N-(1-isobutyl-4- piperidyl)-N-methyl-2- [4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]pyrazol-1- yl]acetamide
    1-298
    Figure US20190233441A1-20190801-C00368
         		4-[[8-[4-(2-amino-2- oxo-ethyl)-4-(4- chlorophenyl)-1- piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-299
    Figure US20190233441A1-20190801-C00369
         		4-[[8-[4-(4- chlorophenyl)-4-[2- (methylamino)-2-oxo- ethyl]-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-300
    Figure US20190233441A1-20190801-C00370
         		4-[[8-[4-(4- chlorophenyl)-4-[2- (dimethylamino)-2-oxo- ethyl]-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-301
    Figure US20190233441A1-20190801-C00371
         		2-[4-(4-chlorophenyl)-1- [2-[4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-4- piperidyl]acetic acid
    1-302
    Figure US20190233441A1-20190801-C00372
         		4-[[8-(4-benzamido-4- methyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    1-303
    Figure US20190233441A1-20190801-C00373
         		4-[[8-[4- (benzenesulfonamido)- 4-methyl-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-1
    Figure US20190233441A1-20190801-C00374
         		ethyl 4-[2-[4-[methyl-(1- methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-2
    Figure US20190233441A1-20190801-C00375
         		cyclopropyl 4-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-3
    Figure US20190233441A1-20190801-C00376
         		4-[[8-[1-(3-hydroxy-3- methyl-butanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-4
    Figure US20190233441A1-20190801-C00377
         		4-[[8-[1-(2- cyclopropylacetyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-5
    Figure US20190233441A1-20190801-C00378
         		4-[[8-[1-(3- cyanoazetidine-1- carbonyl)-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-6
    Figure US20190233441A1-20190801-C00379
         		4-[[8-[1-(2- cyanoacetyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-7
    Figure US20190233441A1-20190801-C00380
         		cyanomethyl 4-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-8
    Figure US20190233441A1-20190801-C00381
         		4-[[8-(1-benzyl-3,6- dihydro-2H-pyridin-4- yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; hydrochloride
    2-9
    Figure US20190233441A1-20190801-C00382
         		4-[[8-[1-(3- hydroxypropanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-10
    Figure US20190233441A1-20190801-C00383
         		4-[[8-[1-[3- (dimethylamino)propanoyl]- 3,6-dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide; dihydrochloride
    2-11
    Figure US20190233441A1-20190801-C00384
         		ethyl 4-[2-[4-[(2-methyl- 2-morpholino- propyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-12
    Figure US20190233441A1-20190801-C00385
         		ethyl 4-[2-[4-[4- (dimethylamino)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-13
    Figure US20190233441A1-20190801-C00386
         		ethyl 4-[2-[4-[2-(4- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-14
    Figure US20190233441A1-20190801-C00387
         		ethyl 4-[2-[4-[methyl(3- pyridylmethyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-15
    Figure US20190233441A1-20190801-C00388
         		ethyl 4-[2-[4-[2-(4- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-16
    Figure US20190233441A1-20190801-C00389
         		ethyl 4-[2-[4-[4-(2- pyridylmethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-17
    Figure US20190233441A1-20190801-C00390
         		ethyl 4-[2-[4-[4-(2- pyridylmethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-18
    Figure US20190233441A1-20190801-C00391
         		ethyl 4-[2-[4-(4- morpholinopiperidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-19
    Figure US20190233441A1-20190801-C00392
         		ethyl 4-[2-[4-[4-(3- pyridyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-20
    Figure US20190233441A1-20190801-C00393
         		ethyl 4-[2-[4-[6- (hydroxymethyl)-4- methyl-1,4-diazepane-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-21
    Figure US20190233441A1-20190801-C00394
         		ethyl 4-[2-[4-[2-(1- methyl-2- piperidyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-22
    Figure US20190233441A1-20190801-C00395
         		ethyl 4-[2-[4-[2-[4- (dimethylamino)-6- methyl-2- pyridyl]pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-23
    Figure US20190233441A1-20190801-C00396
         		ethyl 4-[2-[4-(9-methyl- 3-oxa-7,9- diazabicyclo[3.3.1]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-24
    Figure US20190233441A1-20190801-C00397
         		ethyl 4-[2-[4-(2- methylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-25
    Figure US20190233441A1-20190801-C00398
         		ethyl 4-[2-[4-(1-oxa-4,9- diazaspiro[5.5]undecane- 4-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-26
    Figure US20190233441A1-20190801-C00399
         		ethyl 4-[2-[4-(1-oxa-4,8- diazaspiro[5.5]undecane- 8-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-27
    Figure US20190233441A1-20190801-C00400
         		ethyl 4-[2-[4-(7- azaspiro[3.5]nonan-2- ylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-28
    Figure US20190233441A1-20190801-C00401
         		1-[4-[2-[4-(2,7- diazaspiro[4.4]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-29
    Figure US20190233441A1-20190801-C00402
         		1-[4-[2-[4-(3,9- diazaspiro[5.5]undecane- 3-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-30
    Figure US20190233441A1-20190801-C00403
         		N-(morpholin-2- ylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-31
    Figure US20190233441A1-20190801-C00404
         		N-[2- (methylamino)ethyl]-4- [[8-[1,(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-32
    Figure US20190233441A1-20190801-C00405
         		N-(2-piperazin-1- ylethyl)-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-33
    Figure US20190233441A1-20190801-C00406
         		4,4,4-trifluoro-1-[4-[2- [4-[2- (hydroxymethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-34
    Figure US20190233441A1-20190801-C00407
         		1-[4-[2-[4-(1,8- diazaspiro[5.5]undecane- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-35
    Figure US20190233441A1-20190801-C00408
         		1-[4-[2-[4-(2,7- diazaspiro[3.4]octane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-36
    Figure US20190233441A1-20190801-C00409
         		N-methyl-N-(3- piperidyl)-4-[[8-[1- (4,4,4-trifluorobutanoyl)- 3,6-dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-37
    Figure US20190233441A1-20190801-C00410
         		4,4,4-trifluoro-1-[4-[2- [4-(9-oxa-3,7- diazabicyclo[3.3.1]nonane- 3-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-38
    Figure US20190233441A1-20190801-C00411
         		1-[4-[2-[4-[(3aS,6aS)-1- methyl-2,3,3a,4,6,6a- hexahydropyrrolo[3,4- b]pyrrole-5- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-39
    Figure US20190233441A1-20190801-C00412
         		N-[(1-ethylpyrrolidin-3- yl)methyl]-N-methyl-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-40
    Figure US20190233441A1-20190801-C00413
         		4,4,4-trifluoro-1-[4-[2- [4-(5-methyl-2,5- diazaspiro[3.4]octane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-41
    Figure US20190233441A1-20190801-C00414
         		N-[(4-methyl-2- pyridyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-42
    Figure US20190233441A1-20190801-C00415
         		N-[(2-methyl-3- pyridyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-43
    Figure US20190233441A1-20190801-C00416
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (4,4,4-trifluoro- 3-methyl-butanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-44
    Figure US20190233441A1-20190801-C00417
         		(l-methyl-4-piperidyl)- 4-[[8-[1-(3,3- dimethylcyclobu- tanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoate
    2-45
    Figure US20190233441A1-20190801-C00418
         		4,4,4-trifluoro-1-[4-[2- [4-(3-morpholinopyrrolidine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-46
    Figure US20190233441A1-20190801-C00419
         		4,4,4-trifluoro-1-[4-[2- [4-(4-pyrrolidin-1- ylpiperidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-47
    Figure US20190233441A1-20190801-C00420
         		N-[3-(2-methyl-1- piperidyl)propyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-48
    Figure US20190233441A1-20190801-C00421
         		N-[2-(1- methylpyrrolidin-2- yl)ethyl]-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-49
    Figure US20190233441A1-20190801-C00422
         		N-(1-cyclopentyl-4- piperidyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-50
    Figure US20190233441A1-20190801-C00423
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(5-methyl-2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-51
    Figure US20190233441A1-20190801-C00424
         		1-[4-[2-[4-[3-[5- (dimethylamino)-2- pyridyl]piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-52
    Figure US20190233441A1-20190801-C00425
         		4-[[8-[1-(cyanomethyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-53
    Figure US20190233441A1-20190801-C00426
         		4-[[8-[1-(3- methoxycyclobu- tanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-54
    Figure US20190233441A1-20190801-C00427
         		4-[[8-[1-(3,3- dimethylbutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-55
    Figure US20190233441A1-20190801-C00428
         		ethyl 4-[2-[4-[3- (methylamino)azetidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-56
    Figure US20190233441A1-20190801-C00429
         		ethyl 4-[2-[4-(3- morpholinopropylcarba- moyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-57
    Figure US20190233441A1-20190801-C00430
         		ethyl 4-[2-[4-[2-(4- methylpiperazin-1- yl)ethylcarbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-58
    Figure US20190233441A1-20190801-C00431
         		ethyl 4-[2-[4-[(1- methylazetidin-3- yl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-59
    Figure US20190233441A1-20190801-C00432
         		ethyl 4-[2-[4-[methyl-[2-(2- pyridyl)ethyl]carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-60
    Figure US20190233441A1-20190801-C00433
         		ethyl 4-[2-[4-[(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-61
    Figure US20190233441A1-20190801-C00434
         		ethyl 4-[2-[4-[methyl- [(1-methyl-3- piperidyl)methyl]carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-62
    Figure US20190233441A1-20190801-C00435
         		ethyl 4-[2-[4-[3-(4- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-63
    Figure US20190233441A1-20190801-C00436
         		ethyl 4-[2-[4-[4-(2,6- dimethylmorpholin-4- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-64
    Figure US20190233441A1-20190801-C00437
         		ethyl 4-[2-[4-[4-(2- morpholinoethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-65
    Figure US20190233441A1-20190801-C00438
         		ethyl 4-[2-[4-[(1- isopropylpyrrolidin-3- yl)methyl-methyl- carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-66
    Figure US20190233441A1-20190801-C00439
         		ethyl 4-[2-[4-(3- morpholinopyrrolidine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-67
    Figure US20190233441A1-20190801-C00440
         		ethyl 4-[2-[4-[2-(5- methyl-2- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-68
    Figure US20190233441A1-20190801-C00441
         		ethyl 4-[2-[4-(7-methyl- 2,7-diazaspiro[3.4]octane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-69
    Figure US20190233441A1-20190801-C00442
         		ethyl 4-[2-[4-[[(3R)- quinuclidin-3- yl]carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-70
    Figure US20190233441A1-20190801-C00443
         		ethyl 4-[2-[4-(5,7- dihydropyrrolo[3,4- b]pyridine-6- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-71
    Figure US20190233441A1-20190801-C00444
         		ethyl 4-[2-[4-[4- (aminomethyl)-3- azabicyclo[2.1.1]hexane- 3-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-72
    Figure US20190233441A1-20190801-C00445
         		ethyl 4-[2-[4- [(4aS,7aR)- 3,4a,5,6,7,7a-hexahydro- 2H-pyrrolo[3,4- b][1,4]oxazine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-73
    Figure US20190233441A1-20190801-C00446
         		ethyl 4-[2-[4-[(1S,5R)-5- amino-3- azabicyclo[3.1.0]hexane- 3-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-74
    Figure US20190233441A1-20190801-C00447
         		ethyl 4-[2-[4-(3- aminoazetidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-75
    Figure US20190233441A1-20190801-C00448
         		ethyl 4-[2-[4-(2,9- diazaspiro[5.5]undecane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-76
    Figure US20190233441A1-20190801-C00449
         		ethyl 4-[2-[4-[2- (aminomethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-77
    Figure US20190233441A1-20190801-C00450
         		ethyl 4-[2-[4-(2,6- diazaspiro[3.3]heptane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-78
    Figure US20190233441A1-20190801-C00451
         		ethyl 4-[2-[4-(2,7- diazaspiro[4.4]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-79
    Figure US20190233441A1-20190801-C00452
         		ethyl 4-[2-[4-(2,8- diazaspiro[4.5]decane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-80
    Figure US20190233441A1-20190801-C00453
         		1-[4-[2-[4-[2- (aminomethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-81
    Figure US20190233441A1-20190801-C00454
         		1-[4-[2-[4-(2,7- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-82
    Figure US20190233441A1-20190801-C00455
         		4,4,4-trifluoro-1-[4-[2- [4-(1-oxa-4,8- diazaspiro[5.5]undecane- 4-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-83
    Figure US20190233441A1-20190801-C00456
         		N-(1-oxa-8- azaspiro[4.5]decan-2- ylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-84
    Figure US20190233441A1-20190801-C00457
         		N-(4-piperidylmethyl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-85
    Figure US20190233441A1-20190801-C00458
         		4,4,4-trifluoro-1-[4-[2- [4-[3- (methylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-86
    Figure US20190233441A1-20190801-C00459
         		N-[2-(4-piperidyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-87
    Figure US20190233441A1-20190801-C00460
         		4,4,4-trifluoro-1-[4-[2- [4-(2-methyl-1,3,3a,4,6,6a- hexahydropyrrolo[3,4- c]pyrrole-5- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-88
    Figure US20190233441A1-20190801-C00461
         		1-[4-[2-[4-[3-[2- (dimethylami- no)ethyl]piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6-dihydro- 2H-pyridin-1-yl]-4,4,4- trifluoro-butan-1-one
    2-89
    Figure US20190233441A1-20190801-C00462
         		1-[4-[2-[4-[4- [(dimethylamino)methyl]- 4-hydroxy-azepane-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro- butan-1-one
    2-90
    Figure US20190233441A1-20190801-C00463
         		1-[4-[2-[4-[3-[6- (dimethylamino)-2- methyl-pyrimidin-4- yl]piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-91
    Figure US20190233441A1-20190801-C00464
         		1-[4-[2-[4-[4-[6- (dimethylamino)-2- pyridyl]piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-92
    Figure US20190233441A1-20190801-C00465
         		1-[4-[2-[4-[2-[4- (dimethylamino)-6- methyl-2- pyridyl]pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-93
    Figure US20190233441A1-20190801-C00466
         		4,4,4-trifluoro-1-[4-[2- [4-(8-methyl-2,8- diazaspiro[5.5]undecane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-94
    Figure US20190233441A1-20190801-C00467
         		ethyl 4-[2-[4-[(1-methyl-4- piperidyl)oxycarbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-95
    Figure US20190233441A1-20190801-C00468
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- pyridylmethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-96
    Figure US20190233441A1-20190801-C00469
         		N-methyl-N-[2-(4- pyridyl)ethyl]-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-97
    Figure US20190233441A1-20190801-C00470
         		1-[4-[2-[4-[4- (dimethylamino)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-98
    Figure US20190233441A1-20190801-C00471
         		4,4,4-trifluoro-1-[4-[2- [4-(4-methylpiperazine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-99
    Figure US20190233441A1-20190801-C00472
         		N-[3-(4- methylpiperazin-1- yl)propyl]-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-100
    Figure US20190233441A1-20190801-C00473
         		N-[2-(4-hydroxy-1- piperidyl)ethyl]-4-[[8- [1-4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-101
    Figure US20190233441A1-20190801-C00474
         		N-[2-(3-methyl-1- piperidyl)ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-102
    Figure US20190233441A1-20190801-C00475
         		1-[4-[2-[4-[4-[2- (dimethylami- no)ethyl]piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-103
    Figure US20190233441A1-20190801-C00476
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(1H-pyrrolo[2,3- b]pyridin-2- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-104
    Figure US20190233441A1-20190801-C00477
         		N-methyl-N-[[2-(3- pyridyl)phenyl]methyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-105
    Figure US20190233441A1-20190801-C00478
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (tetrahydropyran-4- carbonyl)-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-106
    Figure US20190233441A1-20190801-C00479
         		N-methyl-4-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxamide; hydrochloride
    2-107
    Figure US20190233441A1-20190801-C00480
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (tetrahydrofuran-3- carbonyl)-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide; hydrochloride
    2-108
    Figure US20190233441A1-20190801-C00481
         		2,2,2-trifluoroethyl 4-[2- [4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-109
    Figure US20190233441A1-20190801-C00482
         		N-methyl-4-[[8-[1-(3- methylbutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methyl-4- piperidyl)benzamide
    2-110
    Figure US20190233441A1-20190801-C00483
         		ethyl 4-[2-[4-[(1,1- dimethyl-2-morpholino- ethyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-111
    Figure US20190233441A1-20190801-C00484
         		ethyl 4-[2-[4-[2-(1- methylpyrrolidin-2- yl)ethylcarbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-112
    Figure US20190233441A1-20190801-C00485
         		ethyl 4-[2-[4-(2- piperazin-1- ylethylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-113
    Figure US20190233441A1-20190801-C00486
         		ethyl 4-[2-[4-(3- piperidylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-114
    Figure US20190233441A1-20190801-C00487
         		ethyl 4-[2-[4-(2- piperidylmethylcarba- moyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-115
    Figure US20190233441A1-20190801-C00488
         		ethyl 4-[2-[4-[3- (dimethylcarbamoyl)azetidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-116
    Figure US20190233441A1-20190801-C00489
         		ethyl 4-[2-[4-[2-(1- methyl-4- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-117
    Figure US20190233441A1-20190801-C00490
         		ethyl 4-[2-[4-[(1- benzylpyrrolidin-3-yl)- methyl-carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-118
    Figure US20190233441A1-20190801-C00491
         		ethyl 4-[2-[4-[3- (diethylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-119
    Figure US20190233441A1-20190801-C00492
         		ethyl 4-[2-[4-[methyl-[2-(4- pyridyl)ethyl]carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-120
    Figure US20190233441A1-20190801-C00493
         		ethyl 4-[2-[4-(8-methyl- 5-oxa-2,8- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-121
    Figure US20190233441A1-20190801-C00494
         		ethyl 4-[2-[4-[4-(4- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-122
    Figure US20190233441A1-20190801-C00495
         		ethyl 4-[2-[4-[(3aS,6aS)- 1-methyl-2,3,3a,4,6,6a- hexahydropyrrolo[3,4- b]pyrrole-5- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-123
    Figure US20190233441A1-20190801-C00496
         		ethyl 4-[2-[4-(7-methyl- 9-oxa-3,7- diazabicyclo[3.3.1]nonane- 3-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-124
    Figure US20190233441A1-20190801-C00497
         		ethyl 4-[2-[4-[(4-methyl-2- pyridyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-125
    Figure US20190233441A1-20190801-C00498
         		ethyl 4-[2-[4- (2,3,4a,5,6,7,8,8a- octahydropyrido[4,3- b][1,4]oxazine-4- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-126
    Figure US20190233441A1-20190801-C00499
         		ethyl 4-[2-[4- (2,3,3a,4,6,6a- hexahydro-1H- pyrrolo[3,4-c]pyrrole-5- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-127
    Figure US20190233441A1-20190801-C00500
         		ethyl 4-[2-[4- [(4aR,7aR)- 3,4a,5,6,7,7a-hexahydro- 2H-pyrrolo[3,4- b][1,4]oxazine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-128
    Figure US20190233441A1-20190801-C00501
         		ethyl 4-[2-[4-(1,7- diazaspiro[3.5]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-129
    Figure US20190233441A1-20190801-C00502
         		ethyl 4-[2-[4- (piperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-130
    Figure US20190233441A1-20190801-C00503
         		ethyl 4-[2-[4-[3- (aminomethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-131
    Figure US20190233441A1-20190801-C00504
         		ethyl 4-[2-[4-(1,8- diazaspiro[5.5]undecane- 8-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-132
    Figure US20190233441A1-20190801-C00505
         		ethyl 4-[2-[4-(2,8- diazaspiro[5.5]undecane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-133
    Figure US20190233441A1-20190801-C00506
         		ethyl 4-[2-[4-(2-amino- 7-azaspiro[3.5]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-134
    Figure US20190233441A1-20190801-C00507
         		ethyl 4-[2-[4-(1-oxa-4,8- diazaspiro[5.5]undecane- 4-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-135
    Figure US20190233441A1-20190801-C00508
         		ethyl 4-[2-[4-(2,8- diazaspiro[4.5]decane-8- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-136
    Figure US20190233441A1-20190801-C00509
         		1-[4-[2-[4-(2,8- diazaspiro[4.5]decane-8- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-137
    Figure US20190233441A1-20190801-C00510
         		N-(3-piperidyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-138
    Figure US20190233441A1-20190801-C00511
         		N-[(3S)-3-piperidyl]-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-139
    Figure US20190233441A1-20190801-C00512
         		1-[4-[2-[4-[(4aS,7aR)- 3,4a,5,6,7,7a-hexahydro- 2H-pyrrolo[3,4- b][1,4]oxazine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-140
    Figure US20190233441A1-20190801-C00513
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(3- piperidyl)indoline-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-141
    Figure US20190233441A1-20190801-C00514
         		N-methyl-N-(8- quinolylmethyl)-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-142
    Figure US20190233441A1-20190801-C00515
         		3-[4-[4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazin- 1-yl]propanenitrile
    2-143
    Figure US20190233441A1-20190801-C00516
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(5-methyl-2- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-144
    Figure US20190233441A1-20190801-C00517
         		4,4,4-trifluoro-1-[4-[2- [4-[6-(hydroxymethyl)- 4-methyl-1,4-diazepane- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-145
    Figure US20190233441A1-20190801-C00518
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(3- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-146
    Figure US20190233441A1-20190801-C00519
         		1-[4-[2-[4-(5,7- dihydropyrrolo[3,4- b]pyridine-6- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-147
    Figure US20190233441A1-20190801-C00520
         		N-[2-(4-methyl-1- piperidyl)ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]aminolbenzamide
    2-148
    Figure US20190233441A1-20190801-C00521
         		N-[(6-methyl-3- pyridyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-149
    Figure US20190233441A1-20190801-C00522
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(1-methyl-4- piperidyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-150
    Figure US20190233441A1-20190801-C00523
         		N-cyclopropyl-N-(1- methyl-4-piperidyl)-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-151
    Figure US20190233441A1-20190801-C00524
         		1-[4-[2-[4- (1,3,4,6,7,8,9,9a- octahydropyrido[1,2- a]pyrazine-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-152
    Figure US20190233441A1-20190801-C00525
         		N-methyl-N-[2-(2- pyridyl)ethyl]-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-153
    Figure US20190233441A1-20190801-C00526
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- hydroxyethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-154
    Figure US20190233441A1-20190801-C00527
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(2- pyridyl)morpholine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-155
    Figure US20190233441A1-20190801-C00528
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(1H-pyrrolo[2,3- b]pyridin-2- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-156
    Figure US20190233441A1-20190801-C00529
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-157
    Figure US20190233441A1-20190801-C00530
         		1-[4-[2-[4-[4-(2,6- dimethylmorpholin-4- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-158
    Figure US20190233441A1-20190801-C00531
         		l-[4-[2-[4-[(3S)-3- (dimethylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-159
    Figure US20190233441A1-20190801-C00532
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(4- methylpiperazine-1- carbonyl)azetidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-160
    Figure US20190233441A1-20190801-C00533
         		4-[[8-[1-(2,2- dimethylcyclo- propanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-161
    Figure US20190233441A1-20190801-C00534
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (2,2,3,3- tetramethylcyclopro- panecarbonyl)- 3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]aminolbenzamide
    2-162
    Figure US20190233441A1-20190801-C00535
         		4-[[8-[1-(1,1-dioxo-1,4- thiazinane-4-carbonyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-163
    Figure US20190233441A1-20190801-C00536
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (3,3,3- trifluoropropanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]aminolbenzamide
    2-164
    Figure US20190233441A1-20190801-C00537
         		4-[[8-[1-(3-hydroxy-3- methyl- cyclobutanecarbonyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-165
    Figure US20190233441A1-20190801-C00538
         		ethyl 4-[2-[4-[3- (aminomethyl)azetidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-166
    Figure US20190233441A1-20190801-C00539
         		ethyl 4-[2-[4-[3-(2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-167
    Figure US20190233441A1-20190801-C00540
         		ethyl 4-[2-[4-[2-(2,6- dimethylmorpholin-4- yl)ethylcarbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-168
    Figure US20190233441A1-20190801-C00541
         		ethyl 4-[2-[4-[4-(2- hydroxyethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-169
    Figure US20190233441A1-20190801-C00542
         		ethyl 4-[2-[4-[2- (dimethylamino)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-170
    Figure US20190233441A1-20190801-C00543
         		ethyl 4-[2-[4-[1-(6- methyl-2- pyridyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-171
    Figure US20190233441A1-20190801-C00544
         		ethyl 4-[2-[4- [cyclopropyl(2- pyridylmethyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-172
    Figure US20190233441A1-20190801-C00545
         		ethyl 4-[2-[4-[2-(4- pyridyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-173
    Figure US20190233441A1-20190801-C00546
         		ethyl 4-[2-[4-[methyl- [(3-methyl-2- pyridyl)methyl]carb- amoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-174
    Figure US20190233441A1-20190801-C00547
         		ethyl 4-[2-[4-[ethyl(4- pyridylmethyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-175
    Figure US20190233441A1-20190801-C00548
         		ethyl 4-[2-[4-(7-methyl- 2,7-diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-176
    Figure US20190233441A1-20190801-C00549
         		ethyl 4-[2-[4-(5-methyl- 2,5-diazaspiro[3.4]octane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-177
    Figure US20190233441A1-20190801-C00550
         		ethyl 4-[2-[4-[(2-methyl-3- pyridyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-178
    Figure US20190233441A1-20190801-C00551
         		ethyl 4-[2-[4-[(5-methyl-3- pyridyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-179
    Figure US20190233441A1-20190801-C00552
         		ethyl 4-[2-[4-[2-(4- methyl-1- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-180
    Figure US20190233441A1-20190801-C00553
         		ethyl 4-[2-[4-(9-oxa-3,7- diazabicyclo[3.3.1]nonane- 3-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-181
    Figure US20190233441A1-20190801-C00554
         		ethyl 4-[2-[4-(3,9- diazaspiro[5.5]undecane- 3-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-182
    Figure US20190233441A1-20190801-C00555
         		ethyl 4-[2-[4-(1,9- diazaspiro[4.6]undecane- 9-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-183
    Figure US20190233441A1-20190801-C00556
         		ethyl 4-[2-[4-(1,8- diazaspiro[4.5]decane-8- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-184
    Figure US20190233441A1-20190801-C00557
         		ethyl 4-[2-[4-(2,7- diazaspiro[3.5]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-185
    Figure US20190233441A1-20190801-C00558
         		ethyl 4-[2-[4-(2,8- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-186
    Figure US20190233441A1-20190801-C00559
         		1-[4-[2-[4-(2,8- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-187
    Figure US20190233441A1-20190801-C00560
         		1-[4-[2-[4-(2,8- diazaspiro[4.5]decane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-188
    Figure US20190233441A1-20190801-C00561
         		N-(1-oxa-8- azaspiro[4.5]decan-3- yl)-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-189
    Figure US20190233441A1-20190801-C00562
         		N-(2-oxa-9- azaspiro[5.5]undecan-3- ylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-190
    Figure US20190233441A1-20190801-C00563
         		4,4,4-trifluoro-1-[4-[2- [4-(1-oxa-4,8- diazaspiro[5.5]undecane- 8-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-191
    Figure US20190233441A1-20190801-C00564
         		1-[4-[2-[4-(2,9- diazaspiro[5.5]undecane- 9-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-192
    Figure US20190233441A1-20190801-C00565
         		N-(3-piperidylmethyl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-193
    Figure US20190233441A1-20190801-C00566
         		N-[2-(3-piperidyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-194
    Figure US20190233441A1-20190801-C00567
         		N-(2-aminoethyl)-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-195
    Figure US20190233441A1-20190801-C00568
         		1-[4-[2-[4-(1,4- diazepane-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-196
    Figure US20190233441A1-20190801-C00569
         		4,4,4-trifluoro-1-[4-[2- [4-(3-methylpiperazine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-197
    Figure US20190233441A1-20190801-C00570
         		1-[4-[2-[4-(1,7- diazaspiro[3.5]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-198
    Figure US20190233441A1-20190801-C00571
         		1-[4-[2-[4-(1,8- diazaspiro[4.5]decane-8- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-199
    Figure US20190233441A1-20190801-C00572
         		N-methyl-N-(2- pyridylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-200
    Figure US20190233441A1-20190801-C00573
         		1-[4-[2-[4-(3,4,6,7,8,8a- hexahydro-1H- pyrrolo[1,2-a]pyrazine- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-201
    Figure US20190233441A1-20190801-C00574
         		4,4,4-trifluoro-1-[4-[2- [4-(3-methyl-3,6- diazabicyclo[3.2.1]octane- 6-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-202
    Figure US20190233441A1-20190801-C00575
         		1-[4-[2-[4-(4- cyclopropylpiperazine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-203
    Figure US20190233441A1-20190801-C00576
         		4,4,4-trifluoro-1-[4-[2- [4-[4-[(1- methylimidazol-2- yl)methyl]piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-204
    Figure US20190233441A1-20190801-C00577
         		1-[4-[2-[4-(6-acetyl-2,6- diazaspiro[3.3]heptane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-205
    Figure US20190233441A1-20190801-C00578
         		4,4,4-trifluoro-1-[4-[2- [4-(7-methyl-9-oxa-3,7- diazabicyclo[3.3.1]nonane- 3-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-206
    Figure US20190233441A1-20190801-C00579
         		N-[(5-methyl-3- pyridyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-207
    Figure US20190233441A1-20190801-C00580
         		1-[4-[2-[4-[3- (aminomethyl)azetidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-208
    Figure US20190233441A1-20190801-C00581
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(4-methyl-1- piperidyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-209
    Figure US20190233441A1-20190801-C00582
         		N-(2-methoxyethyl)-N- (1-methyl-4-piperidyl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-210
    Figure US20190233441A1-20190801-C00583
         		4,4,4-trifluoro-1-[4-[2- [4-(4- morpholinopiperidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-211
    Figure US20190233441A1-20190801-C00584
         		1-[4-[2-[4-[3- (diethylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-212
    Figure US20190233441A1-20190801-C00585
         		N-methyl-N-[2-(3- pyridyl)ethyl]-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]aminolbenzamide
    2-213
    Figure US20190233441A1-20190801-C00586
         		N-(2-methyl-2- morpholino-propyl)-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-214
    Figure US20190233441A1-20190801-C00587
         		N-[(1-methyl-2- piperidyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-215
    Figure US20190233441A1-20190801-C00588
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(5-methyl-2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-216
    Figure US20190233441A1-20190801-C00589
         		N-[2-(6-methyl-2- pyridyl)ethyl]-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-217
    Figure US20190233441A1-20190801-C00590
         		1-[4-[2-[4-[3-[[6- (dimethylamino)pyrimidin- 4-yl]methyl]pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-218
    Figure US20190233441A1-20190801-C00591
         		4,4,4-trifluoro-1-[4-[2- [4-[3-[(5-methyl-2- pyridyl)methyl]pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-219
    Figure US20190233441A1-20190801-C00592
         		N-ethyl-N-(4- pyridylmethyl)-4-[[8-[1- (4,4,4-trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-220
    Figure US20190233441A1-20190801-C00593
         		N-[2-(3-pyridyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-221
    Figure US20190233441A1-20190801-C00594
         		N-[2-(2-piperidyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-222
    Figure US20190233441A1-20190801-C00595
         		N-benzyl-4-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxamide
    2-223
    Figure US20190233441A1-20190801-C00596
         		N-methyl-4-[[8-[1-(2- methylcyclo- propanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methyl-4- piperidyl)benzamide
    2-224
    Figure US20190233441A1-20190801-C00597
         		methyl 4-[2-[4-[methyl- (1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-225
    Figure US20190233441A1-20190801-C00598
         		2,2-difluoroethyl 4-[2- [4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-226
    Figure US20190233441A1-20190801-C00599
         		ethyl 4-[2-[4-[2-(3- methyl-1- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-227
    Figure US20190233441A1-20190801-C00600
         		ethyl 4-[2-[4-[4-[2- (dimethylami- no)ethyl]piperazine- 1-carbonyl]amlino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-228
    Figure US20190233441A1-20190801-C00601
         		ethyl 4-[2-[4-[2-(2- pyridyl)morpholine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-229
    Figure US20190233441A1-20190801-C00602
         		ethyl 4-[2-[4-[2-(6- methyl-2- pyridyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-230
    Figure US20190233441A1-20190801-C00603
         		ethyl 4-[2-[4-[2- (methylamino)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-231
    Figure US20190233441A1-20190801-C00604
         		ethyl 4-[2-[4- (pyrrolidin-3- ylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-231
    Figure US20190233441A1-20190801-C00605
         		ethyl 4-[2-[4-[2-(3- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-233
    Figure US20190233441A1-20190801-C00606
         		ethyl 4-[2-[4- (pyrrolidin-2- ylmethylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-234
    Figure US20190233441A1-20190801-C00607
         		ethyl 4-[2-[4-[3-(2- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-235
    Figure US20190233441A1-20190801-C00608
         		ethyl 4-[2-[4-[2-(2- pyridylmethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-236
    Figure US20190233441A1-20190801-C00609
         		ethyl 4-[2-[4-[4-(2- methoxyethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-237
    Figure US20190233441A1-20190801-C00610
         		ethyl 4-[2-[4-[methyl-[2- (3-pyridyl)ethyl]carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-238
    Figure US20190233441A1-20190801-C00611
         		ethyl 4-[2-[4-[4- (cyclopropylmethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-239
    Figure US20190233441A1-20190801-C00612
         		ethyl 4-[2-[4-[2-(2- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-240
    Figure US20190233441A1-20190801-C00613
         		ethyl 4-[2-[4-(2-methyl- 1,3,3a,4,6,6a- hexahydropyrrolo[3,4- c]pyrrole-5- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-241
    Figure US20190233441A1-20190801-C00614
         		ethyl 4-[2-[4-[4- hydroxy-4-(pyrrolidin-1- ylmethyl)azepane-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-242
    Figure US20190233441A1-20190801-C00615
         		ethyl 4-[2-[4-[3-[2- (dimethylami- no)ethyl]piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-243
    Figure US20190233441A1-20190801-C00616
         		ethyl 4-[2-[4-[2- (dimethylcarbamoyl)-4- methyl-piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-244
    Figure US20190233441A1-20190801-C00617
         		ethyl 4-[2-[4-[(3aS,6aS)- 5-methyl-2,3,3a,4,6,6a- hexahydropyrrolo[2,3- c]pyrrole-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-245
    Figure US20190233441A1-20190801-C00618
         		ethyl 4-[2-[4-[(6-methyl-3- pyridyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-246
    Figure US20190233441A1-20190801-C00619
         		ethyl 4-[2-[4-[(3aS,6aS)- 3,3a,4,5,6,6a-hexahydro- 2H-pyrrolo[2,3- c]pyrrole-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-247
    Figure US20190233441A1-20190801-C00620
         		ethyl 4-[2-[4-(1,8- diazaspiro[5.5]undecane- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-248
    Figure US20190233441A1-20190801-C00621
         		ethyl 4-[2-[4-[(1R,5R)-3,6- diazabicyclo[3.2.0]heptane- 3-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-249
    Figure US20190233441A1-20190801-C00622
         		ethyl 4-[2-[4-[(1-methyl-4- piperidyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-250
    Figure US20190233441A1-20190801-C00623
         		ethyl 4-[2-[4-[[(3S)-3- piperidyl]carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-251
    Figure US20190233441A1-20190801-C00624
         		ethyl 4-[2-[4-[4-(2- pyridyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-252
    Figure US20190233441A1-20190801-C00625
         		ethyl 4-[2-[4-(2,9- diazaspiro[5.5]undecane- 9-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-253
    Figure US20190233441A1-20190801-C00626
         		1-[4-[2-[4-(2,9- diazaspiro[4.5]decane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-254
    Figure US20190233441A1-20190801-C00627
         		4,4,4-trifluoro-1-[4-[2- [4-(1-oxa-4,9- diazaspiro[5.5]undecane- 4-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-255
    Figure US20190233441A1-20190801-C00628
         		N-pyrrolidin-3-yl-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2 4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-256
    Figure US20190233441A1-20190801-C00629
         		1-[4-[2-[4-(3- aminoazetidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-257
    Figure US20190233441A1-20190801-C00630
         		1-[4-[2-[4-(1,9- diazaspiro[4.5]decane-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-258
    Figure US20190233441A1-20190801-C00631
         		1-[4-[2-[4-(1,8- diazaspiro[4.5]decane-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-259
    Figure US20190233441A1-20190801-C00632
         		4,4,4-trifluoro-1-[4-[2- [4-(8-methyl-5-oxa-2,8- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]bulan-1-one
    2-260
    Figure US20190233441A1-20190801-C00633
         		1-[4-[2-[4-(4- cyclobutylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-261
    Figure US20190233441A1-20190801-C00634
         		N,N-dimethyl-2-(4- pyridyl)-1-[4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]pyrrolidine- 2-carboxamide
    2-262
    Figure US20190233441A1-20190801-C00635
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(4- methylpiperazine-1- carbonyl)morpholine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-263
    Figure US20190233441A1-20190801-C00636
         		N-methyl-4-[[8-[1-(3- methylcyclobutanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methyl-4- piperidyl)benzamide
    2-264
    Figure US20190233441A1-20190801-C00637
         		(1-methyl-4-piperidyl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoate
    2-265
    Figure US20190233441A1-20190801-C00638
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(2- pyridylmethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-266
    Figure US20190233441A1-20190801-C00639
         		4,4,4-trifluoro-1-[4-[2- [4-(4-isobutylpiperazine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-267
    Figure US20190233441A1-20190801-C00640
         		N-methyl-N-(1- methylpyrrolidin-3-yl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-268
    Figure US20190233441A1-20190801-C00641
         		N-[2-(2,6- dimethylmorpholin-4- yl)ethyl]-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-269
    Figure US20190233441A1-20190801-C00642
         		N-[2-(3,5-dimethyl-1- piperidyl)ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-270
    Figure US20190233441A1-20190801-C00643
         		N-[2-(4- methylpiperazin-1- yl)ethyl]-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-271
    Figure US20190233441A1-20190801-C00644
         		N-(3- morpholinopropyl)-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-272
    Figure US20190233441A1-20190801-C00645
         		N-cyclopropyl-N-(2- pyridylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-273
    Figure US20190233441A1-20190801-C00646
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(4- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-274
    Figure US20190233441A1-20190801-C00647
         		N-[2-(1-methyl-4- piperidyl)ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-275
    Figure US20190233441A1-20190801-C00648
         		N,1-dimethyl-4-[4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-276
    Figure US20190233441A1-20190801-C00649
         		N,4-dimethyl-1-[4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-277
    Figure US20190233441A1-20190801-C00650
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(3- pyridylmethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-278
    Figure US20190233441A1-20190801-C00651
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(4-pyridyl)-1,4- diazepane-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-279
    Figure US20190233441A1-20190801-C00652
         		N-(2-hydroxyethyl)-N- (3-pyridylmethyl)-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-280
    Figure US20190233441A1-20190801-C00653
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(3- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-281
    Figure US20190233441A1-20190801-C00654
         		4-[[8-[1- (cyclopentanecarbonyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-282
    Figure US20190233441A1-20190801-C00655
         		4-[[8-[1- (cyclobutanecarbonyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-283
    Figure US20190233441A1-20190801-C00656
         		oxetan-3-yl 4-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-284
    Figure US20190233441A1-20190801-C00657
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(1- phenyl-3,6-dihydro-2H- pyridin-4-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-285
    Figure US20190233441A1-20190801-C00658
         		4-[[8-[1-(4- cyanocyclohexanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-286
    Figure US20190233441A1-20190801-C00659
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1-(2- oxa-6- azaspiro[3.3]heptane-6- carbonyl)-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-287
    Figure US20190233441A1-20190801-C00660
         		4-[[8-[1-(3- cyanopropanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-288
    Figure US20190233441A1-20190801-C00661
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-289
    Figure US20190233441A1-20190801-C00662
         		4-[[8-(1-butanoyl-3,6- dihydro-2H-pyridin-4- yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-290
    Figure US20190233441A1-20190801-C00663
         		4-[[8-[1-(3,3- dimethylazetidine-1- carbonyl)-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-291
    Figure US20190233441A1-20190801-C00664
         		ethyl 4-[2-[4-[3-(4- methylpiperazin-1- yl)propylcarbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-292
    Figure US20190233441A1-20190801-C00665
         		ethyl 4-[2-[4-[methyl-(1- methylpyrrolidin-3- yl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-293
    Figure US20190233441A1-20190801-C00666
         		ethyl 4-[2-[4-[(1-methyl-3- piperidyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-294
    Figure US20190233441A1-20190801-C00667
         		ethyl 4-[2-[4-[2-(1- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-295
    Figure US20190233441A1-20190801-C00668
         		ethyl 4-[2-[4-(3- morpholinopiperidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-296
    Figure US20190233441A1-20190801-C00669
         		ethyl 4-[2-[4- (pyrrolidin-3- ylmethylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-297
    Figure US20190233441A1-20190801-C00670
         		ethyl 4-[2-[4-[4-(3- pyridylmethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-298
    Figure US20190233441A1-20190801-C00671
         		ethyl 4-[2-[4-[4-(4- methylpiperazin-1- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-299
    Figure US20190233441A1-20190801-C00672
         		ethyl 4-[2-[4-[4-(2- imidazol-1- ylethyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-300
    Figure US20190233441A1-20190801-C00673
         		ethyl 4-[2-[4-[4-(4- methylpiperazine-1- carbonyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-301
    Figure US20190233441A1-20190801-C00674
         		ethyl 4-[2-[4-(4- isobutylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-302
    Figure US20190233441A1-20190801-C00675
         		ethyl 4-[2-[4-(4- pyrrolidin-1- ylpiperidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-303
    Figure US20190233441A1-20190801-C00676
         		ethyl 4-[2-[4- [cyclopropyl-1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-304
    Figure US20190233441A1-20190801-C00677
         		ethyl 4-[2-[4-[4- [(dimethylamino)methyl]- 4-hydroxy-azepane-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-305
    Figure US20190233441A1-20190801-C00678
         		ethyl 4-[2-[4-[(1- ethylpyrrolidin-3- yl)methyl-methyl- carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-306
    Figure US20190233441A1-20190801-C00679
         		ethyl 4-[2-[4-(6- azaspiro[2.5]octan-2- ylmethylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-307
    Figure US20190233441A1-20190801-C00680
         		ethyl 4-[2-[4-[4- (aminomethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-308
    Figure US20190233441A1-20190801-C00681
         		ethyl 4-[2-[4- (3,3a,4,5,6,6a- hexahydro-2H- pyrrolo[2,3-c]pyrrole-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-309
    Figure US20190233441A1-20190801-C00682
         		ethyl 4-[2-[4-(1-oxa-4,9- diazaspiro[5.5]undecane- 9-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-310
    Figure US20190233441A1-20190801-C00683
         		ethyl 4-[2-[4-(1,7- diazaspiro[4.4]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-311
    Figure US20190233441A1-20190801-C00684
         		ethyl 4-[2-[4-(1,7- diazaspiro[4.4]nonane- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-312
    Figure US20190233441A1-20190801-C00685
         		ethyl 4-[2-[4-(2,9- diazaspiro[4.5]decane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-313
    Figure US20190233441A1-20190801-C00686
         		1-[4-[2-[4- (2,3,3a,4,6,6a- hexahydro-1H- pyrrolo[3,4-c]pyrrole-5- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-314
    Figure US20190233441A1-20190801-C00687
         		1-[4-[2-[4-(2,7- diazaspiro[3.5]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-315
    Figure US20190233441A1-20190801-C00688
         		1-[4-[2-[4-(2-amino-7- azaspiro[3.5]nonane-7- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-316
    Figure US20190233441A1-20190801-C00689
         		N-(2-pyrrolidin-2- ylethyl)-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-317
    Figure US20190233441A1-20190801-C00690
         		N-(pyrrolidin-2- ylmethyl)-4-[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-318
    Figure US20190233441A1-20190801-C00691
         		4,4,4-trifluoro-1-[4-[2- [4-(piperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-319
    Figure US20190233441A1-20190801-C00692
         		4,4,4-trifluoro-1-[4-[2- [4-(2-methylpiperazine- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-320
    Figure US20190233441A1-20190801-C00693
         		1-[4-[2-[4-[(3aS,6aS)- 3,3a,4,5,6,6a-hexahydro- 2H-pyrrolo[2,3- c]pyrrole-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-321
    Figure US20190233441A1-20190801-C00694
         		1-[4-[2-[4-[(3aR,6aS)- 2,3,3a,4,6,6a-hexahydro- 1H-pyrrolo[3,4- c]pyrrole-5- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-322
    Figure US20190233441A1-20190801-C00695
         		N-(7- azaspiro[3.5]nonan-2- yl)-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-323
    Figure US20190233441A1-20190801-C00696
         		1-[4-[2-[4-[(1S,5R)-5- amino-3- azabicyclo[3.1.0]hexane- 3-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-324
    Figure US20190233441A1-20190801-C00697
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(1-methyl-2- piperidyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-325
    Figure US20190233441A1-20190801-C00698
         		N,N,1-trimethyl-4-[4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-326
    Figure US20190233441A1-20190801-C00699
         		1-[4-[2-[4-[(3aS,6aS)-5- methyl-2,3,3a,4,6,6a- hexahydropyrrolo[2,3- c]pyrrole-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-327
    Figure US20190233441A1-20190801-C00700
         		4-isopropyl-N-methyl-1- [4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-328
    Figure US20190233441A1-20190801-C00701
         		4,4,4-trifluoro-1-[4-[2- [4-(7-methyl-2,7- diazaspiro[3.4]octane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-329
    Figure US20190233441A1-20190801-C00702
         		1-[4-[2-[4-(4- cyclohexylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-330
    Figure US20190233441A1-20190801-C00703
         		N-(1-isopropyl-4- piperidyl)-N-methyl-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-331
    Figure US20190233441A1-20190801-C00704
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- methoxyethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-332
    Figure US20190233441A1-20190801-C00705
         		N-(1,2,2,6,6- pentamethyl-4- piperidyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-333
    Figure US20190233441A1-20190801-C00706
         		N-(1,1-dimethyl-2- morpholino-ethyl)-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-334
    Figure US20190233441A1-20190801-C00707
         		N-[1-methyl-2-(1- piperidyl)ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-335
    Figure US20190233441A1-20190801-C00708
         		N-(1-methyl-4- piperidyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-336
    Figure US20190233441A1-20190801-C00709
         		N-[2- (dimethylamino)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-337
    Figure US20190233441A1-20190801-C00710
         		N-[(1-methyl-3- piperidyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-338
    Figure US20190233441A1-20190801-C00711
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(4- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-339
    Figure US20190233441A1-20190801-C00712
         		4,4,4-trifluoro-1-[4-[2- [4-(3- morpholinopiperidine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-340
    Figure US20190233441A1-20190801-C00713
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(tetrahydrofuran-2- ylmethyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-341
    Figure US20190233441A1-20190801-C00714
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-342
    Figure US20190233441A1-20190801-C00715
         		1-benzyl-N-methyl-4-[4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-343
    Figure US20190233441A1-20190801-C00716
         		N-[2-(4-pyridyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-344
    Figure US20190233441A1-20190801-C00717
         		4-[[8-(1-acetyl-3,6- dihydro-2H-pyridin-4- yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-345
    Figure US20190233441A1-20190801-C00718
         		isobutyl 4-[2-[4- [methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-346
    Figure US20190233441A1-20190801-C00719
         		tetrahydrofuran-3-yl 4- [2-[4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-347
    Figure US20190233441A1-20190801-C00720
         		4-[[8-[1-(3,3- dimethylcyclo- butanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-348
    Figure US20190233441A1-20190801-C00721
         		4-[[8-[1- (cyclohexanecarbonyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-349
    Figure US20190233441A1-20190801-C00722
         		propyl 4-[2-[4-[methyl- (1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-350
    Figure US20190233441A1-20190801-C00723
         		4-[[8-[1-(4- cyanocyclohexanecarbonyl)- 3,6-dihydro-2H- pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-351
    Figure US20190233441A1-20190801-C00724
         		benzyl 4-[2-[4-[methyl- (1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-352
    Figure US20190233441A1-20190801-C00725
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-(1- pentanoyl-3,6-dihydro- 2H-pyridin-4-yl)- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-353
    Figure US20190233441A1-20190801-C00726
         		cyclopropylmethyl 4-[2- [4-[methyl-(1-methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-354
    Figure US20190233441A1-20190801-C00727
         		ethyl 4-[2-[4-(4- methylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-355
    Figure US20190233441A1-20190801-C00728
         		ethyl 4-[2-[4-[[2- (dimethylamino)-1- methyl- ethyl]carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-356
    Figure US20190233441A1-20190801-C00729
         		ethyl 4-[2-[4-(1,4- diazepane-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-357
    Figure US20190233441A1-20190801-C00730
         		ethyl 4-[2-[4-[3- (methylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-358
    Figure US20190233441A1-20190801-C00731
         		ethyl 4-[2-[4-[4-(2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-359
    Figure US20190233441A1-20190801-C00732
         		ethyl 4-[2-[4-[methyl(8- quinolylmethyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-360
    Figure US20190233441A1-20190801-C00733
         		ethyl 4-[2-[4-(4- piperidylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-361
    Figure US20190233441A1-20190801-C00734
         		ethyl 4-[2-[4-[methyl(4- pyridylmethyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-362
    Figure US20190233441A1-20190801-C00735
         		ethyl 4-[2-[4-(2- pyrrolidin-2- ylethylcarbamoyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-363
    Figure US20190233441A1-20190801-C00736
         		ethyl 4-[2-[4-[4- (tetrahydrofuran-2- ylmethyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-364
    Figure US20190233441A1-20190801-C00737
         		ethyl 4-[2-[4-[2- methoxyethyl-(1- methyl-4- piperidyl)carbamoyl]anilino]- [1,2,4]triazolol1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-365
    Figure US20190233441A1-20190801-C00738
         		ethyl 4-[2-[4-[(1- isopropyl-4-piperidyl)- methyl-carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-366
    Figure US20190233441A1-20190801-C00739
         		ethyl 4-[2-[4-(3-methyl- 3,6- diazabicyclo[3.2.1]octane- 6-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-367
    Figure US20190233441A1-20190801-C00740
         		ethyl 4-[2-[4-(4- cyclopropylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-368
    Figure US20190233441A1-20190801-C00741
         		ethyl 4-[2-[4-(4- cyclobutylpiperazine-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-369
    Figure US20190233441A1-20190801-C00742
         		ethyl 4-[2-[4-(8-methyl- 2,8- diazaspiro[5.5]undecane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-370
    Figure US20190233441A1-20190801-C00743
         		ethyl 4-[2-[4-[2-(3- pyridyl)pyrrolidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-371
    Figure US20190233441A1-20190801-C00744
         		ethyl 4-[2-[4-[(3aS,6aS)- 2,3,3a,4,6,6a-hexahydro- 1H-pyrrolo[2,3- c]pyrrole- 5-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-372
    Figure US20190233441A1-20190801-C00745
         		ethyl 4-[2-[4-(2,7- diazaspiro[3.4]octane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-373
    Figure US20190233441A1-20190801-C00746
         		ethyl 4-[2-[4-(1,8- diazaspiro[4.5]decane-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-374
    Figure US20190233441A1-20190801-C00747
         		ethyl 4-[2-[4-[2- aminoethyl(methyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine- 1-carboxylate
    2-375
    Figure US20190233441A1-20190801-C00748
         		ethyl 4-[2-[4-(2,6- diazaspiro[3.4]octane-6- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-376
    Figure US20190233441A1-20190801-C00749
         		ethyl 4-[2-[4-(2,6- diazaspiro[4.5]decane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-377
    Figure US20190233441A1-20190801-C00750
         		1-[4-[2-[4-(1,7- diazaspiro[4.4]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-378
    Figure US20190233441A1-20190801-C00751
         		1-[4-[2-[4-(2,6- diazaspiro[4.5]decane-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-379
    Figure US20190233441A1-20190801-C00752
         		1-[4-[2-[4-(2,6- diazaspiro[3.4]octane-6- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-380
    Figure US20190233441A1-20190801-C00753
         		4,4,4-trifluoro-1-[4-[2- [4-(1-oxa-4,9- diazaspiro[5.5]undecane- 9-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-381
    Figure US20190233441A1-20190801-C00754
         		1-[4-[2-[4-(2,7- diazaspiro[4.5]decane-7- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-382
    Figure US20190233441A1-20190801-C00755
         		1-[4-[2-[4-(2,9- diazaspiro[5.5]undecane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-383
    Figure US20190233441A1-20190801-C00756
         		1-[4-[2-[4-(1,8- diazaspiro[5.5]undecane- 8-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-384
    Figure US20190233441A1-20190801-C00757
         		1-[4-[2-[4-(1,9- diazaspiro[4.6]undecane- 9-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-385
    Figure US20190233441A1-20190801-C00758
         		N-(2-piperidylmethyl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-386
    Figure US20190233441A1-20190801-C00759
         		1-[4-[2-[4- (3,3a,4,5,6,6a- hexahydro-2H- pyrrolo[2,3-c]pyrrole-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-387
    Figure US20190233441A1-20190801-C00760
         		1-[4-[2-[4-[(3aS,6aS)- 2,3,3a,4,6,6a-hexahydro- 1H-pyrrolo[2,3- c]pyrrole-5- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-388
    Figure US20190233441A1-20190801-C00761
         		N-(6-azaspiro[2.5]octan- 2-ylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-389
    Figure US20190233441A1-20190801-C00762
         		N-methyl-N-[(1-methyl- 3-piperidyl)methyl]-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-390
    Figure US20190233441A1-20190801-C00763
         		4,4,4-trifluoro-1-[4-[2- [4-[4-hydroxy-4- (pyrrolidin-1- ylmethyl)azepane-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-391
    Figure US20190233441A1-20190801-C00764
         		4,4,4-trifluoro-1-[4-[2- [4-(7-methyl-2,7- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-392
    Figure US20190233441A1-20190801-C00765
         		1-[4-[2-[4-(2,6- diazaspiro[3.3]heptane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-393
    Figure US20190233441A1-20190801-C00766
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(4- methylpiperazin-1- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-394
    Figure US20190233441A1-20190801-C00767
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(3- pyridylmethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-395
    Figure US20190233441A1-20190801-C00768
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(3- pyridyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-396
    Figure US20190233441A1-20190801-C00769
         		4,4,4-trifluoro-1-[4-[2- [4-[2-(2- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-397
    Figure US20190233441A1-20190801-C00770
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- pyridyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-398
    Figure US20190233441A1-20190801-C00771
         		1-[4-[2-[4-[4- (cyclopro- pylmethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-399
    Figure US20190233441A1-20190801-C00772
         		N-[2-(dimethylamino)- 1-methyl-ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-400
    Figure US20190233441A1-20190801-C00773
         		N-cyclopropyl-N-(1- propyl-4-piperidyl)-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-401
    Figure US20190233441A1-20190801-C00774
         		N-[1-(6-methyl-2- pyridyl)ethyl]-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-402
    Figure US20190233441A1-20190801-C00775
         		N-methyl-N-(3- pyridylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-403
    Figure US20190233441A1-20190801-C00776
         		1-[4-[2-[4-[3-(azepan-1- yl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-404
    Figure US20190233441A1-20190801-C00777
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- pyridylmethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-405
    Figure US20190233441A1-20190801-C00778
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(3- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-406
    Figure US20190233441A1-20190801-C00779
         		N-[[4- (dimethylami- no)phenyl]methyl]- N-methyl-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-407
    Figure US20190233441A1-20190801-C00780
         		N-methyl-N-(4- pyridylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-408
    Figure US20190233441A1-20190801-C00781
         		4-[[8-(1-benzoyl-3,6- dihydro-2H-pyridin-4- yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-409
    Figure US20190233441A1-20190801-C00782
         		4-[[8-[1- (cyclopropanecarbonyl)- 3,6-dihydro-2H-pyridin- 4-yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-410
    Figure US20190233441A1-20190801-C00783
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1-(2- methylpropanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-411
    Figure US20190233441A1-20190801-C00784
         		4-[[8-[1-(3- methoxypropanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-412
    Figure US20190233441A1-20190801-C00785
         		N-methyl-4-[[8-[1-(4- methylpentanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(1-methyl-4- piperidyl)benzamide
    2-413
    Figure US20190233441A1-20190801-C00786
         		N-methyl-N-(1-methyl- 4-piperidyl)-4-[[8-[1- (morpholine-4- carbonyl)-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-414
    Figure US20190233441A1-20190801-C00787
         		ethyl 4-[2-[4-[3- (dimethylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-415
    Figure US20190233441A1-20190801-C00788
         		ethyl 4-[2-[4-[(1-methyl-2- piperidyl)methylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-416
    Figure US20190233441A1-20190801-C00789
         		ethyl 4-[2-[4-[2-(3- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-417
    Figure US20190233441A1-20190801-C00790
         		ethyl 4-[2-[4-[4-(2- cyanoethyl)piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-418
    Figure US20190233441A1-20190801-C00791
         		ethyl 4-[2-[4- (3,4,6,7,8,8a-hexahydro- 1H-pyrrolo[1,2- a]pyrazine-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-419
    Figure US20190233441A1-20190801-C00792
         		ethyl 4-[2-[4-[methyl(2- pyridylmethyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-420
    Figure US20190233441A1-20190801-C00793
         		ethyl 4-[2-[4-[(3S)-3- (dimethylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-421
    Figure US20190233441A1-20190801-C00794
         		ethyl 4-[2-[4-[3-(4- methylpiperazine-1- carbonyl)azetidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-422
    Figure US20190233441A1-20190801-C00795
         		ethyl 4-[2-[4-[2-(3- pyridyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-423
    Figure US20190233441A1-20190801-C00796
         		ethyl 4-[2-[4-[2-(2- pyridyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-424
    Figure US20190233441A1-20190801-C00797
         		ethyl 4-[2-[4-[3-(4- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-425
    Figure US20190233441A1-20190801-C00798
         		ethyl 4-[2-[4-(4- piperidylmethylcarba- moyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-426
    Figure US20190233441A1-20190801-C00799
         		ethyl 4-[2-[4-[3-(3- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-427
    Figure US20190233441A1-20190801-C00800
         		ethyl 4-[2-[4-(3- piperidylmethylcarba- moyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-428
    Figure US20190233441A1-20190801-C00801
         		ethyl 4-[2-[4-[2-(2- piperidyl)ethylcarba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-429
    Figure US20190233441A1-20190801-C00802
         		ethyl 4-[2-[4-[4-(4- pyridyl)-1,4-diazepane- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-430
    Figure US20190233441A1-20190801-C00803
         		ethyl 4-[2-[4- (1,3,4,6,7,8,9,9a- octahydropyrido[1,2- a]pyrazine-2- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-431
    Figure US20190233441A1-20190801-C00804
         		ethyl 4-[2-[4-[3- (dimethylcarbamoyl)-4- methyl-piperazine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-432
    Figure US20190233441A1-20190801-C00805
         		ethyl 4-[2-[4-(6-acetyl- 2,6- diazaspiro[3.3]heptane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-433
    Figure US20190233441A1-20190801-C00806
         		ethyl 4-[2-[4-[(1- methylpyrrolidin-3- yl)carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-434
    Figure US20190233441A1-20190801-C00807
         		ethyl 4-[2-[4-[[(1S,5R)- 3- azabicyclo[3.1.0]hexan- 6-yl]carbamoyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-435
    Figure US20190233441A1-20190801-C00808
         		ethyl 4-[2-[4- [(3aR,6aS)- 2,3,3a,4,6,6a-hexahydro- 1H-pyrrolo[3,4- c]pyrrole-5- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-436
    Figure US20190233441A1-20190801-C00809
         		ethyl 4-[2-[4-(1,9- diazaspiro[4.5]decane-1- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-437
    Figure US20190233441A1-20190801-C00810
         		ethyl 4-[2-[4-(2,5- diazaspiro[3.5]nonane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-438
    Figure US20190233441A1-20190801-C00811
         		ethyl 4-[2-[4-[methyl(3- piperidyl)carba- moyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-439
    Figure US20190233441A1-20190801-C00812
         		ethyl 4-[2-[4-(2,7- diazaspiro[4.5]decane-7- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine-1- carboxylate
    2-440
    Figure US20190233441A1-20190801-C00813
         		1-[4-[2-[4-(1,7- diazaspiro[4.4]nonane- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-441
    Figure US20190233441A1-20190801-C00814
         		N-(2-aminoethyl)-N- methyl-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-442
    Figure US20190233441A1-20190801-C00815
         		N-(1-oxa-8- azaspiro[4.5]decan-3- ylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-443
    Figure US20190233441A1-20190801-C00816
         		1-[4-[2-[4-(2,8- diazaspiro[5.5]undecane- 2-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-444
    Figure US20190233441A1-20190801-C00817
         		N-(pyrrolidin-3- ylmethyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-445
    Figure US20190233441A1-20190801-C00818
         		N-(4-piperidyl)-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-446
    Figure US20190233441A1-20190801-C00819
         		1-[4-[2-[4-[4- (aminomethyl)piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-447
    Figure US20190233441A1-20190801-C00820
         		1-[4-[2-[4-[3- (aminomethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-448
    Figure US20190233441A1-20190801-C00821
         		1-[4-[2-[4-[(4aR,7aR)- 3,4a,5,6,7,7a-hexahydro- 2H-pyrrolo[3,4- b][1,4]oxazine-4- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-449
    Figure US20190233441A1-20190801-C00822
         		1-[4-[2-[4-[(1R,5R)-3,6- diazabicyclo[3.2.0]heptane- 3-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-450
    Figure US20190233441A1-20190801-C00823
         		1-[4-[2-[4-(1,9- diazaspiro[5.5]undecane- 1-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-451
    Figure US20190233441A1-20190801-C00824
         		N-(azetidin-3-yl)-N- methyl-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-452
    Figure US20190233441A1-20190801-C00825
         		1-[4-[2-[4-[4- (aminomethyl)-3- azabicyclo[2.1.1]hexane- 3-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-453
    Figure US20190233441A1-20190801-C00826
         		1-[4-[2-[4- (2,3,4a,5,6,7,8,8a- octahydropyrido[4,3- b][1,4]oxazine-4- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-454
    Figure US20190233441A1-20190801-C00827
         		N-[(1R,5S)-3- azabicyclo[3.1.0]hexan- 6-yl]-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-455
    Figure US20190233441A1-20190801-C00828
         		N-[2-(1-piperidyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-456
    Figure US20190233441A1-20190801-C00829
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(4- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-457
    Figure US20190233441A1-20190801-C00830
         		N,N,4-trimethyl-1-[4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-458
    Figure US20190233441A1-20190801-C00831
         		4,4,4-trifluoro-1-[4-[2- [4-(9-methyl-3-oxa-7,9- diazabicyclo[3.3.1]nonane- 7-carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-459
    Figure US20190233441A1-20190801-C00832
         		N-(1-methylpyrrolidin- 3-yl)-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-460
    Figure US20190233441A1-20190801-C00833
         		N-methyl-N-(6- quinolylmethyl)-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-461
    Figure US20190233441A1-20190801-C00834
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(3-methyl-1- piperidyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-462
    Figure US20190233441A1-20190801-C00835
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2-imidazol-1- ylethyl)piperazinc-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-463
    Figure US20190233441A1-20190801-C00836
         		N-[(1- isopropylpyrrolidin-3- yl)methyl]-N-methyl-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-464
    Figure US20190233441A1-20190801-C00837
         		1-[4-[2-[4-[3- (dimethylamino)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-465
    Figure US20190233441A1-20190801-C00838
         		N-(2-morpholinoethyl)- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-466
    Figure US20190233441A1-20190801-C00839
         		N-(2-pyrrolidin-1- ylethyl)-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-467
    Figure US20190233441A1-20190801-C00840
         		N-[(1-methyl-4- piperidyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-468
    Figure US20190233441A1-20190801-C00841
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(6-methyl-2- pyridyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-469
    Figure US20190233441A1-20190801-C00842
         		N-[(3R)-quinuclidin-3- yl]-4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-470
    Figure US20190233441A1-20190801-C00843
         		N-methyl-1-(2- phenylethyl)-4-[4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzoyl]piperazine- 2-carboxamide
    2-471
    Figure US20190233441A1-20190801-C00844
         		4,4,4-trifluoro-1-[4-[2- [4-[3-(2- pyridylmethyl)pyrrolidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-472
    Figure US20190233441A1-20190801-C00845
         		1-[4-[2-[4-[3- [benzyl(me- thyl)amino]piperidine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    2-473
    Figure US20190233441A1-20190801-C00846
         		N-(1-benzylpyrrolidin-3- yl)-N-methyl-4-[[8-[1- (4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-474
    Figure US20190233441A1-20190801-C00847
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(2- morpholinoethyl)piperazine- 1-carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-475
    Figure US20190233441A1-20190801-C00848
         		4,4,4-trifluoro-1-[4-[2- [4-[4-(4- methylpiperazinc-1- carbonyl)piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]butan-1-one
    2-476
    Figure US20190233441A1-20190801-C00849
         		N-methyl-N-[(3-methyl- 2-pyridyl)methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-477
    Figure US20190233441A1-20190801-C00850
         		N-methyl-N-[(1-methyl- 3,4-dihydro-2H- quinolin-6-yl)methyl]-4- [[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-478
    Figure US20190233441A1-20190801-C00851
         		N-[2-(2-pyridyl)ethyl]- 4-[[8-[1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-479
    Figure US20190233441A1-20190801-C00852
         		4-[[8-[1-(3,3- dimethylazetidin-1- yl)sulfonyl-3,6-dihydro- 2H-pyridin-4-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-480
    Figure US20190233441A1-20190801-C00853
         		4-[[8-[1-(3,3- dimethylazetidine-1- carbonyl)-2,3,4,7- tetrahydroazepin-5-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-481
    Figure US20190233441A1-20190801-C00854
         		4-[[8-[1-(3,3- dimethylazetidine-1- carbonyl)-2,5- dihydropyrrol-3-yl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-482
    Figure US20190233441A1-20190801-C00855
         		4-[[8-[1-(2-cyano-1- methyl-ethyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1-methyl- 4-piperidyl)benzamide
    2-483
    Figure US20190233441A1-20190801-C00856
         		N-[[(2R)-1-methyl-2- piperidyl]methyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-484
    Figure US20190233441A1-20190801-C00857
         		N-[2-[(3S)-3-methyl-1- piperidyl]ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-485
    Figure US20190233441A1-20190801-C00858
         		N-[2-[(3R)-3-methyl-1- piperidyl]ethyl]-4-[[8- [1-(4,4,4- trifluorobutanoyl)-3,6- dihydro-2H-pyridin-4- yl]-[1,2,4]triazolo[1,5- a]pyridin-2- yl]amino]benzamide
    2-486
    Figure US20190233441A1-20190801-C00859
         		1-[4-[2-[4-[4-[(2R,6S)- 2,6-dimethylmorpholin- 4-yl]piperidine-1- carbonyl]anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridin-1- yl]-4,4,4-trifluoro-butan- 1-one
    3-1
    Figure US20190233441A1-20190801-C00860
         		N-[8-[4-(aminomethyl)- 4-phenyl-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2- yl]cyclopropanecarboxamide; hydrochloridc
    Figure US20190233441A1-20190801-P00899
    indicates data missing or illegible when filed
  • Compounds of the invention may contain one or more asymmetric carbon atoms. Accordingly, the compounds may exist as diastereomers, enantiomers or mixtures thereof. The syntheses of the compounds may employ racemates, diastereomers or enantiomers as starting materials or as intermediates. Mixtures of particular diastereomeric compounds may be separated, or enriched in one or more particular diastereomers, by chromatographic or crystallization methods. Similarly, enantiomeric mixtures may be separated, or enantiomerically enriched, using the same techniques or others known in the art. Each of the asymmetric carbon or nitrogen atoms may be in the R or S configuration and both of these configurations are within the scope of the invention.
  • In the structures shown herein, where the stereochemistry of any particular chiral atom is not specified, then all stereoisomers are contemplated and included as the compounds of the invention. Where stereochemistry is specified by a solid wedge or dashed line representing a particular configuration, then that stereoisomer is so specified and defined. Unless otherwise specified, if solid wedges or dashed lines are used, relative stereochemistry is intended.
  • Another aspect includes prodrugs of the compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, including known amino-protecting and carboxy-protecting groups which are released, for example hydrolyzed, to yield the compound of the present invention under physiologic conditions.
  • The term “prodrug” refers to a precursor or derivative form of a pharmaceutically active substance that is less efficacious to the patient compared to the parent drug and is capable of being enzymatically or hydrolytically activated or converted into the more active parent form. See, e.g., Wilman, “Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stella et al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery,” Directed Drug Delivery, Borchardt et al., (ed.), pp. 247-267, Humana Press (1985). Prodrugs include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, and 5-fluorocytosine and 5-fluorouridine prodrugs.
  • A particular class of prodrugs are compounds in which a nitrogen atom in an amino, amidino, aminoalkyleneamino, iminoalkyleneamino or guanidino group is substituted with a hydroxy group, an alkylcarbonyl (—CO—R) group, an alkoxycarbonyl (—CO—OR), or an acyloxyalkyl-alkoxycarbonyl (—CO—O—R—O—CO—R) group where R is a monovalent or divalent group, for example alkyl, alkylene or aryl, or a group having the Formula —C(O)—O—CP1P2-haloalkyl, where P1 and P2 are the same or different and are hydrogen, alkyl, alkoxy, cyano, halogen, alkyl or aryl. In a particular embodiment, the nitrogen atom is one of the nitrogen atoms of the amidino group of the compounds of Formula 0, Formula I or Formula II. Prodrugs may be prepared by reacting a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, with an activated group, such as acyl groups, to bond, for example, a nitrogen atom in the compound to the exemplary carbonyl of the activated acyl group. Examples of activated carbonyl compounds are those containing a leaving group bonded to the carbonyl group, and include, for example, acyl halides, acyl amines, acyl pyridinium salts, acyl alkoxides, acyl phenoxides such as p-nitrophenoxy acyl, dinitrophenoxy acyl, fluorophenoxy acyl, and difluorophenoxy acyl. The reactions are generally carried out in inert solvents at reduced temperatures such as −78 to about 50° C. The reactions may also be carried out in the presence of an inorganic base, for example potassium carbonate or sodium bicarbonate, or an organic base such as an amine, including pyridine, trimethylamine, triethylamine, triethanolamine, or the like.
  • Additional types of prodrugs are also encompassed. For instance, a free carboxyl group of a compound of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or suitable free carboxyl-containing compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, can be derivatized as an amide or alkyl ester. As another example, compounds of the present invention comprising free hydroxy groups can be derivatized as prodrugs by converting the hydroxy group into a group such as, but not limited to, a phosphate ester, hemisuccinate, dimethylaminoacetate, or phosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D. et al., (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Advanced Drug Delivery Reviews, 19:115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group can be an alkyl ester optionally substituted with groups including, but not limited to, ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem., (1996), 39:10. More specific examples include replacement of the hydrogen atom of the alcohol group with a group such as (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N-(C1-C6)alkoxycarbonylaminomethyl, succinoyl, (C1-C6)alkanoyl, alpha-amino(C1-C4)alkanoyl, arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl, where each alpha-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, —P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
  • “Leaving group” refers to a portion of a first reactant in a chemical reaction that is displaced from the first reactant in the chemical reaction. Examples of leaving groups include, but are not limited to, halogen atoms, alkoxy and sulfonyloxy groups. Example sulfonyloxy groups include, but are not limited to, alkylsulfonyloxy groups (for example methyl sulfonyloxy (mesylate group) and trifluoromethylsulfonyloxy (triflate group)) and arylsulfonyloxy groups (for example p-toluenesulfonyloxy (tosylate group) and p-nitrosulfonyloxy (nosylate group)).
    • Synthesis of Janus Kinase Inhibitor Compounds
  • Compounds of the present invention may be synthesized by synthetic routes described herein. In certain embodiments, processes well-known in the chemical arts can be used, in addition to, or in light of, the description contained herein. The starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, N.Y. (1967-1999 ed.), Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)), or Comprehensive Heterocyclic Chemistry, Editors Katrizky and Rees, Pergamon Press, 1984.
  • Compounds may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, or 10 to 100 compounds. Libraries of compounds may be prepared by a combinatorial ‘split and mix’ approach or by multiple parallel syntheses using either solution phase or solid phase chemistry, by procedures known to those skilled in the art. Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, le, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1.
  • For illustrative purposes, reaction Schemes 1-24 depicted below provide routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used. Although some specific starting materials and reagents are depicted in the Schemes and discussed below, other starting materials and reagents can be substituted to provide a variety of derivatives or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
  • In the preparation of compounds of the present invention, protection of remote functionality (e.g., primary or secondary amine) of intermediates may be necessary. The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods. Suitable amino-protecting groups include acetyl, trifluoroacetyl, benzyl, phenylsulfonyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
  • Other conversions commonly used in the synthesis of compounds of the present invention, and which can be carried out using a variety of reagents and conditions, include the following:
    • (1) Reaction of a carboxylic acid with an amine to form an amide. Such a transformation can be achieved using various reagents known to those skilled in the art but a comprehensive review can be found in Tetrahedron, 2005, 61, 10827-10852.
    • (2) Reaction of a primary or secondary amine with an aryl halide or pseudo halide, e.g., a triflate, commonly known as a “Buchwald-Hartwig cross-coupling,” can be achieved using a variety of catalysts, ligands and bases. A review of these methods is provided in Comprehensive Organic Name Reactions and Reagents, 2010, 575-581.
    • (3) A palladium cross-coupling reaction between an aryl halide and a vinyl boronic acid or boronate ester. This transformation is a type of “Suzuki-Miyaura cross-coupling,” a class of reaction that has been thoroughly reviewed in Chemical Reviews, 1995, 95(7), 2457-2483.
    • (4) The hydrolysis of an ester to give the corresponding carboxylic acid is well known to those skilled in the art and conditions include: for methyl and ethyl esters, the use of a strong aqueous base such as lithium, sodium or potassium hydroxide or a strong aqueous mineral acid such as HCl; for a tert-butyl ester, hydrolysis would be carried out using acid, for example, HCl in dioxane or trifluoroacetic acid (TFA) in dichloromethane (DCM).
  • Scheme 1 provides details of the reactions available for the preparation of compounds of the invention wherein R2 of Formula 0 is of type (a). Compound (1-3) can be prepared from 3-bromo-2-aminopyridine (1-1) according to WO2009/155551, incorporated herein by reference, and may undergo a Buchwald-Hartwig cross-coupling reaction with an aryl halide, an example of which would be ethyl 4-iodobenzoate, using a catalyst such as tris(dibenzylideneacetone)dipalladium (0) (Pd2(dba)3) or palladium (II) acetate (Pd(OAc)2), a phosphine ligand such as 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) and a base such as caesium carbonate. Where (1-1) has additional substituents in the pyridine ring, a compound (1-3) having additional substitution in the 6-membered ring can be prepared. A wide range of substituted 3-bromo-2-aminopyridines are known in the literature and are commercially available and the preparations of compounds (i), (ii) and (iii) from the corresponding substituted 3-bromo-2-aminopyridine, using analogous chemistry to that shown for (1-3) in Scheme 1, are described in WO2011/092272, WO2010/141796 and WO2010/141796, respectively, each incorporated herein by reference.
  • Figure US20190233441A1-20190801-C00861
  • An ester (1-4) can be hydrolysed to the corresponding carboxylic acid (1-5) using standard conditions which would be dependent upon the particular ester group present. An amide (1-6) may be formed from (1-5) using an amine R′R2NH under standard coupling conditions, for example using (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) (HATU) in the presence of a base such as N,N-diisopropylethylamine (DIPEA). Intermediate (1-6) may also be prepared directly from (1-3) and amide (1-7) using the same chemistries in an alternative sequence. Compound (1-6) may then be converted into (1-9) by reaction with a cyclic secondary amine (1-8) via a Buchwald-Hartwig cross-coupling using a palladium catalyst such as Pd2(dba)3 and a suitable ligand such as Xantphos in the presence of a base providing structures of Formula 0 with R2 being of type (a). Alternatively, ester (1-4) may undergo a palladium catalysed amination with (1-8) to give (1-10). The ester moiety in (1-10) may then be hydrolysed under standard conditions to give an acid (1-11) which then may be reacted with an amine R1R2NH to give a compound (1-9).
  • Figure US20190233441A1-20190801-C00862
  • In Scheme 1, R3 or R4 may be further elaborated. For example, in Scheme 2, where R4 is CH2CN (2-1), the nitrile group may be converted into the corresponding primary amide (2-2). Reagents suitable for this conversion include acetaldoxime in the presence of palladium (II) acetate and triphenylphosphine. The nitrile group in (2-1) may also be hydrolysed to the corresponding carboxylic acid (2-3) which in turn can be treated with an amine R4R5NH under standard amidation conditions to provide compounds of type (2-4).
  • Figure US20190233441A1-20190801-C00863
  • Where R4 in the compounds of Scheme 1 is an ester, exemplified by structure (3-1) of Scheme 3, this group may be hydrolysed under standard conditions to give an acid of type (3-2). Common amidation conditions may then be used to prepare an amide (3-3) from (3-2) and a suitable amine R3R4NH.
  • Figure US20190233441A1-20190801-C00864
  • The cyclic secondary amine (1-8) of Scheme 1, in which R4 is hydroxyl and R3 is an optionally substituted alkyl, aryl or heteroaryl group, may be prepared according to Scheme 4. Reaction of a suitably nitrogen protected aminoketone (4-1) with either a Grignard reagent or an organolithium may provide the alcohol (4-2). Deprotection of the amine nitrogen to give amine (4-3) can then be achieved using conditions designed to remove the protecting group of choice.
  • Figure US20190233441A1-20190801-C00865
  • Schemes 5 to 8 and 18 to 24 describe the methods that can be used to prepare other cyclic secondary amines (1-8), of Scheme 1, which are required for preparation of examples where the required amine (1-8) is hitherto unknown in the scientific literature. The methods use standard reactions known to those skilled in the art.
  • Scheme 5 provides a preparation of 1-oxa-3,7-diazaspiro[4.4]nonan-2-one (5-4). Starting with the commercially available aminoalcohol (5-1), reaction with triphosgene, or one of its equivalents, followed by removal of the benzyl group by catalytic hydrogenation can provide (5-3).
  • Figure US20190233441A1-20190801-C00866
  • Scheme 6 describes routes to secondary amines (1-8) of Scheme 1 in which R3 is phenyl or substituted phenyl and R4 is either cyano (6-6) or hydroxymethyl (6-5). Treatment of a cyanomethylbenzene with a base such as sodium hydride and subsequent reaction of the resultant anion with commercially available (6-1) may provide (6-2). The deprotection of (6-2) under acidic conditions gives amine (6-6). Reduction of the nitrile in intermediate (6-2), using diisobutylaluminium hydride for example, affords the aldehyde (6-3) which may be further reduced to the alcohol (6-4) by treatment with sodium borohydride. Boc deprotection will give the amine (6-5).
  • Figure US20190233441A1-20190801-C00867
  • Scheme 7 shows methods that can be used to prepare a secondary amine (1-8) of Scheme 1 in which R3 is hydrogen and R4 is 2-(2-methoxyethoxy)pyridin-4-ylmethoxy (7-4). Treatment of Boc-protected 4-piperidinol (7-2) with a base such as potassium tert-butoxide, and reaction with commercially available 4-(chloromethyl)-2-(2-methoxyethoxy)pyridine (7-1) in the presence of an iodide source such as terabutylammonium iodide gives (7-3). Treatment of the latter with acid leads to Boc deprotection and provides amine (7-4)
  • Figure US20190233441A1-20190801-C00868
  • Scheme 8 describes routes to amines 1-8 from Scheme 1 in which R3 is a phenyl or substituted phenyl and R4 is either cyanomethyl (8-6), hydroxyethyl (8-9) or cyanoethyl (8-12). The synthesis of intermediates of type (8-5) is described in Journal of Medicinal Chemistry, 2011, 54 (11), 3756-3767 and Boc deprotection can be achieved by treatment with acid. Reduction of the nitrile in (8-5) firstly to the aldehyde (8-7) using diisobutylaluminium hydride and then to the alcohol (8-8) with sodium borohydride provides (8-8) which can be Boc-deprotected in acid to give (8-9). Conversion of the alcohol (8-8) into the corresponding methanesulfonate ester (8-10) and subsequent reaction with a cyanide source such as sodium cyanide provides (8-11). Boc-deprotection of (8-11) results in the formation of amine (8-12).
  • Figure US20190233441A1-20190801-C00869
  • Analogous chemistries to those described in Scheme 1 may be used prepare compounds of the invention wherein R2 of Formula 0 is of type (b) by replacing the cyclic secondary amine (1-8) with an amine of type (iv). Here, R3/R4 may be modified further using standard chemistries.
  • Figure US20190233441A1-20190801-C00870
  • Scheme 9 indicates how other compounds of the invention may be prepared wherein R2 of Formula 0 is of type (d). Ester (1-4) or amide (1-6) from Scheme 1 may undergo a palladium catalysed Buchwald-Hartwig cross-coupling with a diamine (9-1). Where R3 in (9-5), or indeed (9-3), is a protecting group, it may be removed under standard conditions and the resulting amine (9-6) may be further modified through alkylation, arylation, acylation, sulfonylation etc.
  • Figure US20190233441A1-20190801-C00871
  • Scheme 10 indicates how other compounds of the invention may be prepared wherein R2 of Formula 0 is of type (c). Either ester (1-4) or amide (1-6) from Scheme 1 may be reacted with a suitable boronate ester or boronic acid in a Suzuki-Miyaura cross-coupling reaction. An example of a palladium catalyst that may be useful in such a transformation would be bis(triphenylphosphine)palladium (II) dichloride (Pd(PPh3)2Cl2). Where R3 in intermediate (10-2) or (10-5) is a protecting group, it may be removed under standard conditions to give amines (10-3) and (10-6), respectively. The latter may be further modified using standard chemistries, examples of which are given in Scheme 11. The ester may later be converted into an amide if required.
  • Figure US20190233441A1-20190801-C00872
  • By hydrogenation of the double bond in either compound (10-3) or (10-6), or in the preceding intermediates (10-2), (10-4) and (10-5) of Scheme 10, other compounds of the invention may be prepared wherein R2 of Formula 0 is of type (e). The amine (11-1) in Scheme 11 may be further modified using standard acylation, alkylation, arylation and sulfonylation chemistries. These specifically include: (i) Reaction with a chloroformate in the presence of a base such as triethylamine to give the corresponding carbamate; (ii) Alkylation with an alkyl halide in the presence of a base or reductive alkylation using an aldehyde or ketone and a reducing agent such as sodium triacetoxyborohydride; (iii) Acylation by reaction with a carboxylic acid and an amide coupling agent such as HATU or by reaction with an acid chloride in the presence of a base; (iv) Hydrogenation using hydrogen gas over a palladium catalyst; (v) Formation of an activated carbamate by reaction with 4-nitrophenyl chloroformate and then further reaction with an amine to form a urea; (vi) Arylation using an arylboronic acid or boronate ester in the presence of copper (II) acetate; (vii) Formation of a sulphonamide by reaction with a sulfonyl chloride in the presence of a base. The product of hydrogenation (11-2) can be subjected to reactions (i), (ii), (iii), (v), (vi) and (vii) in order to form compounds (11-3) wherein R2 of is of type (e).
  • Figure US20190233441A1-20190801-C00873
  • Scheme 12 indicates how other compounds of the invention may be prepared wherein R2 of Formula 0 is of type (f). Either ester (1-4) or amide (1-6) from Scheme 1 may be reacted with a suitable boronate ester (12-1) or boronic acid in a Suzuki-Miyaura cross-coupling to give (12-2) and (12-4), respectively. The palladium catalyst may be for example Pd(PPh3)2Cl2 or Pd2(dba)3 and the base may be sodium or cesium carbonate or sodium tert-butoxide. Groups R3 and R4 may be further modified using standard chemistries.
  • Figure US20190233441A1-20190801-C00874
  • Scheme 13 shows an alternative approach available for the preparation of compounds of the invention. The Group R1 may be incorporated into a 2-aminopyridine (13-1) prior to formation of the bicycle (13-3) which may then be further modified using the methodologies described herein. This method is of particular use in the synthesis of compounds of Formula 0 wherein R2 is of type (g). A method for preparing compounds (13-1) from 3-bromo-2-aminopyridine is available in WO2012/020848, incorporated herein by reference.
  • Figure US20190233441A1-20190801-C00875
  • An alternative route to compounds of structure (g) wherein R2 is OAr is described in Scheme 14. An intermediate (14-1) can be reacted with a phenol using a copper catalyst. Specifically, (14-1) can be converted into a compound of type (14-2) by heating with the appropriate phenol in the presence of picolinic acid, copper (I) iodide and a base such as potassium phosphate tribasic or caesium carbonate.
  • Figure US20190233441A1-20190801-C00876
  • During the synthesis of compounds of the invention it may be convenient to convert an intermediate carboxylic acid, exemplified by structure (15-1) in Scheme 15, into an ester (15-2) wherein R2 is different to that present in the original intermediate (1-5) of Scheme 1. This can be achieved using standard esterification protocols such as the use of EDC in combination with HOBt as shown in Scheme 15.
  • Figure US20190233441A1-20190801-C00877
  • Analogous chemistries to those described in Scheme 1 to 15 may be used prepare compounds of the invention wherein R2 of Formula 0 is of type (b) by replacing the cyclic analogues where Ar1 present in Formula 0 is replaced by a 1,3 or 1,2-disubstituted phenyl or a di-substituted heteroaryl group.
  • An alternative method for the introduction of an aryl or heteroaryl ring Ar1 in structure (I) is given in Scheme 16. In this case, the 8-substituted [1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1-3) from Scheme 1 may be converted into the 2-iodo analogue (16-1) via the diazonium salt which is formed in situ by the action of sodium nitrite and p-toluenesulfonic acid and which is converted into (16-1) by potassium iodide. Intermediate (16-1) can then undergo a Buchwald-Hartwig cross-coupling with an aryl or heteroaryl amine. One such example of the latter would be aminopyrazole (16-2).
  • Figure US20190233441A1-20190801-C00878
  • Reaction of Intermediate (1-3) from Scheme 1 with an acid chloride such as cyclopropanecarbonyl chloride in the presence of pyridine may give rise to key intermediate (17-1) for the preparation of compounds of Formula (II) as described in Scheme 17. Analogous chemistries to those described in Schemes 1 to 15 may be used to further elaborate the bromo substituent into groups Q1 of Formula (II).
  • Figure US20190233441A1-20190801-C00879
  • Scheme 18 describes routes to amines 1-8 from Scheme 1 in which R3 is a phenyl or substituted phenyl and R4 is methyl acetamido. Reduction of the nitrile (6-2) using a metal catalyzed reduction under an atmosphere of hydrogen with a reagent such as Raney Nickel may be used to afford the methylamino intermediate (18-1) which may be protected as the acetamide using acetic anhydride and a base to afford acetamide intermediate (18-2). Boc deprotection under standard acidic conditions may be used to afford the amine (18-3).
  • Figure US20190233441A1-20190801-C00880
  • Scheme 19 describes routes to amines 1-8 from Scheme 1 in which R3 is ethyl-(2,2,2-trifluoroethyl)amine and R4 is hydroxymethyl. Deprotonation adjacent to the nitrile of commercially available (19-1), using a base such as LDA, followed by treatment with BOM-Cl affords the benzyloxy intermediate (19-2). The nitrile of intermediate (18-2) may be reduced to the aldehyde (18-3) using a suitable reducing agent such as DIBAl-H. The aldehyde may then be converted to the amine (18-4) using trifluoroethylamine and a reducing agent such as sodium cyanoborohydride. Hydrogenation of the benzyloxy intermediate (19-4) using palladium catalysis under an atmosphere of hydrogen may be used to prepare the hydroxymethyl intermediate (19-5). Removal of the Boc protecting group under standard conditions may be used to give the amine (19-6).
  • Figure US20190233441A1-20190801-C00881
  • Scheme 20 describes routes to amines 1-8 from Scheme 1 in which R3 is a 4-difluoromethyl substituted phenyl and R4 is hydroxymethyl. Treatment of commercially available 4-bromobenzylcyanide with a base such as sodium hydride and reaction of the resultant anion with the commercially available alkylating agent (6-1) may be used to prepare intermediate (20-1). The ester (20-2) may be prepared from Intermediate (20-1) using a carbonylation reaction with a palladium catalyst such as Pd(dppf)Cl2 under an atmosphere of carbon monoxide. Reduction of the ester in intermediate (20-2) using, for example, DIBAl-H affords the alcohol (20-3) which may then be oxidized to the aldehyde (20-4) using an oxidant such as DMP. The aldehyde of (20-4) may be converted to the difluoromethyl intermediate (20-5) using a reagent such as DAST. Reduction of the nitrile in Intermediate (20-5), using DIBAl-H for example, may afford the aldehyde (20-6) which may be further reduced to the alcohol (20-7) by treatment with sodium borohydride. Boc deprotection under standard conditionds may be used to prepare the amine (20-8).
  • Figure US20190233441A1-20190801-C00882
  • Scheme 21 describes routes to amines 1-8 from Scheme 1 in which R3 is a phenyl or substituted phenyl and R4 is a propane-1,2-diol. Treatment of methanesulfonate ester (8-10) with a base such as potassium tert-butoxide may provide the alkene (21-1). Intermediate (21-1) may be treated with an oxidant such as osmium tetroxide to afford diol (21-2). Boc deprotection under standard conditions may be used to give the amine (21-3).
  • Figure US20190233441A1-20190801-C00883
  • Scheme 22 describes a route to the amine (22-4) in which R3 is a cycloalkyl and R4 is either cyanomethyl. Conjugate addition to Intermediate (8-2) using reagents such as a Grignard and copper(I) iodide may be used to prepare intermediate (22-1). Hydrolysis of the ester in Intermediate (22-1) with a base such as potassium hydroxide followed by decarboxylation using a reagent such as copper (I) oxide may be used to give Intermediate (22-3). Boc deprotection under standard conditions may be used to give the amine (22-4)
  • Figure US20190233441A1-20190801-C00884
  • Scheme 23 describes routes to amines 1-8 from Scheme 1 in which R3 is a phenyl or substituted phenyl and R4 is a propionic acid ethyl ester. Hydrolysis of the nitrile (8-6) under acidic conditions with a reagent such as HCl in acetic acid gives the acid (23-1). Esterification of the acid with an alcohol such as ethanol under acidic conditions gives the ester (23-2). Boc deprotection under standard conditions may be used to give the amine (23-3).
  • Figure US20190233441A1-20190801-C00885
  • Scheme 24 describes routes to amines 1-8 from Scheme 1 in which R3 is a phenyl or substituted phenyl and R4 is either carboxylic acid (24-6), difluoroethyl (24-7), 2-hydroxyethyl (24-8), 2-hydroxytrifluoroethyl (24-9), or methoxymethyl (24-10). Hydrolysis of the nitrile (6-2) under acidic conditions with a reagent such as HCl in acetic acid may be used to afford the acid (24-1). Treatment of the aldehyde (8-7) with a reagent such as DAST may be used to afford the difluoroethyl intermediate (24-2). Addition of a methyl Grignard such as methyl magnesium bromide to the aldehyde (6-3) may be used to afford the 2-hydroxyethyl intermediate (24-3). Treatment of the aldehyde (6-3) with a reagent such as CF3-TMS in the presence of a base such as potassium carbonate may be used to give the trifluorohydroxy intermediate (24-4). Treatment of the alcohol (6-4) with a base such as sodium hydride in the presence of methyl iodide may be used to afford the methyl ether (24-5). Standard conditions may be used to deprotect Intermediates (24-1) to (24-5) to afford the amines (24-6) to (24-10).
  • Figure US20190233441A1-20190801-C00886
  • Scheme 25 describes a route to compounds of the invention wherein Ar1 is a pyrazole. Ester (16.2) from Scheme 16 may undergo a palladium catalysed Buchwald-Hartwig cross-coupling with an amine (1-8). Where R1 in (25-1) is a protecting group, it may be removed under standard conditions and the resulting acid (25-2) may be further modified through an amide coupling to afford amides of the Formula 25-3.
  • Figure US20190233441A1-20190801-C00887
  • Scheme 26 describes an alternative route towards compounds where Ar1 is a pyrazole. The 2-iodo analogue (16-1) may undergo a palladium catalysed Buchwald-Hartwig cross-coupling with a protected aminopyrazole, such as the SEM amino pyrazole, to afford compounds of Formula (26-1). Compounds of Formula (26-1) may then undergo a further palladium catalysed Buchwald-Hartwig cross-coupling with an amine (1-8) to afford compounds of Formula (26-2). The pyrazole protecting group in (26-2) may then be removed under standard conditions to afford compounds of Formula (26-3) which may be subsequently alkylated with a suitable alkylating agent and base to afford compounds of formula (25-1). Compounds of Formula (25-1) may be further modified as in Scheme 25 to afford amides of Formula (25-3).
  • Figure US20190233441A1-20190801-C00888
    • Methods of Separation
  • In each of the exemplary Schemes it may be advantageous to separate reaction products from one another or from starting materials. The desired products of each step or series of steps is separated or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization or trituration from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; supercritical fluid; high, medium, and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
  • Another class of separation methods involves treatment of a mixture with a reagent selected to bind to or render otherwise separable a desired product, unreacted starting material, reaction by product, or the like. Such reagents include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media, or the like. Alternatively, the reagents can be acids in the case of a basic material, bases in the case of an acidic material, binding reagents such as antibodies, binding proteins, selective chelators such as crown ethers, liquid/liquid ion extraction reagents (LIX), or the like.
  • Selection of appropriate methods of separation depends on the nature of the materials involved. Example separation methods include boiling point, and molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction, and the like. One skilled in the art will apply techniques most likely to achieve the desired separation.
  • Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Also, some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC column or supercritical fluid chromatography.
  • A single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York, 1994; Lochmuller, C. H., J. Chromatogr., 113(3):283-302 (1975)). Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. See: Drug Stereochemistry, Analytical Methods and Pharmacology, Irving W. Wainer, Ed., Marcel Dekker, Inc., New York (1993).
  • Diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, α-methyl-β-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
  • Alternatively, the substrate to be resolved is reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York, 1994, p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the pure or enriched enantiomer. A method of determining optical purity involves making chiral esters, such as a menthyl ester, e.g., (−) menthyl chloroformate in the presence of base, or Mosher ester, α-methoxy-α-(trifluoromethyl)phenyl acetate (Jacob, J. Org. Chem. 47:4165 (1982)), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric enantiomers or diastereomers. Stable diastereomers of atropisomeric compounds can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (WO 96/15111, incorporated herein by reference). By method (3), a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (Chiral Liquid Chromatography W. J. Lough, Ed., Chapman and Hall, New York, (1989); Okamoto, J. of Chromatogr. 513:375-378 (1990)). Enriched or purified enantiomers can be distinguished by methods used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism. The absolute stereochemistry of chiral centers and enatiomers can be determined by x-ray crystallography.
  • Positional isomers, for example E and Z forms, of compounds of Formula 0, Formula I or Formula II, and intermediates for their synthesis, may be observed by characterization methods such as NMR and analytical HPLC. For certain compounds where the energy barrier for interconversion is sufficiently high, the E and Z isomers may be separated, for example by preparatory HPLC.
    • Pharmaceutical Compositions and Administration
  • The compounds with which the invention is concerned are JAK kinase inhibitors, such as JAK1 inhibitors, and are useful in the treatment of several diseases, for example, inflammatory diseases, such as asthma.
  • Accordingly, another embodiment provides pharmaceutical compositions or medicaments containing a compound of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, and a pharmaceutically acceptable carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments.
  • In one example, a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but typically ranges anywhere from about 3 to about 8. In one example, a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
  • Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range for oral administration will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a human, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses. In general, the daily dose range for inhaled administration will lie within the range of from about 0.1 μg to about 1 mg per kg body weight of a human, preferably 0.1 μg to 50 μg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
  • The compounds of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal, inhaled and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, inhaled administration is employed.
  • The compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be administered in any convenient administrative form, e.g., tablets, powders, capsules, lozenges, granules, solutions, dispersions, suspensions, syrups, sprays, vapors, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents (e.g., glucose, lactose or mannitol), carriers, pH modifiers, buffers, sweeteners, bulking agents, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, perfuming agents, flavoring agents, other known additives as well as further active agents.
  • Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. For example, carriers include solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, pp 1289-1329, 1990). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated. Exemplary excipients include dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof. A pharmaceutical composition may comprise different types of carriers or excipients depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration.
  • For example, tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers, for example, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example, magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example, methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavoring or coloring agents.
  • For topical application to the skin, a compound may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
  • Compounds of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may also be formulated for inhalation, for example, as a nasal spray, or dry powder or aerosol inhalers. For delivery by inhalation, the compound is typically in the form of microparticles, which can be prepared by a variety of techniques, including spray-drying, freeze-drying and micronisation. Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, such as by using propellant-driven metered aerosols or propellant-free administration of micronized compounds from, for example, inhalation capsules or other “dry powder” delivery systems.
  • By way of example, a composition of the invention may be prepared as a suspension for delivery from a nebulizer or as an aerosol in a liquid propellant, for example, for use in a pressurized metered dose inhaler (PMDI). Propellants suitable for use in a PMDI are known to the skilled person, and include CFC-12, HFA-134a, HFA-227, HCFC-22 (CCl2F2) and HFA-152 (CH4F2 and isobutane).
  • In some embodiments, a composition of the invention is in dry powder form, for delivery using a dry powder inhaler (DPI). Many types of DPI are known.
  • Microparticles for delivery by administration may be formulated with excipients that aid delivery and release. For example, in a dry powder formulation, microparticles may be formulated with large carrier particles that aid flow from the DPI into the lung. Suitable carrier particles are known, and include lactose particles; they may have a mass median aerodynamic diameter of, for example, greater than 90 μm.
  • In the case of an aerosol-based formulation, an example is:
  • Compound of the invention* 24 mg/canister
  • Lecithin, NF Liq. Conc. 1.2 mg/canister
  • Trichlorofluoromethane, NF 4.025 g/canister
  • Dichlorodifluoromethane, NF 12.15 g/canister.
  • * Such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1.
  • A compound, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-4816 or 3-1, may be dosed as described depending on the inhaler system used. In addition to the compound, the administration forms may additionally contain excipients as described above, or, for example, propellants (e.g., Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g., lactose in the case of powder inhalers) or, if appropriate, further active compounds.
  • For the purposes of inhalation, a large number of systems are available with which aerosols of optimum particle size can be generated and administered, using an inhalation technique which is appropriate for the patient. In addition to the use of adaptors (spacers, expanders) and pear-shaped containers (e.g., Nebulator®, Volumatic®), and automatic devices emitting a puffer spray (Autohaler®), for metered aerosols, in the case of powder inhalers in particular, a number of technical solutions are available (e.g., Diskhaler®, Rotadisk®, Turbohaler® or the inhalers, for example, as described in U.S. Pat. No. 5,263,475, incorporated herein by reference). Additionally, compounds of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be delivered in multi-chamber devices thus allowing for delivery of combination agents.
  • The compound, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the compound can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative or buffering agents can be dissolved in the vehicle.
    • Methods of Treatment With and Uses of Janus Kinase Inhibitors
  • The compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, inhibit the activity of a Janus kinase, such as JAK1 kinase. For example, a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, inhibits the phosphorylation of signal transducers and activators of transcription (STATs) by JAK1 kinase as well as STAT mediated cytokine production. Compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, are useful for inhibiting JAK1 kinase activity in cells through cytokine pathways, such as IL-6, IL-15, IL-7, IL-2, IL-4, IL-9, IL-10, IL-13, IL-21, G-CSF, IFNalpha, IFNbeta or IFNgamma pathways. Accordingly, in one embodiment is provided a method of contacting a cell with a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, to inhibit a Janus kinase activity in the cell (e.g., JAK1 activity).
  • The compounds of the present invention, such as compounds of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, can be used for the treatment of immunological disorders driven by aberrant IL-6, IL-15, IL-7, IL-2, IL-4, IL9, IL-10, IL-13, IL-21, G-CSF, IFNalpha, IFNbeta or IFNgamma cytokine signaling
  • Accordingly, one embodiment includes compounds of of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for use in therapy.
  • In some embodiments, there is provided use a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, in the treatment of an inflammatory disease. Further provided is use of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for the preparation of a medicament for the treatment of an inflammatory disease, such as asthma. Also provided is a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for use in the treatment of an inflammatory disease, such as asthma.
  • Another embodiment includes a method of preventing, treating or lessening the severity of a disease or condition, such as asthma, responsive to the inhibition of a Janus kinase activity, such as JAK1 kinase activity, in a patient. The method can include the step of administering to a patient a therapeutically effective amount of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1. In one embodiment, the disease or condition responsive to the inhibition of a Janus kinase, such as JAK1 kinase, is asthma.
  • In one embodiment, the disease or condition is cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, multiple sclerosis, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, asthma, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with organ transplantation (e.g., transplant rejection), immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, liver disease, pathologic immune conditions involving T cell activation, CNS disorders or a myeloproliferative disorder.
  • In one embodiment, the inflammatory disease is rheumatoid arthritis, psoriasis, asthma, inflammatory bowel disease, contact dermatitis or delayed hypersensitivity reactions. In one embodiment, the autoimmune disease is rheumatoid arthritis, lupus or multiple sclerosis.
  • In one embodiment, the cancer is breast, ovary, cervix, prostate, testis, penile, genitourinary tract, seminoma, esophagus, larynx, gastric, stomach, gastrointestinal, skin, keratoacanthoma, follicular carcinoma, melanoma, lung, small cell lung carcinoma, non-small cell lung carcinoma (NSCLC), lung adenocarcinoma, squamous carcinoma of the lung, colon, pancreas, thyroid, papillary, bladder, liver, biliary passage, kidney, bone, myeloid disorders, lymphoid disorders, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, salivary gland, pharynx, small intestine, colon, rectum, anal, renal, prostate, vulval, thyroid, large intestine, endometrial, uterine, brain, central nervous system, cancer of the peritoneum, hepatocellular cancer, head cancer, neck cancer, Hodgkin's or leukemia.
  • In one embodiment, the disease is a myeloproliferative disorder. In one embodiment, the myeloproliferative disorder is polycythemia vera, essential thrombocytosis, myelofibrosis or chronic myelogenous leukemia (CML).
  • Another embodiment includes the use of a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, for the manufacture of a medicament for the treatment of a disease described herein (e.g., an inflammatory disorder, an immunological disorder or cancer).
    • Combination Therapy
  • The compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be employed alone or in combination with other agents for treatment. The second compound of a pharmaceutical composition or dosing regimen typically has complementary activities to the compound of this invention such that they do not adversely affect each other. Such agents are suitably present in combination in amounts that are effective for the purpose intended. The compounds may be administered together in a unitary pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially. Such sequential administration may be close or remote in time.
  • For example, other compounds may be combined with compounds with which the invention is concerned for the prevention and treatment of inflammatory diseases, such as asthma. Thus the present invention is also concerned with pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention and one or more other therapeutic agents. Suitable therapeutic agents for a combination therapy with compounds of the invention include, but are not limited to: an adenosine A2A receptor antagonist; an anti-infective; a non-steroidal Glucocorticoid Receptor (GR Receptor) agonist; an antioxidant; a □2 adrenoceptor agonist; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; a formyl peptide receptor antagonist; a histone deacetylase activator; a chloride channel hCLCA1 blocker; an epithelial sodium channel blocker (ENAC blocker; an inter-cellular adhesion molecule 1 blocker (ICAM blocker); an IKK2 inhibitor; a JNK inhibitor; a cyclooxygenase inhibitor (COX inhibitor); a lipoxygenase inhibitor; a leukotriene receptor antagonist; a dual □2 adrenoceptor agonist/M3 receptor antagonist (MABA compound); a MEK-1 inhibitor; a myeloperoxidase inhibitor (MPO inhibitor); a muscarinic antagonist; a p38 MAPK inhibitor; a phosphodiesterase PDE4 inhibitor; a phosphatidylinositol 3-kinase ⊏ inhibitor (PI3-kinase ⊏ inhibitor); a peroxisome proliferator activated receptor agonist (PPAR□ agonist); a protease inhibitor; a retinoic acid receptor modulator (RAR □ modulator); a statin; a thromboxane antagonist; or a vasodilator.
  • In addition, compounds of the invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, may be combined with: (1) corticosteroids, such as alclometasone dipropionate, amelometasone, beclomethasone dipropionate, budesonide, butixocort propionate, biclesonide, blobetasol propionate, desisobutyrylciclesonide, dexamethasone, dtiprednol dicloacetate, fluocinolone acetonide, fluticasone furoate, fluticasone propionate, loteprednol etabonate (topical) or mometasone furoate; (2) β2-adrenoreceptor agonists such as salbutamol, albuterol, terbutaline, fenoterol, and long acting β2-adrenoreceptor agonists such as metaproterenol, isoproterenol, isoprenaline, salmeterol, indacaterol, formoterol (including formoterol fumarate), arformoterol, carmoterol, GSK 642444, GSK 159797, GSK 159802, GSK 597501, GSK 678007, or AZD3199; (3) corticosteroid/long acting β2 agonist combination products such as salmeterol/fluticasone propionate (Advair®, also sold as Seretide®), formoterol/budesonide (Symbicort®), formoterol/fluticasone propionate (Flutiform®), formoterol/ciclesonide, formoterol/mometasone furoate, indacaterol/mometasone furoate, indacaterol/QAE 397, GSK 159797/GSK 685698, GSK 159802/GSK 685698, GSK 642444/GSK 685698, GSK 159797/GSK 870086, GSK 159802/GSK 870086, GSK 642444/GSK 870086, or arformoterol/ciclesonide; (4) anticholinergic agents, for example, muscarinic-3 (M3) receptor antagonists such as ipratropium bromide, tiotropium bromide, aclidinium (LAS-34273), NVA-237, GSK 233705, darotropium, GSK 573719, GSK 961081, QAT 370, or QAX 028; (5) dual pharmacology M3-anticholinergic/β2-adrenoreceptor agonists such as GSK961081; (6) leukotriene modulators, for example, leukotriene antagonists such as montelukast, zafirulast or pranlukast or leukotriene biosynthesis inhibitors such as zileuton or BAY-1005, or LTB4 antagonists such as amelubant, or FLAP inhibitors such as GSK 2190914, AM-103; (7) phosphodiesterase-IV (PDE-IV) inhibitors (oral or inhaled), such as roflumilast, cilomilast, oglemilast, ONO-6126, tetomilast, tofimilast, UK 500,001, or GSK 256066; (8) antihistamines, for example, selective histamine-1 (H1) receptor antagonists such as fexofenadine, citirizine, loratidine or astemizole or dual H1/H3 receptor antagonists such as GSK 835726, or GSK 1004723; (9) antitussive agents, such as codeine or dextramorphan; (10) a mucolytic, for example, N-acetyl cysteine or fudostein; (11) a expectorant/mucokinetic modulator, for example, ambroxol, hypertonic solutions (e.g., saline or mannitol) or surfactant; (12) a peptide mucolytic, for example, recombinant human deoxyribonoclease I (dornase-alpha and rhDNase) or helicidin; (13) antibiotics, for example azithromycin, tobramycin or aztreonam; (14) non-selective COX-1/COX-2 inhibitors, such as ibuprofen or ketoprofen; (15) COX-2 inhibitors, such as celecoxib and rofecoxib; (16) VLA-4 antagonists, such as those described in WO97/03094 and WO97/02289, each incorporated herein by reference; (17) TACE inhibitors and TNF-α inhibitors, for example anti-TNF monoclonal antibodies, such as Remicade® and CDP-870 and TNF receptor immunoglobulin molecules, such as Enbrel®; (18) inhibitors of matrix metalloprotease, for example MMP-12; (19) human neutrophil elastase inhibitors, such as ONO-6818 or those described in WO2005/026124, WO2003/053930 and WO06/082412, each incorporated herein by reference; (20) A2b antagonists such as those described in WO2002/42298, incorporated herein by reference; (21) modulators of chemokine receptor function, for example antagonists of CCR3 and CCR8; (22) compounds which modulate the action of other prostanoid receptors, for example, a thromboxane A2 antagonist; DP1 antagonists such as MK-0524, CRTH2 antagonists such as ODC9101 and AZD1981 and mixed DP1/CRTH2 antagonists such as AMG 009; (23) PPAR agonists including PPAR alpha agonists (such as fenofibrate), PPAR delta agonists, PPAR gamma agonists such as pioglitazone, rosiglitazone and balaglitazone; (24) methylxanthines such as theophylline or aminophylline and methylxanthine/corticosteroid combinations such as theophylline/budesonide, theophylline/fluticasone propionate, theophylline/ciclesonide, theophylline/mometasone furoate and theophylline/beclometasone dipropionate; (25) A2a agonists such as those described in EP1052264 and EP1241176; (26) CXCR2 or IL-8 antagonists such as SCH 527123 or GSK 656933; (27) IL-R signalling modulators such as kineret and ACZ 885; and (28) MCP-1 antagonists such as ABN-912.
  • In some embodiments, the compounds of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, can be used in combination with one or more additional drugs, for example anti-hyperproliferative, anti-cancer, cytostatic, cytotoxic, anti-inflammatory or chemotherapeutic agents, such as those agents disclosed in U.S. Publ. Appl. No. 2010/0048557, incorporated herein by reference. A compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, can be also used in combination with radiation therapy or surgery, as is known in the art.
    • Articles of Manufacture
  • Another embodiment includes an article of manufacture (e.g., a kit) for treating a disease or disorder responsive to the inhibition of a Janus kinase, such as a JAK1 kinase. The kit can comprise:
  • (a) a first pharmaceutical composition comprising a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1; and
  • (b) instructions for use.
  • In another embodiment, the kit further comprises:
  • (c) a second pharmaceutical composition, such as a pharmacueitcal composition comprising an agent for treatment as described above, such as an agent for treatment of an inflammatory disorder, or a chemotherapeutic agent.
  • In one embodiment, the instructions describe the simultaneous, sequential or separate administration of said first and second pharmaceutical compositions to a patient in need thereof.
  • In one embodiment, the first and second compositions are contained in separate containers. In another embodiment, the first and second compositions are contained in the same container.
  • Containers for use include, for example, bottles, vials, syringes, blister pack, etc. The containers may be formed from a variety of materials such as glass or plastic. The container includes a compound of the present invention, such as a compound of Formula 0, I, Ia, Ib, Ic, Id, Ie, If, Ig or II, or a compound of any of Examples 1-1 to 1-303, 2-1 to 2-486 or 3-1, or composition thereof, which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert indicates that the compound or composition is used for treating the condition of choice, such as asthma or cancer. In one embodiment, the label or package inserts indicates that the compound or composition can be used to treat a disorder. In addition, the label or package insert may indicate that the patient to be treated is one having a disorder characterized by overactive or irregular Janus kinase activity, such as overactive or irregular JAK1 activity. The label or package insert may also indicate that the compound or composition can be used to treat other disorders.
  • Alternatively, or additionally, the kit may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • In order to illustrate the invention, the following examples are included. However, it is to be understood that these examples do not limit the invention and are only meant to suggest a method of practicing the invention. Persons skilled in the art will recognize that the chemical reactions described may be readily adapted to prepare other compounds of the present invention, and alternative methods for preparing the compounds are within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.
    • EXAMPLES
  • Although the invention has been described and illustrated with a certain degree of particularity, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the combination and arrangement of parts can be resorted to by those skilled in the art without departing from the spirit and scope of the invention, as defined by the claims.
  • Abbreviations
      • AcOH Acetic acid
      • BINAP 2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene
      • n-BuLi n-Butyllithium solution
      • t-BuOH tert-butanol
      • t-BuOK Potassium tert-butoxide
      • t-BuONa Sodium tert-butoxide
      • CDCl3 Deuterated chloroform
      • CD3OD Deuterated methanol
      • CO Carbon monoxide
      • Cs2CO3 Cesium carbonate
      • CuI Copper (I) iodide
      • Cu2O Copper (I) oxide
      • DIBAlI-H Diisobutylaluminum hydride
      • DIPEA Diisopropylethylamine
      • DMF Dimethylformamide
      • DMSO Dimethylsulfoxide
      • DMSO-d6 Deuterated dimethylsulfoxide
      • EtOAc Ethyl acetate
      • EtOH Ethanol
      • g Gram
      • HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate)
      • HCl Hydrochloric acid
      • HCOOH Formic acid
      • HM-N Isolute HM-N is a modified form of diatomaceous earth
      • KOAc Potassium acetate
      • KOH Potassium hydroxide
      • K3PO4 Potassium phosphate tribasic
      • L Litre
      • MeOH Methanol
      • mg Milligram
      • mL Millilitre
      • mmol Millimoles
      • Ms2O Methanesulfonic anhydride
      • NaBH3CN Sodium cyanoborohydride
      • NaBH4 Sodium borohydride
      • NaCN Sodium cyanide
      • NaHCO3 Sodium hydrogen carbonate
      • NaOH Sodium hydroxide
      • Na2SO4 Sodium sulfate
      • NH3.H2O 0.880 ammonia solution
      • NH2OH.HCl Hydroxylamine hydrochloride
      • NH4HCO3 Ammonium bicarbonate
      • NH4OAc Ammonium acetate
      • Pd/C Palladium on carbon
      • Pd2(dba)3 Tris(dibenzylidineacetone)palladium(0)
      • Pd(dppf)Cl2[1,1′-Bis(diphenylphosphino)ferrocene]-dichloropalladium-(II), complex with dichloromethane
      • Pd(OAc)2 Palladium (II) acetate
      • Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium(0)
      • PTSA p-Toluene sulfonic acid
      • r,t or rt or r t Room temperature
      • SCX-2 ISOLUTE® Si-Propylsulfonic acid
      • THF Tetrahydrofuran
      • TFA Trifluoroacetic acid
      • TLC Thin layer chromatography
      • XantPhos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
      • X-phos 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl
  • NMR Analytical Methods 1H NMR spectra were recorded at ambient temperature using a Varian Unity Inova (400 MHz) spectrometer with a 400 4NUC 5 mm probe, a Bruker Avance DRX400 (400 MHz) spectrometer with a PABBO 5 mm probe. Chemical shifts are expressed in ppm relative to tetramethylsilane. The following abbreviations have been used: br=broad signal, s=singlet, d=doublet, dd=double doublet, t=triplet, q=quartet, m=multiplet.
  • LCMS Analytical Methods High Pressure Liquid Chromatography-Mass Spectrometry (LCMS) experiments to determine retention times (RT) and associated mass ions were performed using one of the following methods with either UV detector monitoring at 220 nm and 254 nm or evaporative light scattering detection, and mass spectrometry scanning 110-800 amu in ESI+ ionization mode.
  • Method 1
  • Experiments were performed on a Waters ZMD single quadrupole mass spectrometer with an electrospray source operating in positive and negative ion mode linked to a Waters 1525 LC system. Detection was achieved using a UV diode array detector and a Sedex 85 evaporative light scattering detector. The LC column was a Phenomenex Luna 3 micron C18(2) 30×4.6 mm. The flow rate was 2 mL/minute. The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for 0.5 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. The final solvent system was held constant for a further 1 minute.
  • Method 2
  • Experiments were performed on a Waters Micromass ZQ2000 single quadrupole mass spectrometer with an electrospray source operating in positive and negative ion mode linked to a Waters Acquity UPLC system. Detection was achieved using a UV PDA detector. The flow rate was 2 mL/minute. The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for 0.4 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 5.6 minutes. The final solvent system was held constant for a further 0.8 minute.
  • Method 3
  • Experiments were performed on a Waters Acquity UPLC with a Shim-pack XR-ODS column (50×3.0 mm Acquity BEH C18, 2.2 μm particle size), elution with solvent A: Water/0.05% TFA; solvent B: Acetonitrile/0.05% TFA at 40° C. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    2.00 1.0 0 100
    3.20 1.0 0 100
    3.30 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • MS ionisation method—ESI+
  • Method 4
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (30×2.1 mm Xtimate™-C18, 3 μm particle size), elution with solvent A: water+0.038% trifluoroacetic acid; solvent B: acetonitrile+0.02% trifluoroacetic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.01 1.5 95 5
    0.70 1.5 5 95
    1.1 1.5 5 95
    1.11 1.5 95 5
  • Method 5
  • Experiments were performed on a HPLC Agilent 1200 with an Agilent SB C18 column (30×2.1 mm Agilent SB C18, 1.8 μm particle size), elution with solvent A: Water/0.05% TFA; solvent B: Acetonitrile/0.05% TFA at 25° C. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 0.4 97 3
    0.3 0.4 95 3
    6.8 0.4 5 95
    10 0.4 97 3
  • Detection—UV 254 nm
  • MS ionisation method—ESI+
  • Method 6
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (50×3 mm Xtimate™-C18, 2.2 μm particle size), elution with solvent A: water+0.05% trifluoroacetic acid; solvent B: acetonitrile+0.05% trifluoroacetic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    2.00 1.0 0 100
    3.10 1.0 0 100
    3.30 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • Method 7
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (50×3 mm Xtimate™-C18, 2.2 μm particle size), elution with solvent A: water+0.05% trifluoroacetic acid; solvent B: acetonitrile+0.05% trifluoroacetic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    2.00 1.0 0 100
    3.20 1.0 0 100
    3.30 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • Method 8
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (50×3 mm Xtimate™-C18, 2.2 μm particle size), elution with solvent A: water+0.05% trifluoroacetic acid; solvent B: acetonitrile+0.05% trifluoroacetic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    2.00 1.0 0 100
    3.20 1.0 0 100
    3.30 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • Method 9
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (50×3 mm Xtimate™-C18, 2.2 μm particle size), elution with solvent A: water+0.05% formic acid; solvent B: acetonitrile+0.05% formic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    1.20 1.0 0 100
    2.20 1.0 0 100
    2.30 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • Method 10
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (50×3 mm Xtimate™-C18, 2.2 μm particle size), elution with solvent A: water+0.1% formic acid; solvent B: acetonitrile+0.05% formic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    2.00 1.0 0 100
    3.10 1.0 0 100
    3.20 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • Method 11
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (50×3 mm Xtimate™-C18, 2.2 μm particle size), elution with solvent A: water+0.04% Ammonia; solvent B: acetonitrile. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.2 95 5
    1.20 1.2 0 100
    2.20 1.2 0 100
    2.30 1.2 95 5
  • Detection—UV (220 and 254 nm) and ELSD
  • Method 12
  • Experiments were performed on a SHIMADZU 20A HPLC with a C18-reverse-phase column (30×2.1 mm Xtimate™-C18, 3 μm particle size), elution with solvent A: water+0.05% trifluoroacetic acid; solvent B: acetonitrile+0.05% trifluoroacetic acid. Gradient:
  • Gradient-Time flow ml/min % A % B
    0.00 1.0 95 5
    1.10 1.0 0 100
    1.60 1.0 0 100
    1.70 1.0 95 5
  • Detection—UV (220 and 254 nm) and ELSD
    • Example 1a N-methyl-4-(8-(4-methyl-4-phenylpiperidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(1-methylpiperidin-4-yl)benzamide (Example 1-1 of Table I)
  • Figure US20190233441A1-20190801-C00889
  • A degassed mixture of 4-((8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol), 4-methyl-4-phenylpiperidine (158.2 mg, 0.90 mmol), tBuONa (130.2 mg,1.36 mmol), BINAP (56.4 mg, 0.09 mmol) and tris(dibenzylideneacetone)palladium (0) (41.4 mg, 0.045 mmol) in toluene (8 mL) was heated at 130° C. under nitrogen for 8 h. When the starting material was consumed, the reaction mixture was added to water (10 mL) and extracted with dichloromethane (50 mL×3). The organic layers were dried over Na2SO4 and concentrated to give the residue which was purified by prep-HPLC to give Example 1-1 (see Table I) (120 mg, 56.1%).
  • 1H NMR (400 MHz, CD3OD) □ 8.74 (d, J=6.8 Hz, 1H), 7.95 (d, J=8.0 Hz, 1H), 7.77 (d, J=8.4 Hz, 2H), 7.52 (d, J=0.8 Hz, 2H), 7.50-7.38 (m, 4H), 7.28-7.24 (m, 1H), 7.21-7.18 (m, 1H), 4.6-4.46 (m, 1H), 4.26-4.21 (m, 2H), 3.76-3.70 (m, 2H), 3.61 (d, J=10.8 Hz, 2H), 3.16 (s, 2H), 2.99 (s, 3H), 2.86 (s, 3H), 2.66-2.59 (s, 2H), 2.31-2.21 (m, 4H), 2.07-2.02 (m, 2H), 1.15 (s, 3H).
    • Example 1b 4-{8-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino}-benzoic acid
  • Figure US20190233441A1-20190801-C00890
  • Step 1. A microwave vial was charged with 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid ethyl ester (1.00 g, 2.77 mmol), 4-(4-chloro-phenyl)-piperidin-4-ol (879 mg, 4.15 mmol), tris(dibenzylideneacetone)dipalladium(0) (256 mg, 0.28 mmol), cesium carbonate (1.81 g, 5.54 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (321 mg, 0.55 mmol) and dioxane (12 mL). The vessel was sealed, evacuated and refilled with argon three times before being purged with argon whilst being sonicated for 5 minutes. The reaction mixture was stirred at 110° C. for 18 hours then cooled to room temperature before being filtered through a pad of Celite®, eluting with ethyl acetate. The filtrate was concentrated in vacuo before being purified by flash chromatography on silica eluting with 0-4% MeOH in dichloromethane. 4-{8-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino}-benzoic acid ethyl ester was obtained as a pale yellow solid (1.13 g, 83%). LCMS (Method 1) [M+H]+ 492.4, RT=4.07 min. 1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, 1H), 8.35 (dd, J=6.0, 1.5 Hz, 1H), 7.92-7.86 (m, 2H), 7.82-7.76 (m, 2H), 7.60-7.53 (m, 2H), 7.43-7.34 (m, 2H), 6.99-6.88 (m, 2H), 5.21 (s, 1H), 4.27 (q, J=7.1 Hz, 2H), 4.12 (d, J=11.8 Hz, 2H), 3.22 (t, J=11.4 Hz, 2H), 2.13 (td, J=12.9, 4.3 Hz, 2H), 1.76 (d, J=12.7 Hz, 2H), 1.30 (t, J=7.1 Hz, 3H).
  • Step 2. A mixture of 4-{8-[4-(4-chloro-phenyl)-4-hydroxy-piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino}-benzoic acid ethyl ester (5.12 g, 10.41 mmol), 2M LiOH aqueous solution (10.41 mL, 20.82 mmol), methanol (25 mL), THF (150 mL) and water (15 mL) was stirred at 55° C. for 18 hours then at room temperature for 24 hours. The methanol and THF were removed in vacuo before the solution was adjusted to pH 4 with 1M HCl. The resultant precipitate was collected by filtration then washed with water, diethyl ether and acetonitrile sequentially. The solid was dried under reduced pressure giving the target compound Example 1b as a pale yellow solid (4.38 g, 91%). LCMS (Method 2) [M+H]+ 464.1/466.1, RT=4.32 min. 1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 10.10 (s, 1H), 8.36 (dd, J=5.9, 1.6 Hz, 1H), 7.95-7.84 (m, 2H), 7.78 (d, J=2.1 Hz, 1H), 7.76 (d, J=1.8 Hz, 1H), 7.62-7.51 (m, 2H), 7.44-7.35 (m, 2H), 6.99-6.88 (m, 2H), 5.22 (s, 1H), 4.12 (d, J=11.7 Hz, 2H), 3.21 (dd, J=13.3, 10.9 Hz, 2H), 2.12 (dp, J=20.8, 9.0, 6.6 Hz, 2H), 1.76 (d, J=12.8 Hz, 2H).
    • Example 1c General Methods For Preparation of Amides
  • Figure US20190233441A1-20190801-C00891
    • [4-[[8-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone (Example 1-47 in Table I)
  • A solution of 4-[[8-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzoic acid (25 mg, 0.054 mmol, 1.0 equiv), tert-butyl azetidine-3-ylmethylcarbamate HCl (25 mg, 0.11 mmol, 2.0 equiv), HATU (30 mg, 0.08 mmol, 1.5 equiv) and N,N-diisopropylethylamine (47 □L, 0.27 mmol, 5.0 equiv) in DMF (1.0 mL) was stirred at 50° C. overnight. The reaction mixture was concentrated under vacuum. A solution of crude product in dichloromethane (1 mL) was mixed with trifluoroacetic acid (60 □L, 0.8 mmol, 15 equiv) and stirred at room temperature for 72 hours. The reaction was concentrated under vacuum and the crude product was purified by Prep-HPLC (Column, Gemini C18 100×30 mm; mobile phase, CH3CN:NH4OH/H2O (10 mmol/L)=5%-85%, 10 min; flow rate, 70 mL/min; Detector, UV 254 nm) to give 7.4 mg (26%) of [4-[[8-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]phenyl]-[3-(methylamino)azetidin-1-yl]methanone as an off white solid, Example 1-47. 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.33 (dd, J=5.8, 1.7 Hz, 1H), 7.81-7.70 (m, 2H), 7.63-7.52 (m, 4H), 7.46-7.35 (m, 2H), 6.97-6.86 (m, 2H), 5.19 (s, 1H), 4.43 (s, 1H), 4.16-4.08 (m, 3H), 3.98 (s, 1H), 3.71 (s, 1H), 3.54-3.43 (m, 1H), 3.30-3.16 (m, 2H), 2.22 (s, 3H), 2.19-2.05 (m, 2H), 1.80-1.72 (m, 2H). LCMS (Method 5): Observed MW=532.3; Rt 4.0 min.
    • Example 1d 4-{8-[4-(4-chloro-phenyl)-4-hydroxymethyl-piperidin-1-yl]-1,8a-dihydro-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino}-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (Example 1-246 in Table I)
  • Figure US20190233441A1-20190801-C00892
    Figure US20190233441A1-20190801-C00893
  • Step 1. To the solution of 2-(4-chlorophenyl)acetonitrile (20.1 g, 132.59 mmol, 1.00 equiv) and tert-butyl N,N-bis(2-chloroethyl)carbamate (35.4 g, 146.19 mmol, 1.10 equiv) in anhydrous DMF (200 mL) was added sodium hydride (27 g, 60% in mineral oil, 666.73 mmol, 3.00 equiv) portionwise at 0° C. under N2 over 2 hr. The resulting solution was stirred at 60° C. for 1.5 hr, and then stirred overnight at room temperature. The reaction was quenched by the careful addition of 250 mL of sat. aq. NH4Cl. The resulting solution was extracted with 3×200 mL of dichloromethane. The combined extracts were washed with 2×300 mL of brine, then dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column with dichloromethane/petroleum ether (1:1). 30 g (71%) of tert-butyl 4-(4-chlorophenyl)-4-cyanopiperidine-1-carboxylate was obtained as a yellow solid. TLC: Rf=0.15; ethyl acetate/petroleum ether=1/5.
  • Figure US20190233441A1-20190801-C00894
  • Step 2. The solution of tert-butyl 4-(4-chlorophenyl)-4-cyanopiperidine-1-carboxylate (1 g, 3.12 mmol, 1.00 equiv) in anhydrous tetrahydrofuran (5 mL, 61.71 mmol) was placed in a 100-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, then diisobutyl aluminium hydride (1 M in hexane, 7.8 mL, 7.81 mmol) was added dropwise with cooling in an ice/water bath. The resulting solution was stirred for 1.5 hr at ambient temperature. The reaction mixture was poured into 100 mL water/ice. The resulting solution was extracted with 200 mL of ethyl acetate. The extracts were washed with 2×50 mL of 2M hydrogen chloride solution, then 3×50 mL of sat.aq. sodium bicarbonate and 1×50 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to give 610 mg crude tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate as a yellow solid, which was used in the next step without further purification. TLC: Rf=0.15; ethyl acetate/petroleum ether=1/5.
  • Figure US20190233441A1-20190801-C00895
  • Step 3. The solution of tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate (610 mg, 1.88 mmol, 1.00 equiv) in methanol (5 mL, 123.49 mmol) was placed in a 100-mL round-bottom flask, then NaBH4 (144 mg, 3.81 mmol, 2.00 equiv) was added in ice/water bath. The resulting solution was stirred at room temperature overnight. The reaction was quenched by the addition of three drops of water. The resulting mixture was concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1:10) to give 320 mg (52%) of tert-butyl 4-(4-chlorophenyl)-4-(hydroxymethyl) piperidine-1-carboxylate as a white solid. TLC: Rf=0.4; ethyl acetate/petroleum ether=1/1.
  • Figure US20190233441A1-20190801-C00896
  • Step 4. The solution of tert-butyl 4-(4-chlorophenyl)-4-(hydroxymethyl) piperidine-1-carboxylate (300 mg, 0.92 mmol, 1.00 equiv) in HCl/dioxane (1M, 10 mL) was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum, and sat. aq. NaHCO3 was added to the residue to make pH>10. The resulting mixture was concentrated to dryness under vacuum. The residue was purified on a silica gel column eluting with dichloromethane/methanol (10:1) to give 180mg (86%) of [4-(4-chlorophenyl)piperidin-4-yl]methanol as a yellow solid. LCMS (method 3): RT=1.03 min, m/z=226.0 [M+H]+
  • Figure US20190233441A1-20190801-C00897
  • Step 5. The solution of 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (242 mg, 0.55 mmol, 1.50 equiv) in 1,4-dioxane (20 mL) was placed in a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, then [4-(4-chlorophenyl)piperidin-4-yl]methanol (160 mg, 0.71 mmol, 1.00 equiv), Cs2CO3 (357 mg, 1.10 mmol, 2.00 equiv), Pd2(dba)3.CHCl3 (314.6 mg, 0.30 mmol, 0.45 equiv), BINAP (377.7 mg, 0.61 mmol, 0.90 equiv) was added. The resulting solution was stirred for 48 hours at 100° C. in an oil bath. The solids were filtered off The filtrate was concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane/methanol (5:1) to give a crude product. The crude product was purified again by Prep-HPLC under the following conditions Column, XBridge™ Prep C18 OBD Column, 5 um, 19×150 mm; mobile phase, water with 10 mmol NH4HCO3 and MeCN (30.0% MeCN up to 45.0% in 10 min, up to 95.0% in 1 min, hold 95.0% in 1 min, down to 30.0% in 2 min); Detector, UV 254/220 nm to give 20.8 mg (5%) of 4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide, Example 1-246 as an off-white solid. LCMS (Method 3): RT=2.09 min, m/z=588.2 [M+H]+, 1H NMR (300 MHz, DMSO-d6, ppm): ⊐ 9.87 (s, 1H), 8.29-8.28 (m, 1H), 7.71 (d, J=8.8 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.8 Hz, 2H), 6.29-8.28 (m, 1H), 6.27-6.26 (m, 1H), 4.71 (t, J=5.6 Hz, 1H), 3.88-3.78 (m, 2H), 3.41 (d, J=5.6 Hz, 2H), 3.30 (s, 3H), 3.06-2.92 (m, 2H), 2.90-2.78 (m, 4H), 2.26-2.18 (m, 5H), 2.17-2.02 (m, 2H), 1.73-1.85 (m, 3H), 1.57-1.51 (m, 2H).
    • Example 1e 4-{8-[4-(4-Chloro-phenyl)-4-(2-cyano-ethyl)-piperidin-1-yl]-1,8a-dihydro[1,2,4]triazolo[1,5-a]pyridine-2-ylamino}-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (Example 1-247 in Table I)
  • Figure US20190233441A1-20190801-C00898
  • Step 1. Into a 2-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl 4-oxopiperidine-1-carboxylate (100 g, 501.89 mmol, 1.00 equiv), toluene (800 mL), ethyl 2-cyanoacetate (56.8 g, 502.15 mmol, 1.00 equiv), NH4OAc (38.5 g, 1.00 equiv), acetic acid (80 mL). The resulting solution was stirred for 3 h at 110° C. The reaction mixture was cooled to room temperature and concentrated under vacuum. The resulting solution was diluted with 300 mL of H2O and extracted with 2×1 L of ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate. The solids were filtered off, and the filtrate was concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1:10). 110 g (74%) of tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate was obtained as a white solid. TLC: Rf=0.4; ethyl acetate/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00899
  • Step 2. Into a 3-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl 4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (100 g, 339.74 mmol, 1.00 equiv), tetrahydrofuran (500 mL), CuI (19.4 g, 101.86 mmol, 0.30 equiv). The bromo(4-chlorophenyl)magnesium (1M in THF, 1.02 L, 3.00 equiv) was added dropwise at 0° C. The resulting solution was stirred for 2 h at 0° C. The resulting mixture was warmed to room temperature and concentrated under vacuum. The residue was suspended in 1 L of EtOAc and the solids were filtered off. The filtrate was concentrated under vacuum. The residue was purified on a silica gel column eluting with ethyl acetate/petroleum ether (1:15-1:10). 100 g (72%) of tert-butyl 4-(4-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate was obtained as a light yellow solid. TLC: Rf=0.3; ethyl acetate/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00900
  • Step 3. Into a 3-L 3-necked round-bottom flask, was placed tert-butyl 4-(4-chlorophenyl)-4-(1-cyano-2-ethoxy-2-oxoethyl)piperidine-1-carboxylate (100 g, 245.76 mmol, 1.00 equiv), ethanol (500 mL), water (500 mL), potassium hydroxide (30 g, 534.71 mmol, 2.18 equiv). The resulting solution was stirred for 20 h at room temperature. EtOH was removed under vacuum. The resulting aqueous solution was extracted with 1×200 mL of ether, and the pH value of the aqueous phase was adjusted to 6 with 6N hydrogen chloride solution at 0° C., and then concentrated to dryness under vacuum. The resulting solid was suspended in 500 mL of a mixture of dichloromethane/MeOH (5:1, v/v), and the solid was filtered off. The filtrate was concentrated under vacuum to give 76 g of crude 2-[1-[(tert-butoxy)carbonyl]-4-(4-chlorophenyl)piperidin-4-yl]-2-cyanoacetic acid as a light yellow solid, which was used in next step without further purification. TLC: Rf=0.3; dichloromethane/methanol=5/1.
  • Figure US20190233441A1-20190801-C00901
  • Step 4. Into a 2-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-[1-[(tert-butoxy)carbonyl]-4-(4-chlorophenyl)piperidin-4-yl]-2-cyanoacetic acid (76 g, 200.61 mmol, 1.00 equiv), acetonitrile (800 mL), Cu2O (28 g, 195.68 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at 85° C. The reaction mixture was cooled to room temperature and concentrated under vacuum. The residual solid was suspended in 500 mL of EA and the solid was filtered off. The filtrate was concentrated under vacuum, and the residue was purified on a silica gel column eluting with ethyl acetate/petroleum ether (1:10˜1:2) to yield 50 g (74%) of tert-butyl 4-(4-chlorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate as a light yellow solid. TLC: Rf=0.3; ethyl acetate/petroleum ether=1/2. 1H NMR (300 MHz, DMSO-d6, ppm): ␣ 7.42-7.38 (m, 2 H), 7.34-7.30 (m, 2 H), 3.79-3.72 (m, 2 H), 3.13-3.04 (m, 2 H), 2.54 (s, 2 H), 2.32-2.27 (m, 2 H), 1.91-1.82 (m, 2 H), 1.45 (s, 9 H).
  • Figure US20190233441A1-20190801-C00902
  • Step 5. Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tert-butyl 4-(4-chlorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate (5 g, 14.93 mmol, 1.00 equiv) and anhydrous tetrahydrofuran (80 mL). DIBAL-H solution (1 M in hexane, 30 mL, 2.00 equiv) was added dropwise at 0° C. The resulting solution was stirred for 2 h at 0° C. The reaction was then quenched by addition of 40 mL of water/ice. The resulting solution was extracted with 2×200 mL of ethyl acetate. The organic layers were combined, washed with 1×20 mL of 1 M hydrogen chloride and 1×20 mL of sodium bicarbonate saturated solution, and dried over anhydrous sodium sulfate. The solid was filtered off and the filtrate was concentrated under vacuum to yield 3 g of crude tert-butyl 4-(4-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate as colorless oil. TLC: Rf=0.4; ethyl acetate/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00903
  • Step 6. Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 4-(4-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (3 g, 8.88 mmol, 1.00 equiv) in methanol (80 mL), NaBH4 (680 mg, 17.89 mmol, 1.00 equiv) was added portionwise. The resulting solution was stirred for 10 min at 25° C. The reaction was then quenched by the addition of 5 mL of water. The resulting mixture was concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1:2˜1:1) to yield 1.4 g (46%) of tert-butyl 4-(4-chlorophenyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate as a white solid. TLC: Rf=0.3; ethyl acetate/petroleum ether=1/1.
  • Figure US20190233441A1-20190801-C00904
  • Step 7. To a mixture of tert-butyl 4-(4-chlorophenyl)-4-(2-hydroxyethyl)piperidine-1-carboxylate (600.00 mg, 1.77 mmol, 1.00 equiv) and DIPEA (930 mg, 7.06 mmol, 4.00 equiv) in dry dichloromethane (20.00 mL, 314.60 mmol, 178.20 equiv) was added Ms2O (630 mg, 3.53 mmol, 2.00 equiv) dropwise under N2. The resulting solution was stirred for 4 h at ambient temperature. The resulting mixture was concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1/4) to give 550 mg (67%) of tert-butyl 4-(4-chlorophenyl)-4-[2-(methanesulfonyloxy)ethyl]piperidine-1-carboxylate as colorless oil. TLC: Rf=0.4; ethyl acetate/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00905
  • Step 8. A mixture of tert-butyl 4-(4-chlorophenyl)-4-[2-(methanesulfonyloxy)ethyl]piperidine-1-carboxylate (550.00 mg, 1.32 mmol, 1.00 equiv) and NaCN (650 mg, 13.16 mmol, 10.00 equiv) in DMSO (20.00 mL) was stirred overnight at 100° C. The reaction mixture was cooled, and diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 3×20 mL of H2O. The organic phase was dried over Na2SO4, and concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1:4). The collected fractions were combined and concentrated under vacuum to give 360 mg (71%) of tert-butyl 4-(4-chlorophenyl)-4-(2-cyanoethyl) piperidine-1-carboxylate as colorless oil. TLC: Rf=0.5; ethyl acetate/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00906
  • Step 9. A mixture of tert-butyl 4-(4-chlorophenyl)-4-(2-cyanoethyl)piperidine-1-carboxylate (360 mg, 1.03 mmol, 1.00 equiv) in 1M HCl/1,4-dioxane (30 mL) was stirred for 2 h at 25° C. The reaction mixture was concentrated under vacuum. The residue was dissolved in 5 mL of H2O. The pH value of the solution was adjusted to 8 with potassium carbonate. The resulting mixture was concentrated to dryness under vacuum. The residue was purified on a silica gel column with dichloromethane/methanol (5/1). The collected fractions were combined and concentrated under vacuum. This resulted in 180 mg of 3-[4-(4-chlorophenyl)piperidin-4-yl]propanenitrile as light yellow oil. TLC: Rf=0.3; dichloromethane/methanol=5/1. LCMS (Method 3): RT=1.05 min, m/z=249.0 [M+H]−;
  • Figure US20190233441A1-20190801-C00907
  • Step 10. Into a 100-mL round-bottom flask purged and maintained under an inert atmosphere of nitrogen, was placed 3-[4-(4-chlorophenyl)piperidin-4-yl]propanenitrile (180 mg, 0.72 mmol, 1.00 equiv), 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (320 mg, 0.72 mmol, 1.00 equiv), 1,4-dioxane (20 mL, 335.12 mmol, 463.10 equiv), Cs2CO3 (473 mg, 1.45 mmol, 2.00 equiv), XantPhos (84 mg, 0.15 mmol, 0.20 equiv), Pd2(dba)3 (70 mg, 0.08 mmol, 0.10 equiv). The resulting mixture was stirred for 20 h at 100° C. in an oil bath. The reaction mixture was cooled and concentrated under vacuum. The residue was applied onto a silica gel column eluting with dichloromethane/methanol (10:1 and 5:1). The obtained crude product (200 mg) was purified again by Prep-HPLC with the following conditions (IntelFlash-1): Column, silica gel; mobile phase, CH3CN/H2O=20% increasing to CH3CN/H2O=60% within 17 min; Detector, UV 254 nm to give 27.2 mg (6%) of 4-([8-[4-(4-chlorophenyl)-4-(2-cyanoethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off-white solid. LCMS (Method 3): RT=1.78 min, m/z=611.1 [M+H]+; 1H NMR (400 MHz, DMSO-d6, ppm): □ 9.88 (s, 1 H), 8.30 (d, J=6.0 Hz, 1 H), 7.71 (d, J=8.8 Hz, 2 H), 7.48-7.43 (m, 4 H), 7.33-7.31 (d, J=8.4 Hz, 2 H), 6.86 (t, J=7.2 Hz, 1 H), 6.76 (d, J=8.0 Hz, 1 H), 3.80-3.77 (m, 2 H), 3.32-3.30 (m, 1 H), 3.08-3.03 (m, 2 H), 2.83-2.81 (m, 5 H), 2.33-2.30 (m, 2 H), 2.15-2.00 (m, 5 H), 1.99-1.96 (m, 4 H), 1.95-1.65 (m, 4 H), 1.58-1.55 (m, 2 H).
    • Example 1f 4-{8-[4-(3,3-Dimethyl-azetidine-1-carbonyl)-piperidin-1-yl]-1,8a-dihydro[1,2,4]triazolo[1,5a]pyridine-2-ylamino}-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (Example 1-42 in Table I)
  • Figure US20190233441A1-20190801-C00908
    Figure US20190233441A1-20190801-C00909
    Figure US20190233441A1-20190801-C00910
  • Step 1. The mixture of 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (150 mg, 0.338 mmol) piperidine-4-carboxylic acid ethyl ester (159.4 mg, 1.01 mmol) X-phos (39 mg, 0.067 mmol) Pd2(dba)3 (47 mg, 0.067 mmol) Cs2CO3 (329 mg, 1.01 mmol) in t-BuOH (3 mL) was heated to 100° C. and stirred for 1 h on microwave. The mixture was evaporated and water was added, extracted with EtOAc three times, the combined organic layer was washed with water and brine and dried (Na2SO4). The solvent was concentrated and the residue was purified by column (dichloromethane:MeOH=10:1) to give 1-(2-{4-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-phenylamino}-[1,2,4]triazolo[1,5-a]pyridine-8-yl)-piperidin-4-carboxylic acid ethyl ester (40 mg, 22% yield).
  • Figure US20190233441A1-20190801-C00911
  • Step 2. To a solution of 1-(2-{4-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-phenylamino}-[1,2,4]triazolo[1,5-a]pyridine-8-yl)-piperidin-4-carboxylic acid ethyl ester (100 mg, 0.192 mmol) in dioxane (2 mL) was added 1M NaOH aq (0.2 mL) and the mixture was heated to 80° C. and stirred for 2h. The solvent was evaporated and EtOAc was added, the mixture was extracted with 1M NaOH aq, the combined aqueous layer was adjusted to pH7 with 4M HCl, extracted with dichloromethane three times, the combined organic layer was washed with water and brine, dried (Na2SO4), and the solvent was evaporated in vacuo to give 1-(2-{4-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-phenylamino}-[1,2,4]triazolo[1,5-a]pyridine-8-yl)-piperidin-4-carboxylic acid (70 mg, 98% of yield).
  • Figure US20190233441A1-20190801-C00912
  • The mixture of 1-(2-{4-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-phenylamino}-[1,2,4]triazolo[1,5-a]pyridine-8-yl)-piperidin-4-carboxylic acid (70 mg, 0.142 mmol) HATU (64.7 mg, 0.17 mmol) DIPEA (55 mg, 0.426 mmol) in DMF was stirred for 10 min at r,t. then 3,3-dimethyl azetidine (49.5 mg, 0.284 mmol) was added and the mixture was stirred for 2 h at r,t. The reaction mixture was poured into water and extracted three times with dichloromethane, the combined organic layer was washed with water and brine, dried (Na2SO4) the solvent was evaporated and the residue was purified by preparative scale-TLC to give 4-{8-[4-(3,3-dimethyl-azetidine-1-carbonyl)-piperidin-1-yl]-1,8a-dihydro[1,2,4]triazolo-[1,5a]pyridine-2-ylamino}-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (30 mg, 38% yield).
  • 1H NMR (400 MHz, methanol-d4) □ 8.15 (d, J=5.51 Hz, 1H), 7.74 (d, J=8.60 Hz, 2H), 7.39 (d, J=8.38 Hz, 2H), 6.83-6.91 (m, 2H), 4.24 (d, J=12.13 Hz, 2H), 3.96 (s, 2H), 3.66 (s, 2H), 3.47 (br. s., 2H), 2.97 (s, 4H), 2.72-2.87 (m, 5H), 2.48-2.56 (m, 1H), 2.10-2.19 (m, 2H), 1.90-2.04 (m, 4H), 1.82 (d, J=11.25 Hz, 2H), 1.24-1.41 (m, 8H).
    • Example 1g 4-(8-Benzyloxy-1,8a-dihydro-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (Example 1-249 in Table I)
  • Figure US20190233441A1-20190801-C00913
    Figure US20190233441A1-20190801-C00914
  • Step 1. To a solution of 4-iodobenzoic acid ethyl ester (5.0 g, 18.1 mmol) was added 1M NaOH aq (18.1 mL, 18.1 mmol) and the mixture was heated to 100° C. and stirred for 1.5 h. The solvent was evaporated, the residue was adjusted to pH 6, and the precipitated solid was filtered off and washed with water to give 4-iodobenzoic acid (4.0 g, 89% yield).
  • Figure US20190233441A1-20190801-C00915
  • Step 2. To a mixture of 4-iodobenzoic acid (1.0 g, 4 mmol) HATU (1.8 g, 4.8 mmol) in DMF was added DIPEA (1.5 g, 12 mmol) at 0° C. and the mixture was stirred for 10 min, then methyl-(1-methyl-piperidin-4-yl)-amine (1.02 g, 8 mmol) was added, and the reaction mixture was stirred for 2 h at r,t. The reaction mixture was poured into water and the mixture was extracted with EtOAc three times. The combined organic layer was washed with water and brine, dried (Na2SO4), the solvent was evaporated in vacuo to give 4-iodo-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (1.2 g, 83% of yield).
  • Figure US20190233441A1-20190801-C00916
  • Step 3. The mixture of 3-benzyloxy-pyridin-2-ylamine (400 mg, 2 mmol) EtOCONCS (282 uL) in dioxane was stirred overnight at rt the solvent was evaporated and the residue (600 mg) was used for the next step without purification.
  • Figure US20190233441A1-20190801-C00917
  • Step 4. To a solution of NH2OH-HCl (704 mg, 10.6 mmol) DIPEA (1 mL, 6.6 mmol) in MeOH (4 mL) and EtOH (4 mL) was added a solution of the thiourea prepared in step 3 (600 mg, 2.12 mmol) in MeOH (4 mL) and EtOH (4 mL) at rt the mixture was stirred at r,t for 1 h and then at 60° C. for 2 h. The solvent was evaporated and saturated NaHCO3 solution was added to the residue. The aqueous layer was extracted three times with dichloromethane, the combined organic layer was washed with water and brine, dried (Na2SO4), the solvent was evaporated and solid was washed with petroleum ether to give 8-benzyloxy-[1,2,4]triazolo[1,5-a]pyridine-2-ylamine (430 mg, 86% of yield).
  • 1H NMR (400 MHz, DMSO-d6) □ 8.13 (d, J=6.39 Hz, 1H), 7.42-7.50 (m, 2H), 7.38 (t, J=7.39 Hz, 2H), 7.29-7.35 (m, 1H), 6.96 (d, J=7.72 Hz, 1H), 6.73 (dd, J=6.84, 7.72 Hz, 1H), 5.89 (s, 2H), 5.25 (s, 2H).
  • Figure US20190233441A1-20190801-C00918
  • Step 5. The mixture of 8-benzyloxy-[1,2,4]triazolo[1,5-a]pyridine-2-ylamine (150 mg, 0.625 mmol), 4-iodo-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (268.5 mg, 0.75 mmol) Pd2(dba)3 (57 mg, 0.0625 mmol) Cs2CO3 (610 mg,1.87 mmol) Xantphos (72 mg, 0.125 mmol) in dioxane was stirred for 2 h at 120° C. The solvent was concentrated, water was added and the mixture was extracted three times with EtOAc. The combined organic layer was washed with water and brine, dried (Na2SO4), the solvent was evaporated and the residue was purified by prep TLC (dichloromethane:MeOH=7:1) to give 4-(8-benzyloxy-1,8a-dihydro-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide (55 mg, 18% yield).
  • 1H NMR (400 MHz, methanol-d4) □ 8.23 (d, J=6.39 Hz, 1H), 7.74 (d, J=8.60 Hz, 2H), 7.53 (d, J=7.06 Hz, 2H), 7.29-7.43 (m, 5H), 7.09 (d, J=7.72 Hz, 1H), 6.90-6.94 (m, 1H), 5.34 (s, 2H), 4.58 (s, 1H), 2.96 (s, 3H), 2.63 (br. s., 7H), 2.07 (d, J=11.25 Hz, 2H), 1.93 (br. s., 2H)
    • Example 1h N-Methyl-N-(1-methyl-piperidin-4-yl)-4-(8-phenoxy-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-benzamide (Example 1-248 in Table I)
  • Figure US20190233441A1-20190801-C00919
    Figure US20190233441A1-20190801-C00920
  • Step 1. To a solution of 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-benzoic acid (1 g, 3.0 mmol), methyl-(1-methyl-piperidin-4-yl)-amine (460 mg, 3.6 mmol) and DIPEA (2.65 ml, 15 mmol) in DMSO (10.0 mL) was added HATU (1.37 g, 3.6 mmol). The reaction mixture was stirred at 50° C. for 4 hours. The reaction mixture was filtered, the filter cake was dried to give 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (1.1 g, 82.7%).
  • Figure US20190233441A1-20190801-C00921
  • To a solution of 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (100 mg, 0.23 mmol) and phenol (84.6 mg, 0.9 mmol) in DMSO (5.0 mL) was added K3PO4 (287 mg, 1.35 mmol), picolinic acid (11.1 mg, 0.09 mmol) and CuI (8.6 mg, 0.05 mmol). The reaction mixture was stirred at 120° C. overnight. The reaction mixture was diluted with water (10 mL), extracted with EtOAc (3×10 mL), the combined organic layer was concentrated, then purified by preparative HPLC (YMC—Actus Triart C18 150×30 mm×5 um column eluting with acetonitrile/water+0.05% NH4OH) to give N-methyl-N-(1-methyl-piperidin-4-yl)-4-(8-phenoxy-[1,2,4]triazolo[1,5-a]pyridine-2-ylamino)-benzamide (20.0 mg, 19.6%).
  • 1H NMR (400 MHz, methanol-d4) · 8.41 (d, J=6.17 Hz, 1H), 7.73 (d, J=8.38 Hz, 2H), 7.43 (d, J=7.94 Hz, 2H), 7.38 (d, J=7.28 Hz, 2H), 7.21-7.25 (m, 1H), 7.16 (d, J=7.94 Hz, 2H), 6.92-7.00 (m, 2H), 2.96 (s, 5H), 2.24-2.37 (m, 3H), 1.93-2.01 (m, 2H), 1.73-1.83 (m, 2H), 1.31 (d, J=18.52 Hz, 3H).
  • LCMS(Method 4): RT=0.740 min, m/z: 457.0 (M+H+).
    • Example 1i 4-([8-[1-(1-cyanopropan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl) benzamide (Example 1-264 in Table I)
  • Figure US20190233441A1-20190801-C00922
    Figure US20190233441A1-20190801-C00923
  • Step 1. A mixture of 2,3-dihydro-1,3-benzoxazol-2-one (3 g, 22.2 mmol) and phenyl[(trifluoromethane)sulfonyloxy]-lambda-3-iodanyl trifluoromethanesulfonate (11.6 g, 23.1 mmol) in in trifluoroacetic acid (50 mL) was heated under reflux for 30 min. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with DCM/EtOAc (2/1) to afford 1.6 g (48%) of 5-hydroxy-2,3-dihydro-1,3-benzoxazol-2-one as an off-white solid. Rf=0.3, DCM/EtOAc=1/1.
  • Figure US20190233441A1-20190801-C00924
  • Step 2. A mixture of 5-hydroxy-2,3-dihydro-1,3-benzoxazol-2-one (500 mg, 3.31 mmol), (bromomethyl)benzene (570 mg, 3.33 mmol) and sodium carbonate (350 mg, 3.30 mmol) in N,N-dimethylformamide (10 mL) was heated at 40° C. for 3 h then allowed to cool to room temperature. The pH of the reaction mixture was adjusted to ˜6 by the addition of 3 N HCl. EtOAc (100 mL) was added and the resulting mixture was washed with water (3×30 mL) and brine (2×30 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with DCM/EtOAc (5/1) to afford 0.65 g (81%) of 3-benzyl-5-hydroxy-2,3-dihydro-1,3-benzoxazol-2-one as a white solid. Rf=0.3, DCM/EtOAc=2/1.
  • Figure US20190233441A1-20190801-C00925
  • Step 3. A microwave vial was charged with 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (220 mg, 0.50 mmol), CuI (9.45 mg, 0.05 mmol), Cs2CO3 (485 mg, 1.49 mmol), 3-benzyl-5-hydroxy-2,3-dihydro-1,3-benzoxazol-2-one (120 mg, 0.50 mmol), pyridine-2-carboxylic acid (12.2 mg, 0.10 mmol) and 1,4-dioxane (10 mL). The vessel was evacuated and refilled with nitrogen 3 times. The reaction mixture was heated at 120° C. for 3 h under microwave irradiation. The reaction mixture was allowed to cool to room temperature and the precipitated solid was removed by filtration. The filtrate was concentrated under vacuum and the resultant residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (95/5) to afford 12.2 mg (4%) of 4-([8-[(3-benzyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)oxy]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a white solid. 1H NMR (300 MHz, DMSO-d6): □ 9.55 (s, 1H), 8.69 (d, J=6.0 Hz, 1H), 7.69 (d, J=7.2 Hz, 2H), 7.37-7.16 (m, 9H), 7.08 (d, J =3.6 Hz, 1H), 7.02-6.97 (m, 1H), 6.86-6.82 (m, 1H), 5.00 (s, 2H), 2.81-2.75 (m, 5H), 2.50 (m, 1H), 2.12 (brs, 3H), 1.80 (m, 4H), 1.59 (m, 2H); LCMS (Method 7) RT=1.79 min, m/z=604.2 [M+H]+.
    • Example 1j 4-([8-[4-(4-chlorophenyl)-4-(1,2-dihydroxyethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-253 in Table I)
  • Figure US20190233441A1-20190801-C00926
    Figure US20190233441A1-20190801-C00927
  • Step 1. A mixture of tert-butyl 4-(4-chlorophenyl)-4-[2-(methanesulfonyloxy)-ethyl]piperidine-1-carboxylate (Example 1e, step 7, 1.1 g, 2.63 mmol) and t-BuOK (580 mg, 5.17 mmol) in THF (50 mL) was heated under nitrogen at 60° C. for 4 h then cooled to room temperature. The resulting mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/4) to afford tert-butyl-4-(4-chlorophenyl)-4-ethenylpiperidine-1-carboxylate as colourless oil (400 mg, 47%). TLC: Rf=0.5; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00928
  • Step 2. A mixture of tert-butyl-4-(4-chlorophenyl)-4-ethenylpiperidine-1-carboxylate (400 mg, 1.24 mmol) and a solution of saturated HCl in 1,4-dioxane (10 mL) was stirred for 1 h at room temperature then concentrated under vacuum. The residue was dissolved in H2O (5 mL) and solid K2CO3 (2 g) was added. The resulting mixture was concentrated under vacuum and the residue was triturated with a mixture of DCM/MeOH (3/1(v/v), 40 mL). The remaining solid was removed by filtration and the filtrate was concentrated under vacuum to afford 4-(4-chlorophenyl)-4-ethenylpiperidine as a yellow oil (200 mg). TLC: Rf=0.3; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00929
  • Step 3. A microwave vial was charged with 4-(4-chlorophenyl)-4-ethenylpiperidine (130 mg, 0.59 mmol), 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (250 mg, 0.56 mmol), Pd2(dba)3.CHCl3 (30 mg, 0.03 mmol), BINAP (36 mg, 0.06 mmol), Cs2CO3 (390 mg, 1.20 mmol) and 1,4-dioxane (10 mL). The sealed vial was evacuated and refilled with nitrogen 3 times. The resulting mixture was heated at 100° C. for 20 h, allowed to cool to room temperature and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with a gradient of MeOH in DCM (1/10 to 1/3). Appropriate fractions were collected and evaporated to afford 200 mg (58%) of 4-([8-[4-(4-chlorophenyl)-4-ethenylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a yellow solid. LCMS (Method 11) RT=1.65 min, m/z=584.2 [M+H]+.
  • Figure US20190233441A1-20190801-C00930
  • Step 4: A mixture of 4-([8-[4-(4-chlorophenyl)-4-ethenylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (200 mg, 0.34 mmol), 4-methylmorpholin-4-ium-4-olate (80 mg, 0.68 mmol) and osmium tetraoxide (174 mg, 0.68 mmol) in THF (30 mL) was stirred at room temperature for 20 h. The reaction mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/20 to 1/3). Appropriate fractions were collected and evaporated and the residue was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=50% over 20 min; Detection, UV 254 nm to afford 26.2 mg (12%) of 4-([8-[4-(4-chlorophenyl)-4-(1,2-dihydroxyethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off white solid.1H NMR (300 MHz, DMSO-d6): □ 9.88 (s, 1H), 8.28 (d, J=6.0 Hz, 1H), 7.71 (d, J=8.7 Hz, 2H), 7.47-7.30 (m, 6H), 6.82 (t, J=3.3 Hz, 1H), 6.71 (d, J=8.1 Hz, 1H), 4.88 (d, J=4.8 Hz, 1H), 4.33 (t, J=2.7 Hz, 1H), 4.05-3.91 (m, 2H), 3.50-3.41 (m, 1H), 3.28-3.19 (m, 1H), 2.91-2.64 (m, 8H), 2.46-2.30 (m, 3H), 2.21-2.03 (m, 5H), 1.93-1.69 (m, 4H), 1.63-1.49 (m, 2H); LCMS (Method 7) RT=2.01 min, m/z=618.2 [M+H]+.
    • Example 1k 4-([8-[4-(4-chlorophenyl)-4-(1-hydroxyethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-253 in Table I)
  • Figure US20190233441A1-20190801-C00931
  • Methyl magnesium bromide (3 M in Et2O, 0.28 mL, 0.9 mmol) was added to a solution of 4-([8-[4-(4-chlorophenyl)-4-formylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (50 mg, 0.09 mmol) in THF (10 mL) at 0° C. The resulting solution was stirred at 0° C. for 1 h then quenched by the addition of MeOH (2 mL). The resulting mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with MeOH/DCM (1/3). Appropriate fractions were combined and concentrated under vacuum and the crude residue was purified by Flash-Prep-HPLC with the following conditions: Column: X Bridge C18, 19*150 mm, 5 um; Mobile Phase A:Water/10 mmol NH4HCO3, Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 30% B to 70% B over 10 min; Detection, UV 254 nm to afford 13.1 mg (26%) of 4-([8-[4-(4-chlorophenyl)-4-(1-hydroxyethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off-white solid. 1H NMR (300 MHz, DMSO-d6): □ 9.84 (s, 1H), 8.27 (d, J=6.3 Hz, 1H), 7.71 (d, J=8.7 Hz, 2H), 7.46-7.37 (m, 4H), 7.32 (d, J=8.7 Hz, 2H), 6.83 (t, J=7.2 Hz, 1H), 6.71 (d, J=8.1 Hz, 1H), 4.65 (d, J=4.8 Hz, 1H), 4.05-3.95 (m, 2H), 3.60 (t, J=5.7 Hz, 1H), 2.82-2.75 (m, 5H), 2.73-2.63 (m, 4H), 2.28-2.26 (m, 1H), 2.12-1.85 (m, 5H), 1.85-1.75 (m, 4H), 1.58-1.56 (m, 2H), 0.76 (d, J=6.3 Hz, 3H); LCMS (Method 10) RT=1.64 min, m/z=602.2 [M+H]+.
    • Example 1 4-(8-(4-(4-chlorophenyl)-4-(2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-253 in Table I)
  • Figure US20190233441A1-20190801-C00932
  • A mixture of trimethyl(trifluoromethyl)silane (242 mg, 1.70 mmol), 4-([8-[4-(4-chlorophenyl)-4-formylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (100 mg, 0.17 mmol) and potassium carbonate (23 mg, 0.17 mmol) in N,N-dimethylformamide (10 mL) was heated under nitrogen at 80° C. for 5 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. The residue purified using a short pad of silica gel eluting with DCM/MeOH (3/1). Appropriate fractions were collected and concentrated under vacuum and the crude residue was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=50% over 20 min; Detection, UV 254 nm to afford 13.1 mg (12%) of 4-(8-(4-(4-chlorophenyl)-4-(2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off white solid. 1H NMR (300 MHz, DMSO-d6): □ 9.85 (s, 1H), 8.28 (d, J=6.0 Hz, 1H), 7.71 (d, J=8.7 Hz, 2H), 7.53 (d, J=9.0 Hz, 2H), 7.40 (d, J=8.7 Hz, 2H), 7.32 (d, J=8.7 Hz, 2H), 6.84 (t, J=7.2 Hz, 1H), 6.72-6.66 (m, 2H), 4.10-4.04 (m, 3H), 2.87-2.76 (m, 5H), 2.75-2.62 (m, 2H), 2.49-2.40 (m, 3H), 2.35-2.06 (m, 5H), 1.92-1.70 (m, 4H), 1.65-1.51 (m, 2H); LCMS (Method 7) RT=2.20 min, m/z=656.4 [M+H]+.
    • Example 1m Ethyl 2-[4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]acetate (Example 1-254 in Table I)
  • Figure US20190233441A1-20190801-C00933
    Figure US20190233441A1-20190801-C00934
  • Step 1. A mixture of tert-butyl 4-(4-chlorophenyl)-4-(cyanomethyl)piperidine-1-carboxylate (2 g, 5.97 mmol) and a solution of saturated HCl in 1,4-dioxane (30 mL) was stirred at room temperature overnight. The resulting mixture was concentrated under vacuum, the residue dissolved in H2O (20 mL) and the pH of the solution was adjusted to 9 by the addition of solid potassium carbonate. The resulting mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (3/1) to afford 1.3 g (93%) of 2-[4-(4-chlorophenyl)piperidin-4-yl]acetonitrile as light yellow oil. TLC: Rf=0.2; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00935
  • Step 2. 2-[4-(4-chlorophenyl)piperidin-4-yl]acetonitrile (318 mg, 1.35 mmol) and 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (500 mg, 1.13 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (10/1) to afford 410 mg (61%) of 4-([8-[4-(4-chlorophenyl)-4-(cyanomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a light yellow solid. LCMS (Method 10) RT=1.25 min, m/z=597.0 [M+H]+.
  • Figure US20190233441A1-20190801-C00936
  • Step 3. A mixture of 4-([8-[4-(4-chlorophenyl)-4-(cyanomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (400 mg, 0.67 mmol) in concentrated HCl (4 mL) and AcOH (1 mL) was heated at 100° C. for 20 h then allowed to cool to room temperature. The resulting mixture was concentrated under vacuum to afford 450 mg of 2-[4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]acetic acid; hydrochloride salt as yellow crude oil. TLC: Rf=0.3; DCM/MeOH=4/1.
  • Figure US20190233441A1-20190801-C00937
  • Step 4. Thionyl chloride (4 mL, 55 mmol) was added dropwise to a solution of 2-[4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]acetic acid (450 mg, 0.73 mmol) in ethanol (20 mL) at room temperature. The resulting solution was heated at 80° C. for 3 h then allowed to cool to room temperature. The resulting mixture was concentrated under vacuum and the resultant residue treated with saturated aqueous NaHCO3 solution (4 mL). The resulting mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/10 to 1/5). Appropriate fractions were combined and concentrated under vacuum and the crude residue was purified by Prep-HPLC with the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol NH4HCO3 and MeCN (12% MeCN up to 55% over 9 min); Detection, UV 254 nm to afford 52.9 mg (11%) of ethyl 2-[4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]acetate as an off-white solid. 1H NMR (400 MHz, DMSO-d6): □ 9.87 (s, 1H), 8.31 (d, J=6.4 Hz, 1H), 7.71 (d, J=8.8 Hz, 2H), 7.47 (d, J=8.8 Hz, 2H), 7.40 (d, J=8.8 Hz, 2H), 7.32 (d, J=8.0 Hz, 2H), 6.87 (t, J=7.2 Hz, 1H), 6.79 (d, J=8.0 Hz, 1H), 3.83 (t, J=7.0 Hz, 2H), 3.79-3.68 (m, 2H), 3.27-3.22 (m, 2H), 2.82-2.73 (m, 5H), 2.70-2.67 (m, 2H), 2.51-2.50 (m, 2H), 2.37-2.33 (m, 2H), 2.20-2.12 (m, 5H), 1.86-1.79 (m, 3H), 1.65-1.56 (m, 2H), 0.95 (t, J=7.5 Hz, 3H); LCMS (Method 7) RT=2.88 min, m/z=644.3 [M+H]+.
    • Example 1n 4-([8-[4-(carbamoylmethyl)-4-(4-chlorophenyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-b]pyridazin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-298 in Table I)
  • Figure US20190233441A1-20190801-C00938
  • A mixture of 4-([8-[4-(4-chlorophenyl)-4-(cyanomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (200 mg, 0.33 mmol), (E)-N-ethylidenehydroxylamine (110 mg, 1.67 mmol), PPh3 (89 mg, 0.33 mmol) and Pd(OAc)2 (38 mg, 0.17 mmol) in ethanol (20 mL) was heated under nitrogen at 85° C. for 20 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. The residue was purified using a short pad of silica gel eluting with DCM/MeOH (5/1). Appropriate fractions were combined and concentrated under vacuum and the crude residue was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=55% over 13 min; Detection, UV 254 nm to afford 55.3 mg (27%) of 4-([8-[4-(carbamoylmethyl)-4-(4-chlorophenyl)piperidin-1-yl]-[1,2,4]-triazolo[1,5-b]pyridazin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide as an off-white solid. 1H NMR (400 MHz, DMSO-d6): ⊐ 9.85 (s, 1H), 8.29 (d, J=6.0 Hz, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 7.32 (d, J=8.8 Hz, 2H), 7.01 (s, 1H), 6.86 (t, J=7.2 Hz, 1H), 6.76 (d, J=7.6 Hz, 1H), 6.58 (s, 1H), 3.75-3.72 (m, 2H), 3.31-3.29 (m, 1H), 3.17-3.12 (m, 2H), 2.85-2.75 (m, 5H), 2.42-2.38 (m, 2H), 2.33-2.19 (m, 5H), 2.12 (s, 3H), 1.79-1.56 (m, 5H); LCMS (Method 8) RT=1.76 min, m/z=615.1 [M+H]+.
    • Example 1o 4-([8-[4-(4-chlorophenyl)-4-[(dimethylcarbamoyl)methyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-300 in Table I)
  • Figure US20190233441A1-20190801-C00939
  • A mixture of crude 2-[4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]acetic acid (200 mg), dimethylamine hydrochloride (132 mg, 1.62 mmol), DIPEA (260 mg, 2.01 mmol) and HATU (190 mg, 0.50 mmol) in DMF (10 mL) was stirred at room temperature for 20 h. The reaction mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM/MeOH (10/1). The filtrate was concentrated under vacuum and the crude product was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O (containing NH3.H2O)=13% increasing to MeCN/H2O (containing NH3.H2O)=45% over 13 min; Detection, UV 254 nm to afford 19.9 mg of 4-([8-[4-(4-chlorophenyl)-4-[(dimethylcarbamoyl)-methyl]piperidin-1-yl]-[1,2,4]triazolo-[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off-white solid. 1H NMR (300 MHz, DMSO-d6): □ 9.85 (s, 1H), 8.29 (d, J=6.0 Hz, 1H), 7.71 (d, J=8.7 Hz, 2H), 7.46 (d, J=9.0 Hz, 2H), 7.38 (d, J=8.7 Hz, 2H), 7.32 (d, J=8.7 Hz, 2H), 6.86 (t, J=6.6 Hz, 1H), 6.77 (d, J=8.4 Hz, 1H), 3.80-3.70 (m, 2H), 3.29-3.19 (m, 2H), 2.85-2.75 (m, 4H), 2.69-2.51 (m, 8H), 2.49-2.37 (m, 3H), 2.36-2.23 (m, 3H), 2.20-2.10 (m, 3H), 1.90-1.70 (m, 4H), 1.65-1.50 (m, 2H); LCMS (Method 7) RT=2.15 min, m/z=643.3 [M+H]+.
    • Example 1p 4-([8-[4-(4-chlorophenyl)-4-(2,2-difluoroethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-256 in Table I)
  • Figure US20190233441A1-20190801-C00940
    Figure US20190233441A1-20190801-C00941
  • Step 1. DAST (0.5 mL, 2.87 mmol) was added dropwise to a solution of tert-butyl 4-(4-chlorophenyl)-4-(2-oxoethyl)piperidine-1-carboxylate (1.6 g, 4.74 mmol) in DCM (100 mL) at 0° C. The resulting solution was stirred at 0° C. for 10 min then quenched by the addition of water (30 mL). The resulting solution was extracted with DCM (2×100 mL) and the combined organic layer was concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with EtOAc/hexane (1/10) to afford 500 mg (29%) of tert-butyl 4-(4-chlorophenyl)-4-(2,2-difluoroethyl)piperidine-1-carboxylate as light yellow oil. TLC: Rf=0.5; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00942
  • Step 2. A mixture of tert-butyl-4-(4-chlorophenyl)-4-(2,2-difluoroethyl)-piperidine-1-carboxylate (500 mg, 1.39 mmol) in saturated HCl solution of 1,4-dioxane (30 mL) was stirred at room temperature for 2 h. The reaction mixture was concentrated under vacuum, the residue dissolved in H2O (5 mL) and solid K2CO3 (1 g) was added. The resulting mixture was concentrated under vacuum and the residue was triturated with DCM (100 mL). The remaining solid was removed by filtration and the filtrate was concentrated under vacuum to afford 300 mg (crude) of 4-(4-chlorophenyl)-4-(2,2-difluoroethyl)piperidine as a off white solid. LCMS (Method 7) RT=1.16 min, m/z=260.1 [M+H]+.
  • Figure US20190233441A1-20190801-C00943
  • Step 3. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (300 mg, 0.68 mmol) and 4-(4-chlorophenyl)-4-(2,2-difluoroethyl)piperidine (260 mg, 1.00 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica eluting with DCM/MeOH (5/1). Appropriate fractions were combined and concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=40% over 13 min; Detection, UV 254 nm to afford 38.8 mg (8%) of 4-([8-[4-(4-chlorophenyl)-4-(2,2-difluoroethyl)piperidin-1-yl]-[1,2,4]triazolo-[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide; formic acid salt as a light yellow solid. 1H NMR (400 MHz, DMSO-d6): □ 9.85 (s, 1H), 8.30 (d, J=6.0 Hz, 1H), 8.19 (s, 1H), 7.71 (d, J=8.8 Hz, 2H), 7.53 (d, J=8.8 Hz, 2H), 7.44 (d, J=8.8 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 6.86 (t, J=7.2 Hz, 1H), 6.77 (d, J=7.6 Hz, 1H), 5.82-5.53 (m, 1H), 3.79-3.76 (m, 2H), 3.14-3.09 (m, 2H), 2.83-2.81 (m, 4H), 2.50-2.06 (m, 10H), 1.91-1.57 (m, 6H); LCMS (Method 10) RT=1.85 min, m/z=622.2 [M+H]+.
    • Example 1q 4-([8-[4-(4-chlorophenyl)-4-[1(1E)-(methoxyimino)methyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-250 in Table I)
  • Figure US20190233441A1-20190801-C00944
  • A mixture of 4-([8-[4-(4-chlorophenyl)-4-formylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (50 mg, 0.09 mmol), DIPEA (2 mL, 12.10 mmol) and N-methylhydroxylamine hydrochloride (630 mg, 7.54 mmol) in MeOH (10 mL) was stirred at room temperature for 20 h. The resulting mixture was concentrated under vacuum and the residue purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/5 to 1/3). Appropriate fractions were combined and concentrated and the resultant residue was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=20% increasing to MeCN/H2O=40% over 20 min; Detection, UV 254 nm to afford 3.2 mg (6%) of 4-([4-[4-(4-chlorophenyl)-4-[(1E)-(methoxyimino)methyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off white solid. 1H NMR (400 MHz, CD3OD): ⊐ 8.07-8.06 (m, 1H), 7.64 (d, J=8.8 Hz, 2H), 7.34-7.23 (m, 7H), 6.80-6.77 (d, J=6.4, 10.0 Hz, 2H), 3.80-3.76 (m, 2H), 3.75 (s, 3H), 3.21-3.20 (m, 3H), 2.90-2.80 (m, 5H), 2.30-1.95 (m, 8H), 1.90-1.75 (m, 3H), 1.65-1.55 (m, 2H); LCMS (Method 6) RT=1.76 min, m/z=615.2 [M+H]+.
    • Example 1r 4-([8-[4-(4-chlorophenyl)-4-(acetamidomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-268 in Table I)
  • Figure US20190233441A1-20190801-C00945
    Figure US20190233441A1-20190801-C00946
  • Step 1. Acetic anhydride (2.5 g, 24.49 mmol) was added to a solution of tert-butyl 4-(aminomethyl)-4-(4-chlorophenyl)piperidine-1-carboxylate (800 mg, 2.46 mmol) (prepared according to the procedure contained in Journal of Medicinal Chemistry, 2008, 51(7), 2147-2157) and DIPEA (3.2 g, 24.8 mmol) in DCM (50 mL). On complete addition the reaction mixture was stirred at room temperature for 20 h then concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/4) to afford tert-butyl 4-(4-chlorophenyl)-4-(acetamidomethyl)piperidine-1-carboxylate as an off-white solid (900 mg, 99%). TLC: Rf=0.4; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00947
  • Step 2. A mixture of tert-butyl 4-(4-chlorophenyl)-4-(acetamidomethyl)piperidine-1-carboxylate (900 mg, 2.45 mmol) in a saturated solution of HCl in 1,4-dioxane (20 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum and the residue was dissolved in H2O (5 mL) and treated with solid K2CO3 (1 g). The resulting mixture was concentrated under vacuum and the residue triturated with a mixture of DCM/MeOH (3/1(v/v), 50 mL). The remaining solid was removed by filtration and the filtrate was evaporated to afford N-[[4-(4-chlorophenyl)piperidin-4-yl]methyl]acetamide as a white solid (400 mg). TLC: Rf=0.3; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00948
  • Step 3. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (420 mg, 0.95 mmol) and N-[4-(4-chlorophenyl)piperidin-4-yl]methylacetamide (266 mg, 1.00 mmol) were coupled following the procedure detailed in Example 1j, step 3. The resulting mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM/MeOH (3/1). Appropriate fractions were combined and concentrated to afford crude 4-([8-[4-(4-chlorophenyl)-4-(acetamidomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a light-yellow solid (450 mg). A third of the above crude product (150 mg) was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=40% over 20 min; Detection, UV 254 nm to afford 4-([8-[4-(4-chlorophenyl)-4-(acetamidomethyl)-piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methyl-piperidin-4-yl)benzamide as a off white solid (37.4 mg). 1H NMR (400 MHz, CD3OD): □□8.17 (d, J=6.4 Hz, 1H), 7.76 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.8 Hz, 2H), 7.40 (d, J=8.8 Hz, 4H), 6.88 (t, J=7.0 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 3.87-3.84 (m, 2H), 3.43 (s, 2H), 3.12 (t, J=10 Hz, 2H), 3.03-3.00 (br, 2H), 2.98 (s, 3H), 2.42-2.10 (m, 8H), 2.06-1.90 (m, 3H), 1.88 (s, 3H), 1.79 (br, 2H); LCMS (Method 6) RT=2.51 min, m/z=629.4 [M+H]+.
    • Example 1s: 4-([8-[4-(4-chlorophenyl)-4-(acetamidomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-265 in Table I)
  • Figure US20190233441A1-20190801-C00949
  • A solution of 4-([8-[4-(4-chlorophenyl)-4-(acetamidomethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)-benzamide (200 mg, 0.32 mmol) in 12 N HCl aqueous solution (8 mL) and AcOH (2 mL) was heated at 100° C. for 20 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. DIPEA (1 mL) was added and the mixture was concentrated under vacuum. The residue was purified by Prep-HPLC using the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol HCOOH and MeCN (10% MeCN to 55% over 9 min); Detection, UV 254 nm to afford 4.1 mg of 4-([8-[4-(aminomethyl)-4-(4-chlorophenyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]-pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide; formic acid salt as a light yellow solid. 1H NMR (400 MHz, CD3OD): □ 8.60-8.50 (m, 1H), 8.19 (d, J=6.4 Hz, 1H), 7.77 (d, J=8.8 Hz, 2H), 7.56-7.52 (m, 4H), 7.42 (d, J=8.4 Hz, 2H), 6.90-6.85 (m, 2H), 3.95-3.85 (m, 2H), 3.33-3.30 (m, 2H), 3.22 (s, 2H), 3.11-3.05 (m, 2H), 3.00 (s, 3H), 2.90-2.35 (m, 7H), 2.30-1.80 (m, 7H); LCMS (Method 6): RT=1.75 min, m/z=587.2 [M+H]+.
    • Example 1t 4-[(8-[4-[4-(difluoromethyl)phenyl]-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-267 in Table I)
  • Figure US20190233441A1-20190801-C00950
    Figure US20190233441A1-20190801-C00951
    Figure US20190233441A1-20190801-C00952
  • Step 1. Sodium hydride (4.00 g, 166 mmol) was added portionwise to a solution of 2-(4-bromophenyl)acetonitrile (8 g, 40.8 mmol) and tert-butyl-N,N-bis(2-chloroethyl)carbamate (10.0 g, 41.3 mmol) in DMF (100 mL). On complete addition the resulting solution was stirred at room temperature for 1 h and at 65° C. for an additional 2 h. The reaction mixture was allowed to cool to room temperature, poured into crushed ice (200 g) and extracted with DCM (3×500 mL). The combined organic layer was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with EtOAc/hexane (1/4) to give tert-butyl-4-(4-bromophenyl)-4-cyanopiperidine-1-carboxylate as an off white solid (6.00 g, 40%). TLC: Rf=0.3; ethyl acetate/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00953
  • Step 2. Into a 250-mL pressure tank reactor purged and maintained with an inert atmosphere of nitrogen, were placed tert-butyl-4-(4-bromophenyl)-4-cyanopiperidine-1-carboxylate (5 g, 13.69 mmol), DIPEA (5 g, 38.69 mmol), Pd(dppf)Cl2 (1.00 g, 1.37 mmol), DMSO (2.2 g, 28.16 mmol) and MeOH (150 mL) and the resulting solution was heated at 100° C. for 20 h under a pressure of 10 atm of CO. The reaction mixture was allowed to cool to room temperature and the solvent evaporated. The residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/10 to 1/4) to afford tert-butyl-4-cyano-4-[4-(methoxycarbonyl)phenyl]piperidine-1-carboxylate as a off white solid (3.5 g, 74%). TLC: Rf=0.3; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00954
  • Step 3. DIBAl-H (1 M in hexanes, 20 mL, 20 mmol) was added dropwise to a solution of tert-butyl-4-cyano-4-[4-(methoxycarbonyl)phenyl]piperidine-1-carboxylate (3.5 g, 10.2 mmol) and THF (100 mL) at 0° C. The resulting solution was stirred at 0° C. for 0.5 h, quenched by the addition of water (3 mL) and concentrated under vacuum. The resultant residue was purified by column chromatography on silica eluting with petroleum ether on a gradient of EtOAc (1/4 to 4/1). Appropriate fractions were combined and evaporated to afford tert-butyl 4-cyano-4-[4-(hydroxymethyl)-phenyl]piperidine-1-carboxylate as a white solid (3.00 g, 93%). TLC: Rf=0.3; EtOAc/petroleum ether=1/1.
  • Figure US20190233441A1-20190801-C00955
  • Step 4. A mixture of tert-butyl 4-cyano-4-[4-(hydroxymethyl)phenyl]piperidine-1-carboxylate (3.00 g, 9.48 mmol), sodium bicarbonate (800 mg, 9.52 mmol) and DMP (4 g, 9.43 mmol) in DCM (100 mL) was stirred at room temperature for 20 h. The resulting mixture was evaporated and the resultant residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/4). Appropriate fractions were combined and evaporated to afford tert-butyl-4-cyano-4-(4-formylphenyl)piperidine-1-carboxylate as colourless oil (2.3 g, 77%). 1H NMR (400 MHz, CDCl3): □□10.04 (s, 1H), 7.94 (d, J=8.4 Hz, 2H), 7.67 (d, J=8.4 Hz, 2H), 4.48-4.19 (m, 2H), 3.34-3.10 (m, 2H), 2.16-2.07 (m, 2H), 2.04-1.91 (m, 2H), 1.49 (s, 9H).
  • Figure US20190233441A1-20190801-C00956
  • Step 5. DAST (2.0 mL, 12.4 mmol) was added to a solution of tert-butyl 4-cyano-4-(4-formylphenyl)piperidine-1-carboxylate (2.50 g, 7.95 mmol) in DCM (100 mL) under nitrogen. The resulting solution was stirred at room temperature for 20 h and quenched by the addition of saturated aqueous NaHCO3 solution (50 mL). The resulting solution was extracted with DCM (3×100 mL) and the combined organic layer was dried over Na2SO4 and concentrated. The residue was purified by flash chromatography on silica gel eluting with EtOAc/hexane (1/10) to afford tert-butyl 4-cyano-4-[4-(difluoromethyl)phenyl]piperidine-1-carboxylate as colourless oil (1.20 g, 45%). TLC: Rf=0.3; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00957
  • Step 6. DIBAl-H (1 M in hexanes, 3 mL, 3 mmol) was added dropwise to a solution of tert-butyl-4-cyano-4-[4-(difluoromethyl)phenyl]piperidine-1-carboxylate (500 mg, 1.49 mmol) in diethyl ether (50 mL) under nitrogen at 0° C. The resulting solution was stirred at 0° C. for 1 h then quenched by the addition of water (1 mL). The precipitated solid was removed by filtration and the filtrate was concentrated under vacuum to afford crude tert-butyl-4-[4-(difluoromethyl)phenyl]-4-formylpiperidine-1-carboxylate as colourless oil (340 mg). The product was used in the next step without purification. TLC: Rf=0.5; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00958
  • Step 7. NaBH4 (38 mg, 1.00 mmol) was added to a solution of crude tert-butyl-4-[4-(difluoromethyl)phenyl]-4-formylpiperidine-1-carboxylate (340 mg, 1.00 mmol) in MeOH (10 mL). The resulting solution was stirred at room temperature for 10 min then quenched by the addition of water (2 mL). The reaction mixture was concentrated under vacuum and the resultant residue was purified by flash chromatography on silica gel eluting with hexane on a gradient of EtOAc (1/4 to 4/1). Appropriate fractions were collected and evaporated to afford tert-butyl-4-[4-(difluoromethyl)phenyl]-4-(hydroxymethyl)piperidine-1-carboxylate as colourless oil (150 mg, 44%). TLC: Rf=0.3; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00959
  • Step 8. A mixture of tert-butyl 4-[4-(difluoromethyl)phenyl]-4-(hydroxymethyl)piperidine-1-carboxylate (150 mg, 0.44 mmol) in a saturated solution of HCl in 1,4-dioxane (10 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum to afford crude [4-[4-(difluoromethyl)phenyl]piperidin-4-yl]methanol as a light yellow solid (90 mg) as the hydrochloride salt. TLC: Rf=0.4; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00960
  • Step 9. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide; hydrochloride salt (200 mg, 0.45 mmol) and 4-[4-(difluoromethyl)phenyl]piperidin-4-ylmethanol (110 mg, 0.46 mmol) were coupled following the procedure detailed in Example 1j, step 3. The resulting mixture was concentrated under vacuum and the residue was purified using a short pad of silica gel eluting with DCM/MeOH (3/1). Appropriate fractions were combined and evaporated to afford a residue that was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=40% over 20 min; Detection, UV 254 nm to afford 4-[(8-[4-[4-(difluoromethyl)phenyl]-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a off white solid (37 mg, 14%). 1H NMR (400 MHz, DMSO-d6): □ 9.87 (s, 1H), 8.29 (d, J=6.0 Hz, 1H), 7.72 (d, J=8.8 Hz, 2H), 7.60-7.53 (m, 4H), 7.32 (d, J=8.4 Hz, 2H), 7.16-6.83 (m, 2H), 6.75 (d, J=8.0 Hz, 1H), 4.74 (t, J=5.4 Hz, 1H), 3.87-3.83 (m, 2H), 3.45 (d, J=5.6 Hz, 2H), 3.03-2.97 (m, 2H), 2.88-2.72 (m, 5H), 2.31-2.21 (m, 2H), 2.16-2.05 (m, 5H), 1.81-1.50 (m, 7H); LCMS (Method 10) RT=1.52 min, m z=604.3 [M+H]+.
    • Example 1u: 4-([8-[4-(hydroxymethyl)-4-[4-(methylsulfanyl)phenyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-251 in Table I)
  • Figure US20190233441A1-20190801-C00961
    Figure US20190233441A1-20190801-C00962
  • Step 1. Sodium hydride (370 mg, 15.42 mmol) was added portionwise to a mixture of 2-[4-(methylsulfanyl)phenyl]acetonitrile (500 mg, 3.06 mmol) and tert-butyl-N,N-bis(2-chloroethyl)carbamate (890 mg, 3.68 mmol) in N,N-dimethylformamide (20 mL) at 0° C. The resulting solution was stirred for 10 min at 0° C. and then heated at 60° C. for 2 h. The reaction mixture was allowed to cool to room temperature and poured onto saturated aqueous ammonium chloride solution (50 mL). EtOAc (200 mL) was added and the phases were separated. The organic phase was washed with H2O (3×50 mL), dried, filtered and the filtrate concentrated under vacuum. The resultant residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/5) to afford 570 mg (56%) of tert-butyl-4-cyano-4-[4-(methylsulfanyl)phenyl]piperidine-1-carboxylate as a light yellow solid. TLC: Rf=0.3; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00963
  • Step 2. DIBAl-H (1 M in hexanes, 3.4 mL, 3.4 mmol) was added dropwise to a solution of tert-butyl-4-cyano-4-[4-(methylsulfanyl)phenyl]piperidine-1-carboxylate (570 mg, 1.71 mmol) in diethyl ether (20 mL) at 0° C. The resulting solution was stirred at 0° C. for 10 min and quenched by the addition of water (1 mL), citric (0.5 g) and celite (5 g). The precipitated solid was removed by filtration. The filtrate was concentrated under vacuum to afford 300 mg of crude tert-butyl-4-formyl-4-[4-(methylsulfanyl)-phenyl]piperidine-1-carboxylate as a light yellow solid. TLC: Rf=0.2; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00964
  • Step 3. NaBH4 (68 mg, 1.80 mmol) was added to a solution of tert-butyl-4-formyl-4-[4-(methylsulfanyl)phenyl]piperidine-1-carboxylate (300 mg, 0.89 mmol) in MeOH (10 mL). The resulting solution was stirred for 30 min at room temperature then quenched by the addition of water (2 mL). The resulting mixture was concentrated under vacuum and the residue purified by flash chromatography on silica gel eluting with petroleum ether on a gradient of EtOAc (1/4 to 1/1) to afford 150 mg (50%) of tert-butyl-4-(hydroxymethyl)-4-[4-(methylsulfanyl)phenyl]piperidine-1-carboxylate as light yellow oil. TLC: Rf=0.3; EtOAc/petroleum ether=1/1.
  • Figure US20190233441A1-20190801-C00965
  • Step 4. A mixture of tert-butyl-4-(hydroxymethyl)-4-[4-(methylsulfanyl)-phenyl]piperidine-1-carboxylate (150 mg, 0.44 mmol) in a saturated solution of HCl in 1,4-dioxane (10 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum, H2O (10 mL) was added and the pH of the solution was adjusted to 9 by the addition of solid potassium carbonate. The resulting mixture was concentrated under vacuum and the residue was triturated with a mixture of DCM/MeOH (5/1(v/v), 30 mL). The remaining solid was removed by filtration and the filtrate was concentrated under vacuum to afford 200 mg (crude) of [4-[4-(methylsulfanyl)phenyl]piperidin-4-yl]methanol as a light yellow solid. LCMS (Method 7) RT=1.08 min, m/z=238.1 [M+H]+.
  • Figure US20190233441A1-20190801-C00966
  • Step 5. 4-[4-(methylsulfanyl)-phenyl]piperidin-4-ylmethanol (170 mg, 0.72 mmol) and 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (317 mg, 0.72 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated and the residue was purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/10 to 1/2). The filtrate was concentrated under vacuum and the resultant residue was purified by Prep-HPLC using the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol NH4HCO3 and MeCN (15% MeCN up to 55% over 11 min); Detection, UV 254 nm to afford 31.8 mg (7%) of 4-([8-[4-(hydroxymethyl)-4-[4-(methylsulfanyl)phenyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-ethylpiperidin-4-yl)benzamide as an off-white solid. 1H NMR (400 MHz, DMSO-d6): □□9.86 (s, 1H), 8.29 (d, J=6.4 Hz, 1H), 7.72 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.8 Hz, 2H), 7.24 (d, J=8.8 Hz, 2H), 6.85 (t, J=7.2 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 4.67 (t, J=5.4 Hz, 1H), 3.88-3.85 (m, 2H), 3.40-3.36 (m, 2H), 2.96 (t, J=10.2 Hz, 2H), 2.86-2.72 (m, 5H), 2.46 (s, 3H), 2.25-2.01 (m, 7H), 1.91-1.70 (m, 4H), 1.62-1.49 (m, 3H). LCMS (Method 10) RT=1.85 min, m/z=600.3 [M+H]+.
    • Example 1v 4-([8-[4-(4-chlorophenyl)-4-(cyanomethyl)cyclohex-1-en-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-294 in Table I)
  • Figure US20190233441A1-20190801-C00967
    Figure US20190233441A1-20190801-C00968
  • Step 1. A mixture of 1,4-dioxaspiro[4.5]decan-8-one (10 g, 64.0 mmol), ethyl 2-cyanoacetate (7.24 g, 64.0 mmol), NH4OAc (4.94 g, 64.1 mmol) and acetic acid (20 mL, 349 mmol) in toluene (200 mL) was heated under nitrogen at 110° C. for 3 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum, diluted with EtOAc (200 mL), washed with H2O (50 mL) and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with petroleum ether on a gradient of EtOAc (1/10 to 1/5) to afford 10 g (57%) of ethyl 2-cyano-2-[1,4-dioxaspiro[4.5]decan-8-ylidene]acetate as a white solid. TLC: Rf=0.4; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00969
  • Step 2. A solution of bromo(4-chlorophenyl)magnesium (1 M in THF, 12 mL, 12 mmol) was added dropwise to a mixture of ethyl 2-cyano-2-[1,4-dioxaspiro[4.5]decan-8-ylidene]acetate (1.00 g, 3.98 mmol) and CuI (230 mg, 1.21 mmol) in THF (20 mL) under nitrogen at 0° C. The resulting solution was stirred for 2 h at 0° C., quenched by the addition of 10 mL of ethanol and concentrated under vacuum. The resultant residue was purified by flash chromatography on silica gel eluting with petroleum ether on a gradient of EtOAc (1/10 to 1/5) to afford 1.2 g (70%) of ethyl 2-[8-(4-chlorophenyl)-1,4-dioxaspiro-[4.5]decan-8-yl]-2-cyanoacetate as light yellow oil. TLC: Rf=0.3; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00970
  • Step 3. A solution of KOH (1.2 g, 21.39 mmol) in water (10 mL) was added dropwise to a solution of ethyl 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]-2-cyanoacetate (1.2 g, 3.30 mmol) in ethanol (10 mL). On complete addition the mixture was stirred at room temperature for 20 h then concentrated under vacuum. The resultant residue was dissolved in H2O (20 mL) and washed with diethylether (2×50 mL). The pH of the aqueous phase was adjusted to 6 by the addition of 6N HCl and the resulting mixture was concentrated under vacuum. The residue was triturated with DCM and the remaining solid removed by filtration. The filtrate was concentrated under vacuum to afford 1 g of 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]-2-cyanoacetic acid as a light yellow solid. TLC: Rf=0.3; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00971
  • Step 4. A mixture of 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]-2-cyanoacetic acid (1 g, 2.98 mmol) and Cu2O (480 mg, 3.35 mmol) in MeCN (30 mL) was heated under nitrogen at 85° C. for 2 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. The resultant residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/3) to afford 600 mg (62%) of 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]acetonitrile as light yellow oil. TLC: Rf=0.3; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00972
  • Step 5. A mixture of 2-[8-(4-chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-yl]acetonitrile (600 mg, 2.06 mmol) and PTSA (71 mg, 0.41 mmol) in propan-2-one (20 mL) and water (5 mL) was heated at 80° C. for 20 h. The reaction mixture was allowed to cool to room temperature and concentrated under vacuum. Water (20 mL) was added and the aqueous phase extracted with EtOAc (2×100 mL). The combined organic phase was evaporated and the resultant residue purified by silica gel eluting with petroleum ether on a gradient of EtOAc (1/5 to 1/2) to give 400 mg (72%) of 2-[1-(4-chlorophenyl)-4-oxocyclohexyl]acetonitrile as a white solid. TLC: Rf=0.2; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00973
  • Step 6. A solution of n-BuLi (2.5 M in hexanes, 0.6 mL, 1.5 mmol) was added dropwise to a solution of diisopropylamine (190 mg, 1.88 mmol) in THF (20 mL) under nitrogen at −70° C. The resulting solution was stirred at −70° C. for 0.5 h then a solution of 2-[1-(4-chlorophenyl)-4-oxocyclohexyl]acetonitrile (300 mg, 1.21 mmol) in a minimum amount of THF was added. The resulting solution was stirred at −70° C. for 0.5 h before the addition of 1,1,1-trifluoro-N-phenyl-N-(trifluoromethane)sulfonylmethane-sulfonamide (520 mg, 1.46 mmol). The resulting solution was stirred for 0.5 h at −70° C. then allowed to warm to room temperature. The reaction mixture was concentrated under vacuum and the resultant residue purified by flash chromatography on silica gel eluting with petroleum ether on a gradient of EtOAc (1/10 to 1/5) to afford 130 mg (20%) of 4-(4-chlorophenyl)-4-(cyanomethyl)cyclohex-1-en-1-yl trifluoromethanesulfonate as light yellow oil. TLC: Rf=0.4; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00974
  • Step 7. A mixture of 4-(4-chlorophenyl)-4-(cyanomethyl)cyclohex-1-en-1-yl trifluoromethanesulfonate (130 mg, 0.34 mmol), KOAc (100 mg, 1.02 mmol), 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (105 mg, 0.41 mmol) and Pd(dppf)Cl2 (57 mg, 0.08 mmol, 0.20 equiv) in DMSO (10 mL) was heated under nitrogen at 70° C. for 16 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (100 mL) and washed with H2O (3×20 mL). The organic phase was evaporated and the resultant residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/10) to afford 2-[1-(4-chlorophenyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]acetonitrile (100 mg, 49%) as light yellow oil. TLC: Rf=0.6; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00975
  • Step 8. A mixture of 2-[1-(4-chlorophenyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]acetonitrile (150 mg, 0.42 mmol), 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (190 mg, 0.43 mmol), K3PO4 (270 mg, 1.27 mmol) and Pd(PPh3)4 (100 mg, 0.09 mmol) in 1,4-dioxane (30 mL) and water (3 mL) was degassed and refilled with nitrogen 3 times. The reaction mixture was heated at 100° C. for 20 h, allowed to cool to room temperature and concentrated under vacuum. The residue was purified using a short pad of silica gel eluting with DCM/MeOH (10/1). Appropriate fractions were combined and concentrated under vacuum. The resultant residue was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H20=13% increasing to MeCN/H2O=45% over 11 min; Detection, UV 254 nm to afford 61.4 mg (24%) of 4-([8-[4-(4-chlorophenyl)-4-(cyanomethyl)cyclohex-1-en-1-yl]-[1,2,4]-triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a white solid. 1H NMR (300 MHz, DMSO-d6): □□09.93 (s, 1H), 8.66 (d, J=5.7 Hz, 1H), 7.74 (d, J=8.7 Hz, 2H), 7.55 (d, J=8.7 Hz, 2H), 7.44 (t, J=9.0 Hz, 4H) , 7.33 (d, J=8.4 Hz, 2H), 6.98 (t, J=7.0 Hz, 1H) , 3.29 (s, 1H), 3.07-2.82 (m, 8H), 2.74-2.56 (m, 2H), 2.27-2.12 (m , 6H), 1.80 (s, 4H), 1.59-1.56 (m, 2H); LCMS (Method 8) RT=1.78 min, m/z=594.1 [M+H]+.
    • Example 1w 4-([8-[4-(hydroxymethyl)-4-[[(2,2,2-trifluoroethyl)amino]methyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-266 in Table I)
  • Figure US20190233441A1-20190801-C00976
    Figure US20190233441A1-20190801-C00977
  • Step 1. DIBAl-H (1 M in hexane, 30 mL, 30 mmol) was added dropwise to a solution of tert-butyl-4-[(benzyloxy)methyl]-4-cyanopiperidine-1-carboxylate (4 g, 12.11 mmol) in diethyl ether (100 mL) under nitrogen at 0° C. The resulting solution was stirred at 0° C. for 1 h then quenched by the addition of water (2 mL). The precipitated solid was removed by filtration and the filtrate was concentrated under vacuum. The resultant residue was purified by chromatography on silica gel eluting with EtOAc/hexane (1/2) to afford tert-butyl-4-[(benzyloxy)methyl]-4-formylpiperidine-1-carboxylate as yellow oil (1.3 g, 32%). TLC: Rf=0.4; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00978
  • Step 2. A mixture of tert-butyl-4-[(benzyloxy)methyl]-4-formylpiperidine-1-carboxylate (1 g, 3.00 mmol), 2,2,2-trifluoroethan-1-amine (1.5 g, 15.14 mmol), and tetrakis(propan-2-yloxy)titanium (850 mg, 2.99 mmol) in ethanol (30 mL) was heated under nitrogen at 60° C. for 2 h. AcOH (0.1 mL, 1.75 mmol) was added, followed by NaBH3CN (370 mg, 5.89 mmol). The resulting solution was heated at 60° C. for an additional 2 h then allowed to cool to room temperature. The mixture was concentrated under vacuum and the resultant residue was purified by flash chromatography on silica gel eluting with EtOAc/hexane (1/10) to afford tert-butyl-4-[(benzyloxy)methyl]-4-[[(2,2,2-trifluoroethyl)amino]methyl]piperidine-1-carboxylate as colourless oil (310 mg, 25%). TLC: Rf=0.5; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00979
  • Step 3. A mixture of tert-butyl-4-[(benzyloxy)methyl]-4-[[(2,2,2-trifluoroethyl)amino]methyl]piperidine-1-carboxylate (300 mg, 0.72 mmol) and 10% Pd/C (50 mg) in MeOH (20 mL) and aqueous 6 N HCl solution (1 mL) was stirred under H2 at room temperature for 20 h. The catalyst was removed by filtration and the filtrate was concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (1/3) to afford tert-butyl-4-(hydroxymethyl)-4-[[(2,2,2-trifluoroethyl)amino]methyl]piperidine-1-carboxylate as colourless oil (120 mg, 51%). LCMS (Method 12) RT=0.66 min, m/z=327.0 [M+H]+.
  • Figure US20190233441A1-20190801-C00980
  • Step 4. A solution of tert-butyl-4-(hydroxymethyl)-4-[[(2,2,2-trifluoroethyl)amino]-methyl]piperidine-1-carboxylate (120 mg, 0.37 mmol) in a saturated solution of HCl in 1,4-dioxane (6 mL) was stirred at room temperature for 1 h. The resulting mixture was evaporated, H2O (1mL) was added, followed by solid K2CO3 (0.5 g). The resulting mixture was concentrated under vacuum and the residue was triturated with a mixture of DCM/MeOH (3/1(v/v), 30 mL) and the remaining solid was removed by filtration. The filtrate was concentrated under vacuum to afford (4-[[(2,2,2-trifluoroethyl)-amino]methyl]piperidin-4-yl)methanol as colourless oil (65 mg). TLC: Rf=0.2; DCM/MeOH=4/1.
  • Figure US20190233441A1-20190801-C00981
  • Step 5. (4-[[(2,2,2-trifluoroethyl)amino]-methyl]piperidin-4-yl)methanol (55 mg, 0.24 mmol) and 4-(8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (100 mg, 0.23 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated under vacuum and the residue purified using a short pad of silica gel eluting with DCM/MeOH (10/1). Appropriate fractions were combined and evaporated and the resultant residue was purified by Flash-Prep-HPLC using the following conditions: Column, silica gel; mobile phase, MeCN/H2O=15% increasing to MeCN/H2O=40% over 20 min; Detection, UV 254 nm to afford 4-([8-[4-(hydroxymethyl)-4-[[(2,2,2-trifluoroethyl)amino]methyl]piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a off white solid (12.2 mg, 9%). 1H NMR (400 MHz, DMSO-d6): □ 9.86 (s, 1H), 8.31 (d, J=6.4 Hz, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 6.88 (t, J=3.4 Hz, 1H), 6.82 (d, J=3.6Hz, 1H), 4.61 (t, J=3.2 Hz, 1H), 3.51-3.36 (m, 6H), 3.31-3.23 (m, 3H), 2.85-2.76 (m, 5H), 2.70-2.65 (m, 2H), 2.33-2.24 (m, 1H), 2.18-2.04 (m, 3H), 1.91-1.70 (m, 4H), 1.64-1.50 (m, 6H); LCMS (Method 7) RT=1.21 min, m/z=589.4 [M+H]+.
    • Example 1x 4-([8-[4-(cyanomethyl)-4-cyclopentylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-257 in Table I)
  • Figure US20190233441A1-20190801-C00982
    Figure US20190233441A1-20190801-C00983
  • Step 1. A solution of bromo(cyclopentyl)magnesium (1 M in THF, 20 mL, 115.4 mmol) was added dropwise to a mixture of tert-butyl-4-(1-cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (Example 1e, step 2, 2 g, 6.79 mmol) and CuI (380 mg, 2.00 mmol) in THF (20 mL) under nitrogen at 0° C. The resulting solution was stirred 0° C. for 2 h at then quenched by the addition of ethanol (10 mL). The mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/10) to afford 1.7 g (69%) of tert-butyl-4-(1-cyano-2-ethoxy-2-oxoethyl)-4-cyclopentylpiperidine-1-carboxylate as light yellow oil. TLC: Rf=0.4; EtOAc/petroleum ether=1/4.
  • Figure US20190233441A1-20190801-C00984
  • Step 2. A mixture of potassium hydroxide (2.0 g, 35.65 mmol) and tert-butyl-4-(1-cyano-2-ethoxy-2-oxoethyl)-4-cyclopentylpiperidine-1-carboxylate (1.7 g, 4.66 mmol) in ethanol (20 mL) and water (20 mL) was stirred at room temperature overnight. The reaction mixture was evaporated to half original volume and washed with ether (3×30 mL). The pH of the aqueous phase was adjusted to 6 by the addition of 6N HCl aqueous solution and the resulting mixture was concentrated under vacuum. The residue was triturated with a mixture of DCM and MeOH (5/1 (v/v), 50 mL) and the remaining solid was removed by filtration. The filtrate evaporated to afford 1.3 g (83%) of 2-[1-[(tert-butoxy)carbonyl]-4-cyclopentylpiperidin-4-yl]-2-cyanoacetic acid as a light yellow solid. TLC: Rf=0.5; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00985
  • Step 3. A mixture of 2-[1-[(tert-butoxy)carbonyl]-4-cyclopentylpiperidin-4-yl]-2-cyanoacetic acid (1.3 g, 3.86 mmol) and Cu2O (550 mg, 3.84 mmol) in MeCN (30 mL) was heated at 85° C. for 2 h under nitrogen then allowed to cool to room temperature. The reaction mixture was concentrated under vacuum and the residue purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/4) to afford 830 mg (73%) of tert-butyl-4-(cyanomethyl)-4-cyclopentylpiperidine-1-carboxylate as colourless oil. TLC: Rf=0.4; EtOAc/petroleum ether=1/2.
  • Figure US20190233441A1-20190801-C00986
  • Step 4. A mixture of tert-butyl-4-(cyanomethyl)-4-cyclopentylpiperidine-1-carboxylate (830 mg, 2.84 mmol) in saturated HCl in 1,4-dioxane (30 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under vacuum and the residue was dissolved in H2O (10 mL). The pH of the aqueous phase was adjusted to 9 by the addition of solid potassium carbonate. The resultant mixture was concentrated under vacuum and the residue triturated with a mixture of DCM and MeOH (5/1(v/v), 10 mL). The precipitated solid was removed by filtration and the filtrate evaporated to afford 580 mg (crude) of 2-(4-cyclopentylpiperidin-4-yl)acetonitrile as light yellow oil. TLC: Rf=0.3; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C00987
  • Step 5. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol) and 2-(4-cyclopentylpiperidin-4-yl)acetonitrile (173 mg, 0.90 mmol) were coupled following the procedure detailed in Example 1j, step 3. The resulting mixture was concentrated under vacuum and the residue purified using a short pad of silica gel eluting with DCM/MeOH (10/1). Appropriate fractions were combined and concentrated under vacuum and the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol NH4HCO3 and MeCN (13% MeCN up to 55% over 12 min); Detection, UV 254 nm to afford 55.6 mg (22%) of 4-([8-[4-(cyanomethyl)-4-cyclopentylpiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a white solid. 1H NMR (300 MHz, DMSO-d6,): □ 9.85 (s, 1H), 8.34 (t, J=3.1 Hz, 1H), 7.71 (d, J=8.7 Hz, 2H), 7.32 (d, J=8.7 Hz, 2H), 6.93-6.84 (m, 2H), 3.84-3.82 (m, 2H), 3.18 (t, J=10.2 Hz, 2H), 2.82-2.73 (m, 7H), 2.12 (s, 4H), 1.90-1.35 (m, 19H); LCMS (Method 10) RT=1.69 min, m/z=555.3 [M+H]+.
    • Example 1y N-methyl-N-[1-(2-methylpropyl)piperidin-4-yl]-2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetamide (Example 1-297 in Table I)
  • Figure US20190233441A1-20190801-C00988
    Figure US20190233441A1-20190801-C00989
    Figure US20190233441A1-20190801-C00990
  • Step 1. A mixture of tert-butyl 4-[2-amino-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,2,3,6-tetrahydropyridine-1-carboxylate (13 g, 41.22 mmol) in a saturated solution of HCl in 1,4-dioxane (150 mL) was stirred at room temperature overnight. The precipitated solid was collected by filtration to afford 10 g of (crude) of the hydrochloride salt of 8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine as a yellow solid. LCMS (Method 7) RT=0.49 min, m/z=216.0 [M+H]+.
  • Figure US20190233441A1-20190801-C00991
  • Step 2. A mixture of 8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine hydrochloride (10 g, 39.73 mmol), DIPEA (14 g, 108.32 mmol), 4,4,4-trifluorobutanoic acid (6 g, 42.23 mmol) and HATU (16 g, 42.08 mmol) in N,N-dimethylformamide (100 mL) was stirred at room temperature overnight. The reaction mixture was evaporated; water (250 mL) and EtOAc (200 mL) were added. The phases were separated, and the aqueous phase was extracted with EtOAc (200 mL). The combined organic phase was washed with brine, dried over sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with 65% EtOAc/petroleum ether. Appropriate fractions were combined and evaporated to afford 1-(4-[2-amino-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,2,3,6-tetrahydropyridin-1-yl)-4,4,4-trifluorobutan-1-one (10 g, 74%) as a yellow solid. LCMS (Method 8) RT=1.18 min, m/z=340.0 [M+H]+.
  • Figure US20190233441A1-20190801-C00992
  • Step 3. tert-butyl nitrite (15.20 g, 147.4 mmol) was added to a solution of 1-(4-[2-amino-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,2,3,6-tetrahydropyridin-1-yl)-4,4,4-trifluorobutan-1-one (10.0 g, 29.5 mmol) and CuI (11.23 g, 59.0 mmol) in MeCN (150 mL) under nitrogen. The mixture was stirred for 20 min at room temperature then heated at 55° C. for 30 min. The reaction mixture was allowed to cool to room temperature and the precipitated solid removed by filtration. The filtrate was concentrated under vacuum and the residue was dissolved in water (500 mL). The pH of the aqueous phase was adjusted to 7 by the addition of 2M aqueous sodium hydroxide solution then extracted with DCM (3×200 mL). The combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography eluting with DCM/EtOAc (3/1). Appropriate fractions were combined and evaporated to afford 4,4,4-trifluoro-1-(4-[2-iodo-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-1,2,3,6-tetrahydropyridin-1-yl)butan-1-one (5.3 g, 40%) as a light yellow solid. LCMS (Method 7) RT=1.48 min, m/z=450.9 [M+H]+.
  • Figure US20190233441A1-20190801-C00993
  • Step 4. A degassed mixture of tert-butyl-2-(4-amino-1H-pyrazol-1-yl)acetate (796 mg, 4.04 mmol), Cs2CO3 (2.63 g, 8.07 mmol), 4,4,4-trifluoro-1-(4-2-iodo-[1,2,4]triazolo[1,5-a]pyridin-8-yl-1,2,3,6-tetrahydropyridin-1-yl)butan-1-one (2 g, 4.44 mmol), Pd2(dba)3.CHCl3 (418 mg, 0.40 mmol) and XantPhos (468 mg, 0.81 mmol) in 1,4-dioxane (100 mL) was was heated at 100° C. overnight. The reaction mixture was allowed to cool to room temperature and the precipitated solid was removed by filtration. The filtrate was concentrated under vacuum and the residue purified by flash chromatography on silica gel eluting with 70% EtOAc/petroleum ether to afford 1.2 g (57%) of tert-butyl 2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]-triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetate as a yellow solid. LCMS (Method 7) RT=1.46 min, m/z=520.0 [M+H]+.
  • Figure US20190233441A1-20190801-C00994
  • Step 5. A mixture of tert-butyl-2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetate (1.2 g, 2.31 mmol) in DCM (15 mL) and TFA (20 mL) was stirred at room temperature overnight. The resulting mixture was concentrated under vacuum to afford 2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetic acid (900 mg, 84%) as a yellow solid.
  • Figure US20190233441A1-20190801-C00995
  • Step 6. A mixture of 2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetic acid hydrochloride (200 mg, 0.40 mmol), DIPEA (104 mg, 0.80 mmol), N-methyl-1-(2-methylpropyl)piperidin-4-amine (88 mg, 0.52 mmol) and HATU (198 mg, 0.52 mmol) in DMF (5 mL) was stirred at room temperature for 3 h. The mixture was concentrated under vacuum and the residue diluted with water (60 mL). The aqueous phase was extracted with DCM (3×50 mL) and the combined organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography on silica eluting with DCM/MeOH (20/1). The crude product was purified by Prep-HPLC using the following conditions: Column, XBridge Prep C18 OBD Column, 5 um, 19*150 mm,; mobile phase, water with 10 mmol NH3.H2O and MeCN (40% MeCN up to 55% over 10 min, up to 95% over 1 min, hold 95.0% for 1 min, down to 40% over 2 min); Detection, UV 254/220 nm to afford 94.3 mg (38%) of N-methyl-N-[1-(2-methylpropyl)piperidin-4-yl]-2-[4-([8-[1-(4,4,4-trifluorobutanoyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetamide as a yellow solid. 1H NMR (400 MHz, DMSO-d6): □□9.31 (s, 1H), 8.59-8.58 (m, 1H), 7.80-7.77 (m, 1H), 7.48-7.37 (m, 3H), 6.99-6.95 (m, 1H), 5.11-5.04 (m, 2H), 4.33-4.24 (m, 3H), 3.76-3.62 (m, 2H), 2.86-2.52 (m, 11H), 2.01-1.43 (m, 9H), 0.89-0.77 (m, 6H); LCMS (Method 7) RT=1.10 min, m/z=616.3 [M+H]+.
    • Example 1z Methyl 3-(4-[2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetyl]piperazin-1-yl)propanoate (Example 1-290 in Table I)
  • Figure US20190233441A1-20190801-C00996
    Figure US20190233441A1-20190801-C00997
  • Step 1. A microwave vial was charged with 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-amine (630 mg, 2.95 mmol), 8-bromo-2-iodo-[1,2,4]triazolo[1,5-a]pyridine (960 mg, 2.96 mmol), Pd2(dba)3 (150 mg, 0.16 mmol), XantPhos (170 mg, 0.29 mmol), Cs2CO3 (1.9 g, 5.83 mmol) and 1,4-dioxane (15 mL). The vessel was evacuated and refilled with nitrogen 3 times. The reaction mixture was heated at 60° C. for 20 h then allowed to cool to room temperature. The resulting mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1/1) to afford 800 mg (66%) of N[8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-amine as a red solid. TLC: Rf=0.5; EtOAc/petroleum ether=1/1.
  • Figure US20190233441A1-20190801-C00998
  • Step 2. N-[8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1-[[2-(trimethylsilyl)-ethoxy]methyl]-1H-pyrazol-4-amine (400 mg, 0.98 mmol) and [4-(4-chlorophenyl)piperidin-4-yl]methanol (270 mg, 1.20 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1:1) to give 350 mg (65%) of [4-(4-chlorophenyl)-1-[2-[(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl)amino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]methanol as a yellow solid. LCMS (Method 12) RT=1.12 min, m/z=554.2 [M+H]+.
  • Figure US20190233441A1-20190801-C00999
  • Step 3. A mixture of [4-(4-chlorophenyl)-1-[2-[(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl)amino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]methanol (650 mg, 1.17 mmol) in a saturated solution of HCl in 1,4-dioxane (20 mL) was stirred at room temperature for 20 h. The mixture was concentrated under vacuum to afford 500 mg of [4-(4-chlorophenyl)-1-[2-[(1H-pyrazol-4-yl)amino]-[1,2,4]triazolo[1,5-a]pyridine-8-yl]piperidin-4-yl]methanol as a light yellow solid. LCMS (Method 12) RT=0.61 min, m/z=424.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01000
  • Step 4. A mixture of [4-(4-chlorophenyl)-1-[2-[(1H-pyrazol-4-yl)amino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidin-4-yl]methanol (400 mg, 0.94 mmol), Cs2CO3 (1.00 g, 3.07 mmol) and tert-butyl-2-bromoacetate (190 mg, 0.97 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc (100 mL) and washed with H2O (3×30 mL). The organic phase was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with EtOAc to afford 500 mg (98%) of tert-butyl-2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetate as yellow oil. LCMS (Method 12) RT=0.98 min, m/z=538.3 [M+H]+.
  • Figure US20190233441A1-20190801-C01001
  • Step 5. A mixture of tert-butyl-2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)-piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetate (500 mg, 0.93 mmol) in a saturated solution of HCl in 1,4-dioxane (20 mL) was stirred at room temperature for 20 h then concentrated under vacuum to afford 400 mg of 2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetic acid as a light yellow crude solid. LCMS (Method 12) RT=0.44 min, m/z=482.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01002
  • Step 6. A mixture of 2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetic acid (100 mg, 0.207 mmol), HATU (95 mg, 0.250 mmol), DIPEA (108 mg, 0.836 mmol) and methyl 3-(piperazin-1-yl)propanoate (72 mg, 0.418 mmol) in N,N-dimethylformamide (10 mL) was stirred at room temperature overnight then concentrated under vacuum. The residue was purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/10 to 1/4). Appropriate fractions were combined and evaporated and the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol HCOOH and MeCN (10% MeCN up to 55% over 11 min); Detection, UV 254 nm to afford 10.8 mg (8%) of methyl 3-(4-[2-[4-([8-[4-(4-chlorophenyl)-4-(hydroxymethyl)piperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-1H-pyrazol-1-yl]acetyl]piperazin-1-yl)propanoate; formic acid salt as an off-white solid. 1H NMR (400 MHz, DMSO-d6): □ 9.21 (s, 1H), 8.26 (s, 1H), 8.17 (d, J=6.4 Hz, 1H), 7.72 (s, 1H), 7.47-7.37 (m, 5H), 6.77 (t, J=7.2 Hz, 1H), 6.69 (d, J=8.0 Hz, 1H), 5.06 (s, 2H), 4.69 (s, 1H), 3.86-3.78 (m, 2H), 3.59 (s, 3H), 3.50-3.35 (m, 8H), 3.05-2.91 (m, 2H), 2.61-2.57 (m, 2H), 2.44-2.32 (m, 4H), 2.25-2.14 (m, 2H), 2.09-1.97 (m, 2H); LCMS (Method 6) RT=2.59 min, m/z=636.4 [M+H]+.
    • Example 1aa 4-([8-[(3aR,5R,6aS)-5-hydroxy-5-phenyl-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-292 in Table I)
  • Figure US20190233441A1-20190801-C01003
    Figure US20190233441A1-20190801-C01004
  • Step 1. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol) and octahydrocyclopenta[c]pyrrol-5-ol (86 mg, 0.68 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was concentrated and the residue was purified by flash chromatography on silica eluting with DCM on a gradient of MeOH (1/10 to 1/5). Appropriate fractions were combined and concentrated under vacuum to afford 300 mg of 4-[(8-[5-hydroxy-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a light yellow solid. LCMS (Method 8) RT=1.04 min, m/z=490.1 [M+H]+.
  • Figure US20190233441A1-20190801-C01005
  • Step 2. A mixture of 4-[(8-[5-hydroxy-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (280 mg, 0.57 mmol), 4-methylmorpholin-4-ium-4-olate (340 mg, 2.90 mmol) and rutheniumoylolate; tetrapropylazanium (200 mg, 0.57 mmol) in DCM (20 mL) was stirred at room temperature for 0.5 h. The resulting mixture was concentrated under vacuum and the residue purified by flash chromatography on silica gel eluting with DCM on a gradient of MeOH (1/10 to 1/3) to afford 130 mg (47%) of N-methyl-N-(1-methylpiperidin-4-yl) -4-[(8-[5-oxo-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo-[1,5-a]pyridin-2-yl)amino]benzamide as a light yellow solid. TLC: Rf=0.3; DCM/MeOH=5/1.
  • Figure US20190233441A1-20190801-C01006
  • Step 3. Phenyl magnesium chloride (2 M solution in THF, 0.45 mL, 0.9 mmol) was added dropwise to a solution of N-methyl-N-(1-methylpiperidin-4-yl)-4-[(8-[5-oxo-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]benzamide (110 mg, 0.23 mmol) in THF (10 mL) under nitrogen at 0° C. On complete addition, the reaction mixture was stirred at 0° C. for 0.5 h, quenched by the addition of MeOH (2 mL) and concentrated under vacuum. The residue was purified using a short pad of silica gel eluting with DCM on a gradient of MeOH (1/10 to 1/2). Appropriate fractions were combined and concentrated under vacuum. The crude product was purified by Prep-HPLC using the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol NH4HCO3 and MeCN (12% MeCN up to 56% over 13 min); Detection, UV 254 nm to afford 4.4 mg (3%) of 4-([8-[(3aR,5R,6aS)-5-hydroxy-5-phenyl-octahydrocyclopenta[c]pyrrol-2-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as an off white solid. 1H NMR (400 MHz, DMSO-d6): □ 9.76 (s, 1H), 8.20 (d, J=6.4 Hz, 1H), 7.72 (d, J=8.8 Hz, 2H), 7.50 (d, J=8.4 Hz, 2H), 7.34-7.30 (m, 4H), 7.22 (t, J=7.2 Hz, 1H), 6.89-6.86 (m, 1H), 6.54 (d, J=7.6 Hz, 1H), 5.09 (s, 1H), 3.89-3.84 (m, 2H), 3.73-3.69 (m, 2H), 3.01-2.89 (m, 2H), 2.88-2.72 (m, 5H), 2.35-2.24 (m, 3H), 2.15-2.08 (m, 3H), 2.00-1.94 (m, 2H), 1.89-1.66 (m, 4H), 1.62-1.54 (m, 2H); LCMS (Method 8) RT=2.22 min, m/z=566.1 [M+H]+.
    • Example 1ab 4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidine-4-carboxylic acid (Example 1-269 in Table I)
  • Figure US20190233441A1-20190801-C01007
  • A mixture of 4-([8-[4-(4-chlorophenyl)-4-cyanopiperidin-1-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (100 mg, 0.17 mmol) in 12 N aqueous HCl (4 mL) and acetic (1 mL) was heated at 100° C. for 8 h then allowed to cool to room temperature. The reaction mixture was evaporated; MeOH (10 mL) and DIPEA (1 mL) were added. The resulting mixture was concentrated under vacuum and the residue was purified by Prep-HPLC using the following conditions: Column, XBridge Shield RP18 OBD Column, 19*150 mm 5 um 13 nm; mobile phase, Water with 10 mmol HCOOH and MeCN (10% MeCN up to 55% over 11 min); Detection, UV 254 nm to afford 4-(4-chlorophenyl)-1-[2-([4-[methyl(1-methylpiperidin-4-yl)carbamoyl]phenyl]amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]piperidine-4-carboxylic acid; formic acid salt as an off white solid (11.9 mg, 10%). 1H NMR (400 MHz, DMSO-d6): □9.90 (s, 1H), 8.33 (t, J=3.6 Hz, 1H), 8.20 (s, 1H), 7.73 (d, J=8.8 Hz, 2H), 7.50 (d, J=8.8 Hz, 2H), 7.44 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.4 Hz, 2H), 6.92-6.86 (m, 2H), 4.08-4.04 (m, 2H), 3.04 (t, J=11.2 Hz, 2H), 2.82 (s, 3H), 2.81 (br, 2H), 2.60-2.51 (m, 3H), 2.13 (s, 3H), 2.00 (t, J=10.2 Hz, 2H), 1.91-1.70 (m, 4H), 1.60-1.57 (m, 2H); LCMS (Method 6) RT=1.61 min, m/z=602.4 [M+H]+.
    • Example 1ac N-methyl-4-([8-[4-methyl-4-(N-methylbenzenesulfonamido)cyclohexyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-(1-methylpiperidin-4-yl)benzamide (Example 1-261 in Table I)
  • Figure US20190233441A1-20190801-C01008
    Figure US20190233441A1-20190801-C01009
  • Step 1: Benzenesulfonyl chloride (329 mg, 1.86 mmol) was added dropwise to a solution of tert-butyl-4-amino-4-methylpiperidine-1-carboxylate (400 mg, 1.87 mmol) and DIPEA (1 mL, 6.05 mmol) in DCM (50 mL) at room temperature. The resulting solution was stirred for 2 h then concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with EtOAc/petroleum ether (1:5) to afford 540 mg (82%) of tert-butyl-4-benzene-sulfonamido-4-methylpiperidine-1-carboxylate as a white solid. LCMS (Method 12) RT=1.19 min, m/z=355.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01010
  • Step 1. A mixture of tert-butyl 4-benzenesulfonamido-4-methylpiperidine-1-carboxylate (350 mg, 0.99 mmol) and sodium hydride (80 mg, 3.33 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 20 min before addition of iodomethane (560 mg, 3.95 mmol). The resulting solution was stirred for 2 h at room temperature and then quenched by the addition of H2O (50 mL). The resulting solution was extracted with EtOAc (100 mL) and the layers separated. The organic phase was dried over sodium sulfate and concentrated under vacuum to afford 350 mg (96%) of tert-butyl-4-methyl-4-(N-methylbenzenesulfonamido)piperidine-1-carboxylate as a white solid. LCMS (Method 7) RT=1.57 min, m/z=369.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01011
  • Step 2. Using similar boc deprotection conditions described for Example 1r, step 2, N-methyl-N-(4-methylpiperidin-4-yl)benzenesulfonamide hydrochloride (230 mg, 79%) was prepared from tert-butyl-4-methyl-4-(N-methylbenzene-sulfonamido)piperidine-1-carboxylate (350 mg). LCMS (Method 9) RT=1.05 min, m/z=269.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01012
  • Step 3. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (150 mg, 0.34 mmol) and N-methyl-N-(4-methylpiperidin-4-yl)benzenesulfonamide hydrochloride (150 mg, 0.49 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was allowed to cool to room temperature and the precipitated solid was removed by filtration. The filtrate was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (100/6) to afford 85 mg (40%) of N-methyl-4-([8-[4-methyl-4-(N-methylbenzenesulfonamido)-cyclohexyl]-[1,2,4]triazolo-[1,5-a]pyridin-2-yl]amino)-N-(1-methylpiperidin-4-yl)benzamide as a white solid. 1H NMR (300 MHz, DMSO-d6): □ 9.85 (s, 1H), 8.33 (d, J=6.0 Hz, 1H), 7.87 (dd, J=1.2, 7.8, Hz, 1H),7.72-7.57 (m, 5H), 7.33(d, J=8.7 Hz, 2H), 6.89 (t, J=7.2 Hz, 1H), 6.77 (d, J=7.2 Hz, 1H), 3.57-3.54 (m, 2H), 3.40-3.28 (m, 3H), 2.88 (s, 3H), 2.82-2.71 (m, 5H), 2.28-2.49 (m, 2H), 2.11 (s, 3H), 1.97-1.70 (m,6H), 1.62-1.51 (m, 2H), 1.23 (s, 3H); LCMS (Method 11) RT=1.59 min, m/z=631.2 [M+H]+.
    • Example 1ad: 4-[[8-(4-acetamido-4-methylpiperidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 1-260 in Table I)
  • Figure US20190233441A1-20190801-C01013
    • Error! Objects Cannot be Created From Editing Field Codes
  • Step 1. Acetyl chloride (350 mg, 4.46 mmol) was added dropwise to a solution of tert-butyl 4-amino-4-methylpiperidine-1-carboxylate (600 mg, 2.80 mmol) and DIPEA (2 mL, 12.10 mmol) in DCM (50 mL). The reaction mixture was stirred at room temperature for 2 h then washed with H2O (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford 850 mg of tert-butyl-4-acetamido-4-methylpiperidine-1-carboxylate as brown oil. LCMS (Method 7) RT=1.26 min, m/z=257.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01014
  • Step 2. Using the boc deprotection method described in Example 1r, step 2, N-(4-methylpiperidin-4-yl)acetamide as a brown oil (350 mg) was prepared from tert-butyl-4-acetamido-4-methylpiperidine-1-carboxylate (850 mg). LCMS (Method 6) RT=0.69 min, m/z=157.0 [M+H]+.
  • Figure US20190233441A1-20190801-C01015
  • Step 3. 4-([8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (200 mg, 0.45 mmol) and N-(4-methylpiperidin-4-yl)acetamide (106 mg, 0.68 mmol) were coupled following the procedure detailed in Example 1j, step 3. The reaction mixture was allowed to cool to room temperature and the precipitated solid removed by filtration. The filtrate was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (100/7) to afford 45 mg (19%) of 4-[[8-(4-acetamido-4-methylpiperidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a white solid.1H NMR (400 MHz, DMSO-d6): □ 9.85 (s, 1H), 8.32 (d, J=5.6 Hz, 1H), 7.73 (d, J=8.8 Hz, 2H), 7.73 (s, 1H), 6.89 (t, J=7.2 Hz, 1H), 6.83 (d, J=7.6 Hz, 1H), 3.78-3.75 (m, 2H), 3.33 (s, 1H), 3.12 (t, J=10.2 Hz, 2H), 2.82-2.75 (m, 5H), 2.26 (d, J=13.6 Hz, 2H), 2.11 (s, 3H), 1.83-1.72 (m, 6H), 1.57-1.56 (m, 4H), 1.34 (s, 3H); LCMS (Method 8) RT=1.69 min, m/z=519.2 [M+H]+.
  • The immediately preceding Examples may be modified via conventionally known chemistries to provide access to other compounds that fall within the scope of the present invention, such as compounds of Formula 0, non-limiting examples of which are seen in Table I.
  • TABLE I
    Figure US20190233441A1-20190801-C01016
    Ex R2
    Figure US20190233441A1-20190801-C01017
         		LCMS(ESI) m/z [M + H+]
    1-1 
    Figure US20190233441A1-20190801-C01018
    Figure US20190233441A1-20190801-C01019
         		538
    1-2 
    Figure US20190233441A1-20190801-C01020
         		″ 546
    1-3 
    Figure US20190233441A1-20190801-C01021
         		″ 464
    1-4 
    Figure US20190233441A1-20190801-C01022
         		″ 522
    1-5 
    Figure US20190233441A1-20190801-C01023
         		″ 554
    1-6 
    Figure US20190233441A1-20190801-C01024
         		″ 478
    1-7 
    Figure US20190233441A1-20190801-C01025
         		″ 554
    1-8 
    Figure US20190233441A1-20190801-C01026
         		″ 478
    1-9 
    Figure US20190233441A1-20190801-C01027
         		″ 505
    1-10 
    Figure US20190233441A1-20190801-C01028
         		″ 491
    1-11 
    Figure US20190233441A1-20190801-C01029
         		″ 473
    1-12 
    Figure US20190233441A1-20190801-C01030
         		″ 448
    1-13 
    Figure US20190233441A1-20190801-C01031
         		″ 525
    1-14 
    Figure US20190233441A1-20190801-C01032
         		″ 536
    1-15 
    Figure US20190233441A1-20190801-C01033
         		″ 536
    1-16 
    Figure US20190233441A1-20190801-C01034
         		″ 542
    1-17 
    Figure US20190233441A1-20190801-C01035
         		″ 574
    1-18 
    Figure US20190233441A1-20190801-C01036
         		″ 574
    1-19 
    Figure US20190233441A1-20190801-C01037
         		″ 541
    1-20 
    Figure US20190233441A1-20190801-C01038
         		″ 541
    1-21 
    Figure US20190233441A1-20190801-C01039
         		″ 565
    1-22 
    Figure US20190233441A1-20190801-C01040
         		″ 565
    1-23 
    Figure US20190233441A1-20190801-C01041
         		″ 503
    1-24 
    Figure US20190233441A1-20190801-C01042
         		″ 505
    1-25 
    Figure US20190233441A1-20190801-C01043
         		″ 505
    1-26 
    Figure US20190233441A1-20190801-C01044
         		″ 594
    1-27 
    Figure US20190233441A1-20190801-C01045
         		″ 517
    1-28 
    Figure US20190233441A1-20190801-C01046
         		″ 519
    1-29 
    Figure US20190233441A1-20190801-C01047
         		″ 506
    1-30 
    Figure US20190233441A1-20190801-C01048
         		″ 581
    1-31 
    Figure US20190233441A1-20190801-C01049
         		″ 518
    1-32 
    Figure US20190233441A1-20190801-C01050
         		″ 519
    1-33 
    Figure US20190233441A1-20190801-C01051
         		″ 519
    1-34 
    Figure US20190233441A1-20190801-C01052
         		″ 560
    1-35 
    Figure US20190233441A1-20190801-C01053
         		″ 574
    1-36 
    Figure US20190233441A1-20190801-C01054
         		″ 568
    1-37 
    Figure US20190233441A1-20190801-C01055
         		″ 558
    1-38 
    Figure US20190233441A1-20190801-C01056
         		″ 582
    1-39 
    Figure US20190233441A1-20190801-C01057
         		″ 554
    1-40 
    Figure US20190233441A1-20190801-C01058
         		″ 570
    1-41 
    Figure US20190233441A1-20190801-C01059
         		″ 563
    1-42 
    Figure US20190233441A1-20190801-C01060
         		″ 559
    1-43 
    Figure US20190233441A1-20190801-C01061
         		″ 540
    1-44 
    Figure US20190233441A1-20190801-C01062
         		″ 629
    1-45 
    Figure US20190233441A1-20190801-C01063
         		″ 549
    1-46 
    Figure US20190233441A1-20190801-C01064
         		″ 496
    1-47 
    Figure US20190233441A1-20190801-C01065
    Figure US20190233441A1-20190801-C01066
         		532
    1-48  ″
    Figure US20190233441A1-20190801-C01067
         		572
    1-49  ″
    Figure US20190233441A1-20190801-C01068
         		588
    1-50  ″
    Figure US20190233441A1-20190801-C01069
         		588
    1-51  ″
    Figure US20190233441A1-20190801-C01070
         		644
    1-52  ″
    Figure US20190233441A1-20190801-C01071
         		614
    1-53  ″
    Figure US20190233441A1-20190801-C01072
         		586
    1-54  ″
    Figure US20190233441A1-20190801-C01073
         		572
    1-55  ″
    Figure US20190233441A1-20190801-C01074
         		572
    1-56  ″
    Figure US20190233441A1-20190801-C01075
         		586
    1-57  ″
    Figure US20190233441A1-20190801-C01076
         		568
    1-58  ″
    Figure US20190233441A1-20190801-C01077
         		568
    1-59  ″
    Figure US20190233441A1-20190801-C01078
         		572
    1-60  ″
    Figure US20190233441A1-20190801-C01079
         		572
    1-61  ″
    Figure US20190233441A1-20190801-C01080
         		588
    1-62  ″
    Figure US20190233441A1-20190801-C01081
         		546
    1-63  ″
    Figure US20190233441A1-20190801-C01082
         		568
    1-64  ″
    Figure US20190233441A1-20190801-C01083
         		568
    1-65  ″
    Figure US20190233441A1-20190801-C01084
         		588
    1-66  ″
    Figure US20190233441A1-20190801-C01085
         		614
    1-67  ″
    Figure US20190233441A1-20190801-C01086
         		626
    1-68  ″
    Figure US20190233441A1-20190801-C01087
         		594
    1-69  ″
    Figure US20190233441A1-20190801-C01088
         		590
    1-70  ″
    Figure US20190233441A1-20190801-C01089
         		588
    1-71  ″
    Figure US20190233441A1-20190801-C01090
         		617
    1-72  ″
    Figure US20190233441A1-20190801-C01091
         		608
    1-73  ″
    Figure US20190233441A1-20190801-C01092
         		666
    1-74  ″
    Figure US20190233441A1-20190801-C01093
         		665
    1-75  ″
    Figure US20190233441A1-20190801-C01094
         		572
    1-76  ″
    Figure US20190233441A1-20190801-C01095
         		572
    1-77  ″
    Figure US20190233441A1-20190801-C01096
         		618
    1-78  ″
    Figure US20190233441A1-20190801-C01097
         		659
    1-79  ″
    Figure US20190233441A1-20190801-C01098
         		651
    1-80  ″
    Figure US20190233441A1-20190801-C01099
         		602
    1-81  ″
    Figure US20190233441A1-20190801-C01100
         		586
    1-82  ″
    Figure US20190233441A1-20190801-C01101
         		617
    1-83  ″
    Figure US20190233441A1-20190801-C01102
         		608
    1-84  ″
    Figure US20190233441A1-20190801-C01103
         		576
    1-85  ″
    Figure US20190233441A1-20190801-C01104
         		582
    1-86  ″
    Figure US20190233441A1-20190801-C01105
         		574
    1-87  ″
    Figure US20190233441A1-20190801-C01106
         		560
    1-88  ″
    Figure US20190233441A1-20190801-C01107
         		560
    1-89  ″
    Figure US20190233441A1-20190801-C01108
         		572
    1-90  ″
    Figure US20190233441A1-20190801-C01109
         		528 (M + H − H2O)
    1-91  ″
    Figure US20190233441A1-20190801-C01110
         		604
    1-92  ″
    Figure US20190233441A1-20190801-C01111
         		532
    1-93  ″
    Figure US20190233441A1-20190801-C01112
         		604
    1-94  ″
    Figure US20190233441A1-20190801-C01113
         		604
    1-95  ″
    Figure US20190233441A1-20190801-C01114
         		590
    1-96  ″
    Figure US20190233441A1-20190801-C01115
         		603
    1-97  ″
    Figure US20190233441A1-20190801-C01116
         		589
    1-98  ″
    Figure US20190233441A1-20190801-C01117
         		590
    1-99  ″
    Figure US20190233441A1-20190801-C01118
         		588
    1-100 ″
    Figure US20190233441A1-20190801-C01119
         		588
    1-101 ″
    Figure US20190233441A1-20190801-C01120
         		576
    1-102 ″
    Figure US20190233441A1-20190801-C01121
         		574
    1-103 ″
    Figure US20190233441A1-20190801-C01122
         		574
    1-104 ″
    Figure US20190233441A1-20190801-C01123
         		574
    1-105 ″
    Figure US20190233441A1-20190801-C01124
         		560
    1-106 ″
    Figure US20190233441A1-20190801-C01125
         		560
    1-107 ″
    Figure US20190233441A1-20190801-C01126
         		548
    1-108 ″
    Figure US20190233441A1-20190801-C01127
         		534
    1-109 ″
    Figure US20190233441A1-20190801-C01128
         		582
    1-110 ″
    Figure US20190233441A1-20190801-C01129
         		608
    1-111 ″
    Figure US20190233441A1-20190801-C01130
         		568
    1-112 ″
    Figure US20190233441A1-20190801-C01131
         		609
    1-113 ″
    Figure US20190233441A1-20190801-C01132
         		639 (M + H − H2O)
    1-114 ″
    Figure US20190233441A1-20190801-C01133
         		623
    1-115 ″
    Figure US20190233441A1-20190801-C01134
         		582
    1-116 ″
    Figure US20190233441A1-20190801-C01135
         		626
    1-117 ″
    Figure US20190233441A1-20190801-C01136
         		629
    1-118 ″
    Figure US20190233441A1-20190801-C01137
         		644
    1-119 ″
    Figure US20190233441A1-20190801-C01138
         		645
    1-120 ″
    Figure US20190233441A1-20190801-C01139
         		618
    1-121 ″
    Figure US20190233441A1-20190801-C01140
         		622
    1-122 ″
    Figure US20190233441A1-20190801-C01141
         		623
    1-123 ″
    Figure US20190233441A1-20190801-C01142
         		623
    1-124 ″
    Figure US20190233441A1-20190801-C01143
         		608
    1-125 ″
    Figure US20190233441A1-20190801-C01144
         		616
    1-126 ″
    Figure US20190233441A1-20190801-C01145
         		609
    1-127 ″
    Figure US20190233441A1-20190801-C01146
         		602
    1-128 ″
    Figure US20190233441A1-20190801-C01147
         		600
    1-129 ″
    Figure US20190233441A1-20190801-C01148
         		602
    1-130 ″
    Figure US20190233441A1-20190801-C01149
         		602
    1-131 ″
    Figure US20190233441A1-20190801-C01150
         		588
    1-132 ″
    Figure US20190233441A1-20190801-C01151
         		600
    1-133 ″
    Figure US20190233441A1-20190801-C01152
         		590
    1-134 ″
    Figure US20190233441A1-20190801-C01153
         		582
    1-135 ″
    Figure US20190233441A1-20190801-C01154
         		582
    1-136 ″
    Figure US20190233441A1-20190801-C01155
         		586
    1-137 ″
    Figure US20190233441A1-20190801-C01156
         		586
    1-138 ″
    Figure US20190233441A1-20190801-C01157
         		568
    1-139 ″
    Figure US20190233441A1-20190801-C01158
         		603
    1-140 ″
    Figure US20190233441A1-20190801-C01159
         		582
    1-141 ″
    Figure US20190233441A1-20190801-C01160
         		574
    1-142 ″
    Figure US20190233441A1-20190801-C01161
         		594
    1-143 ″
    Figure US20190233441A1-20190801-C01162
         		616
    1-144 ″
    Figure US20190233441A1-20190801-C01163
         		608
    1-145 ″
    Figure US20190233441A1-20190801-C01164
         		622
    1-146 ″
    Figure US20190233441A1-20190801-C01165
         		608
    1-147 ″
    Figure US20190233441A1-20190801-C01166
         		594
    1-148 ″
    Figure US20190233441A1-20190801-C01167
         		610
    1-149 ″
    Figure US20190233441A1-20190801-C01168
         		608
    1-150 ″
    Figure US20190233441A1-20190801-C01169
         		693
    1-151 ″
    Figure US20190233441A1-20190801-C01170
         		652
    1-152 ″
    Figure US20190233441A1-20190801-C01171
         		603
    1-153 ″
    Figure US20190233441A1-20190801-C01172
         		679
    1-154 ″
    Figure US20190233441A1-20190801-C01173
         		588
    1-155 ″
    Figure US20190233441A1-20190801-C01174
         		608
    1-156 ″
    Figure US20190233441A1-20190801-C01175
         		622
    1-157 ″
    Figure US20190233441A1-20190801-C01176
         		608
    1-158 ″
    Figure US20190233441A1-20190801-C01177
         		622
    1-159 ″
    Figure US20190233441A1-20190801-C01178
         		582
    1-160 ″
    Figure US20190233441A1-20190801-C01179
         		568
    1-161 ″
    Figure US20190233441A1-20190801-C01180
         		568
    1-162 ″
    Figure US20190233441A1-20190801-C01181
         		568
    1-163 ″
    Figure US20190233441A1-20190801-C01182
         		603
    1-164 ″
    Figure US20190233441A1-20190801-C01183
         		574
    1-165 ″
    Figure US20190233441A1-20190801-C01184
         		629
    1-166 ″
    Figure US20190233441A1-20190801-C01185
         		560
    1-167 ″
    Figure US20190233441A1-20190801-C01186
         		585
    1-168 ″
    Figure US20190233441A1-20190801-C01187
         		572
    1-169 ″
    Figure US20190233441A1-20190801-C01188
         		618
    1-170 ″
    Figure US20190233441A1-20190801-C01189
         		588
    1-171 ″
    Figure US20190233441A1-20190801-C01190
         		636
    1-172 ″
    Figure US20190233441A1-20190801-C01191
         		616
    1-173 ″
    Figure US20190233441A1-20190801-C01192
         		574
    1-174 ″
    Figure US20190233441A1-20190801-C01193
         		631
    1-175 ″
    Figure US20190233441A1-20190801-C01194
         		506
    1-176 ″
    Figure US20190233441A1-20190801-C01195
         		532
    1-177 ″
    Figure US20190233441A1-20190801-C01196
         		532
    1-178 ″
    Figure US20190233441A1-20190801-C01197
         		561
    1-179 ″
    Figure US20190233441A1-20190801-C01198
         		546
    1-180 ″
    Figure US20190233441A1-20190801-C01199
         		546
    1-181 ″
    Figure US20190233441A1-20190801-C01200
         		546
    1-182 ″
    Figure US20190233441A1-20190801-C01201
         		546
    1-183 ″
    Figure US20190233441A1-20190801-C01202
         		560
    1-184 ″
    Figure US20190233441A1-20190801-C01203
         		560
    1-185 ″
    Figure US20190233441A1-20190801-C01204
         		560
    1-186 ″
    Figure US20190233441A1-20190801-C01205
         		574
    1-187 ″
    Figure US20190233441A1-20190801-C01206
         		575
    1-188 ″
    Figure US20190233441A1-20190801-C01207
         		562
    1-189 ″
    Figure US20190233441A1-20190801-C01208
         		518
    1-190 ″
    Figure US20190233441A1-20190801-C01209
         		558
    1-191 ″
    Figure US20190233441A1-20190801-C01210
         		532
    1-192 ″
    Figure US20190233441A1-20190801-C01211
         		546
    1-193 ″
    Figure US20190233441A1-20190801-C01212
         		560
    1-194 ″
    Figure US20190233441A1-20190801-C01213
         		520
    1-195 ″
    Figure US20190233441A1-20190801-C01214
         		546
    1-196 ″
    Figure US20190233441A1-20190801-C01215
         		562
    1-197 ″
    Figure US20190233441A1-20190801-C01216
         		558
    1-198 ″
    Figure US20190233441A1-20190801-C01217
         		546
    1-199 ″
    Figure US20190233441A1-20190801-C01218
         		572
    1-200 ″
    Figure US20190233441A1-20190801-C01219
         		546
    1-201 ″
    Figure US20190233441A1-20190801-C01220
         		572
    1-202 ″
    Figure US20190233441A1-20190801-C01221
         		560
    1-203 ″
    Figure US20190233441A1-20190801-C01222
         		544
    1-204 ″
    Figure US20190233441A1-20190801-C01223
         		546
    1-205 ″
    Figure US20190233441A1-20190801-C01224
         		558
    1-206 ″
    Figure US20190233441A1-20190801-C01225
         		546
    1-207 ″
    Figure US20190233441A1-20190801-C01226
         		572
    1-208 ″
    Figure US20190233441A1-20190801-C01227
         		572
    1-209 ″
    Figure US20190233441A1-20190801-C01228
         		572
    1-210 ″
    Figure US20190233441A1-20190801-C01229
         		572
    1-211 ″
    Figure US20190233441A1-20190801-C01230
         		586
    1-212 ″
    Figure US20190233441A1-20190801-C01231
         		586
    1-213 ″
    Figure US20190233441A1-20190801-C01232
         		586
    1-214 ″
    Figure US20190233441A1-20190801-C01233
         		586
    1-215 ″
    Figure US20190233441A1-20190801-C01234
         		600
    1-216 ″
    Figure US20190233441A1-20190801-C01235
         		600
    1-217 ″
    Figure US20190233441A1-20190801-C01236
         		600
    1-218 ″
    Figure US20190233441A1-20190801-C01237
         		600
    1-219 ″
    Figure US20190233441A1-20190801-C01238
         		600
    1-220 ″
    Figure US20190233441A1-20190801-C01239
         		616
    1-221 ″
    Figure US20190233441A1-20190801-C01240
         		602
    1-222 ″
    Figure US20190233441A1-20190801-C01241
         		616
    1-223 ″
    Figure US20190233441A1-20190801-C01242
         		600
    1-224 ″
    Figure US20190233441A1-20190801-C01243
         		558
    1-225 ″
    Figure US20190233441A1-20190801-C01244
         		602
    1-226 ″
    Figure US20190233441A1-20190801-C01245
         		586
    1-227 ″
    Figure US20190233441A1-20190801-C01246
         		586
    1-228 ″
    Figure US20190233441A1-20190801-C01247
         		586
    1-229 ″
    Figure US20190233441A1-20190801-C01248
         		602
    1-230 ″
    Figure US20190233441A1-20190801-C01249
         		602
    1-231 ″
    Figure US20190233441A1-20190801-C01250
         		602
    1-232 ″
    Figure US20190233441A1-20190801-C01251
         		544
    1-233 ″
    Figure US20190233441A1-20190801-C01252
         		586
    1-234 ″
    Figure US20190233441A1-20190801-C01253
         		558
    1-235 ″
    Figure US20190233441A1-20190801-C01254
         		558
    1-236 ″
    Figure US20190233441A1-20190801-C01255
         		572
    1-237 ″
    Figure US20190233441A1-20190801-C01256
         		544
    1-238 ″
    Figure US20190233441A1-20190801-C01257
         		544
    1-239 ″
    Figure US20190233441A1-20190801-C01258
         		574
    1-240 ″
    Figure US20190233441A1-20190801-C01259
         		558
    1-241 ″
    Figure US20190233441A1-20190801-C01260
         		558
    1-242 ″
    Figure US20190233441A1-20190801-C01261
         		574
    1-243 ″
    Figure US20190233441A1-20190801-C01262
         		574
    1-244 ″
    Figure US20190233441A1-20190801-C01263
         		588
    1-245 ″
    Figure US20190233441A1-20190801-C01264
         		630
    1-246
    Figure US20190233441A1-20190801-C01265
    Figure US20190233441A1-20190801-C01266
         		589
    1-247
    Figure US20190233441A1-20190801-C01267
         		″ 611
    1-248
    Figure US20190233441A1-20190801-C01268
         		″ 457
    1-249
    Figure US20190233441A1-20190801-C01269
         		″ 471
    1-250
    Figure US20190233441A1-20190801-C01270
         		″ 615
    1-251
    Figure US20190233441A1-20190801-C01271
         		″ 600
    1-252
    Figure US20190233441A1-20190801-C01272
         		″ 602
    1-253
    Figure US20190233441A1-20190801-C01273
         		″ 656
    1-254
    Figure US20190233441A1-20190801-C01274
         		″ 644
    1-255
    Figure US20190233441A1-20190801-C01275
         		″ 603
    1-256
    Figure US20190233441A1-20190801-C01276
         		″ 623
    1-257
    Figure US20190233441A1-20190801-C01277
         		″ 555
    1-258
    Figure US20190233441A1-20190801-C01278
         		″ 603
    1-259
    Figure US20190233441A1-20190801-C01279
         		″ 595
    1-260
    Figure US20190233441A1-20190801-C01280
         		″ 519
    1-261
    Figure US20190233441A1-20190801-C01281
         		″ 631
    1-262
    Figure US20190233441A1-20190801-C01282
         		″ 573
    1-263
    Figure US20190233441A1-20190801-C01283
         		″ 616
    1-264
    Figure US20190233441A1-20190801-C01284
         		″ 604
    1-265
    Figure US20190233441A1-20190801-C01285
         		″ 588
    1-266
    Figure US20190233441A1-20190801-C01286
         		″ 589
    1-267
    Figure US20190233441A1-20190801-C01287
         		″ 604
    1-268
    Figure US20190233441A1-20190801-C01288
         		″ 630
    1-269
    Figure US20190233441A1-20190801-C01289
         		″ 603
    1-270
    Figure US20190233441A1-20190801-C01290
         		″ 619
    1-271
    Figure US20190233441A1-20190801-C01291
    Figure US20190233441A1-20190801-C01292
         		657
    1-272 ″
    Figure US20190233441A1-20190801-C01293
         		603
    1-273 ″
    Figure US20190233441A1-20190801-C01294
         		617
    1-274 ″
    Figure US20190233441A1-20190801-C01295
         		587
    1-275 ″
    Figure US20190233441A1-20190801-C01296
         		587
    1-276 ″
    Figure US20190233441A1-20190801-C01297
         		623
    1-277 ″
    Figure US20190233441A1-20190801-C01298
         		619
    1-278 ″
    Figure US20190233441A1-20190801-C01299
         		619
    1-279 ″
    Figure US20190233441A1-20190801-C01300
         		609
    1-280 ″
    Figure US20190233441A1-20190801-C01301
         		629
    1-281 ″
    Figure US20190233441A1-20190801-C01302
         		659
    1-282 ″
    Figure US20190233441A1-20190801-C01303
         		659
    1-283 ″
    Figure US20190233441A1-20190801-C01304
         		547
    1-284 ″
    Figure US20190233441A1-20190801-C01305
         		583
    1-285 ″
    Figure US20190233441A1-20190801-C01306
         		619
    1-286 ″
    Figure US20190233441A1-20190801-C01307
         		605
    1-287 ″
    Figure US20190233441A1-20190801-C01308
         		597
    1-288 ″
    Figure US20190233441A1-20190801-C01309
         		609
    1-289 ″
    Figure US20190233441A1-20190801-C01310
         		649
    1-290 ″
    Figure US20190233441A1-20190801-C01311
         		637
    1-291 ″
    Figure US20190233441A1-20190801-C01312
         		579
    1-292
    Figure US20190233441A1-20190801-C01313
    Figure US20190233441A1-20190801-C01314
         		566
    1-293
    Figure US20190233441A1-20190801-C01315
         		″ 551
    1-294
    Figure US20190233441A1-20190801-C01316
    Figure US20190233441A1-20190801-C01317
         		595
    1-295
    Figure US20190233441A1-20190801-C01318
    Figure US20190233441A1-20190801-C01319
         		586
    1-296
    Figure US20190233441A1-20190801-C01320
    Figure US20190233441A1-20190801-C01321
         		632
    1-297
    Figure US20190233441A1-20190801-C01322
    Figure US20190233441A1-20190801-C01323
         		616
    1-298
    Figure US20190233441A1-20190801-C01324
    Figure US20190233441A1-20190801-C01325
         		616
    1-299
    Figure US20190233441A1-20190801-C01326
         		″ 630
    1-300
    Figure US20190233441A1-20190801-C01327
         		″ 644
    1-301
    Figure US20190233441A1-20190801-C01328
         		″ 617
    1-302
    Figure US20190233441A1-20190801-C01329
         		″ 581
    1-303
    Figure US20190233441A1-20190801-C01330
         		″ 617
    • Example 2a Tert-butyl 4-(2-((4-(methyl(1-methylpiperidin-4-yl)carbamoyl)phenyl)-amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5,6-dihydropyridine-1(2H)-carboxylate
  • Figure US20190233441A1-20190801-C01331
  • Step 1. To a solution of 4-((8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (2.5g, 5.1mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1.8, 6.12mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (360mg, 0.5 mmol) in dioxane (60 mL) was added saturated sodium carbonate (20 mL); then the reaction mixture was degassed and heated at 110° C. under nitrogen for 4 h. The reaction mixture was poured into water (50 mL) and the mixture was extracted with ethyl acetate (150 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and the filtrate was evaporated. The residue was purified on silica gel column (eluting with 2% to 5% methanol in dichloromethane) to give tert-butyl 4-(2-((4-(methyl(1-methylpiperidin-4-yl)carbamoyl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5,6-dihydropyridine-1(2H)-carboxylate (2 g, 72%) as a solid. 1H NMR (400 MHz, DMSO-d6) 9.92 (s, 1H), 8.68 (d, J=6.6 Hz, 1H), 7.71 (d, J=8.6 Hz, 2H), 7.50 (d, J=7.5 Hz, 1H), 7.31 (d, J=8.2 Hz, 2H), 7.02 (t, J=7.1 Hz, 1H), 4.17-4.00 (m, 3H), 3.65-3.49 (m, 2H), 3.14 (d, J=5.3 Hz, 2H), 2.79 (s, 5H), 2.61 (brs, 2H), 2.11 (brs, 2H), 1.78 (d, J=8.6 Hz, 1H), 1.56 (d, J=10.4 Hz, 2H), 1.42 (s, 9H), MS (Method 4): m/z 546.1 [M+H1]+.
  • Figure US20190233441A1-20190801-C01332
  • Step 2. A mixture of tert-butyl 4-(2-((4-(methyl(1-methylpiperidin-4-yl)carbamoyl)phenyl) amino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1.7 g, 3.1 mmol) in methanolic hydrochloride solution (4 M, 10 mL) was stirred at room temperature for 1.5 h. The solvent was evaporated to afford 2.3 g of the hydrochloride salt of N-methyl-N-(1-methylpiperidin-4-yl)-4-((8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)benzamide; bis-hydrochloride salt. 1H NMR (400MHz, DMSO-d6): 10.00 (s, 1H), 9.47 (brs, 1H), 8.74 (d, J=6.6 Hz, 1H), 7.74 (d, J=8.6 Hz, 2H), 7.59 (d, J=7.5 Hz, 1H), 7.46 (brs, 1H), 7.37 (d, J=8.4 Hz, 2H), 7.07 (t, J=7.2 Hz, 1H), 3.49-3.28 (m, 4H), 2.86-2.80 (m, 5H), 2.65 (brs, 2H), 2.21 (d, J=11.9 Hz, 2H), 1.89 (s, 5H), 1.81 (d, J=12.6 Hz, 2H); LCMS (Method 4) m/z 446.1 [M+H]+.
  • Figure US20190233441A1-20190801-C01333
  • Step 3. |To a mixture of N-methyl-N-(1-methylpiperidin-4-yl)-4-((8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)benzamide; bis-hydrochloride salt (100 mg, 0.224 mmol) and Et3N (75 mg, 0.448 mmol) in dichloromethane (5 mL) was added dropwise cyclopropanecarbonyl chloride (26 mg, 0.248 mmol) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred 0.5 h. MeOH (1 ml) was added and the reaction mixture was concentrated. The residue was purified by prep-HPLC to give the final compound (Example 2-409, Table II) (40 mg, 36.4% yield). 1H NMR (400 MHz, DMSO-d6) □⊏9.95 (s, 1H), 8.72-8.71 (m, 1H), ␣7.75 (d, J=8.4 Hz,2H), ␣7.55 (d, J=7.2 Hz, 1H),7.44-7.33 (m,3H), ␣7.06 (t, J=6.8 Hz, 1H), 4.52 (s, 1H), □□□⊏□(s, 2H), 3.95 (s, 2H), □3.75 (s, 1H), 2.82-2.75 (m, 6H), □2.62 (s, 1H), 2.12-2.02 (m, 5H), ⊏1.81 (d, J=7.2Hz, 4H), □⊏□□⊐ (d, J=8.8 Hz, 2H) 0.78- 0.73 (m, 4H). LCMS (Method 4): RT=0.711 min, m/z: 514.1 (M+H+).
    • Example 2b 4-{8-[1-(4,4,4-Trifluoro-butyryl)-1,2,3,6-tetrahydro-pyridin-4-yl]-[1,2,4]triazolo[1,5a]pyridin-2-ylamino}-benzoic acid
  • Figure US20190233441A1-20190801-C01334
  • To a suspension of 4-[8-(1,2,3,6-tetrahydro-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid trifluoroacetic acid salt (5.00 g, 11.15 mmol) in dichloromethane (80 mL) was added triethylamine (5.13 mL, 36.80 mmol) and the reaction cooled to 0° C. To the reaction mixture was added a solution of 4,4,4-trifluoro-butyric acid (1.88 g, 11.71 mmol) in dichloromethane (20 mL). The resultant reaction mixture was warmed to room temperature and stirred for 18 hours before the further addition of a solution of 4,4,4-trifluoro-butyric acid (1.88 g, 11.71 mmol) in dichloromethane (5 mL) and stirred for 5 hours at room temperature. The reaction was quenched with water then diluted with a mixture of dichloromethane/water/acetonitrile. The suspension was loaded onto a SCX-2 cartridge and eluted with a mixture of dichloromethane/methanol/water/acetonitrile. The solution was concentrated in vacuo giving the title compound as a triethylamine salt. The salt was suspended in dioxane (160 mL) and water (40 mL) before being treated with SCX-2 resin (50 g). The mixture was stirred for 20 minutes before the suspension was filtered and the filtrate concentrated in vacuo. The resultant residue was taken up into 1M NaOH and washed with ethyl acetate (×3) then diethyl ether. The yellow aqueous phase was acidified with 1M HCl to pH 5, forming a precipitate. The precipitate was collected by filtration and washed with water then diethyl ether before being dried under reduced pressure. This gave the title compound as an off white solid (3.73 g, 73%). LCMS (Method 1) [M+H]+460.3, RT=3.14 min. 1H NMR (400 MHz, DMSO-d6) δ 10.21 (s, 1H), 8.75 (dd, J=6.5, 1.1 Hz, 1H), 7.90 (d, J=8.6 Hz, 2H), 7.79 (dd, J=8.9, 2.3 Hz, 2H), 7.55 (t, J=7.6 Hz, 1H), 7.44-7.35 (m, 1H), 7.08 (t, J=7.1 Hz, 1H), 4.29 (dd, J=26.4, 3.5 Hz, 2H), 3.74 (dt, J=11.1, 5.7 Hz, 2H), 2.78-2.50 (m, 6H).
    • Example 2c 4-[2-(4-Carboxy-phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid ethyl ester
  • Figure US20190233441A1-20190801-C01335
  • To a suspension of 4-[8-(1,2,3,6-tetrahydro-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid trifluoroacetic acid salt (10.00 g, 22.3 mmol) in dichloromethane (100 mL) was added N,N-diisopropylethylamine (19 mL, 111.5 mmol) and the reaction cooled to 0° C. To the reaction mixture was added a solution of ethyl chloroformate (2.4 g, 22.3 mmol) dropwise over 5 minutes. The resultant mixture was stirred at 0° C. for 1 h then evaporated under reduced pressure. The resultant residue was quenched with water and the resultant solid collected by filtration. The solid was washed with water, methanol and diethyl ether and left to air dry. The solid was purified by flash column chromatography on silica eluting with toluene on a gradient of acetic acid (10-20%). Appropriate fractions were collected and evaporated to afford a solid. The solid was triturated with methanol then diethyl ether to afford a white solid (6.2 g, 68%). 1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 10.17 (s, 1H), 8.73 (dd, J=6.5, 1.1 Hz, 1H), 7.92-7.87 (m, 2H), 7.81-7.76 (m, 2H), 7.54 (t, dd =7.4, 1.0 Hz, 1H), 7.34 (brs, 1H), 7.07 (dd, J=7.5, 7.5 Hz, 1H), 4.18 (brs, 2H), 4.10 (dt, J=7.0, 7.0 Hz, 2H), 3.65 (t, J=5.6 Hz, 2H), 2.68-2.62 (m, 2H), 1.23 (t, J=7.1 Hz, 3H).
    • General Method For Preparation of Amides
  • Figure US20190233441A1-20190801-C01336
    • Example 2d Ethyl 4-[2-[4-[3-(methylamino)azetidine-1-carbonyl]anilino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-3,6-dihydro-2H-pyridine-1-carboxylate
  • A solution of 4-[[8-(1-ethoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzoic acid (30 mg, 0.074 mmol, 1.0 equiv), tert-butyl azetidine-3-ylmethylcarbamate HCl (33 mg, 0.15 mmol, 2.0 equiv), HATU (42 mg, 0.11 mmol, 1.5 equiv) and N,N-diisopropylethylamine (65 uL, 0.37 mmol, 5.0 equiv) in DMF (1.0 mL) was stirred at 50° C. overnight. The reaction mixture was concentrated under vacuum. A solution of crude product in dichloromethane (1 mL) was mixed with trifluoroacetic acid (56 uL, 0.74 mmol, 10 equiv) and stirred at 50° C. overnight. The reaction was concentrated under vacuum and the crude product was purified by Prep-HPLC (Column, Gemini C18 100×30 mm; mobile phase, CH3CN:NH4OH/H2O (10 mmol/L)=5%-85%, 10 min; flow rate, 70 mL/min; Detector, UV 254 nm) to give 5.7 mg (16%) of Ethyl 4-[2-[4-[3-(methylamino)azetidine-1-carbonyl]anilino]-[1,2,4]triazolo[1,5-a]pyridin-8-yl]-3,6-dihydro-2H-pyridine-1-carboxylate as an off white solid, (Example 2-55, Table II). 1H NMR (400 MHz, DMSO-d6) δ 10.01 (s, 1H), 8.71 (dd, J=6.5, 1.1 Hz, 1H), 7.78-7.71 (m, 2H), 7.65-7.57 (m, 2H), 7.53 (d, J=7.4 Hz, 1H), 7.32 (s, 1H), 7.06 (t, J=7.0 Hz, 1H), 4.43 (s, 1H), 4.18 (s, 2H), 4.10 (q, J=7.0 Hz, 2H), 3.98 (s, 1H), 3.65 (t, J=5.7 Hz, 2H), 3.48 (s, 1H), 3.40-3.23 (m, 1H), 3.20-3.14 (m, 1H), 2.68-2.62 (m, 2H), 2.21 (s, 3H), 1.22 (t, J=7.1 Hz, 3H). LCMS (method 5): Found 476.3 [M+H]+ Rt 3.8 min).
    • Example 2e 4-([8-[1-(1-cyanopropan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide (Example 2-482 in Table II)
  • Figure US20190233441A1-20190801-C01337
  • A mixture of triethylamine (49.96 mg, 0.494 mmol), N-methyl-N-(1-methylpiperidin-4-yl)-4-[[8-(1,2,3,6-tetrahydropyridin-4-yl)-[1,2,4]-triazolo[1,5-a]pyridin-2-yl]amino]benzamide (110 mg, 0.247 mmol), (2E)-but-2-enenitrile (33 mg, 0.494 mmol) in propane-1,2,3-triol (5 mL) was heated at 80° C. for 14 h. The resulting mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel eluting with DCM/MeOH (10/1) to afford 15.6 mg (12%) of 4-([8-[1-(1-cyanopropan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amino)-N-methyl-N-(1-methylpiperidin-4-yl)benzamide as a light yellow solid. 1H NMR (300 MHz, DMSO-d6): δ 9.94 (s, 1H), 8.68 (d, J=6.0 Hz, 1H), 7.72 (d, J=8.7 Hz, 2H), 7.49 (d, J=7.2 Hz, 1H), 7.42 (s, 1H), 7.32 (d, J=8.7 Hz, 2H), 7.06-7.01 (m, 1H), 3.32-3.09 (m, 2H), 2.82-2.76 (m, 1H), 2.74-2.68 (m, 9H), 2.66-2.62 (m, 2H), 2.54-2.51 (m, 1H), 2.28-2.27 (m, 3H), 1.80-1.59 (m, 4H), 1.56-1.53 (m, 2H), 1.16-1.14 (m, 3H). LCMS (Method 7) RT=2.48 min, m/z=513.0 [M+H]−.
  • The immediately preceding Examples may be modified via conventionally known chemistries to provide access to other compounds that fall within the scope of the present invention, such as compounds of Formula 0, non-limiting examples of which are seen in Table II.
  • TABLE II
    Figure US20190233441A1-20190801-C01338
    Ex
    Figure US20190233441A1-20190801-C01339
         		R8 n LCMS (ESI) m/z [M + H+]
    2-1
    Figure US20190233441A1-20190801-C01340
    Figure US20190233441A1-20190801-C01341
         		1 518
    2-2 ″
    Figure US20190233441A1-20190801-C01342
         		1 530
    2-3 ″
    Figure US20190233441A1-20190801-C01343
         		1 546
    2-4 ″
    Figure US20190233441A1-20190801-C01344
         		1 528
    2-5 ″
    Figure US20190233441A1-20190801-C01345
         		1 554
    2-6 ″
    Figure US20190233441A1-20190801-C01346
         		1 485
    2-7 ″
    Figure US20190233441A1-20190801-C01347
         		1 529
    2-8 ″
    Figure US20190233441A1-20190801-C01348
         		1 536
    2-9 ″
    Figure US20190233441A1-20190801-C01349
         		1 518
    2-10 ″
    Figure US20190233441A1-20190801-C01350
         		1 545
    2-11
    Figure US20190233441A1-20190801-C01351
    Figure US20190233441A1-20190801-C01352
         		1 548
    2-12
    Figure US20190233441A1-20190801-C01353
         		″ 1 518
    2-13
    Figure US20190233441A1-20190801-C01354
         		″ 1 518
    2-14
    Figure US20190233441A1-20190801-C01355
         		″ 1 512
    2-15
    Figure US20190233441A1-20190801-C01356
         		″ 1 538
    2-16
    Figure US20190233441A1-20190801-C01357
         		″ 1 566
    2-17
    Figure US20190233441A1-20190801-C01358
         		″ 1 567
    2-18
    Figure US20190233441A1-20190801-C01359
         		″ 1 560
    2-19
    Figure US20190233441A1-20190801-C01360
         		″ 1 553
    2-20
    Figure US20190233441A1-20190801-C01361
         		″ 1 534
    2-21
    Figure US20190233441A1-20190801-C01362
         		″ 1 558
    2-22
    Figure US20190233441A1-20190801-C01363
         		″ 1 595
    2-23
    Figure US20190233441A1-20190801-C01364
         		″ 1 532
    2-24
    Figure US20190233441A1-20190801-C01365
         		″ 1 490
    2-25
    Figure US20190233441A1-20190801-C01366
         		″ 1 546
    2-26
    Figure US20190233441A1-20190801-C01367
         		″ 1 546
    2-27
    Figure US20190233441A1-20190801-C01368
         		″ 1 530
    2-28
    Figure US20190233441A1-20190801-C01369
    Figure US20190233441A1-20190801-C01370
         		1 568
    2-29
    Figure US20190233441A1-20190801-C01371
         		″ 1 596
    2-30
    Figure US20190233441A1-20190801-C01372
         		″ 1 558
    2-31
    Figure US20190233441A1-20190801-C01373
         		″ 1 516
    2-32
    Figure US20190233441A1-20190801-C01374
         		″ 1 571
    2-33
    Figure US20190233441A1-20190801-C01375
         		″ 1 558
    2-34
    Figure US20190233441A1-20190801-C01376
         		″ 1 596
    2-35
    Figure US20190233441A1-20190801-C01377
         		″ 1 554
    2-36
    Figure US20190233441A1-20190801-C01378
         		″ 1 556
    2-37
    Figure US20190233441A1-20190801-C01379
         		″ 1 570
    2-38
    Figure US20190233441A1-20190801-C01380
         		″ 1 568
    2-39
    Figure US20190233441A1-20190801-C01381
         		″ 1 584
    2-40
    Figure US20190233441A1-20190801-C01382
         		″ 1 568
    2-41
    Figure US20190233441A1-20190801-C01383
         		″ 1 564
    2-42
    Figure US20190233441A1-20190801-C01384
         		″ 1 564
    2-43
    Figure US20190233441A1-20190801-C01385
    Figure US20190233441A1-20190801-C01386
         		1 584
    2-44
    Figure US20190233441A1-20190801-C01387
    Figure US20190233441A1-20190801-C01388
         		1 543
    2-45
    Figure US20190233441A1-20190801-C01389
    Figure US20190233441A1-20190801-C01390
         		1 598
    2-46
    Figure US20190233441A1-20190801-C01391
         		″ 1 596
    2-47
    Figure US20190233441A1-20190801-C01392
         		″ 1 598
    2-48
    Figure US20190233441A1-20190801-C01393
         		″ 1 570
    2-49
    Figure US20190233441A1-20190801-C01394
         		″ 1 610
    2-50
    Figure US20190233441A1-20190801-C01395
         		″ 1 618
    2-51
    Figure US20190233441A1-20190801-C01396
         		″ 1 647
    2-52
    Figure US20190233441A1-20190801-C01397
    Figure US20190233441A1-20190801-C01398
         		1 485
    2-53 ″
    Figure US20190233441A1-20190801-C01399
         		1 558
    2-54 ″
    Figure US20190233441A1-20190801-C01400
         		1 544
    2-55
    Figure US20190233441A1-20190801-C01401
    Figure US20190233441A1-20190801-C01402
         		1 476
    2-56
    Figure US20190233441A1-20190801-C01403
         		″ 1 534
    2-57
    Figure US20190233441A1-20190801-C01404
         		″ 1 533
    2-58
    Figure US20190233441A1-20190801-C01405
         		″ 1 476
    2-59
    Figure US20190233441A1-20190801-C01406
         		″ 1 526
    2-60
    Figure US20190233441A1-20190801-C01407
         		″ 1 504
    2-61
    Figure US20190233441A1-20190801-C01408
         		″ 1 532
    2-62
    Figure US20190233441A1-20190801-C01409
         		″ 1 538
    2-63
    Figure US20190233441A1-20190801-C01410
         		″ 1 588
    2-64
    Figure US20190233441A1-20190801-C01411
         		″ 1 589
    2-65
    Figure US20190233441A1-20190801-C01412
         		″ 1 546
    2-66
    Figure US20190233441A1-20190801-C01413
         		″ 1 546
    2-67
    Figure US20190233441A1-20190801-C01414
         		″ 1 552
    2-68
    Figure US20190233441A1-20190801-C01415
         		″ 1 516
    2-69
    Figure US20190233441A1-20190801-C01416
         		″ 1 516
    2-70
    Figure US20190233441A1-20190801-C01417
         		″ 1 510
    2-71
    Figure US20190233441A1-20190801-C01418
         		″ 1 502
    2-72
    Figure US20190233441A1-20190801-C01419
         		″ 1 518
    2-73
    Figure US20190233441A1-20190801-C01420
         		″ 1 488
    2-74
    Figure US20190233441A1-20190801-C01421
         		″ 1 462
    2-75
    Figure US20190233441A1-20190801-C01422
         		″ 1 544
    2-76
    Figure US20190233441A1-20190801-C01423
         		″ 1 490
    2-77
    Figure US20190233441A1-20190801-C01424
         		″ 1 488
    2-78
    Figure US20190233441A1-20190801-C01425
         		″ 1 516
    2-79
    Figure US20190233441A1-20190801-C01426
         		″ 1 530
    2-80
    Figure US20190233441A1-20190801-C01427
    Figure US20190233441A1-20190801-C01428
         		1 542
    2-81
    Figure US20190233441A1-20190801-C01429
         		″ 1 568
    2-82
    Figure US20190233441A1-20190801-C01430
         		″ 1 598
    2-83
    Figure US20190233441A1-20190801-C01431
         		″ 1 612
    2-84
    Figure US20190233441A1-20190801-C01432
         		″ 1 556
    2-85
    Figure US20190233441A1-20190801-C01433
         		″ 1 542
    2-86
    Figure US20190233441A1-20190801-C01434
         		″ 1 570
    2-87
    Figure US20190233441A1-20190801-C01435
         		″ 1 568
    2-88
    Figure US20190233441A1-20190801-C01436
         		″ 1 598
    2-89
    Figure US20190233441A1-20190801-C01437
         		″ 1 614
    2-90
    Figure US20190233441A1-20190801-C01438
         		″ 1 662
    2-91
    Figure US20190233441A1-20190801-C01439
         		″ 1 647
    2-92
    Figure US20190233441A1-20190801-C01440
         		″ 1 647
    2-93
    Figure US20190233441A1-20190801-C01441
         		″ 1 610
    2-94
    Figure US20190233441A1-20190801-C01442
    Figure US20190233441A1-20190801-C01443
         		1 505
    2-95
    Figure US20190233441A1-20190801-C01444
    Figure US20190233441A1-20190801-C01445
         		1 619
    2-96
    Figure US20190233441A1-20190801-C01446
         		″ 1 578
    2-97
    Figure US20190233441A1-20190801-C01447
         		″ 1 570
    2-98
    Figure US20190233441A1-20190801-C01448
         		″ 1 542
    2-99
    Figure US20190233441A1-20190801-C01449
         		″ 1 599
    2-100
    Figure US20190233441A1-20190801-C01450
         		″ 1 586
    2-101
    Figure US20190233441A1-20190801-C01451
         		″ 1 584
    2-102
    Figure US20190233441A1-20190801-C01452
         		″ 1 599
    2-103
    Figure US20190233441A1-20190801-C01453
         		″ 1 643
    2-104
    Figure US20190233441A1-20190801-C01454
         		″ 1 640
    2-105
    Figure US20190233441A1-20190801-C01455
    Figure US20190233441A1-20190801-C01456
         		1 558
    2-106 ″
    Figure US20190233441A1-20190801-C01457
         		1 503
    2-107 ″
    Figure US20190233441A1-20190801-C01458
         		1 544
    2-108 ″
    Figure US20190233441A1-20190801-C01459
         		1 572
    2-109 ″
    Figure US20190233441A1-20190801-C01460
         		1 530
    2-110
    Figure US20190233441A1-20190801-C01461
    Figure US20190233441A1-20190801-C01462
         		1 548
    2-111
    Figure US20190233441A1-20190801-C01463
         		″ 1 518
    2-112
    Figure US20190233441A1-20190801-C01464
         		″ 1 519
    2-113
    Figure US20190233441A1-20190801-C01465
         		″ 1 490
    2-114
    Figure US20190233441A1-20190801-C01466
         		″ 1 504
    2-115
    Figure US20190233441A1-20190801-C01467
         		″ 1 518
    2-116
    Figure US20190233441A1-20190801-C01468
         		″ 1 532
    2-117
    Figure US20190233441A1-20190801-C01469
         		″ 1 580
    2-118
    Figure US20190233441A1-20190801-C01470
         		″ 1 532
    2-119
    Figure US20190233441A1-20190801-C01471
         		″ 1 526
    2-120
    Figure US20190233441A1-20190801-C01472
         		″ 1 532
    2-121
    Figure US20190233441A1-20190801-C01473
         		″ 1 552
    2-122
    Figure US20190233441A1-20190801-C01474
         		″ 1 516
    2-123
    Figure US20190233441A1-20190801-C01475
         		″ 1 532
    2-124
    Figure US20190233441A1-20190801-C01476
         		″ 1 512
    2-125
    Figure US20190233441A1-20190801-C01477
         		″ 1 532
    2-126
    Figure US20190233441A1-20190801-C01478
         		″ 1 502
    2-127
    Figure US20190233441A1-20190801-C01479
         		″ 1 518
    2-128
    Figure US20190233441A1-20190801-C01480
         		″ 1 516
    2-129
    Figure US20190233441A1-20190801-C01481
         		″ 1 476
    2-130
    Figure US20190233441A1-20190801-C01482
         		″ 1 490
    2-131
    Figure US20190233441A1-20190801-C01483
         		″ 1 544
    2-132
    Figure US20190233441A1-20190801-C01484
         		″ 1 544
    2-133
    Figure US20190233441A1-20190801-C01485
         		″ 1 530
    2-134
    Figure US20190233441A1-20190801-C01486
         		″ 1 546
    2-135
    Figure US20190233441A1-20190801-C01487
         		″ 1 530
    2-136
    Figure US20190233441A1-20190801-C01488
    Figure US20190233441A1-20190801-C01489
         		1 582
    2-137
    Figure US20190233441A1-20190801-C01490
         		″ 1 542
    2-138
    Figure US20190233441A1-20190801-C01491
         		″ 1 542
    2-139
    Figure US20190233441A1-20190801-C01492
         		″ 1 570
    2-140
    Figure US20190233441A1-20190801-C01493
         		″ 1 644
    2-141
    Figure US20190233441A1-20190801-C01494
         		″ 1 614
    2-142
    Figure US20190233441A1-20190801-C01495
         		″ 1 581
    2-143
    Figure US20190233441A1-20190801-C01496
         		″ 1 604
    2-144
    Figure US20190233441A1-20190801-C01497
         		″ 1 586
    2-145
    Figure US20190233441A1-20190801-C01498
         		″ 1 590
    2-146
    Figure US20190233441A1-20190801-C01499
         		″ 1 562
    2-147
    Figure US20190233441A1-20190801-C01500
         		″ 1 584
    2-148
    Figure US20190233441A1-20190801-C01501
         		″ 1 564
    2-149
    Figure US20190233441A1-20190801-C01502
         		″ 1 624
    2-150
    Figure US20190233441A1-20190801-C01503
         		″ 1 596
    2-151
    Figure US20190233441A1-20190801-C01504
         		″ 1 582
    2-152
    Figure US20190233441A1-20190801-C01505
         		″ 1 578
    2-153
    Figure US20190233441A1-20190801-C01506
         		″ 1 572
    2-154
    Figure US20190233441A1-20190801-C01507
         		″ 1 606
    2-155
    Figure US20190233441A1-20190801-C01508
         		″ 1 643
    2-156
    Figure US20190233441A1-20190801-C01509
         		″ 1 604
    2-157
    Figure US20190233441A1-20190801-C01510
         		″ 1 640
    2-158
    Figure US20190233441A1-20190801-C01511
         		″ 1 556
    2-159
    Figure US20190233441A1-20190801-C01512
         		″ 1 625
    2-160
    Figure US20190233441A1-20190801-C01513
    Figure US20190233441A1-20190801-C01514
         		1 542
    2-161 ″
    Figure US20190233441A1-20190801-C01515
         		1 570
    2-162 ″
    Figure US20190233441A1-20190801-C01516
         		1 607
    2-163 ″
    Figure US20190233441A1-20190801-C01517
         		1 556
    2-164 ″
    Figure US20190233441A1-20190801-C01518
         		1 558
    2-165
    Figure US20190233441A1-20190801-C01519
    Figure US20190233441A1-20190801-C01520
         		1 476
    2-166
    Figure US20190233441A1-20190801-C01521
         		″ 1 552
    2-167
    Figure US20190233441A1-20190801-C01522
         		″ 1 548
    2-168
    Figure US20190233441A1-20190801-C01523
         		″ 1 520
    2-169
    Figure US20190233441A1-20190801-C01524
         		″ 1 478
    2-170
    Figure US20190233441A1-20190801-C01525
         		″ 1 526
    2-171
    Figure US20190233441A1-20190801-C01526
         		″ 1 538
    2-172
    Figure US20190233441A1-20190801-C01527
         		″ 1 512
    2-173
    Figure US20190233441A1-20190801-C01528
         		″ 1 526
    2-174
    Figure US20190233441A1-20190801-C01529
         		″ 1 526
    2-175
    Figure US20190233441A1-20190801-C01530
         		″ 1 530
    2-176
    Figure US20190233441A1-20190801-C01531
         		″ 1 516
    2-177
    Figure US20190233441A1-20190801-C01532
         		″ 1 512
    2-178
    Figure US20190233441A1-20190801-C01533
         		″ 1 512
    2-179
    Figure US20190233441A1-20190801-C01534
         		″ 1 532
    2-180
    Figure US20190233441A1-20190801-C01535
         		″ 1 518
    2-181
    Figure US20190233441A1-20190801-C01536
         		″ 1 544
    2-182
    Figure US20190233441A1-20190801-C01537
         		″ 1 544
    2-183
    Figure US20190233441A1-20190801-C01538
         		″ 1 530
    2-184
    Figure US20190233441A1-20190801-C01539
         		″ 1 516
    2-185
    Figure US20190233441A1-20190801-C01540
         		″ 1 516
    2-186
    Figure US20190233441A1-20190801-C01541
    Figure US20190233441A1-20190801-C01542
         		1 568
    2-187
    Figure US20190233441A1-20190801-C01543
         		″ 1 582
    2-188
    Figure US20190233441A1-20190801-C01544
         		″ 1 598
    2-189
    Figure US20190233441A1-20190801-C01545
         		″ 1 626
    2-190
    Figure US20190233441A1-20190801-C01546
         		″ 1 598
    2-191
    Figure US20190233441A1-20190801-C01547
         		″ 1 596
    2-192
    Figure US20190233441A1-20190801-C01548
         		″ 1 556
    2-193
    Figure US20190233441A1-20190801-C01549
         		″ 1 570
    2-194
    Figure US20190233441A1-20190801-C01550
         		″ 1 502
    2-195
    Figure US20190233441A1-20190801-C01551
         		″ 1 542
    2-196
    Figure US20190233441A1-20190801-C01552
         		″ 1 542
    2-197
    Figure US20190233441A1-20190801-C01553
         		″ 1 568
    2-198
    Figure US20190233441A1-20190801-C01554
         		″ 1 582
    2-199
    Figure US20190233441A1-20190801-C01555
         		″ 1 564
    2-200
    Figure US20190233441A1-20190801-C01556
         		″ 1 568
    2-201
    Figure US20190233441A1-20190801-C01557
         		″ 1 568
    2-202
    Figure US20190233441A1-20190801-C01558
         		″ 1 568
    2-203
    Figure US20190233441A1-20190801-C01559
         		″ 1 622
    2-204
    Figure US20190233441A1-20190801-C01560
         		″ 1 582
    2-205
    Figure US20190233441A1-20190801-C01561
         		″ 1 584
    2-206
    Figure US20190233441A1-20190801-C01562
         		″ 1 564
    2-207
    Figure US20190233441A1-20190801-C01563
         		″ 1 528
    2-208
    Figure US20190233441A1-20190801-C01564
         		″ 1 624
    2-209
    Figure US20190233441A1-20190801-C01565
         		″ 1 614
    2-210
    Figure US20190233441A1-20190801-C01566
         		″ 1 612
    2-211
    Figure US20190233441A1-20190801-C01567
         		″ 1 584
    2-212
    Figure US20190233441A1-20190801-C01568
         		″ 1 578
    2-213
    Figure US20190233441A1-20190801-C01569
         		″ 1 600
    2-214
    Figure US20190233441A1-20190801-C01570
         		″ 1 570
    2-215
    Figure US20190233441A1-20190801-C01571
         		″ 1 618
    2-216
    Figure US20190233441A1-20190801-C01572
         		″ 1 578
    2-217
    Figure US20190233441A1-20190801-C01573
         		″ 1 648
    2-218
    Figure US20190233441A1-20190801-C01574
         		″ 1 618
    2-219
    Figure US20190233441A1-20190801-C01575
         		″ 1 578
    2-220
    Figure US20190233441A1-20190801-C01576
         		″ 1 564
    2-221
    Figure US20190233441A1-20190801-C01577
         		″ 1 570
    2-222
    Figure US20190233441A1-20190801-C01578
    Figure US20190233441A1-20190801-C01579
         		1 579
    2-223 ″
    Figure US20190233441A1-20190801-C01580
         		1 528
    2-224 ″
    Figure US20190233441A1-20190801-C01581
         		1 504
    2-225 ″
    Figure US20190233441A1-20190801-C01582
         		1 554
    2-226
    Figure US20190233441A1-20190801-C01583
    Figure US20190233441A1-20190801-C01584
         		1 532
    2-227
    Figure US20190233441A1-20190801-C01585
         		″ 1 547
    2-228
    Figure US20190233441A1-20190801-C01586
         		″ 1 554
    2-229
    Figure US20190233441A1-20190801-C01587
         		″ 1 526
    2-230
    Figure US20190233441A1-20190801-C01588
         		″ 1 464
    2-231
    Figure US20190233441A1-20190801-C01589
         		″ 1 476
    2-232
    Figure US20190233441A1-20190801-C01590
         		″ 1 552
    2-233
    Figure US20190233441A1-20190801-C01591
         		″ 1 490
    2-234
    Figure US20190233441A1-20190801-C01592
         		″ 1 552
    2-235
    Figure US20190233441A1-20190801-C01593
         		″ 1 566
    2-236
    Figure US20190233441A1-20190801-C01594
         		″ 1 534
    2-237
    Figure US20190233441A1-20190801-C01595
         		″ 1 526
    2-238
    Figure US20190233441A1-20190801-C01596
         		″ 1 530
    2-239
    Figure US20190233441A1-20190801-C01597
         		″ 1 552
    2-240
    Figure US20190233441A1-20190801-C01598
         		″ 1 516
    2-241
    Figure US20190233441A1-20190801-C01599
         		″ 1 588
    2-242
    Figure US20190233441A1-20190801-C01600
         		″ 1 546
    2-243
    Figure US20190233441A1-20190801-C01601
         		″ 1 561
    2-244
    Figure US20190233441A1-20190801-C01602
         		″ 1 516
    2-245
    Figure US20190233441A1-20190801-C01603
         		″ 1 512
    2-246
    Figure US20190233441A1-20190801-C01604
         		″ 1 502
    2-247
    Figure US20190233441A1-20190801-C01605
         		″ 1 544
    2-248
    Figure US20190233441A1-20190801-C01606
         		″ 1 488
    2-249
    Figure US20190233441A1-20190801-C01607
         		″ 1 518
    2-250
    Figure US20190233441A1-20190801-C01608
         		″ 1 490
    2-251
    Figure US20190233441A1-20190801-C01609
         		″ 1 553
    2-252
    Figure US20190233441A1-20190801-C01610
         		″ 1 544
    2-253
    Figure US20190233441A1-20190801-C01611
    Figure US20190233441A1-20190801-C01612
         		1 582
    2-254
    Figure US20190233441A1-20190801-C01613
         		″ 1 598
    2-255
    Figure US20190233441A1-20190801-C01614
         		″ 1 528
    2-256
    Figure US20190233441A1-20190801-C01615
         		″ 1 514
    2-257
    Figure US20190233441A1-20190801-C01616
         		″ 1 582
    2-258
    Figure US20190233441A1-20190801-C01617
         		″ 1 582
    2-259
    Figure US20190233441A1-20190801-C01618
         		″ 1 584
    2-260
    Figure US20190233441A1-20190801-C01619
         		″ 1 582
    2-261
    Figure US20190233441A1-20190801-C01620
         		″ 1 661
    2-262
    Figure US20190233441A1-20190801-C01621
         		″ 1 655
    2-263
    Figure US20190233441A1-20190801-C01622
    Figure US20190233441A1-20190801-C01623
         		1 542
    2-264
    Figure US20190233441A1-20190801-C01624
    Figure US20190233441A1-20190801-C01625
         		1 557
    2-265
    Figure US20190233441A1-20190801-C01626
         		″ 1 618
    2-266
    Figure US20190233441A1-20190801-C01627
         		″ 1 584
    2-267
    Figure US20190233441A1-20190801-C01628
         		″ 1 556
    2-268
    Figure US20190233441A1-20190801-C01629
         		″ 1 600
    2-269
    Figure US20190233441A1-20190801-C01630
         		″ 1 598
    2-270
    Figure US20190233441A1-20190801-C01631
         		″ 1 585
    2-271
    Figure US20190233441A1-20190801-C01632
         		″ 1 586
    2-272
    Figure US20190233441A1-20190801-C01633
         		″ 1 590
    2-273
    Figure US20190233441A1-20190801-C01634
         		″ 1 590
    2-274
    Figure US20190233441A1-20190801-C01635
         		″ 1 584
    2-275
    Figure US20190233441A1-20190801-C01636
         		″ 1 599
    2-276
    Figure US20190233441A1-20190801-C01637
         		″ 1 599
    2-277
    Figure US20190233441A1-20190801-C01638
         		″ 1 618
    2-278
    Figure US20190233441A1-20190801-C01639
         		″ 1 619
    2-279
    Figure US20190233441A1-20190801-C01640
         		″ 1 594
    2-280
    Figure US20190233441A1-20190801-C01641
         		″ 1 604
    2-281
    Figure US20190233441A1-20190801-C01642
    Figure US20190233441A1-20190801-C01643
         		1 542
    2-282 ″
    Figure US20190233441A1-20190801-C01644
         		1 528
    2-283 ″
    Figure US20190233441A1-20190801-C01645
         		1 546
    2-284 ″
    Figure US20190233441A1-20190801-C01646
         		1 522
    2-285 ″
    Figure US20190233441A1-20190801-C01647
         		1 581
    2-286 ″
    Figure US20190233441A1-20190801-C01648
         		1 571
    2-287 ″
    Figure US20190233441A1-20190801-C01649
         		1 527
    2-288 ″
    Figure US20190233441A1-20190801-C01650
         		1 570
    2-289 ″
    Figure US20190233441A1-20190801-C01651
         		1 516
    2-290 ″
    Figure US20190233441A1-20190801-C01652
         		1 556
    2-291
    Figure US20190233441A1-20190801-C01653
    Figure US20190233441A1-20190801-C01654
         		1 547
    2-292
    Figure US20190233441A1-20190801-C01655
         		″ 1 504
    2-293
    Figure US20190233441A1-20190801-C01656
         		″ 1 518
    2-294
    Figure US20190233441A1-20190801-C01657
         		″ 1 518
    2-295
    Figure US20190233441A1-20190801-C01658
         		″ 1 560
    2-296
    Figure US20190233441A1-20190801-C01659
         		″ 1 490
    2-297
    Figure US20190233441A1-20190801-C01660
         		″ 1 567
    2-298
    Figure US20190233441A1-20190801-C01661
         		″ 1 573
    2-299
    Figure US20190233441A1-20190801-C01662
         		″ 1 570
    2-300
    Figure US20190233441A1-20190801-C01663
         		″ 1 601
    2-301
    Figure US20190233441A1-20190801-C01664
         		″ 1 532
    2-302
    Figure US20190233441A1-20190801-C01665
         		″ 1 544
    2-303
    Figure US20190233441A1-20190801-C01666
         		″ 1 544
    2-304
    Figure US20190233441A1-20190801-C01667
         		″ 1 562
    2-305
    Figure US20190233441A1-20190801-C01668
         		″ 1 532
    2-306
    Figure US20190233441A1-20190801-C01669
         		″ 1 530
    2-307
    Figure US20190233441A1-20190801-C01670
         		″ 1 504
    2-308
    Figure US20190233441A1-20190801-C01671
         		″ 1 502
    2-309
    Figure US20190233441A1-20190801-C01672
         		″ 1 546
    2-310
    Figure US20190233441A1-20190801-C01673
         		″ 1 516
    2-311
    Figure US20190233441A1-20190801-C01674
         		″ 1 516
    2-312
    Figure US20190233441A1-20190801-C01675
         		″ 1 530
    2-313
    Figure US20190233441A1-20190801-C01676
    Figure US20190233441A1-20190801-C01677
         		1 554
    2-314
    Figure US20190233441A1-20190801-C01678
         		″ 1 568
    2-315
    Figure US20190233441A1-20190801-C01679
         		″ 1 582
    2-316
    Figure US20190233441A1-20190801-C01680
         		″ 1 556
    2-317
    Figure US20190233441A1-20190801-C01681
         		″ 1 542
    2-318
    Figure US20190233441A1-20190801-C01682
         		″ 1 528
    2-319
    Figure US20190233441A1-20190801-C01683
         		″ 1 542
    2-320
    Figure US20190233441A1-20190801-C01684
         		″ 1 554
    2-321
    Figure US20190233441A1-20190801-C01685
         		″ 1 554
    2-322
    Figure US20190233441A1-20190801-C01686
         		″ 1 582
    2-323
    Figure US20190233441A1-20190801-C01687
         		″ 1 540
    2-324
    Figure US20190233441A1-20190801-C01688
         		″ 1 610
    2-325
    Figure US20190233441A1-20190801-C01689
         		″ 1 613
    2-326
    Figure US20190233441A1-20190801-C01690
         		″ 1 568
    2-327
    Figure US20190233441A1-20190801-C01691
         		″ 1 627
    2-328
    Figure US20190233441A1-20190801-C01692
         		″ 1 568
    2-329
    Figure US20190233441A1-20190801-C01693
         		″ 1 610
    2-330
    Figure US20190233441A1-20190801-C01694
         		″ 1 598
    2-331
    Figure US20190233441A1-20190801-C01695
         		″ 1 586
    2-332
    Figure US20190233441A1-20190801-C01696
         		″ 1 612
    2-333
    Figure US20190233441A1-20190801-C01697
         		″ 1 600
    2-334
    Figure US20190233441A1-20190801-C01698
         		″ 1 584
    2-335
    Figure US20190233441A1-20190801-C01699
         		″ 1 556
    2-336
    Figure US20190233441A1-20190801-C01700
         		″ 1 530
    2-337
    Figure US20190233441A1-20190801-C01701
         		″ 1 570
    2-338
    Figure US20190233441A1-20190801-C01702
         		″ 1 590
    2-339
    Figure US20190233441A1-20190801-C01703
         		″ 1 612
    2-340
    Figure US20190233441A1-20190801-C01704
         		″ 1 612
    2-341
    Figure US20190233441A1-20190801-C01705
         		″ 1 604
    2-342
    Figure US20190233441A1-20190801-C01706
         		″ 1 675
    2-343
    Figure US20190233441A1-20190801-C01707
         		″ 1 564
    2-344
    Figure US20190233441A1-20190801-C01708
    Figure US20190233441A1-20190801-C01709
         		1 488
    2-345 ″
    Figure US20190233441A1-20190801-C01710
         		1 530
    2-346 ″
    Figure US20190233441A1-20190801-C01711
         		1 560
    2-347 ″
    Figure US20190233441A1-20190801-C01712
         		1 556
    2-348 ″
    Figure US20190233441A1-20190801-C01713
         		1 556
    2-349 ″
    Figure US20190233441A1-20190801-C01714
         		1 532
    2-350 ″
    Figure US20190233441A1-20190801-C01715
         		1 581
    2-351 ″
    Figure US20190233441A1-20190801-C01716
         		1 580
    2-352 ″
    Figure US20190233441A1-20190801-C01717
         		1 530
    2-353 ″
    Figure US20190233441A1-20190801-C01718
         		1 544
    2-354
    Figure US20190233441A1-20190801-C01719
    Figure US20190233441A1-20190801-C01720
         		1 490
    2-355
    Figure US20190233441A1-20190801-C01721
         		″ 1 492
    2-356
    Figure US20190233441A1-20190801-C01722
         		″ 1 490
    2-357
    Figure US20190233441A1-20190801-C01723
         		″ 1 490
    2-358
    Figure US20190233441A1-20190801-C01724
         		″ 1 552
    2-359
    Figure US20190233441A1-20190801-C01725
         		″ 1 562
    2-360
    Figure US20190233441A1-20190801-C01726
         		″ 1 490
    2-361
    Figure US20190233441A1-20190801-C01727
         		″ 1 512
    2-362
    Figure US20190233441A1-20190801-C01728
         		″ 1 504
    2-363
    Figure US20190233441A1-20190801-C01729
         		″ 1 560
    2-364
    Figure US20190233441A1-20190801-C01730
         		″ 1 562
    2-365
    Figure US20190233441A1-20190801-C01731
         		″ 1 546
    2-366
    Figure US20190233441A1-20190801-C01732
         		″ 1 516
    2-367
    Figure US20190233441A1-20190801-C01733
         		″ 1 516
    2-368
    Figure US20190233441A1-20190801-C01734
         		″ 1 530
    2-369
    Figure US20190233441A1-20190801-C01735
         		″ 1 558
    2-370
    Figure US20190233441A1-20190801-C01736
         		″ 1 538
    2-371
    Figure US20190233441A1-20190801-C01737
         		″ 1 502
    2-372
    Figure US20190233441A1-20190801-C01738
         		″ 1 502
    2-373
    Figure US20190233441A1-20190801-C01739
         		″ 1 530
    2-374
    Figure US20190233441A1-20190801-C01740
         		″ 1 464
    2-375
    Figure US20190233441A1-20190801-C01741
         		″ 1 502
    2-376
    Figure US20190233441A1-20190801-C01742
         		″ 1 530
    2-377
    Figure US20190233441A1-20190801-C01743
    Figure US20190233441A1-20190801-C01744
         		1 568
    2-378
    Figure US20190233441A1-20190801-C01745
         		″ 1 582
    2-379
    Figure US20190233441A1-20190801-C01746
         		″ 1 554
    2-380
    Figure US20190233441A1-20190801-C01747
         		″ 1 598
    2-381
    Figure US20190233441A1-20190801-C01748
         		″ 1 582
    2-382
    Figure US20190233441A1-20190801-C01749
         		″ 1 596
    2-383
    Figure US20190233441A1-20190801-C01750
         		″ 1 596
    2-384
    Figure US20190233441A1-20190801-C01751
         		″ 1 596
    2-385
    Figure US20190233441A1-20190801-C01752
         		″ 1 556
    2-386
    Figure US20190233441A1-20190801-C01753
         		″ 1 554
    2-387
    Figure US20190233441A1-20190801-C01754
         		″ 1 554
    2-388
    Figure US20190233441A1-20190801-C01755
         		″ 1 582
    2-389
    Figure US20190233441A1-20190801-C01756
         		″ 1 584
    2-390
    Figure US20190233441A1-20190801-C01757
         		″ 1 640
    2-391
    Figure US20190233441A1-20190801-C01758
         		″ 1 582
    2-392
    Figure US20190233441A1-20190801-C01759
         		″ 1 540
    2-393
    Figure US20190233441A1-20190801-C01760
         		″ 1 625
    2-394
    Figure US20190233441A1-20190801-C01761
         		″ 1 619
    2-395
    Figure US20190233441A1-20190801-C01762
         		″ 1 605
    2-396
    Figure US20190233441A1-20190801-C01763
         		″ 1 604
    2-397
    Figure US20190233441A1-20190801-C01764
         		″ 1 605
    2-398
    Figure US20190233441A1-20190801-C01765
         		″ 1 582
    2-399
    Figure US20190233441A1-20190801-C01766
         		″ 1 544
    2-400
    Figure US20190233441A1-20190801-C01767
         		″ 1 624
    2-401
    Figure US20190233441A1-20190801-C01768
         		″ 1 578
    2-402
    Figure US20190233441A1-20190801-C01769
         		″ 1 564
    2-403
    Figure US20190233441A1-20190801-C01770
         		″ 1 624
    2-404
    Figure US20190233441A1-20190801-C01771
         		″ 1 618
    2-405
    Figure US20190233441A1-20190801-C01772
         		″ 1 604
    2-406
    Figure US20190233441A1-20190801-C01773
         		″ 1 606
    2-407
    Figure US20190233441A1-20190801-C01774
         		″ 1 564
    2-408
    Figure US20190233441A1-20190801-C01775
    Figure US20190233441A1-20190801-C01776
         		1 488
    2-409 ″
    Figure US20190233441A1-20190801-C01777
         		1 514
    2-410 ″
    Figure US20190233441A1-20190801-C01778
         		1 516
    2-411 ″
    Figure US20190233441A1-20190801-C01779
         		1 532
    2-412 ″
    Figure US20190233441A1-20190801-C01780
         		1 544
    2-413 ″
    Figure US20190233441A1-20190801-C01781
         		1 559
    2-414
    Figure US20190233441A1-20190801-C01782
    Figure US20190233441A1-20190801-C01783
         		1 504
    2-415
    Figure US20190233441A1-20190801-C01784
         		″ 1 518
    2-416
    Figure US20190233441A1-20190801-C01785
         		″ 1 518
    2-417
    Figure US20190233441A1-20190801-C01786
         		″ 1 529
    2-418
    Figure US20190233441A1-20190801-C01787
         		″ 1 516
    2-419
    Figure US20190233441A1-20190801-C01788
         		″ 1 512
    2-420
    Figure US20190233441A1-20190801-C01789
         		″ 1 504
    2-421
    Figure US20190233441A1-20190801-C01790
         		″ 1 573
    2-422
    Figure US20190233441A1-20190801-C01791
         		″ 1 512
    2-423
    Figure US20190233441A1-20190801-C01792
         		″ 1 512
    2-424
    Figure US20190233441A1-20190801-C01793
         		″ 1 552
    2-425
    Figure US20190233441A1-20190801-C01794
         		″ 1 504
    2-426
    Figure US20190233441A1-20190801-C01795
         		″ 1 552
    2-427
    Figure US20190233441A1-20190801-C01796
         		″ 1 504
    2-428
    Figure US20190233441A1-20190801-C01797
         		″ 1 518
    2-429
    Figure US20190233441A1-20190801-C01798
         		″ 1 567
    2-430
    Figure US20190233441A1-20190801-C01799
         		″ 1 530
    2-431
    Figure US20190233441A1-20190801-C01800
         		″ 1 561
    2-432
    Figure US20190233441A1-20190801-C01801
         		″ 1 530
    2-433
    Figure US20190233441A1-20190801-C01802
         		″ 1 490
    2-434
    Figure US20190233441A1-20190801-C01803
         		″ 1 488
    2-435
    Figure US20190233441A1-20190801-C01804
         		″ 1 502
    2-436
    Figure US20190233441A1-20190801-C01805
         		″ 1 530
    2-437
    Figure US20190233441A1-20190801-C01806
         		″ 1 516
    2-438
    Figure US20190233441A1-20190801-C01807
         		″ 1 504
    2-439
    Figure US20190233441A1-20190801-C01808
         		″ 1 530
    2-440
    Figure US20190233441A1-20190801-C01809
    Figure US20190233441A1-20190801-C01810
         		1 568
    2-441
    Figure US20190233441A1-20190801-C01811
         		″ 1 516
    2-442
    Figure US20190233441A1-20190801-C01812
         		″ 1 612
    2-443
    Figure US20190233441A1-20190801-C01813
         		″ 1 596
    2-444
    Figure US20190233441A1-20190801-C01814
         		″ 1 542
    2-445
    Figure US20190233441A1-20190801-C01815
         		″ 1 542
    2-446
    Figure US20190233441A1-20190801-C01816
         		″ 1 556
    2-447
    Figure US20190233441A1-20190801-C01817
         		″ 1 542
    2-448
    Figure US20190233441A1-20190801-C01818
         		″ 1 570
    2-449
    Figure US20190233441A1-20190801-C01819
         		″ 1 540
    2-450
    Figure US20190233441A1-20190801-C01820
         		″ 1 596
    2-451
    Figure US20190233441A1-20190801-C01821
         		″ 1 528
    2-452
    Figure US20190233441A1-20190801-C01822
         		″ 1 554
    2-453
    Figure US20190233441A1-20190801-C01823
         		″ 1 584
    2-454
    Figure US20190233441A1-20190801-C01824
         		″ 1 540
    2-455
    Figure US20190233441A1-20190801-C01825
         		″ 1 570
    2-456
    Figure US20190233441A1-20190801-C01826
         		″ 1 604
    2-457
    Figure US20190233441A1-20190801-C01827
         		″ 1 613
    2-458
    Figure US20190233441A1-20190801-C01828
         		″ 1 584
    2-459
    Figure US20190233441A1-20190801-C01829
         		″ 1 542
    2-460
    Figure US20190233441A1-20190801-C01830
         		″ 1 614
    2-461
    Figure US20190233441A1-20190801-C01831
         		″ 1 624
    2-462
    Figure US20190233441A1-20190801-C01832
         		″ 1 622
    2-463
    Figure US20190233441A1-20190801-C01833
         		″ 1 598
    2-464
    Figure US20190233441A1-20190801-C01834
         		″ 1 556
    2-465
    Figure US20190233441A1-20190801-C01835
         		″ 1 572
    2-466
    Figure US20190233441A1-20190801-C01836
         		″ 1 556
    2-467
    Figure US20190233441A1-20190801-C01837
         		″ 1 570
    2-468
    Figure US20190233441A1-20190801-C01838
         		″ 1 618
    2-469
    Figure US20190233441A1-20190801-C01839
         		″ 1 568
    2-470
    Figure US20190233441A1-20190801-C01840
         		″ 1 689
    2-471
    Figure US20190233441A1-20190801-C01841
         		″ 1 604
    2-472
    Figure US20190233441A1-20190801-C01842
         		″ 1 646
    2-473
    Figure US20190233441A1-20190801-C01843
         		″ 1 632
    2-474
    Figure US20190233441A1-20190801-C01844
         		″ 1 641
    2-475
    Figure US20190233441A1-20190801-C01845
         		″ 1 653
    2-476
    Figure US20190233441A1-20190801-C01846
         		″ 1 578
    2-477
    Figure US20190233441A1-20190801-C01847
         		″ 1 632
    2-478
    Figure US20190233441A1-20190801-C01848
         		″ 1 564
    2-479
    Figure US20190233441A1-20190801-C01849
    Figure US20190233441A1-20190801-C01850
         		1 593
    2-480
    Figure US20190233441A1-20190801-C01851
    Figure US20190233441A1-20190801-C01852
         		2 571
    2-481
    Figure US20190233441A1-20190801-C01853
         		″ 0 543
    2-482
    Figure US20190233441A1-20190801-C01854
    Figure US20190233441A1-20190801-C01855
         		1 513
    2-483
    Figure US20190233441A1-20190801-C01856
    Figure US20190233441A1-20190801-C01857
         		1 570
    2-484
    Figure US20190233441A1-20190801-C01858
         		″ 1 584
    2-485
    Figure US20190233441A1-20190801-C01859
         		″ 1 584
    2-486
    Figure US20190233441A1-20190801-C01860
         		″ 1 640
    • Example 3a Cyclopropanecarboxylic acid (8-Bromo-1,8a-dihydro-[1,2,4]triazolo[1,5-a]pyridine-2-yl)-amide
  • Figure US20190233441A1-20190801-C01861
  • Cyclopropanecarboxylic acid (8-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide may be prepared according to WO 2010/010186, incorporated herein by reference, and functionalised using the methods described above in Examples 1 and 2.
  • TABLE III
    Figure US20190233441A1-20190801-C01862
    LCMS(ESI)
    m/z
    Ex Q1 Q2 [M + H+]
    3-1
    Figure US20190233441A1-20190801-C01863
    Figure US20190233441A1-20190801-C01864
         		391
    • Enzymatic Assays
  • JAK Enzyme Assays were carried out as follows:
  • The activity of the isolated recombinant JAK1 and JAK2 kinase domain was measured by monitoring phosphorylation of a peptide derived from JAK3 (Val-Ala-Leu-Val-Asp-Gly-Tyr-Phe-Arg-Leu-Thr-Thr, fluorescently labeled on the N-terminus with 5-carboxyfluorescein) using the Caliper LabChip® technology (Caliper Life Sciences, Hopkinton, Mass.). To determine inhibition constants (Ki), compounds were diluted serially in DMSO and added to 50 μL kinase reactions containing purified enzyme (1.5 nM JAK1, or 0.2 nM JAK2), 100 mM HEPES buffer (pH 7.2), 0.015% Brij-35, 1.5 μM peptide substrate, ATP (25 μM), 10 mM MgCl2, 4 mM DTT at a final DMSO concentration of 2%. Reactions were incubated at 22° C. in 384-well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25 μL of an EDTA containing solution (100 mM HEPES buffer (pH 7.2), 0.015% Brij-35, 150 mM EDTA), resulting in a final EDTA concentration of 50 mM. After termination of the kinase reaction, the proportion of phosphorylated product was determined as a fraction of total peptide substrate using the Caliper LabChip® 3000 according to the manufacturer's specifications. Ki values were then determined using the Morrison tight binding model (Morrison, J. F., Biochim. Biophys. Acta. 185:269-296 (1969); William, J. W. and Morrison, J. F., Meth. Enzymol., 63:437-467 (1979)) modified for ATP-competitive inhibition [Ki=Ki,app/(1+[ATP]/Km,app)].
  • JAK1 Pathway Assay in Cell Lines was carried out as follows:
  • Inhibitor potency (EC50) was determined in cell-based assays designed to measure JAK1 dependent STAT phosphorylation. As noted above, inhibition of IL-4, IL-13, and IL-9 signaling by blocking the Jak/Stat signaling pathway can alleviate asthmatic symptoms in pre-clinical lung inflammation models (Mathew et al., 2001, J Exp Med 193(9): 1087-1096; Kudlacz et. al., 2008, Eur J. Pharmacol 582(1-3): 154-161).
  • In one assay approach, TF-1 human erythroleukemia cells obtained from the American Type Culture Collection (ATCC; Manassas, Va.) were used to measure JAK1-dependent STAT6 phosphorylation downstream of IL-13 stimulation. Prior to use in the assays, TF-1 cells were starved of GM-CSF overnight in OptiMEM medium (Life Technologies, Grand Island, N.Y.) supplemented with 0.5% charcoal/dextran stripped fetal bovine serum (FBS), 0.1 mM non-essential amino acids (NEAA), and 1 mM sodium pyruvate. The assays were run in 384-well plates in serum-free OptiMEM medium using 300,000 cells per well. In a second assay approach, BEAS-2B human bronchial epithelial cells obtained from ATCC were plated at 100,000 cells per well of a 96-well plate one day prior to the experiment. The BEAS-2B assay was run in complete growth medium (bronchial epithelial basal medium plus bulletkit; Lonza; Basel, Switzerland).
  • Test compounds were serially diluted 1:2 in DMSO and then diluted 1:50 in medium just before use. Diluted compounds were added to the cells, for a final DMSO concentration of 0.2%, and incubated for 30 min (for the TF-1 assay) or 1 hr (for the BEAS-2B assay) at 37° C. Then, cells were stimulated with human recombinant cytokine at their respective EC90 concentrations, as previously determined for each individual lot. Cells were stimulated with IL-13 (R&D Systems, Minneapolis, Minn.) for 15 min at 37° C. The TF-1 cell reactions were stopped by the direct addition of 10× lysis buffer (Cell Signaling Technologies, Danvers, Mass.), whereas the BEAS-2B cell incubations were halted by the removal of medium and addition of 1× lysis buffer. The resultant samples were frozen in the plates at −80° C. Compound mediated inhibition of STAT6 phosphorylation was measured in the cell lysates using MesoScale Discovery (MSD) technology (Gaithersburg, Md.). ECso values were determined as the concentration of compound required for 50% inhibition of STAT phosphorylation relative to that measured for the DMSO control.
  • Table 4 provides JAK1 Ki, JAK2 Ki and IL-13-pSTAT6 IC50 information for the noted Examples of the indicated Tables.
  • TABLE 4
    IL13-
    IL-13- pSTAT6
    JAK1 JAK2 pSTAT6 BEASB2B
    Table Example Ki Ki IC50 IC50
    number number (□M) (□M) (□M) (□M)
    1 1-1  0.01672 0.00085
    1 1-2  0.07402 0.01425
    1 1-3  0.45468 0.09239 >10
    1 1-4  0.08151 0.01240 6.5881
    1 1-5  0.04475 0.00515 0.7669
    1 1-6  0.26472 0.03993 3.0729
    1 1-7  0.06210 0.00651
    1 1-8  0.14044 0.02309 0.7563
    1 1-9  0.48874 0.06321 >10
    1 1-10 0.32136 0.07465 >10
    1 1-11 0.02593 0.00628 0.2352
    1 1-12 0.40601 0.07747 3.4017
    1 1-13 0.05838 0.01312 0.4936
    1 1-14 0.05240 0.00753
    1 1-15 0.18745 0.01220
    1 1-16 0.18468 0.02552
    1 1-17 0.00291 0.00112 0.0339 0.1530
    1 1-18 0.08788 0.01733
    1 1-19 0.17775 0.03197
    1 1-20 0.19653 0.03681
    1 1-21 0.01461 0.00649 0.3330
    1 1-22 0.17116 0.03212
    1 1-23 0.01108 0.00250 0.0737
    1 1-24 0.15679 0.01914
    1 1-25 0.39046 0.04911
    1 1-26 0.03691 0.00408
    1 1-27 0.22126 0.01721
    1 1-28 0.07039 0.00821
    1 1-29 0.40172 0.04742
    1 1-30 0.00170 0.00027 0.2523
    1 1-31 0.45295 0.05243
    1 1-32 0.10910 0.02875
    1 1-33 0.21856 0.03866
    1 1-34 0.01874 0.00861 0.9155
    1 1-35 0.18364 0.02768
    1 1-36 0.00735 0.00432 0.1422
    1 1-37 0.02357 0.00670 0.0763
    1 1-38 0.00686 0.00559 0.1517
    1 1-39 0.00773 0.00352
    1 1-40 0.01146 0.00458
    1 1-41 0.00205 0.00020 0.0159 0.0420
    1 1-42 0.91987 1.09362
    1 1-43 0.03101 0.00784 0.9680
    1 1-44 0.05244 0.00703 0.1679
    1 1-45 0.19352 0.02040
    1 1-46 0.10061 0.01013
    1 1-47 0.00135 0.0103 0.0581
    1 1-48 0.00230
    1 1-49 0.00321
    1 1-50 0.00311
    1 1-51 0.00374
    1 1-52 0.00188 0.0211
    1 1-53 0.00103 0.0274
    1 1-54 0.00115 0.1004
    1 1-55 0.00319
    1 1-56 0.00430
    1 1-57 0.00336
    1 1-58 0.00318
    1 1-59 0.00127 0.0155
    1 1-60 0.00106 0.0122
    1 1-61 0.00253
    1 1-62 0.00142 0.0228
    1 1-63 0.00413
    1 1-64 0.00227
    1 1-65 0.00234
    1 1-66 0.00222
    1 1-67 0.00341
    1 1-68 0.00216
    1 1-69 0.00612
    1 1-70 0.00257
    1 1-71 0.00450
    1 1-72 0.00353
    1 1-73 0.01098
    1 1-74 0.00134 0.0335
    1 1-75 0.00248
    1 1-76 0.00151 0.0127
    1 1-77 0.00329
    1 1-78 0.00326
    1 1-79 0.00479
    1 1-80 0.00347
    1 1-81 0.00082 0.0109
    1 1-82 0.00309
    1 1-83 0.00324
    1 1-84 0.00237
    1 1-85 0.00249
    1 1-86 0.00201 0.0213
    1 1-87 0.00474
    1 1-88 0.00270
    1 1-89 0.00190 0.1266
    1 1-90 0.00297
    1 1-91 0.00255
    1 1-92 0.00168 0.0593
    1 1-93 0.00613
    1 1-94 0.00258
    1 1-95 0.00193 0.1148
    1 1-96 0.00172 0.0646
    1 1-97 0.00198 0.0250
    1 1-98 0.00144 0.0119 0.0424
    1 1-99 0.00332
    1  1-100 0.00281
    1  1-101 0.00194 0.0140
    1  1-102 0.00173 0.0450 0.0547
    1  1-103 0.00154 0.0238
    1  1-104 0.00326
    1  1-105 0.00114 0.0141
    1  1-106 0.00227
    1  1-107 0.00277
    1  1-108 0.00277
    1  1-109 0.00408
    1  1-110 0.00458
    1  1-111 0.00149 0.0156
    1  1-112 0.01145 0.00380
    1  1-113 0.00164 0.0267
    1  1-114 0.00186 0.0297
    1  1-115 0.00302
    1  1-116 0.00295 0.0340
    1  1-117 0.00252 0.00085 0.0292
    1  1-118 0.00269 0.1120
    1  1-119 0.00266
    1  1-120 0.00510
    1  1-121 0.00297 0.1311
    1  1-122 0.00271
    1  1-123 0.00257 0.00070 0.0258
    1  1-124 0.00542
    1  1-125 0.00225 0.00063 0.0164 0.0428
    1  1-126 0.00322
    1  1-127 0.00199 0.0147 0.0245
    1  1-128 0.00448
    1  1-129 0.00187 0.00174 0.0377
    1  1-130 0.00371
    1  1-131 0.00720
    1  1-132 0.00279
    1  1-133 0.00278
    1  1-134 0.00207
    1  1-135 0.00148
    1  1-136 0.00342
    1  1-137 0.00388
    1  1-138 0.00153 0.00356 0.1351
    1  1-139 0.00248 0.00195 0.0206
    1  1-140 0.00488
    1  1-141 0.00171 0.0579
    1  1-142 0.00311
    1  1-143 0.00349
    1  1-144 0.00424
    1  1-145 0.00576
    1  1-146 0.00305
    1  1-147 0.00210 0.00141 0.0665
    1  1-148 0.00565
    1  1-149 0.00896
    1  1-150 0.00559
    1  1-151 0.00280 0.1073 0.1670
    1  1-152 0.00279 0.0650
    1  1-153 0.00243 0.00114 0.0260
    1  1-154 0.00198 0.00064 0.0373
    1  1-155 0.00320
    1  1-156 0.00651
    1  1-157 0.00370
    1  1-158 0.00401
    1  1-159 0.00482
    1  1-160 0.00285
    1  1-161 0.00199 0.0234 0.0485
    1  1-162 0.00291
    1  1-163 0.00257
    1  1-164 0.00080 0.0108
    1  1-165 0.00088 0.0251
    1  1-166 0.00213
    1  1-167 0.00179 0.00286 0.0121
    1  1-168 0.00275 0.0226
    1  1-169 0.00670
    1  1-170 0.00151 0.00098 0.0155
    1  1-171 0.01426
    1  1-172 0.00303
    1  1-173 0.00195 0.00245 0.0231
    1  1-174 0.00241 0.00231 0.0311
    1  1-175 0.00174 0.00092 0.1889
    1  1-176 0.00192 0.00207 0.2792
    1  1-177 0.00208 0.00151 0.0232
    1  1-178 0.00115 0.00107 0.0983
    1  1-179 0.00169 0.0843
    1  1-180 0.00164 0.3219
    1  1-181 0.00140 0.1812
    1  1-182 0.00259
    1  1-183 0.00177 0.5361
    1  1-184 0.00115 0.1273
    1  1-185 0.00218
    1  1-186 0.00203 1.0299
    1  1-187 0.00147 0.4620
    1  1-188 0.00135 0.0347
    1  1-189
    1  1-190
    1  1-191
    1  1-192
    1  1-193 0.00195 0.2487
    1  1-194 0.00352
    1  1-195 0.00374
    1  1-196 0.00164 0.0531
    1  1-197 0.00163 0.1575
    1  1-198 0.00157 0.0685
    1  1-199 0.00066 0.1061
    1  1-200 0.00360
    1  1-201 0.00254
    1  1-202 0.00335
    1  1-203 0.00148 0.3424
    1  1-204 0.00408
    1  1-205 0.00189 0.5215
    1  1-206 0.00234
    1  1-207 0.00197 0.1915
    1  1-208 0.00231
    1  1-209 0.00563
    1  1-210 0.00091 0.0435
    1  1-211 0.00219
    1  1-212 0.00188 0.1962
    1  1-213 0.00280
    1  1-214 0.00253
    1  1-215 0.00228
    1  1-216 0.00234
    1  1-217 0.00230
    1  1-218 0.00192 0.1647
    1  1-219 0.00260
    1  1-220 0.00131 0.6369
    1  1-221 0.00117 0.8665
    1  1-222 0.00212
    1  1-223 0.00354
    1  1-224 0.00095 0.1109
    1  1-225 0.00179 0.0308
    1  1-226 0.00181 0.0794
    1  1-227 0.00285
    1  1-228 0.00216
    1  1-229 0.00294
    1  1-230 0.00263 0.0581
    1  1-231 0.00178 0.9157
    1  1-232 0.00283
    1  1-233 0.00258 0.1645
    1  1-234 0.00193 0.0361
    1  1-235 0.00186 0.3105
    1  1-236 0.00256
    1  1-237 0.00147 0.0107
    1  1-238 0.00173 0.1805
    1  1-239 0.00355
    1  1-240 0.00372
    1  1-241 0.00163 0.1154
    1  1-242 0.00251
    1  1-243 0.00252
    1  1-244 0.00270
    1  1-245 0.00261
    1  1-246 0.00036 0.00033 0.0054 0.0892
    1  1-247 0.00050 0.00033 0.0184 0.1150
    1  1-248 0.10335 0.02210
    1  1-249 0.37191 0.05267
    1  1-250 0.00393 0.00129 0.732
    1  1-251 0.00061 0.00041 0.0566
    1  1-252 0.00048 0.00050 0.0902
    1  1-253 0.00116 0.00092 0.4177
    1  1-254 0.00064 0.00039 0.0899 0.661
    1  1-255 0.00085 0.00035 0.0271 0.159
    1  1-256 0.00117 0.00069 0.0563 0.426
    1  1-257 0.02663 0.00234
    1  1-258 0.00181 0.00052 0.0934 1.44
    1  1-259 0.02629 0.01070
    1  1-260 0.10551 0.01633
    1  1-261 0.04149 0.00356
    1  1-262 0.00222 0.00064 0.1201
    1  1-263 0.00082 0.00096 0.0182
    1  1-264 0.13357 0.12124
    1  1-265 0.00084 0.00057 0.0948
    1  1-266 0.00880 0.00254
    1  1-267 0.00042 0.00025 0.0324
    1  1-268 0.00071 0.00038 0.0562
    1  1-269 0.02853 0.01321
    1  1-270 0.00064 0.00045 0.114
    1  1-271 0.00088 0.00094 0.1125 0.533
    1  1-272 0.00048 0.00039 0.0487 0.172
    1  1-273 0.00059 0.00044 0.1525 0.259
    1  1-274 0.00020 0.00017 0.0079 0.0289
    1  1-275 0.00021 0.00014 0.003 0.0555
    1  1-276 0.00085 0.00048 0.0957 0.082
    1  1-277 0.00039 0.00024 0.0231 0.0733
    1  1-278 0.00033 0.00023 0.0163 0.0376
    1  1-279 0.00041 0.00025 0.0281 0.0346
    1  1-280 0.00030 0.00023 0.1245 0.0528
    1  1-281 0.00063 0.00039 0.0702 0.134
    1  1-282 0.00037 0.00021 0.0426 0.0556
    1  1-283 0.00018 0.00015 0.0155 0.0313
    1  1-284 0.00057 0.00049 0.0177 0.031
    1  1-285 0.00056 0.00055 0.0221 0.0576
    1  1-286 0.00027 0.00026 0.0067 0.0762
    1  1-287 0.00054 0.00039 0.0225 0.0364
    1  1-288 0.00051 0.00040 0.028 0.0677
    1  1-289 0.00026 0.00042 0.0081
    1  1-290 0.00018 0.00030 0.0059
    1  1-291 0.00018 0.00036 0.525
    1  1-292 0.14231 0.01850
    1  1-293 0.17252 0.11010
    1  1-294 0.00068 0.00040 0.0627
    1  1-295 0.00738 0.01611 0.729
    1  1-296 0.00013 0.00020 0.0126
    1  1-297 0.00170 0.00944 0.0367
    1  1-298 0.00063 0.00045 0.1252
    1  1-299 0.00103 0.00057 0.0557
    1  1-300 0.00123 0.00055 0.0263
    1  1-301 0.00123 0.00032 0.1792
    1  1-302 0.0222 0.00637
    1  1-303 0.046 0.00498
    2 2-1  0.00525 0.00107 0.0237
    2 2-2  0.00499 0.00081 0.0340
    2 2-3  0.00226 0.00074 0.1630
    2 2-4  0.00327 0.00062 0.0466
    2 2-5  0.00223 0.00044 1.0911
    2 2-6  0.00223 0.00038 0.5846
    2 2-7  0.00114 0.00025 0.0429
    2 2-8  0.04210 0.01367 0.8488
    2 2-9  0.00876 0.00148 0.6195
    2 2-10 0.05312 0.01562
    2 2-11 0.00194 0.0067
    2 2-12 0.00271
    2 2-13 0.00154 0.00244 0.3382
    2 2-14 0.00251
    2 2-15 0.00128 0.00066 0.0171
    2 2-16 0.00267
    2 2-17 0.00267
    2 2-18 0.00219 0.1340
    2 2-19 0.00190 0.00033 0.0557
    2 2-20 0.00162 0.00145 0.2562
    2 2-21 0.00285
    2 2-22 0.00760
    2 2-23 0.00379
    2 2-24 0.00156 0.00098 0.0216
    2 2-25 0.00285
    2 2-26 0.00305
    2 2-27 0.00163 0.00116 0.2568
    2 2-28 0.00142 0.2074
    2 2-29 0.00149 0.0803
    2 2-30 0.00143 0.0403
    2 2-31 0.00151 0.1811
    2 2-32 0.00138 0.5361
    2 2-33 0.00063 0.0233
    2 2-34 0.00193 0.3523
    2 2-35 0.00082 0.0950
    2 2-36 0.00229
    2 2-37 0.00116 0.0854
    2 2-38 0.00121 0.00056 0.0029 0.0286
    2 2-39 0.00179 0.0347
    2 2-40 0.00051 0.00046 0.0035 0.0187
    2 2-41 0.00058 0.0052
    2 2-42 0.00056 0.00040 0.0047
    2 2-43 0.00258 0.00136 0.0278
    2 2-44 0.00070 0.00050 0.0482
    2 2-45 0.00113 0.00038 0.0090
    2 2-46 0.00140 0.00043 0.0205
    2 2-47 0.00073 0.00060 0.0157
    2 2-48 0.00071 0.00067 0.0335
    2 2-49 0.00061 0.00058 0.0038 0.0102
    2 2-50 0.00121 0.00058 0.0651
    2 2-51 0.00140 0.00060 0.0702
    2 2-52 0.00619 0.00183 0.0600
    2 2-53 0.01531 0.00271
    2 2-54 0.00329 0.00076 0.0163
    2 2-55 0.00175 0.00117 0.0100
    2 2-56 0.00142 0.00086 0.0067 0.0594
    2 2-57 0.00275
    2 2-58 0.00269
    2 2-59 0.00239
    2 2-60 0.00129 0.00096 0.0204
    2 2-61 0.00364
    2 2-62 0.00109 0.00041 0.0300
    2 2-63 0.00284 0.1510
    2 2-64 0.00277
    2 2-65 0.00257
    2 2-66 0.00241 0.2240
    2 2-67 0.00294 0.0409
    2 2-68 0.00112 0.00092 0.0119
    2 2-69 0.00410
    2 2-70 0.00194 0.00080 0.0298
    2 2-71 0.00604
    2 2-72 0.00501
    2 2-73 0.00258
    2 2-74 0.00082 0.00101 0.0189
    2 2-75 0.00893
    2 2-76 0.00508
    2 2-77 0.00072 0.00109 0.1340
    2 2-78 0.00136 0.00099 0.3603
    2 2-79 0.00280
    2 2-80 0.00067 0.0794
    2 2-81 0.00157 0.0600
    2 2-82 0.00141 0.2235
    2 2-83 0.00126 0.1971
    2 2-84 0.00093 0.0714
    2 2-85 0.00051 0.0626
    2 2-86 0.00159 0.2155
    2 2-87 0.00149 0.0086
    2 2-88 0.00225
    2 2-89 0.00218
    2 2-90 0.00299
    2 2-91 0.00367
    2 2-92 0.00044 0.0209
    2 2-93 0.00127 0.00093 0.0047
    2 2-94 0.00168 0.00105 0.0236
    2 2-95 0.00075 0.00034 0.0043
    2 2-96 0.00068 0.00034 0.0052
    2 2-97 0.00107 0.00021 0.0137
    2 2-98 0.00111 0.00034 0.0115
    2 2-99 0.00058 0.00050 0.0294
    2  2-100 0.00065 0.00064 0.0847
    2  2-101 0.00081 0.00074 0.0035 0.0318
    2  2-102 0.00084 0.00035 0.0337
    2  2-103 0.00269 0.00132 0.1453
    2  2-104 0.00194 0.00044 0.0597
    2  2-105 0.00757 0.00144 0.3728
    2  2-106 0.03856 0.00729 8.5694
    2  2-107 0.00550 0.00104 0.4219
    2  2-108 0.00137 0.00050 0.0098
    2  2-109 0.00502 0.00098 0.0343
    2  2-110 0.00327
    2  2-111 0.00159 0.00106 0.0226
    2  2-112 0.00170 0.00147 0.2326
    2  2-113 0.00142 0.00109 0.0968
    2  2-114 0.00173 0.00140 0.0692
    2  2-115 0.00129 0.00092 0.0190
    2  2-116 0.00214
    2  2-117 0.00457
    2  2-118 0.00348
    2  2-119 0.00168 0.00067 0.0239
    2  2-120 0.00878
    2  2-121 0.00223
    2  2-122 0.00474
    2  2-123 0.00194 0.00067 0.0488
    2  2-124 0.00134 0.00085 0.0385
    2  2-125 0.00382
    2  2-126 0.00233
    2  2-127 0.00313
    2  2-128 0.00273
    2  2-129 0.00402
    2  2-130 0.00128 0.00109 0.2256
    2  2-131 0.00287
    2  2-132 0.00239
    2  2-133 0.00265
    2  2-134 0.00235
    2  2-135 0.00299
    2  2-136 0.00170 0.1631
    2  2-137 0.00083 0.00079 0.0788
    2  2-138 0.00047 0.0619
    2  2-139 0.00118 0.3584
    2  2-140 0.00429
    2  2-141 0.00299
    2  2-142 0.00118 0.0066
    2  2-143 0.00091 0.0079
    2  2-144 0.00098 0.1870
    2  2-145 0.00066 0.0064
    2  2-146 0.00163 0.0065
    2  2-147 0.00681 0.0066
    2  2-148 0.00044 0.00051 0.0032 0.0150
    2  2-149 0.00087 0.00040 0.0107
    2  2-150 0.00125 0.00087 0.0083
    2  2-151 0.00149 0.00036 0.0057
    2  2-152 0.00167 0.00049 0.0093
    2  2-153 0.00103 0.00030 0.0286
    2  2-154 0.00091 0.00055 0.0045 0.0806
    2  2-155 0.00151 0.00060 0.1317
    2  2-156 0.00056 0.00020 0.0083
    2  2-157 0.00071 0.00027 0.0047
    2  2-158 0.00105 0.0073
    2  2-159 0.00041 0.00044 0.0351
    2  2-160 0.01113 0.00151 0.0470
    2  2-161 0.00838 0.00172 0.0442
    2  2-162 0.03732 0.00652
    2  2-163 0.00135 0.00029 0.0284
    2  2-164 0.01502 0.00217
    2  2-165 0.00161 0.00121 0.1874
    2  2-166 0.00357
    2  2-167 0.00198 0.0158
    2  2-168 0.00253
    2  2-169 0.00274
    2  2-170 0.00139 0.00086 0.0148
    2  2-171 0.00351
    2  2-172 0.00153 0.00082 0.0120
    2  2-173 0.00496
    2  2-174 0.00251
    2  2-175 0.00119 0.00077 0.0122
    2  2-176 0.00141 0.00078 0.0081
    2  2-177 0.00087 0.00054 0.0154
    2  2-178 0.00097 0.00057 0.0326
    2  2-179 0.00234
    2  2-180 0.00556
    2  2-181 0.00274
    2  2-182 0.00320
    2  2-183 0.00335
    2  2-184 0.00351
    2  2-185 0.00093 0.00095 0.0299
    2  2-186 0.00135 0.0233
    2  2-187 0.00160 0.6517
    2  2-188 0.00068 0.2390
    2  2-189 0.00088 0.1096
    2  2-190 0.00176 0.0409
    2  2-191 0.00133 0.0637
    2  2-192 0.00058 0.2133
    2  2-193 0.00150 0.2781
    2  2-194 0.00154 0.0942
    2  2-195 0.00066 0.1629
    2  2-196 0.00111 0.0299
    2  2-197 0.00171 0.2953
    2  2-198 0.00145 0.0539
    2  2-199 0.00104 0.00050 0.0042
    2  2-200 0.00185 0.00058 0.0041
    2  2-201 0.00186 0.0060
    2  2-202 0.00104 0.0115
    2  2-203 0.00152 0.0301
    2  2-204 0.00056 0.0897
    2  2-205 0.00122 0.0100
    2  2-206 0.00458 0.00734 0.0034
    2  2-207 0.00223 0.1412
    2  2-208 0.00095 0.00036 0.0044
    2  2-209 0.00199 0.00095 0.0299
    2  2-210 0.00081 0.00029 0.0069 0.0456
    2  2-211 0.00132 0.00056 0.0071
    2  2-212 0.00091 0.00023 0.0080
    2  2-213 0.00075 0.00058 0.0056 0.0206
    2  2-214 0.00061 0.00070 0.0055
    2  2-215 0.00055 0.00021 0.0135
    2  2-216 0.00078 0.00043 0.0074
    2  2-217 0.00076 0.00033 0.0095
    2  2-218 0.00099 0.00044 0.0154
    2  2-219 0.00066 0.00028 0.0033 0.0372
    2  2-220 0.00057 0.00039 0.0058
    2  2-221
    2  2-222 0.00413 0.00156 0.4679
    2  2-223 0.00136 0.00035 0.0173
    2  2-224 0.01502 0.00279 0.2044
    2  2-225 0.00129 0.00035 0.0113
    2  2-226 0.00337
    2  2-227 0.00371
    2  2-228 0.00320
    2  2-229 0.00339
    2  2-230 0.00240 0.00096 0.1574
    2  2-231 0.00139 0.00114 0.2677
    2  2-232 0.00210 0.00115 0.2879
    2  2-233 0.00280
    2  2-234 0.00372
    2  2-235 0.00168 0.00047 0.0231
    2  2-236 0.00294
    2  2-237 0.00237
    2  2-238 0.00288
    2  2-239 0.00321
    2  2-240
    2  2-241 0.00108 0.00061 0.0637
    2  2-242 0.00640
    2  2-243 0.00547
    2  2-244 0.00328
    2  2-245 0.00304 0.00074 0.0122
    2  2-246 0.00209 0.00074
    2  2-247 0.00437
    2  2-248 0.00413
    2  2-249 0.01960
    2  2-250 0.00134 0.00103 0.0767
    2  2-251 0.00369
    2  2-252 0.00234
    2  2-253 0.00143 0.1513
    2  2-254 0.00137 0.5875
    2  2-255 0.00286 0.2970
    2  2-256 0.00067 0.0684
    2  2-257 0.00187 0.0605
    2  2-258 0.00194 0.2379
    2  2-259 0.00097 0.0058
    2  2-260 0.00183 0.0053
    2  2-261 0.00167 0.0465
    2  2-262 0.00091 0.0971
    2  2-263 0.00143 0.00065 0.0296
    2  2-264 0.00081 0.00071 0.0117
    2  2-265 0.00056 0.00026 0.0042
    2  2-266 0.00134 0.00039 0.0097
    2  2-267 0.00161 0.00075 0.0087
    2  2-268 0.00060 0.00048 0.0030 0.0266
    2  2-269 0.00088 0.00071 0.0051
    2  2-270 0.00062 0.00079 0.0164
    2  2-271 0.00048 0.00045 0.0053 0.0159
    2  2-272 0.00076 0.00046 0.0039 0.1065
    2  2-273 0.00049 0.00035 0.0055
    2  2-274 0.00062 0.00076 0.0450
    2  2-275 0.00115 0.00053 0.0372
    2  2-276 0.00129 0.00066 0.1290
    2  2-277 0.00068 0.00023 0.0198
    2  2-278 0.00121 0.00008 0.0393
    2  2-279 0.00076 0.00039 0.0388
    2  2-280 0.00067 0.00026 0.0095
    2  2-281 0.00253 0.00066 0.0394
    2  2-282 0.00261 0.00045 0.0464
    2  2-283 0.00465 0.00085 0.0540
    2  2-284 0.01229 0.00135 0.1629
    2  2-285 0.00643 0.00187 0.7389
    2  2-286 0.00899 0.00172 1.7549
    2  2-287 0.00110 0.00022 0.2475
    2  2-288 0.00132 0.00044 0.0127 0.0777
    2  2-289 0.00578 0.00101 0.0429
    2  2-290 0.00164 0.00044 0.0377
    2  2-291 0.00190 0.00135 0.0223
    2  2-292 0.00527
    2  2-293 0.00126 0.00121 0.0295
    2  2-294 0.00315
    2  2-295 0.00327
    2  2-296 0.00173 0.00128 0.3831
    2  2-297 0.00205 0.00033
    2  2-298 0.00308
    2  2-299 0.00305
    2  2-300
    2  2-301 0.00371
    2  2-302 0.00348
    2  2-303 0.00361
    2  2-304 0.00624
    2  2-305 0.00384
    2  2-306 0.00144 0.00116 0.4378
    2  2-307 0.00265
    2  2-308 0.00198 0.00089 0.0761
    2  2-309 0.00209
    2  2-310 0.00387
    2  2-311 0.00686 0.00093
    2  2-312 0.00206 0.00087
    2  2-313 0.00157 0.1836
    2  2-314 0.00063 0.1939
    2  2-315 0.00173 0.1089
    2  2-316 0.00069 0.1448
    2  2-317 0.00303 0.00399 0.2284
    2  2-318 0.00065 0.0377
    2  2-319 0.00057 0.0243
    2  2-320 0.00076 0.1199
    2  2-321 0.00078 0.2500
    2  2-322 0.00086 0.1040
    2  2-323 0.00144 0.0175
    2  2-324 0.00105 0.0082
    2  2-325 0.00159 0.1910
    2  2-326 0.00098 0.00066 0.0042
    2  2-327 0.00180 0.0199
    2  2-328 0.00050 0.0123
    2  2-329 0.00091 0.00042 0.0083
    2  2-330 0.00162 0.00073 0.0134
    2  2-331 0.00118 0.00032 0.0089
    2  2-332 0.00051 0.00062 0.0092
    2  2-333 0.00101 0.00039 0.0055
    2  2-334 0.00105 0.00062 0.0043 0.0307
    2  2-335 0.00061 0.00064 0.0143
    2  2-336 0.00085 0.00085 0.0086
    2  2-337 0.00057 0.00061 0.0289
    2  2-338 0.00040 0.00022 0.0033 0.0234
    2  2-339 0.00116 0.00037 0.0098
    2  2-340 0.00095 0.00031 0.0039
    2  2-341 0.00084 0.00038 0.0114
    2  2-342 0.00074 0.00032 0.0162
    2  2-343 0.00061 0.00037 0.0046 0.0383
    2  2-344 0.01982 0.00369 1.7992
    2  2-345 0.00531 0.00153 0.0237
    2  2-346 0.00452 0.00099 0.0891
    2  2-347 0.00110 0.00033 0.0175 0.0411
    2  2-348 0.00493 0.00154 0.0347
    2  2-349 0.00346 0.00087 0.0216
    2  2-350 0.01759 0.00481 0.7190
    2  2-351 0.00195 0.00077 0.0526
    2  2-352 0.00557 0.00077 0.0342
    2  2-353 0.00262 0.00079 0.0327
    2  2-354 0.00385
    2  2-355 0.00302
    2  2-356 0.00613
    2  2-357 0.00393
    2  2-358 0.00199 0.0413
    2  2-359 0.00611
    2  2-360 0.00132 0.00108 0.4112
    2  2-361 0.00170 0.00061 0.0089
    2  2-362 0.00175 0.00133 0.2286
    2  2-363 0.00267
    2  2-364 0.00569
    2  2-365 0.00434
    2  2-366 0.00366
    2  2-367 0.00462
    2  2-368 0.00357
    2  2-369 0.00262
    2  2-370
    2  2-371 0.00268
    2  2-372 0.00137 0.00100 0.2962
    2  2-373 0.00276
    2  2-374 0.00252 0.00158 0.0625
    2  2-375 0.00318
    2  2-376 0.00254
    2  2-377 0.00110 0.0555
    2  2-378 0.00153 0.2376
    2  2-379 0.00146 0.2821
    2  2-380 0.00141 0.0384
    2  2-381
    2  2-382 0.00115 0.3755
    2  2-383 0.00155 0.0090
    2  2-384 0.00173 0.0930
    2  2-385 0.00106 0.1738
    2  2-386 0.00121 0.1548
    2  2-387 0.00088 0.1472
    2  2-388 0.00114 0.1413
    2  2-389 0.00134 0.0126
    2  2-390 0.00202 0.1779
    2  2-391 0.00071 0.0057
    2  2-392 0.00118 0.2170
    2  2-393 0.00096 0.00039 0.0234
    2  2-394 0.00063 0.00024 0.0040
    2  2-395 0.00065 0.00018 0.0046
    2  2-396 0.00097 0.00044 0.0054
    2  2-397 0.00118 0.00034 0.0202
    2  2-398 0.00239 0.00068 0.0086
    2  2-399 0.00128 0.00079 0.0121
    2  2-400 0.00135 0.00095 0.0068
    2  2-401 0.00058 0.00034 0.0060
    2  2-402 0.00060 0.00029 0.0056
    2  2-403 0.00085 0.00037 0.0074
    2  2-404 0.00060 0.00024 0.0132
    2  2-405 0.00060 0.00027 0.0075
    2  2-406 0.00112 0.00062 0.0404
    2  2-407 0.00063 0.00028 0.0047
    2  2-408 0.02337 0.00422 0.1878
    2  2-409 0.00400 0.00112 0.1243
    2  2-410 0.00912 0.00155 0.1299
    2  2-411 0.00667 0.00197 0.3481
    2  2-412 0.00435 0.00070 0.0265
    2  2-413 0.01955 0.00359 1.2609
    2  2-414 0.00320
    2  2-415 0.00171 0.00132 0.0130
    2  2-416 0.00164 0.00125 0.5977
    2  2-417 0.00123 0.00045 0.0143
    2  2-418 0.00329
    2  2-419 0.00510
    2  2-420 0.00289
    2  2-421 0.00131 0.00082 0.0241
    2  2-422 0.00180 0.0140
    2  2-423 0.00190 0.00088 0.0173
    2  2-424 0.00225
    2  2-425 0.00085 0.00100 0.2262
    2  2-426 0.00189 0.00055 0.0510
    2  2-427 0.00101 0.00098 0.2152
    2  2-428 0.00168 0.00115 0.4627
    2  2-429 0.00126 0.00068 0.0274
    2  2-430 0.00479
    2  2-431 0.00679
    2  2-432 0.00164 0.00062 0.0430
    2  2-433 0.00121 0.00112 0.0132
    2  2-434 0.00155 0.00114 0.2315
    2  2-435 0.00233
    2  2-436 0.00299
    2  2-437 0.00179 0.00114 0.0337
    2  2-438 0.00403
    2  2-439 0.00289
    2  2-440 0.00047 0.1555
    2  2-441 0.00053 0.0824
    2  2-442 0.00088 0.3050
    2  2-443 0.00120 0.0723
    2  2-444 0.00092 0.00090 0.1538
    2  2-445 0.00127 0.06143 0.4557
    2  2-446 0.00040 0.2085
    2  2-447 0.00090 0.2752
    2  2-448 0.00103 0.1198
    2  2-449 0.00117 0.3546
    2  2-450 0.00177 0.1152
    2  2-451 0.00146 0.2871
    2  2-452 0.00097 0.1343
    2  2-453 0.00123 0.1713
    2  2-454 0.00057 0.0879
    2  2-455 0.00123 0.0055
    2  2-456 0.00092 0.0075
    2  2-457 0.00259
    2  2-458 0.00115 0.0459
    2  2-459 0.00061 0.0205
    2  2-460 0.00093 0.0276
    2  2-461 0.00084 0.00030 0.0061
    2  2-462 0.00087 0.00029 0.0444
    2  2-463 0.00116 0.00065 0.0260
    2  2-464 0.00108 0.00044 0.0091
    2  2-465 0.00052 0.00073 0.0094
    2  2-466 0.00097 0.00079 0.0179
    2  2-467 0.00164 0.00068 0.0209
    2  2-468 0.00069 0.00026 0.0128
    2  2-469 0.00068 0.00076 0.0838
    2  2-470 0.00075 0.00033 0.0130
    2  2-471 0.00083 0.00040 0.0064
    2  2-472 0.00182 0.00062 0.0679
    2  2-473 0.00261 0.00139 0.0481
    2  2-474 0.00100 0.00029 0.0141
    2  2-475 0.00075 0.00038 0.0429
    2  2-476 0.00092 0.00042 0.0105
    2  2-477 0.00157 0.00080 0.1128
    2  2-478 0.00076 0.00043 0.0048
    2  2-479 0.01796 0.00310 0.2390
    2  2-480 0.00446 0.00085 0.1779
    2  2-481 0.26562 0.05267
    3 3-1  0.10799 0.14510
    Blank: not determined

Claims (36)

1. A compound of Formula 0:
Figure US20190233441A1-20190801-C01865
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 is phenylene or 3-11 membered heteroarylene, wherein Ar1 is optionally substituted;
X is —O— or —N(R1b)—(CRx1RY1y)p—, wherein Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl and p is 0 to 6, and wherein the —N(R1b)— portion of —N(R1b)—(CRx1Ry1)p— is bound to the carbonyl carbon of Formula 0;
R1a is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, phenyl, or 3-11 membered heterocyclyl and R1a is optionally substituted by R9;
R1b is hydrogen, C1-C6 alkyl, or C3-C8 cycloalkyl, and wherein one or more alkylene units of said alkyl group is optionally substituted by —O— and wherein any alkyl or cycloalkyl group is optionally substituted by OH, or
when p is 0 and X is —N(R1b)—, R1a and R1b may be joined together with the nitrogen atom to which R1a and R1b is attached to form a 3-11 membered heterocyclyl optionally substituted by R9;
R2 is a 3-11 membered heterocyclyl containing at least 1 nitrogen, selected from groups (a)-(e) and (h)-(j), or a C5-C8 cycloalkenyl ring (f), or a —O—(CRxRy)q—Ar2 group (g) where Rx and Ry are independently hydrogen or C1-C6 alkyl, q is 0 to 3 and Ar2 is optionally substituted C6-C10 aryl or optionally substituted 5-11 membered heteroaryl:
Figure US20190233441A1-20190801-C01866
Figure US20190233441A1-20190801-C01867
R3, R4 and R5 are each independently selected from the group consisting of hydrogen, CH3, CH2CH3, OCH3, CF3, F and Cl;
R6 and R7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene) 3-11 membered heterocyclyl, (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaC(O)(C1-C6 alkyl), (C0-C6 alkylene)NRaC(O)(phenyl), (C0-C6 alkylene)C(O)R8a, (C0-C6 alkylene)C(O)OR8a, C1-C6 alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, —C═N—O—(C1-C6 alkyl), —O—(C1-C6 alkyl) 3- membered heterocyclyl, (C0-C6 alkylene)NRaSO2(C1-C6 alkyl), (C0-C6 alkylene)NRaSO2(phenyl), and —O— (3-11 membered heterocyclyl); wherein said alkyl, alkylene, alkoxy, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted,
or R6 and R7 together form an optionally substituted phenyl or optionally substituted 3-11 membered heterocyclyl;
R8 is H, C1-C6 alkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene) 3-11 membered heterocyclyl, C(O)NRaRb, SO2NRaRb, (C1-C6 alkylene)C(O)OR8a or C(O)R8a, wherein said alkyl, alkylene, heterocyclyl and phenyl are each independently optionally substituted;
R8a is H, NRaRb, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, or (C0-C6 alkylene) 3-11 membered heterocyclyl, wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
R8aa is H, C1-C6 alkyl optionally substituted by OH, or C(O)NRaRb; or
or R8 and R8aa together form an optionally substituted 3-11 membered heterocyclyl;
R9, independently at each occurrence, is OH, halogen, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene) 3-11 membered heterocyclyl, (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene) NRaRb, or C(O)(C1-C6 alkyl), wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
Ra and Rb, independently at each occurrence, are selected from the group consisting of hydrogen, C1-C6 alkyl optionally substituted by halogen or CN, (C0-C6 alkylene) C3-C8 cycloalkyl, or (C0-C6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl;
m1, m2, m3 and m4 are each independently 0, 1 or 2; and
n is 0 or 1.
2. The compound of claim 1, further defined as a compound of Formula Ia:
Figure US20190233441A1-20190801-C01868
wherein Ar1, X, R1a, R3-R7, m1, m2 and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m1 is 1 and m2 is 1, or m1 is 2 and m2 is 1.
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R6 and R7 are attached to the ring at the same carbon atom; or
R6 is C1-C6 alkyl or C1-C6-alkoxy, and R7 is optionally substituted phenyl; or
R6 is C1-C6 alkyl, C3-C6 cycloalkyl or optionally substituted phenyl and R7 is OH, (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene) CN or —O— (C0-C6 alkyl)CN; or
R6 is hydrogen and R7 is selected from (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene) CN, C1-C6-alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, and —O—(C1-C6 alkylene)CN; or
R6 and R7 together form a 3-11 membered heterocycloalkyl optionally substituted by oxo.
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
Figure US20190233441A1-20190801-C01869
is selected from
Figure US20190233441A1-20190801-C01870
wherein R7a is selected from hydrogen, halogen, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and —CN.
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein one or both of R6 and R7 is located at the para position of the ring.
7. The compound of claim 1, further defined as a compound of Formula Ib:
Figure US20190233441A1-20190801-C01871
wherein Ar1, X, R1a, R3-R7, m1, m2 and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m1 is 1 and m2 is 2, or m1 is 2 and m2 is 1, or m1 is 1 and m2 is 1.
9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is H and R7 and is substituted phenyl.
10. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein
Figure US20190233441A1-20190801-C01872
is selected from
Figure US20190233441A1-20190801-C01873
wherein R7a is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl and CN.
11. The compound of claim 1, further defined as a compound of Formula Ic:
Figure US20190233441A1-20190801-C01874
wherein Ar1, X, R1a, R3-R5, R8, m3, m4 and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein m3 is 1 and m4 is 1, or m3 is 1 and m4 is 2, or m3 is 1 and m4 is 0.
13. The compound as in claim 11, or a pharmaceutically acceptable salt thereof, wherein
Figure US20190233441A1-20190801-C01875
is selected from
Figure US20190233441A1-20190801-C01876
14. The compound of claim 1, further defined as a compound of Formula Id:
Figure US20190233441A1-20190801-C01877
wherein Ar1, R1a, R1b, R3-R5, R8, m3, m4 and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein m3 is 1 and m4 is 1, m3 is 1 and m4 is 1, or m3 is 1 and m4 is 2.
16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R8 is substituted phenyl, C(O)NRaRb or C(O)R8a.
17. The compound of claim 1, further defined as a compound of Formula Ie:
Figure US20190233441A1-20190801-C01878
wherein Ar1, R1a, R1b, R3-R6, R8, m3, m4 and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein m3 is 0 and m4 is 1 or m3 is 1 and m4 is 1.
19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R8 is C(O)NRaRb.
20. The compound of claim 1, further defined as a compound Formula If:
Figure US20190233441A1-20190801-C01879
wherein Ar1, R1a, R1b, R3-R7, m3, m4 and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein m3 is 1 and m4 is 1.
22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R7 is OH or C1-C6-alkoxy.
23. The compound of claim 1, further defined as a compound of Formula Ig:
Figure US20190233441A1-20190801-C01880
wherein Ar1, R1a, R1b, R3-R5, R7a and n are as defined in claim 1, R7a is selected from hydrogen, OH, halogen, C1-C6 alkyl, C1-C6 alkoxy, (C1-C6 alkyl)phenyl, C1-C6 haloalkyl, oxo and CN, and q is either 0 or 1, and when q is 1, then Rx and Ry are hydrogen or a pharmaceutically acceptable salt thereof.
24. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3, R4 and R5 are each hydrogen.
25. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ar1 is phenylene or pyrazolylene.
26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the moiety
Figure US20190233441A1-20190801-C01881
is further defined as
Figure US20190233441A1-20190801-C01882
27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein —X—R1a is —N(R1b)—(CRx1Ry1)p—R1a.
28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein:
(1) R1b is C1-C6 alkyl optionally substituted by C1-C6 alkoxy, p is 0-3, Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl, R1a is C1-C6 alkyl and R9 is NRaRb; or
(2) R1b is C1-C6 alkyl optionally substituted by C1-C6 alkoxy, p is 0-3, Rx1 and Ry1 are each independently hydrogen or C1-C6 alkyl, and R1a is 3-11 membered heterocyclyl optionally substituted by R9; or
(3) p is 0 and R1a and R1b are joined to form a 3-11 membered heterocyclyl optionally substituted by R9.
29. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R9 is optionally substituted C1-C6 alkyl or optionally substituted 3-11 membered heterocyclyl.
30. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein the optional substituents of said optionally substituted C1-C6 alkyl of R9 or optionally substituted 3-11 membered heterocyclyl of R9 are selected from OH; halogen; CN; NRaRb; C1-C6 alkyl optionally substituted by halogen; C3-C8 cycloalkyl; C1-C6 alkoxy; phenyl; 3-11 membered heterocyclyl optionally substituted by C1-C6 alkyl or NRaRb; C(O)C1-C6 alkyl; and C(O)— 3-11 membered heterocyclyl optionally substituted by C1-C6 alkyl.
31. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein —N(R1b)—(CRx1Ry1)p—R1a is selected from
Figure US20190233441A1-20190801-C01883
Figure US20190233441A1-20190801-C01884
32. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R1b is hydrogen or CH3.
33. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3.
34. A compound of Formula II:
Figure US20190233441A1-20190801-C01885
or a pharmaceutically acceptable salt thereof, wherein:
Q1 is a 3-11 membered heterocyclyl containing at least 1 nitrogen, selected from groups (a)-(e) and (h)-(j), or a C5-C8 cycloalkenyl ring (f), or a —O—(CRxRy)q—Ar2 group (g) where Rx and Ry are independently hydrogen or C1-C6 alkyl, q is 0 to 3 and Ar2 is optionally substituted C6-C10 aryl or optionally substituted 3-11 membered heteroaryl:
Figure US20190233441A1-20190801-C01886
Figure US20190233441A1-20190801-C01887
R6 and R7 are independently selected from the group consisting of hydrogen, halogen, OH, CN, phenyl, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, (C0-C6 alkylene) 3-11 membered heterocyclyl, (C0-C6 alkylene) C(O)NRaRb, (C0-C6 alkylene) NRaC(O)(C1-C6 alkyl), (C0-C6 alkylene)C(O)R8a, (C0-C6 alkylene) C(O)OR8a, C1-C6 alkoxy, —O—(C3-C6 cycloalkyl), —O—(C0-C6 alkylene)C(O)NRaRb, and —O— (3-11 membered heterocyclyl); wherein said alkyl, alkylene, alkoxy, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted,
or R6 and R7 together form an optionally substituted phenyl or optionally substituted 3-11 membered heterocyclyl;
R8 is C1-C6 alkyl, (C0-C6 alkylene)phenyl, C(O)NRaRb, SO2NRaRb, C(O)OR8a or C(O)R8a, wherein said alkyl, alkylene and phenyl are each independently optionally substituted;
R8a is C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, or (C0-C6 alkylene) 3-11 membered heterocyclyl, wherein said alkyl, alkylene, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
R8aa is H; or
or R8 and R8aa together form an optionally substituted 3-11 membered heterocyclyl;
R9, independently at each occurrence, is OH, halogen, C1-C6 alkyl, (C0-C6 alkylene)C3-C8 cycloalkyl, (C0-C6 alkylene)phenyl, (C0-C6 alkylene) 3-11 membered heterocyclyl, (C0-C6 alkylene)C(O)NRaRb, (C0-C6 alkylene)NRaRb, or C(O)(C1-C6 alkyl), wherein said alkyl, cycloalkyl, phenyl and heterocyclyl are each independently optionally substituted;
Ra and Rb are independently at each occurrence hydrogen, C1-C6 alkyl, (C0-C6 alkylene) C3-C8 cycloalkyl, or (C0 -C6 alkylene)phenyl, and wherein one or more alkylene units of any alkyl group is independently optionally substituted by —O—, or alternatively Ra and Rb may be joined together with the nitrogen atom to which they are attached to form an optionally substituted 3-11 membered heterocyclyl;
m1, m2, m3 and m4 are each independently 0, 1 or 2; and
Q2 is C3-C8 cycloalkyl optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, F, Cl, Br, I, OH, SH, NH2, CN or N3.
35. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
36. A method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
US16/373,435 2013-09-05 2019-04-02 Triazolopyridine compounds, compositions and methods of use thereof Abandoned US20190233441A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/373,435 US20190233441A1 (en) 2013-09-05 2019-04-02 Triazolopyridine compounds, compositions and methods of use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361874038P 2013-09-05 2013-09-05
PCT/CN2014/085276 WO2015032286A1 (en) 2013-09-05 2014-08-27 Triazolopyridine compounds, compositions and methods of use thereof
US15/061,760 US20160185780A1 (en) 2013-09-05 2016-03-04 Triazolopyridine compounds, compositions and methods of use thereof
US15/499,662 US9873709B2 (en) 2013-09-05 2017-04-27 Triazolopyridine compounds, compositions and methods of use thereof
US15/842,642 US20180298033A1 (en) 2013-09-05 2017-12-14 Triazolopyridine compounds, compositions and methods of use thereof
US16/373,435 US20190233441A1 (en) 2013-09-05 2019-04-02 Triazolopyridine compounds, compositions and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/842,642 Continuation US20180298033A1 (en) 2013-09-05 2017-12-14 Triazolopyridine compounds, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
US20190233441A1 true US20190233441A1 (en) 2019-08-01

Family

ID=52627792

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/061,760 Abandoned US20160185780A1 (en) 2013-09-05 2016-03-04 Triazolopyridine compounds, compositions and methods of use thereof
US15/499,662 Active US9873709B2 (en) 2013-09-05 2017-04-27 Triazolopyridine compounds, compositions and methods of use thereof
US15/842,642 Abandoned US20180298033A1 (en) 2013-09-05 2017-12-14 Triazolopyridine compounds, compositions and methods of use thereof
US16/373,435 Abandoned US20190233441A1 (en) 2013-09-05 2019-04-02 Triazolopyridine compounds, compositions and methods of use thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US15/061,760 Abandoned US20160185780A1 (en) 2013-09-05 2016-03-04 Triazolopyridine compounds, compositions and methods of use thereof
US15/499,662 Active US9873709B2 (en) 2013-09-05 2017-04-27 Triazolopyridine compounds, compositions and methods of use thereof
US15/842,642 Abandoned US20180298033A1 (en) 2013-09-05 2017-12-14 Triazolopyridine compounds, compositions and methods of use thereof

Country Status (17)

Country Link
US (4) US20160185780A1 (en)
EP (1) EP3041841B1 (en)
JP (1) JP6472803B2 (en)
KR (1) KR20160050080A (en)
CN (1) CN105745209B (en)
AU (1) AU2014317600A1 (en)
CA (1) CA2922770A1 (en)
CL (1) CL2016000496A1 (en)
CR (1) CR20160070A (en)
EA (1) EA201690523A1 (en)
IL (1) IL244066A0 (en)
MA (1) MA38884A1 (en)
MX (1) MX2016002764A (en)
PE (1) PE20161323A1 (en)
PH (1) PH12016500347A1 (en)
SG (1) SG11201601707PA (en)
WO (1) WO2015032286A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244539A1 (en) * 2022-06-13 2023-12-21 Apm Therapeutics 1, Inc. Triazolopyridine polymorph a

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265464A1 (en) * 2015-03-04 2018-01-10 F. Hoffmann-La Roche AG Triazolopyridine compounds and methods of use thereof
WO2017103188A1 (en) * 2015-12-18 2017-06-22 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
EP3438109B1 (en) * 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
PE20190632A1 (en) 2016-09-06 2019-04-26 Hoffmann La Roche COMPOUNDS 8- (AZETIDIN-1-IL) - [1,2,4] TRIAZOLO [1,5-A] PIRIDINYL, COMPOSITIONS AND METHODS OF USING THEMSELVES
CN109400610A (en) * 2017-08-18 2019-03-01 浙江海正药业股份有限公司 Pyrrolo-triazine analog derivative, preparation method and its purposes in medicine
US20240158386A1 (en) * 2021-03-02 2024-05-16 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
TW202334136A (en) * 2021-11-03 2023-09-01 美商傳達治療有限公司 Pi3kα inhibitors and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141796A2 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
YU25500A (en) 1999-05-11 2003-08-29 Pfizer Products Inc. Process for the synthesis of nucleosite analogues
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
PE20110063A1 (en) * 2008-06-20 2011-02-16 Genentech Inc DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS
MX2010014005A (en) * 2008-06-20 2011-02-15 Genentech Inc Triazolopyridine jak inhibitor compounds and methods.
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
TWI453207B (en) * 2008-09-08 2014-09-21 Signal Pharm Llc Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
JO3030B1 (en) 2009-06-26 2016-09-05 Galapagos Nv Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
KR20130091464A (en) * 2012-02-08 2013-08-19 한미약품 주식회사 Triazolopyridine derivatives as a tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141796A2 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244539A1 (en) * 2022-06-13 2023-12-21 Apm Therapeutics 1, Inc. Triazolopyridine polymorph a

Also Published As

Publication number Publication date
CL2016000496A1 (en) 2016-10-07
EP3041841A4 (en) 2017-04-19
US20160185780A1 (en) 2016-06-30
JP2016529299A (en) 2016-09-23
WO2015032286A1 (en) 2015-03-12
CR20160070A (en) 2016-04-01
MA38884A1 (en) 2017-06-30
US20170226132A1 (en) 2017-08-10
MX2016002764A (en) 2016-05-26
EP3041841A1 (en) 2016-07-13
CN105745209B (en) 2018-10-23
SG11201601707PA (en) 2016-04-28
US20180298033A1 (en) 2018-10-18
PH12016500347A1 (en) 2016-05-16
JP6472803B2 (en) 2019-02-20
AU2014317600A1 (en) 2016-03-03
EA201690523A1 (en) 2016-07-29
US9873709B2 (en) 2018-01-23
CN105745209A (en) 2016-07-06
KR20160050080A (en) 2016-05-10
EP3041841B1 (en) 2019-06-05
IL244066A0 (en) 2016-04-21
PE20161323A1 (en) 2016-11-25
CA2922770A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
US9873709B2 (en) Triazolopyridine compounds, compositions and methods of use thereof
US9051310B2 (en) Nicotinamide derivative or salt thereof
US10597377B2 (en) Somatostatin modulators and uses thereof
US7977331B1 (en) Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
JP4143669B2 (en) Four-ring condensed heterocyclic compounds and their use as HCV polymerase inhibitors
JP2022502515A (en) TYK2 inhibitors and their use
MX2014013734A (en) Nampt inhibitors.
EP1361225B1 (en) Compounds substituted with bicyclic amino groups
JP2007084530A (en) Pharmaceutical composition containing indanol derivative
JP2018507236A (en) Triazolopyridine compounds and methods of use thereof
JP4853992B2 (en) Indanol derivatives
RU2323937C1 (en) Indanol derivatives
WO2021076448A1 (en) Somatostatin modulators for treating pituitary adenomas
JP2002284782A (en) Bicyclic amino group-substituted compound
CZ20002629A3 (en) Heteroaryl-substituted pyrrole derivatives, process of their preparation and their therapeutic use

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION